



**2025 World Conference
on Lung Cancer**

SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

PROGRAM BOOK

wclc.iaslc.org



#WCLC25

accord

COMMITTED TO TRANSFORMING CANCER CARE

Accord is a fast-growing pharmaceutical company that is:

Established in oncology

>60 cancer related therapies available across Europe

Driven by innovation

>15 pipeline medicines aiming to reach patients within 5 years

Focused on patient-centred care

Addressing unmet needs and improving availability of essential treatments



Scan to learn
more about our
work in oncology

Date of preparation: June 2025 EUR-Non-P-01419

TABLE OF CONTENTS

05

OVERVIEW

Important Information
Welcome Messages
IASLC Staff and WCLC Committees
IASLC and Conference Awards
Program at a Glance

37

SCIENTIFIC PROGRAM SATURDAY, SEPTEMBER 6

53

SCIENTIFIC PROGRAM SUNDAY, SEPTEMBER 7

79

SCIENTIFIC PROGRAM MONDAY, SEPTEMBER 8

105

SCIENTIFIC PROGRAM TUESDAY, SEPTEMBER 9

123

POSTERS

Posters - Sunday, September 7
Posters - Monday, September 8
Posters - Tuesday, September 9
ePosters

211

GENERAL INFORMATION

Exhibit and Supporter Information
Satellite CME Symposia, Industry Sponsored Symposia
Non-Profit Presentation
Conference Information
Venue Floor Plans

IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

The IASLC's headquarters are located at:
**1775 N. Sherman Street, Suite 1600,
Denver, CO 80203-4317**
Phone: **+1 855 464 2752** | Website: **www.iaslc.org**

CONFERENCE SECRETARIAT

International Conference Services Ltd. (ICS)
555 Burrard Street (Bentall Center 2), Vancouver, BC, Canada, V7X 1M8
+1 604 681 2153 | **www.icsevents.com**

ICS
International Conference Services

IVONESCIMAB NSCLC & BEYOND

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's NMPA.

IVONESCIMAB PIPELINE

36 Ivonescimab Clinical Trials
Ongoing or Completed in
Multiple Tumor Types¹

Phase 3

Planned and Ongoing Studies Sponsored by Summit Therapeutics

HARMONI₁ 2L+ NSCLC EGFR+
Enrollment Complete

HARMONI₁ 3 1L NSCLC

HARMONI₁ 7 1L NSCLC

Phase 3

Conducted in China, Fully Sponsored and Managed by Akeso

HARMONI₁ A 2L+ NSCLC EGFR+

HARMONI₁ 2 1L NSCLC

HARMONI₁ 6 1L NSCLC

HARMONI₁ 8A 2L+ NSCLC

HARMONI₁ 9 SCLC

HARMONI₁ BC1 1L TNBC

HARMONI₁ HNI 1L HNSCC

HARMONI₁ GI1 1L Biliary Tract

HARMONI₁ GI2 1L Pancreatic

HARMONI₁ GI6 1L Colorectal

Phase 1 - 2

NSCLC G/GEJ Colorectal Breast
Ovarian Hepatocellular SCLC



First-in-Class*

PD-1/VEGF Bispecific

Antibody in Clinical Development

Cooperative Binding²

Increased:
Avidity in TME, Activity of T Cells

Globally, 2,300+ Patients Treated

with Ivonescimab Across
All Summit & Akeso Trials to Date³

13 Phase 3 Trials Announced Ongoing or Completed¹

For More Information
Visit Us at Booth #204
MedInfo@smmtx.com

THE COMMENCEMENT OF A NEW ERA



*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration or the European Medicines Agency.

References: 1. Ivonescimab Clinical Trials. Available at: <https://clinicaltrials.gov/search?term=ivonescimab%20OR%20AK112>. Accessed on: May 19, 2025; 2. Dong Y, Science. 2024;283(11722): 3. Data on file. © Summit Therapeutics Inc.

Abbreviations: 1L=first-line; 2L=second-line; EGFR=epidermal growth factor receptor positive; G/GEJ=gastro/gastroesophageal junction;

HNSCC=head and neck squamous cell carcinoma; NMPA=National Medical Products Administration; NSCLC=non-small cell lung cancer;

PD-1=programmed cell death protein 1; SCLC=small cell lung cancer; TME=tumor microenvironment; TNBC=triple-negative breast cancer;

MedInfo@smmtx.com

AKT-SMT112-023



01

CONFERENCE OVERVIEW

Welcome Messages

CONFERENCE OVERVIEW

Dear Colleagues and Friends,

We are honored to welcome you to the IASLC 2025 World Conference on Lung Cancer (WCLC 2025) in Barcelona.

You are now part of one of the world's largest gatherings dedicated to thoracic oncology - a community of researchers, clinicians, nurses, patients, survivors, advocates, industry representatives, and thought leaders from across the globe. Your presence here matters. Together, we are united by one extraordinary goal: to conquer thoracic cancers worldwide in the 21st century.

This Conference reflects the heart of the IASLC's mission and the power of its people. Our shared work lives in three core objectives that guide everything we do:

DRIVING DISCOVERY

By advancing research and exploring bold new frontiers.

CONNECTING CHANGEMAKERS

By building collaborations that break silos and spark progress.

ELEVATING EXPERTISE

By sharing knowledge, skills, and ideas that improve care and save lives.

Over the next four days, we encourage you to be part of that mission in action. Share your science. Ask questions. Make new connections. Challenge yourself. Learn something unexpected. Mentor someone. Let this experience expand your perspective, fuel your purpose, and inspire your next steps.

The program you will experience has been thoughtfully curated to reflect the progress we have made together and the momentum we continue to build. It spans disciplines, geographies, and career stages—with something meaningful for everyone who is committed to advancing thoracic cancer care.

Thank you for being here. Thank you for being part of this global movement.

Welcome to Barcelona. Welcome to WCLC 2025.

WCLC 2025 Conference Chairs,



Umberto Malapelle
Italy



Jarushka Naidoo
Ireland



Isabelle Opitz
Switzerland



Noemi Reguart
Spain

CONFERENCE OVERVIEW

Welcome Messages

Greetings WCLC Delegates,

As the President and the CEO of the IASLC, we are delighted to welcome you to the IASLC 2025 World Conference on Lung Cancer (WCLC 2025) in beautiful Barcelona, Spain. We are honored that you have chosen to join us for what is sure to be a rigorous, fascinating, and collaborative meeting.

Over the last 51 years, we have witnessed extraordinary progress in every facet of thoracic malignancies from epidemiology, biology, diagnosis, and treatment. Throughout its long history, the WCLC has played a strong role in facilitating that progress. Providing a platform for sharing cutting-edge research, creating space for new collaborations and partnerships, connecting established researchers with young investigators, and serving as a foundational meeting for healthcare professionals (representing the full spectrum of the multidisciplinary team), patients, and advocates who have dedicated their lives to conquering these challenging diseases.

This enduring importance is illustrated by the remarkable growth of the WCLC, which has evolved from a small gathering to the world's largest meeting dedicated to thoracic oncology, now attracting over 7,000 international participants each year.

While the story of the WCLC is well-established, we recognize that we must continually look to the future if we are to continue making progress in the treatment of thoracic cancers. That is why, for WCLC 2025, we are proud to announce that the Conference Chairs, along with the WCLC 2025 Program Committee, have assembled an incredible educational and scientific program that highlights emerging talent, multidisciplinary expertise, and international perspectives to foster richer dialogue and innovation. We are confident you will find WCLC 2025 to be an exceptional educational experience. We want to thank the Program Committee for their hard work and are especially grateful for the dedication and leadership of our Conference Chairs: Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemi Reguart.

Thank you for attending WCLC 2025, and thank you for your engagement with the IASLC. We hope you enjoy the Conference, explore Barcelona, find opportunities to develop new relationships and collaborations, and gain novel skills and insights that you can apply to improve the lives of thoracic cancer patients in your local communities and worldwide. Like so much of what the IASLC does, the success of the WCLC hinges on the passion, commitment, and engagement of those who participate. In short, your participation is one of the main reasons why the event has remained the world's leading thoracic cancer conference for 51 years. We appreciate you being a part of our ongoing story.




Paul Van Schil
IASLC President,
Belgium



Karen Kelly
IASLC CEO,
USA

SINGULA™ Lung



The first molecular test to predict individual response to targeted therapy and chemotherapy in NSCLC.

Avoid ineffective regimens and unnecessary toxicity.

One Test. Current Workflow. Personalized Therapy.

Cellworks

www.cellworks.life



A Meet the Expert session at WCLC on Challenging conventional thinking: Understanding activating HER2 (ERBB2) mutations in NSCLC

Location & Time:

Bayer Medical Booth (#203)
September 7, 2025
14:00–14:30 (CET)

with:

Bruna Pellini, MD
Moffitt Cancer Center
and Research Institute
Tampa, FL, USA




Bayer sponsored 'Meet the Expert' session at the 2025 IASLC World Conference on Lung Cancer (WCLC)

© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer. MA-BY-ES-0013-1 08/25



Precise innovation in lung cancer research

Guided by **chemistry**
and driven by **purpose**,
we are committed to
advancing lung cancer
research that puts
patients first.



Nuvalent's therapies are
investigational candidates
and have not been
approved by the FDA or any
other regulatory authority.

© 2025 Nuvalent, Inc.
All rights reserved.

MC-2500012

Visit us at **booth #413**
or **nuvalent.com**



Get Connected
FREE WIFI

Stay connected throughout the Conference with complimentary WiFi. Simply select the network WCLC2025 and follow the login instructions.

Network Name: **WCLC2025**
Password: **WCLC2025**

Complimentary Public Transportation Pass

WCLC 2025 is pleased to offer delegates a complimentary 4-day public transportation pass, valid on Barcelona's buses, metro, trams, and trains. Passes are available for pickup at the Material Pick Up Desk during the Conference. Travel easily and explore the city while attending WCLC 2025!

For more information scan the QR code or visit:
wclc.iaslc.org/complimentary-public-transport-pass



Let's Get **SOCIAL!**

Stay connected with the IASLC community and get the latest updates on the IASLC World Conference on Lung Cancer (#WCLC25) through our social media channels! Follow us to engage with fellow attendees, access exclusive content, and be the first to know about important announcements and highlights from the Conference.



Share Your
WCLC 2025 Experience!
Tag @IASLC and use #WCLC25

DISCLAIMER

The organizers have made every attempt to ensure that all the information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur due to changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency, and reliability of the content, the organizers accept no responsibility in that regard.

The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. Since its founding in 1974, the association's membership has grown to more than 8,000 lung and thoracic cancer specialists from all disciplines and more than 100 countries.

By hosting global conferences, funding cutting-edge research, and educating the health care community and the public about thoracic cancers, the IASLC works to alleviate the burden lung cancer places on patients, families, and communities.

THE IASLC'S MISSION

Be the multidisciplinary world authority on lung and other thoracic cancers through collaborative science, education, and advocacy in order to ensure optimal prevention and patient care.

THE IASLC'S VISION

Conquering Lung and Other Thoracic Cancers Worldwide in the 21st Century.

IASLC Staff

- Karen Kelly**, Chief Executive Officer
- Elizabeth Donahue**, Chief Financial Officer
- J. Michael Hoehn**, Chief Operating Officer
- Jennifer C. King**, Chief Science Officer
- Matt Yeingst**, Chief Development Officer
- Andrea Alarcon**, Scientific Program Manager
- Ruth Barratt**, Senior Scientific Program Manager
- Tessa Baxter**, Development Program Manager
- Bernina Bijou**, Executive Assistant & Board Liaison
- Becky Bunn**, Director, Strategic Initiatives
- Carey Burgess**, Education Coordinator
- Bailey Creamer**, Editorial Coordinator
- Kathy Doherty**, Director, Human Resources
- Gena Erwin**, Associate Director, Conferences
- Sierra Esparza**, Grants Coordinator
- Thalia Giraldo**, Data Analyst
- Rory Graham**, Web Content Administrator
- Debbie Hadala**, Marketing & Communications Coordinator
- Kelsey Hecker**, Conference Manager
- Kelly Heemsbergen**, Conference Manager
- O'Ryan Jackson**, Development Specialist



- Lauren Karls**, Senior Accountant
- Maggie Lilac**, Sponsorship & Exhibits Coordinator
- Sara Lindsey Patton**, Patient Advocacy Manager
- Sunhee Malinowski**, Controller
- Katie Maher**, Membership Manager
- Courtland Matthews**, Marketing & Communications Manager
- Beanie Montoya**, Associate Director, Marketing & Communications
- Uli Neitzel**, Accountant
- Kahri Nestingen**, Corporate Development Specialist
- Kelly Nevins**, Director, Education
- Alan Nguyen**, Education Coordinator
- Kelsey Petri**, Membership Specialist
- William Sanders**, Scientific Affairs Coordinator
- Savannah Spakes**, Membership Coordinator
- Alexander Watson**, Office Administrator
- Cayla Williby**, Conference Coordinator
- Kelsey Wood**, Director, Membership
- Laura Woodruff**, Education Manager
- Murry Wynes**, Senior Advisor, Scientific Affairs
- Keelan Zius**, Scientific Program Manager

IASLC Board of Directors 2023 - 2025

- President:** Paul Van Schil, Belgium
- Past President:** Heather Wakelee, USA
- President-Elect:** Caicun Zhou, China
- Secretary:** Ming-Sound Tsao, Canada
- Treasurer:** Joachim Aerts, Netherlands
- Chief Executive Officer:** Karen Kelly, USA

Board Members

- Joe Chang, USA
- Carlos Gil Moreira Ferreira, Brazil
- Jhanelle Gray, USA
- Young Tae Kim, Republic of Korea
- Natasha Leighi, Canada
- Morten Quist, Denmark
- Antoni Rosell, Spain
- Lecia Sequist, USA
- Benjamin Solomon, Australia
- Paula Ugalde, USA
- Ignacio Wistuba, USA
- Wen-Zhao Zhong, China

IASLC Board of Directors 2025 - 2027

- President:** Caicun Zhou, China
- Past President:** Paul Van Schil, Belgium
- President-Elect:** Alex A. Adjei, USA
- Secretary:** Benjamin Solomon, Australia
- Treasurer:** Ignacio Wistuba, USA
- Chief Executive Officer:** Karen Kelly, USA

Board Members

- Fredrick Chite Asirwa, Kenya
- Clarissa Baldotto, Brazil
- Joe Chang, USA
- Narjust Florez, USA
- Hidehito Horinouchi, Japan
- Natasha Leighi, Canada
- Isabelle Opitz, Switzerland
- Mary Pasquinelli, USA
- Helmut Prosch, Austria
- Antoni Rosell, Spain
- Tripama Sen, USA
- Motoko Tachihara, Japan
- Jie Wang, China
- Wen-Zhao Zhong, China

WCLC 2025 PROGRAM COMMITTEE

RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

- Co-Chair:** Silvia Novello, Italy
- Co-Chair:** Abhishek Shankar, India
- Marcelo Corassa, Brazil
- Angeline Low, Australia
- Laura Mezquita, Spain
- Ugo Pastorino, Italy
- Biagio Ricciuti, USA
- Conor E Steuer, USA
- Randi Williams, USA

TUMOR BIOLOGY - PRECLINICAL BIOLOGY

- Co-Chair:** Montse Sanchez-Cespedes, Spain
- Co-Chair:** Tripama Sen, USA
- Roberto Bianco, Italy
- David Paul Carbone, USA
- Diego de Miguel Perez, USA
- Carminia Maria Della Corte, Italy
- Mervat El Deftar, Egypt
- Aya El Helali, Ireland
- Mariam Jamal-Hanjani, UK
- Hongbing Ji, China

WCLC 2025 PROGRAM COMMITTEE

TUMOR BIOLOGY - TRANSLATIONAL BIOLOGY

Co-Chair: **Caroline Dive**, UK

Co-Chair: **Deepali Jain**, India

Chiara Ambrogio, Italy

Fiona Blackhall, UK

Milena Cavic, Serbia

Yuchen Han, China

Cheryl Ho, Canada

George Oblitas, Peru

Christian Diego Rolfo, USA

Jon Zugazagoitia, Spain

PULMONOLOGY & STAGING

Co-Chair: **James Huang**, USA

Co-Chair: **Jeremy John Erasmus**, USA

Fredrick Chite Asirwa, Kenya

Zeno Gouw, Netherlands

Anna Rita Larici, Italy

Tracey Leong, Australia

Carole Ridge, UK

Valerie Rusch, USA

Jacob Sands, USA

EARLY-STAGE NON-SMALL CELL LUNG CANCER

Co-Chair: **Tina Cascone**, USA

Co-Chair: **Eric Lim**, UK

Co-Chair: **Ricardo Terra**, Brazil

Antonio Calles, Spain

Kristen Marrone, USA

Yuko Oya, Japan

Martin Reck, Germany

Hisashi Saji, Japan

Pamela Samson, USA

Jonathan Spicer, Canada

Agathe Seguin, France

SCREENING & EARLY DETECTION

Co-Chair: **Long Jiang**, China

Co-Chair: **David Baldwin**, UK

Ricardo Sales dos Santos, Brazil

Thomas Frauentfelder, Switzerland

Anita McGrath, Australia

Rachael Murray, UK

Coral Olazagasti, USA

Betty Tong, USA

Doug Wood, USA

Chi-Fu Yang, USA

PATHOLOGY & BIOMARKERS

Co-Chair: **Beatriz Bellosillo**, Spain

Co-Chair: **Jia Luo**, USA

Co-Chair: **Luisella Righi**, Italy

Lukas Bubendorf, Switzerland

Guilherme Harada, Brazil

Rosalyn Juegens, Canada

Herbert Loong, Hong Kong

Fernando Lopez Rios, Spain

Ellen Caroline Nascimento, Brazil

Cristina Teixeira, Spain

LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

Co-Chair: **Nasser Altorki**, USA

Co-Chair: **Ernest Nadal**, Spain

Co-Chair: **Luisella Righi**, Italy

Monica Castro, Argentina

Kevin Chua, Singapore

Dusty Donaldson, USA

Jessica Donington, USA

Corinne Faivre-Finn, USA

Salma Jabbour, USA

Francesco Passiglia, Italy

Juan Carlos Trujillo Reyes, Spain

WCLC 2025 PROGRAM COMMITTEE

METASTATIC NON-SMALL CELL LUNG CANCER - LOCAL THERAPIES

Co-Chair: **Matthias Guckenberger**, Switzerland

Co-Chair: **Myung-Ju Ahn**, Republic of Korea

Pablo Munoz Schuffenegger, Chile

Anne-Marie Dingemans, Netherlands

Shanker Siva, Australia

Mara Antonoff, USA

Lilian Faroni, Brazil

Patricia Mondragon, Mexico

Gabriela Antelo, Spain

Vanessa Costa Menezes, Brazil

METASTATIC NON-SMALL CELL LUNG CANCER - ANTIBODY-DRUG CONJUGATE AND CYTOTOXIC THERAPY

Co-Chair: **Mauricio Cuello Toledo**, Uruguay

Co-Chair: **Fiona McDonald**, UK

Benjamin Levy, USA

Alfredo Addeo, Switzerland

Riyaz Shah, UK

Sally Lau, USA

Gerard Walls, UK

Deborah Doherty, Ireland

Li Zhang, China

METASTATIC NON-SMALL CELL LUNG CANCER - IMMUNOTHERAPY

Co-Chair: **Misako Nagasaka**, USA

Co-Chair: **Delys Rodriguez-Abreu**, Spain

Co-Chair: **Giannis Mountziros**, Greece

Andres Cardona, Colombia

Seamus Cotter, Ireland

Enriqueta Felip, Spain

Lizza Hendriks, Netherlands

Jin-Hyoung Kang, Republic of Korea

Ola Khorshid, Egypt

Luis Raez, USA

Vamsidhar Velcheti, USA

METASTATIC NON-SMALL CELL LUNG CANCER - TARGETED THERAPY

Co-Chair: **Sewanti Limaye**, India

Co-Chair: **Jordi Remon**, France

Christina Baik, USA

Prunella Blimman, Australia

Laura Book, USA

Charo Campelo, Spain

Luis Corrales, Costa Rica

Alessandra Curioni-Fontecedro, Switzerland

Jianchun Duan, China

Koichi Goto, Japan

Victor Marcondes Lopes dos Santos, Brazil

MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

Co-Chair: **Nicolas Girard**, France

Co-Chair: **Joshua Reuss**, USA

Co-Chair: **Melissa Culligan**, USA

Prasad Adusumilli, USA

John Cho, Canada

Marc de Perrot, Canada

Federica Grosso, Italy

Samina Park, Republic of Korea

Ross Soo, Singapore

SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

Co-Chair: **Luis Paz-Ares**, Spain

Co-Chair: **Motoko Tachihara**, Japan

Noura Choudhury, USA

Julie George, Germany

Antonin Levy, France

Tatiane Montella, Brazil

Alejandro Navarro, Spain

Taofeek K Owonikoko, USA

Angus Pratt, Canada

Junko Tanizaki, Japan

WCLC 2025 PROGRAM COMMITTEE

MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH & PALLIATIVE CARE

Co-Chair: Lucia Viola, Colombia
Co-Chair: Santiago Viteri, Spain
 Cristiane Bergerot, Brazil
 Caitlin Broderick, Australia
 Elizabeth Castronovo, USA
 Rafał Działdziejzko, Poland
 Juan Carlos Laguna, Spain
 Stephanie McDonald, USA
 Beth Sandy, USA

GLOBAL HEALTH, HEALTH SERVICES, & HEALTH ECONOMICS

Co-Chair: Clarissa Mathias, Brazil
Co-Chair: Navneet Singh, India
 Sze Wai Chan, South Africa
 Verna Vanderpuye, Ghana
 Annie Wong, New Zealand
 Drew Moghanaki, USA
 Matthew Evison, UK
 Tomohito Saito, Japan
 Emmet O'Brien, Ireland
 Samuel Kareff, USA

PATIENT ADVOCACY

Co-Chair: Luciana Holtz, Brazil
Co-Chair: Cecilia Pompili, UK
 Sydney Barned, USA
 Daniel Black, Switzerland
 Lauren Pretorius, South Africa
 Maria Clara Rodriguez, Uruguay
 Eric Singhi, USA
 Antoinette Wozniak, USA

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Alfredo Addeo, Switzerland	Luis Corrales, Costa Rica
Prasad Adusumilli, USA	Francesco Cortiula, Netherlands
Myung-Ju Ahn, Republic of Korea	Mauricio Cuello, Uruguay
Nasser Khaled Altorki, USA	Melissa Culligan, USA
Chiara Ambrogio, Italy	Gianluigi De Gennaro, Italy
Mihaela Angelova, UK	Diego de Miguel Perez, USA
Gabriela Antelo, Spain	Fabio de Moraes, Canada
Mara Antonoff, USA	Marc de Perrot, Canada
Marisol Arroyo Hernández, Mexico	Carminia Maria Della Corte, Italy
Fredrick Asirwa, Kenya	Jules Derks, Netherlands
Lekan Ayo-Yusuf, South Africa	Anne-Marie Dingemans, Netherlands
Christina Baik, USA	Caroline Dive, UK
Amanjit Bai, India	Dusty Donaldson, USA
Clarissa Baldotto, Brazil	Victor dos Santos, Brazil
David Baldwin, UK	Jian Chun Duan, China
Sydney Barned, USA	Mary Duffy, Australia
Upal Basu Roy, USA	Jazmin Eckhaus, Australia
Beatriz Bellosillo, Spain	Aya El Helali, China
Cristiane Bergerot, Brazil	Lawson Eng, Canada
Roberto Bianco, Italy	Jeremy Erasmus, USA
Andrea Billé, UK	Matthew Evison, USA
Fiona Blackhall, UK	Lilian Faroni, Brazil
Caitlin Broderick, Australia	Enriqueta Felip, Spain
Lukas Bubendorf, Switzerland	Thomas Frauenfelder, Switzerland
Antonio Calles, Spain	Naoki Furuya, Japan
Maria Rosario Campelo, Spain	Thomas Gaisi, Switzerland
David Carbone, USA	Julie George, Germany
Andrés F. Cardona, Colombia	Ritu Gill, USA
Tina Cascone, USA	Nicolas Girard, France
Mónica Castro, Argentina	Koichi Goto, Japan
Milena Cavic, Serbia	Zeno Gouw, Netherlands
Fabiana Cecere, Italy	Dario Gregori, Italy
Jamie Chaff, USA	Federica Grosso, Italy
Sze Wai Chan, South Africa	Matthias Guckenberger, Switzerland
Veronica Cheung, Australia	Balazs Halmos, USA
John Cho, Canada	Yuchen Han, China
Noura Choudhury, USA	Guilherme Harada, Brazil
Kevin Chua, Singapore	Lizza Hendriks, Netherlands
Esther Conde, Spain	Merel Hennink, Netherlands
Terri Conneran, USA	Cheryl Ho, Canada
Marcelo Corassa, Brazil	Luciana Holtz, Brazil

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Hidehito Horinouchi, Japan
 James Huang, USA
 Salima Jabbour, USA
 Deepali Jain, India
 Hongbin Ji, China
 Long Jiang, China
 Tom John, Australia
 Melissa Johnson, USA
 Rosalyn Juergens, Canada
 Jin Hyoung Kang, Republic of Korea
 Ryohei Katayama, Japan
 Ola Khorsid, Egypt
 Aki Kobayashi, Japan
 Juan Carlos Laguna, Spain
 Anna Rita Larici, Italy
 Sally Lau, USA
 Chee Khoon Lee, Australia
 Jay Lee, USA
 Tracy Leong, Australia
 Antonin Levy, France
 Benjamin Levy, USA
 Sun Min Lim, Republic of Korea
 Herbert Loong, China
 Gilberto Lopes, USA
 Fernando Lopez-Rios, Spain
 Angelina Low, Australia
 Jia Luo, USA
 Margherita Majem, Spain
 Alessandro Mariani, Brazil
 Kristen Marrone, USA
 Celine Mascaux, France
 Clarissa Mathias, Brazil
 Julien Mazieres, France
 Stephanie McDonald, USA
 Anita McGrath, Australia
 Vanessa Costa Menezes, Brazil
 Jessica Menis, Italy
 Laura Mezquita, Spain
 Satoru Miura, Japan
 Drew Moghanaki, USA
 Tatiane Montella, Brazil
 Giannis Mountzios, Greece
 Pablo Munoz Schuffenegger, Chile
 Rachael Murray, UK
 Ernest Nadal, Spain
 Misako Nagasaka, USA
 Ellen Nascimento, Brazil
 Alejandro Navarro, Spain
 Calvin Ng, Hong Kong

Silvia Novello, Italy
 Emmet O'Brien, Ireland
 Mary O'Brien, UK
 Deborah O'Doherty, Ireland
 George Oblitas, Peru
 Coral Olazagasti, USA
 Yuko Oya, Japan
 Giovanni Pappagallo, Italy
 Kaushal Parikh, USA
 Samina Park, Republic of Korea
 Sehhoon Park, Republic of Korea
 Francesco Passiglia, Italy
 Ugo Pastorino, Italy
 Luis Paz-Ares, Spain
 Giuseppe Pelosi, Italy
 Cecilia Pompili, UK
 Angus Pratt, Canada
 Arselia Prelaj, Italy
 Lauren Pretorius, South Africa
 Morten Quist, Denmark
 Luis Raez, USA
 Sara Ramella, Italy
 Meredith Ray, USA
 Martin Reck, Germany
 Jordi Remon, France
 Joshua Reuss, USA
 Biagio Ricciuti, USA
 Carole A Ridgely, UK
 Luisella Righi, Italy
 Maria Clara Rodriguez, Uruguay
 Rafael Roselli, Spain
 Rossana Ruiz, Peru
 Valerie Rusch, USA
 Tomohito Saito, Japan
 Hisashi Saji, Japan
 Pamela Samson, USA
 Montse Sanchez, Spain
 Jacob Sands, USA
 Yoshitaka Sekido, Japan
 Triparna Sen, USA
 Riyaz Shah, UK
 Abhisek Shankar, India
 Mahdi Sheikh, France
 Lynette Sholl, USA
 Navneet Singh, India
 Pawan Kumar Singh, India
 Eric Singhi, USA
 Shankar Siva, Australia
 Matthew Smeltzer, USA

WCLC 2025 INTERNATIONAL ABSTRACT REVIEW COMMITTEE

Ross Andrew Soo Lai Kit, Singapore
 Conor Steuer, USA
 Motoko Tachihara, Japan
 Junko Tanizaki, Japan
 Cristina Teixido, Spain
 Anish Thomas, USA
 Juan Carlos Trujillo, Spain
 Mylene Truong, USA
 Lucia Viola, Colombia
 Santiago Viteri, Spain
 Rozemarijn Vliegenthart, Netherlands
 Gerard Walls, UK
 Randi Williams, USA
 Annie Wong, New Zealand
 Douglas Wood, USA
 Antoinette Wozniak, USA
 Chi-Fu Yang, USA
 Soo-Ryum Yang, USA
 Li Zhang, China
 Wen-Zhao Zhong, China
 Qing Zhou, China
 Jon Zugazagoitia, Spain

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Adi F. Gazdar IASLC Merit Award proudly recognizes Dr. Gazdar and honors his lifelong dedication to lung cancer research and his pioneering work in molecular pathology.



ADI F. GAZDAR IASLC MERIT AWARD

Pasi A. Jänne

USA

Dr. Pasi Jänne is Senior Vice President for Translational Medicine at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and holds the David M. Livingston, MD Chair at Dana-Farber. He also directs the Belfer Center for Applied Cancer Science and the Chen-Huang Center for EGFR Mutant Lung Cancers. Dr. Jänne received his MD and PhD from the University of Pennsylvania School of Medicine, completed his internship and residency at Brigham and Women's Hospital, along with a fellowship in medical oncology through the combined Dana-Farber Cancer Institute/Massachusetts General Hospital program. In 2002, he earned a Master's Degree in Clinical Investigation from Harvard University.

Dr. Jänne is internationally recognized for his contributions to the understanding and treatment of lung cancer, particularly for co-discovering EGFR mutations. His research combines laboratory science with translational research and clinical trials, focusing on the therapeutic importance of oncogenic alterations in lung cancer. His work has led to numerous seminal discoveries and the development of multiple clinical trials. He has received honors from the American Association for Cancer Research, the European Society for Medical Oncology, the American Society of Clinical Oncology, and the American Cancer Society, which awarded him the Medal of Honor.

Dr. Jänne has been actively involved with the IASLC, contributing to its mission through scientific presentations, participation on the Education Committee (2011–2015), and serving on the Board of Directors (2013–2017).

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The Joseph W. Cullen Prevention/Early Detection Award recognizes an IASLC scientist for a lifetime achievement in the prevention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the National Cancer Institute, Division of Cancer Prevention and Control. He created the Smoking, Tobacco and Cancer Program at the NCI in 1982.



JOSEPH W. CULLEN PREVENTION / EARLY DETECTION AWARD

Witold Rzyman

POLAND

Prof. Witold Rzyman is Chief Surgeon of the Department of Thoracic Surgery at the Medical University of Gdańsk and the Provincial Hospital for Lung Diseases in Prabuty, Poland. He began his medical career in 1986 as a general and vascular surgeon and transitioned to thoracic surgery in 1993. He has served as Poland's National Consultant in Thoracic Surgery and is a board member of the Polish Society of Cardiothoracic Surgery.

Prof. Rzyman has authored over 122 scientific publications and is recognized for his work in minimally invasive surgery and multimodality treatment of thoracic malignancies. He co-leads the Gdańsk Lung Cancer Research Group and oversees biobanking initiatives. He is also a leader in lung cancer screening, having authored Poland's national LCS consensus statement and served on the Steering Committee for the national pilot program (2020–2023). He has led four major grants supporting LDCT-based screening and molecular diagnostics, collectively screening over 18,000 individuals.

Prof. Rzyman has been thoroughly engaged with the IASLC through his service on the Early Detection and Screening Committee (2017–2027) and as Associate Editor of International Lung Cancer News. In 2024, he received the IASLC Regional Cancer Care Team Award.

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The **Mary J. Matthews Pathology/Translational Award** recognizes an IASLC scientist for lifetime achievement in pathology and translational research of thoracic malignancies. **Mary J. Matthews** served as a senior investigator and pathologist at the National Cancer Institute. She was a pioneer in defining the histologic subtypes of lung cancer.



MARY J. MATTHEWS PATHOLOGY / TRANSLATIONAL RESEARCH AWARD

Sanja Dacic

USA

Dr. Sanja Dacic is Professor of Pathology, Vice Chair and Director of Anatomic Pathology, and Director of Thoracic Pathology at Yale School of Medicine. She earned her MD and PhD from the University of Zagreb in Croatia. Dr. Dacic completed her residency in anatomic and clinical pathology at the University of Pittsburgh, along with a fellowship in surgical thoracic pathology. Immediately following, she joined as faculty, serving as Professor of Pathology at the University of Pittsburgh, Director of Anatomic Pathology at UPMC Presbyterian Hospital, Director of Thoracic Pathology Center of Excellence and Interim Director of the Molecular Anatomic Pathology.

Dr. Dacic's research focuses on diagnostic pulmonary and molecular pathology, with extensive work in lung cancer and pleural mesotheliomas. She has authored over 200 peer-reviewed publications, book chapters, and guidelines. She was a co-author for the 4th edition and an editorial board member for the 5th edition of the WHO Classification of Thoracic Tumors. She currently serves as a Deputy Editor-in-Chief of Archives of Pathology & Laboratory Medicine and as an editorial board member of several high-impact journals.

Dr. Dacic has been a dedicated member of the IASLC, serving on the Pathology Committee (2011-2027) and chairing the group (2023-2025). She has contributed to WCLC as invited faculty, abstract reviewer, and program committee member since 2011. In 2020, she received the IASLC Fred R. Hirsch Lectureship Award for Translational Research.

Congratulations

2025 DISTINGUISHED SERVICE AWARD WINNERS

The IASLC Distinguished Service Awards will be presented during the Opening Plenary Session on **Saturday, September 6, 16:15 – 17:45.**

The **Paul A. Bunn, Jr. Scientific Award** recognizes an IASLC scientist for a lifetime achievement of scientific contributions to thoracic cancer research. The award is named after IASLC's longtime CEO, **Paul A. Bunn, Jr.**, whose studies set worldwide standards for the treatment of lung cancer.



PAUL A. BUNN, JR. SCIENTIFIC AWARD

Solange Peters

SWITZERLAND

Prof. Solange Peters is a Full Professor and Director of Medical Oncology, along with the Thoracic Malignancies Program within the Department of Oncology at the University Hospital of Lausanne in Switzerland. She earned her MD and PhD at the University Hospital of Lausanne and completed clinical training in medical oncology and molecular biology in Switzerland and Italy.

Prof. Peters' research interests span new biomarkers discovery and validation in preclinical and clinical settings, multimodality strategies for locally advanced non-small cell lung cancer (NSCLC), as well as cancer immunotherapy. She has authored over 500 peer-reviewed manuscripts and book chapters and serves as Associate Editor for Annals of Oncology and ESMO Open. She is the former Editor-in-Chief of Lung Cancer and continues to serve on several editorial boards. She holds prominent leadership roles, including President of Oncosuisse, President of the Swiss Academy of Multidisciplinary Oncology, Vice Director of the Swiss National Cancer League, and Strategic Advisory Board President for the Paris Saclay Cancer Cluster.

Prof. Peters has been a long-time supporter of the IASLC, acting as past Deputy Editor of the Journal of Thoracic Oncology (JTO), serving to enhance the collaborative educational programs of the IASLC and ESMO, participating on the Publications Committee (2011-2017), and serving on the Board of Directors (2013-2017).

Congratulations IASLC 2025 LECTURESHIP AWARD WINNERS

SUNDAY, SEPTEMBER 7, 2025

The following IASLC Lectureship Awards will be presented during the Presidential Symposium 1 on **Sunday, September 7, 08:15 - 10:30.**

Robert J. Ginsberg Lectureship Award for Surgery

Andrea Wolf, USA

James D. Cox Lectureship Award for Radiation Oncology

Suresh Senan, Netherlands

IASLC Lectureship Award for Tobacco Control and Smoking Cessation

Lawson Eng, Canada

MONDAY, SEPTEMBER 8, 2025

The following IASLC Lectureship Awards will be presented during the Presidential Symposium 2 on **Monday, September 8, 08:15 - 10:30.**

Tsuguo Naruke Lectureship Award for Surgery

Kazuhiro Asufuku, Canada

Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Ying Cheng, China IN MEMORIAM

TUESDAY, SEPTEMBER 9, 2025

The following IASLC Lectureship Awards will be presented during the morning Plenary Session on **Tuesday, September 9, 08:30 - 10:30.**

Clifton F. Mountain Lectureship Award for Staging

Jin Mo Goo, Republic of Korea

Fred R. Hirsch Lectureship Award for Translational Research

Mary Beth Beasley, USA

Daniel C. Ihde Lectureship Award for Medical Oncology

Lizza Hendriks, Netherlands

Congratulations WCLC 2025 EDUCATION AWARD WINNERS

All WCLC 2025 Education Award Winners will be presented with their award during the IASLC Award Luncheon on **Saturday, September 6, 11:30 - 13:00.**

EARLY CAREER EDUCATION AWARDS

Hanie Abofathi, Canada

Abstract #: MA07.04

Abstract Title: Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma

Alessandro Leonetti, Italy

Abstract #: MA02.05

Abstract Title: Liquid Biopsy in BRAF V600E NSCLC Treated with Dabrafenib Plus Trametinib: Final Analysis of LIBRA Study (GOIRC-03-2020)

Yin Li, China

Abstract #: P2.02.01

Abstract Title: Characterizing UPPI Expression in Non-Tumor Cells of Lung Cancer and Its Clinical Implications

Elham Khodayari Moez, Canada

Abstract #: MA05.06

Abstract Title: Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts

Ezekiel Olumuyide, USA

Abstract #: P3.03.13

Abstract Title: HLA II Genetics Shapes Lung Cancer Immunosurveillance

Masahiro Torasawa, Japan

Abstract #: P3.03.36

Abstract Title: Whole Genome Doubling Drives Genomic Instability and Poor Postoperative Outcomes in Stage I Driver-Negative Lung Adenocarcinoma

Sarah Waliyany, USA

Abstract #: MA02.01

Abstract Title: Contemporary Landscape of Acquired Resistance to Next-Generation ALK Inhibitors: Paired Pre-/Post-Treatment Biopsy Analysis

Runchen Wang, China

Abstract #: P1.07.01

Abstract Title: Wearable-Based Evaluation of Tubeless Thoracic Surgery for Early-Stage Lung Cancer

Xiao Wang, USA

Abstract #: MA06.01

Abstract Title: Real-World Outcomes of First-Line Immunotherapy Intensification of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)



Discover the many individuals advancing IASLC's mission by visiting the **IASLC Awards Alley**, located at the **entrance to the Exhibit Hall**. Explore overviews of IASLC award winners, grant recipients, and program participants, and learn about IASLC committees and their ongoing projects.

Congratulations
**WCLC 2025
 EDUCATION AWARD WINNERS**

DEVELOPING COUNTRIES EDUCATION AWARDS

Ayah Al-Bzour, Jordan

Abstract #: P3.03.31
Abstract Title: Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients with Lung Adenocarcinoma

Gabriela Carmona De Souza, Brazil

Abstract #: OA18.02
Abstract Title: Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050

Yanan Cui, China

Abstract #: MA11.10
Abstract Title: IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer

Maria Raquel Gomes Fernandes, Brazil

Abstract #: PT1.03.03
Abstract Title: Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles

Zixuan Hu, China

Abstract #: P3.03.43
Abstract Title: Gut Klebsiella Pneumoniae Drives Lung Cancer Progression by Modulating Macrophage Hpgds and Suppressing the PGJ2-PPAR γ Signaling Pathway

Guang-Ling Jie, China

Abstract #: P3.03.14
Abstract Title: PCSK9-Mediated Immune Escape as a Mechanism of Acquired Resistance to PD-1/PD-L1 Blockade

Shangbiao Li, China

Abstract #: OA14.02
Abstract Title: DCBLD2high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance

Shencheng Ren, China

Abstract #: P2.02.30
Abstract Title: Targeting MTA2 Lactylation as a Therapeutic Strategy to Overcome Chemoresistance in Lung Adenocarcinoma

Haojie Si, China

Abstract #: OA11.04
Abstract Title: Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-small Cell Lung Cancer Receiving Neoadjuvant Therapy

Osama Younis, Jordan

Abstract #: P2.10.11
Abstract Title: Single-Cell RNA Sequencing Identifies ALCAM and Gpmb as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung

Abstract #: P2.10.09

Abstract Title: Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-small Cell Lung Cancer

Abstract #: P2.06.62

Abstract Title: Integrin- β 6 Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma

Congratulations
**WCLC 2025
 EDUCATION AWARD WINNERS**

NURSE OR ALLIED HEALTH PROFESSIONAL AWARDS

Aline Barreto, Brazil

Abstract #: EP15.01
Abstract Title: Anorexia, an Underreported Adverse Event, Predicts Mortality in Lung Cancer Patients

Jaimini Patoliya, India

Abstract #: P3.01.14
Abstract Title: The Rising Toll: Global Burden and Future Projections of Tracheal, Bronchus, and Lung Cancer in Women, 1990-2050

Feifei Huang, China

Abstract #: P2.15.07
Abstract Title: Effect of Message Framing in a Digital Lung Cancer Screening Decision Navigation Intervention: A Three-Arm Randomized Controlled Trial

**TOBACCO CONTROL AND SMOKING
 CESSATION AWARDS**

EARLY CAREER

Lawson Eng, Canada

Abstract #: OA11.01
Abstract Title: Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database

DEVELOPING COUNTRIES

Durre Aden, India

Abstract #: EP01.27
Abstract Title: Gender and Tobacco Use Status Shape Support for Endgame Strategies in India

PATIENT ADVOCACY EDUCATION AWARDS

Anne Fidler, Australia

Bernard Gaspar, Spain

Micki Goldfrain, Israel

Mami Hanada, Japan

Virginia Harrison, UK

Vendi Jukic Buca, France

Wee-Hau Lee, Singapore

Omoghemiinyi Ojole, Nigeria

Urvashi Prasad, India

Sanjeev Sharma, India

Ashley Vassallo, USA

Suzanne Vincze, USA

Congratulations IASLC INTERNATIONAL MENTORSHIP PROGRAM PARTICIPANTS

Oussama Aazzane, Morocco
 Abstract #: P2.10.07

Abstract Title: Combined Immunoscoring for Predictive Stratification of Unresectable Non-small Cell Lung Cancer

Huizhao Hong, China
 Abstract #: OA03.01

Abstract Title: Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis

Zi-Xuan Rong, China
 Abstract #: OA03.04

Abstract Title: TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy

Nattanit Suriyaphan, Thailand
 Abstract #: P3.12.28

Abstract Title: Association of PD-L1 Expression with Clinical Outcome in Advanced NSCLC with ALK Rearrangement

Weng-Fang Tang, China
 Abstract #: OA03.02

Abstract Title: Deciphering Genomic Evolution of Metastatic Organotropism with Large-Scale Paired Primary Lung Cancers and Metastases

Pragadeesh Thamaraiselvan, India
 Abstract #: P3.01.21

Abstract Title: Lifting the Smoke Screen: A Real-World Comparative Study of Lung Cancer in Never-Smokers Versus Ever-Smokers

Rogelio Velasco Jr., Philippines
 Abstract #: P1.11.79

Abstract Title: A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs

Yanpei Zhang, China
 Abstract #: P2.02.33

Abstract Title: Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer

Abstract #: P2.08.59

Abstract Title: SCGB1A1 Enhances Radioimmunotherapy Efficacy and Mitigates Pulmonary Toxicity via Dendritic Cell Functional Reprogramming

International Mentorship Program supported by

Johnson & Johnson



A MAZING CASE RACE

RACING TOWARD IMPACT

Explore a series of compelling, real-world thoracic oncology cases featured in the Amazing Case Race. Displayed throughout the conference venue, each case showcases clinical decision-making at its finest. Review the cases, consider the challenges, and vote for the one you think stands out.


SCAN THE QR CODE TO CHECK WHO'S LEADING THE RACE AND CAST YOUR VOTE FOR YOUR FAVORITE CASE!



WHERE TO FIND THE CASES? FIND THE COMPETING CASES ON DISPLAY BOARDS THROUGHOUT THE WCLC 2025 VENUE.


PROGRAM AT A GLANCE

Monday, September 8, 2025



PROGRAM AT A GLANCE

Tuesday, September 9, 2025



PROGRAM AT A GLANCE

INDUSTRY SPONSORED SYMPOSIA

Saturday, September 6, 2025

09:00 - 10:00	IS01: Industry Sponsored Symposium by AstraZeneca: Preparing NSCLC for the Future of Diagnostic Biomarker Testing	IS02: Industry Sponsored Symposium by Eli Lilly and Company: Precision Starts Early: The Evolving Role of Biomarker Testing in Early-Stage NSCLC
10:30 - 11:30	IS04: Industry Sponsored Symposium by Daiichi Sankyo and MSD: Empowering Clinicians in SCLC Management: Key Insights on Diagnosis, Treatment, and Emerging Strategies	IS06: Industry Sponsored Symposium by Pfizer: Sustained Clinical Benefit in 1L ALK+ aNSCLC: How to Optimise Outcomes for Our Patients
12:00 - 13:00	IS05: Industry Sponsored Symposium by Abbvie: What SEZ6 Says About Small Cell Lung Cancer (SCLC) and Neuroendocrine Neoplasms (NENS)	IS08: Industry Sponsored Symposium by Accord Healthcare: Recent Developments in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
13:30 - 14:30		

Sunday, September 7, 2025

13:45 - 14:45	IS11: Industry Sponsored Symposium by AstraZeneca: Maximising a Multidisciplinary Approach: Shaping the Future of Lung Cancer Care with Immunotherapy	IS12: Industry Sponsored Symposium by Johnson & Johnson: Advancing EGFR-mutant NSCLC Care	IS13: Industry Sponsored Symposium by Nuvation Bio Inc.: Under the Micro-Scope: Focusing on ROS1+ NSCLC	IS14: Industry Sponsored Symposium by Regeneron: NSCLC Reimagined: Novel Treatment Strategies in Advanced NSCLC
18:30 - 19:30	IS15: Industry Sponsored Symposium by Natera: Signatera Ultrasensitive MRD Testing for Lung Cancer			

Monday, September 8, 2025

13:45 - 14:45	IS16: Industry Sponsored Symposium by Daiichi Sankyo, Inc.: Multidisciplinary Care for Patients with Brain Metastases in EGFRm NSCLC or SCLC	IS17: Industry Sponsored Symposium by Boehringer Ingelheim International GmbH: Targeted Therapies, Personalized Care: Patient-Centered Advances for the Treatment of NSCLC and SCLC	IS18: Industry Sponsored Symposium by MSD: A Decade of Progress: Advances in Immunotherapy for NSCLC?	IS19: Industry Sponsored Symposium by AstraZeneca: Metastatic EGFRm NSCLC: Adapting to Patients, Grounded in Evidence
---------------	---	--	--	--

PROGRAM AT A GLANCE

SATELLITE CME SYMPOSIA

Saturday, September 6, 2025

10:30 - 11:30	IS03: Satellite EBAC/CME Symposium by Answers in CME on Behalf of Daiichi Sankyo, Inc.: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes
13:30 - 14:30	IS07: Satellite EBAC/CME Symposium by PeerVoice on behalf of Bayer: Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
15:00 - 16:00	IS09: Satellite CME Symposium by Physicians' Education Resource on Behalf of Summit Therapeutics, Inc.: A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sunday, September 7, 2025

18:30 - 19:30	IS10: Satellite CME Symposium by Physicians' Education Resource on Behalf of AstraZeneca: Tumor Board: Advances in Managing EGFR-Mutant NSCLC – Applying Evidence Across the Disease Continuum
---------------	---



PROGRAM:
SATURDAY




Find WCLC News at **ILCN.org**

Stay informed on the latest from #WCLC25 at [ILCN.org](https://www.ilcn.org)
the official news source of the IASLC, the only global association
dedicated to the multidisciplinary study of lung cancer.



 **IASLC 2025 World
Conference on Lung Cancer**
SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN



FRIDAY, SEPTEMBER 5, 2025

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

08:00 – 16:00 IASLC ACADEMY WORKSHOP
(BY INVITATION ONLY)

ROOM 12

08:00 – 16:00 IASLC STAGING COMMITTEE MEETING
(BY INVITATION ONLY)

ROOM 10

SATURDAY, SEPTEMBER 6, 2025

07:30 – 11:30 IASLC PARTNERS FOR THORACIC CANCER CARE MEETING
(BY INVITATION ONLY)

MEETING ROOM C

NOT FOR CME CREDIT

**08:15 – 09:45 WS01 - HUMANS HELPING HUMANS: OVERCOMING
COMPASSION FATIGUE AND BUILDING RESILIENCE IN
ONCOLOGY CARE**

ROOM 10

NOT FOR CME CREDIT

Chair: Shani Shilo, Israel

08:15 Welcome & Introduction
Shani Shilo, Israel

08:20 WS01.02 Impact of Compassion Fatigue and Resilience-Building Strategies
Jennifer Bickel, USA

08:40 WS01.03 Panel Discussion:
Clarissa Mathias, Brazil, Elaine Shum, USA, Fred Hirsch, USA, Maria Mathias, Brazil

09:40 Q&A



HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

08:15 - 09:45 WS02 - PERSONALIZING APPROACHES TO SCLC: TRANSLATING NEW UNDERSTANDINGS OF SCLC HETEROGENEITY INTO BIOMARKER-DRIVEN SMALL CELL LUNG CANCER THERAPIES

ROOM 09

Chair: Anne Chiang, USA

08:15 Welcome & Introduction
Anne Chiang, USA

Part 1 - "Tissue is the Issue": Best Practices and New Technologies in SCLC

08:20 WS02.01 - Panel Discussion

Moderator: SoYeon Kim, USA

Panelists: Ignacio Wistuba, USA, Alberto Chiappori, USA, Kurt Schalper, USA, Alexander Bagaev, USA, Zsolt Megyesfalvi, Austria

Part 2: Translating New Understanding of SCLC Subtypes and Biology to the Clinic

Moderator: Nan Sethakorn, USA

08:50 WS02.02 - New Insights into SCLC Biology and Subtypes

Lauren Byers, USA

09:10 WS02.03 - Biomarker-driven Clinical Trials

Anne Chiang, USA

09:25 WS02.04 - Translational Approaches to Studying SCLC

Ana Ortega Franco, UK

09:40 Q&A

08:30 - 11:30 WS03.01 - EARLY CAREER INVESTIGATOR WORKSHOP - PART 1

ROOM 03

Chairs: Sabita Jivnani, India and Jair Bar, Israel and Zhaohui Arter, USA and Ticiana Leal, USA

Panelists: Keith Kerr, Canada, Carl Ferreira, Brazil

Part 1: Oncology Career Strategies: Navigate, Network, and Thrive

08:30 Welcome & Introduction

Jair Bar, Israel

08:37 WS03.01.02 - Study Design 101: Key Study Types, Critical Components, and Pitfalls to Avoid

Jair Bar, Israel

08:45 WS03.01.03 - Biostatistic Basics: Sample Size, Statistical Plan, and Key Concepts

Matthew Smeltzer, USA

08:54 WS03.01.04 - From Bench to Bedside: A Translational Study

Arianna Marinello, France

09:03 WS03.01.05 - Panel Discussion: Translational Study

Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:12 WS03.01.06 - Learning from Practice: A Real-World Study

Rafeh Naqash, USA

09:21

WS03.01.07 - Panel Discussion: Real-World Study

Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:30

WS03.01.08 - Clinical Trials in Action: A Clinical Trial Study

Chul Kim, USA

09:39

WS03.01.09 - Panel Discussion: Clinical Trial Study

Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:48

WS03.01.10 - Summary

Matthew Smeltzer, USA, Patrick Forde, USA, Alessandra Curioni, Switzerland

09:53

Break

Part 2: Oncology Career Strategies: Navigate, Network, and Thrive

09:58 WS03.01.11 - The Importance of Career Development in Thoracic Oncology

Tindara Franchina, Italy

10:03 WS03.01.12 - Charting Your Course: Making the Most from Early to Mid-Career

Naijust Florez, USA

10:13 WS03.01.13 - Bridging the Gap: Cultivating Your Role as a Clinician-Scientist in Oncology

Jonathan David Spicer, Canada

10:23 Q&A

10:28 WS03.01.14 - Panel Discussion: Navigating Different Phases and Diverse Pathways in Lung Cancer

Moderator: Sabita Jivnani, India

Panelists: David Moore, UK, Fiona Hegi-Johnson, Australia, Clarissa Baldoito, Brazil, Linda Martin, USA, Mihaela Aldea, USA, Navneet Singh, India

11:03 Q&A

11:08 WS03.01.15 - Unlocking Career Growth: How IASLC Can Boost Your Professional Development

Karen Kelly, USA

Early Career Investigator Workshop will continue at 13:00.

08:30 - 11:30

WS04 - JOINT IASLC-CSCO-CAALC SESSION: GLOBAL PERSPECTIVES IN LUNG CANCER TREATMENT: TACKLING REAL-WORLD CHALLENGES TOGETHER

ROOM 06

NOT FOR CME CREDIT

Chairs: Karen Kelly, USA, Yi Long Wu, China, Caicun Zhou, China, Chunxue Bai, China, Si-Yang Liu, China, Fei Zhou, China, Dawei Yang, China

08:30 Welcome & Introduction Including Statement of the Objectives of the Session

Karen Kelly, USA, Yi Long Wu, China, Caicun Zhou, China, Chunxue Bai, China, Si-Yang Liu, China, Fei Zhou, China, Dawei Yang, China

08:40 WS04.02 - Case Scenario 1: Early-Stage Lung Cancer

Dawei Yang, China

08:45 WS04.03 - Case Scenario 1: Panel Discussion

Moderators: Chunxue Bai, China, Dawei Yang, China

Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China

09:05 WS04.04 - Case Scenario 2: Locally Advanced Lung Cancer

Si-Yang Liu, China

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

09:10	WS04.05 - Case Scenario 2: Panel Discussion <i>Moderators: Yi Long Wu, China, Si-Yang Liu, China</i> <i>Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China, Keith Kerr, Canada, Carl Ferreira, Brazil</i>
09:30	WS04.06 - Case Scenario 3: Metastatic Lung Cancer <i>Fei Zhou, China</i>
09:35	WS04.7 - Case Scenario 3: Panel Discussion <i>Moderators: Caicun Zhou, China, Fei Zhou, China</i> <i>Panelists: Helmut Prosch, Austria, Mara Antonoff, USA, Feng-Ming Kong, China</i>
09:55	Take Away Message from Each Panelist
10:05	Interactive Audience Polling
10:22	WS04.8 - A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC <i>Di Liu, China</i>
10:28	WS04.9 - Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study <i>Pengxin Zhang, China</i>
10:34	WS04.10 - Clinical Outcomes and Single-Cell Map of Neoadjuvant Immunochemotherapy for Stage II-IIIb LS-SCLC: A Real-World Study <i>Chen Huang, China</i>
10:40	WS04.11 - Discussant WS04.08 - WS04.10 <i>Qian Chu, China</i>
10:49	Q&A
10:54	WS04.12 - Efficacy and Safety of TQB2102, a Biparatopic HER2-Targeting ADC, in HER-2 Aberrant NSCLC: A Phase II Study <i>Li Zhang, China</i>
11:00	WS04.13 - Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study <i>Jie Wang, China</i>
11:06	WS04.14 - IF16-High Cancer-Associated Fibroblasts Impede Immunotherapy Response in NSCLC <i>Leyi Lin, China</i>
11:12	WS04.15 Discussant WS04.12 - WS04.14 <i>Xiuning Le, USA</i>
11:21	Q&A
11:26	Closing Remarks

08:30 - 11:30**WS05 - IASLC / IMIG WORKSHOP****ROOM 07**

NOT FOR CME CREDIT

*Chair: Aaron Mansfield, USA***08:30****Welcome & Introduction**
*Aaron Mansfield, USA***08:35****WS05.02 - Update on ASCO Guidelines for Mesothelioma, Reconciling Controversies in Management**
*Hedy Kindler, USA***08:50****WS05.03 - Novel Minimally Invasive Surgical Approaches**
*Stefan Watzka, Austria***09:05****WS05.04 - Applications of Radiation in Mesothelioma**
*Crispin Hiley, UK***09:20****WS05.05 - Young Investigator: Treatment of Mesothelioma After First Line Immunotherapy**
*Cornedine de Gooijer, Netherlands***09:35****WS05.06 - Young Investigator: Impact of Soluble Mesothelin on Mesothelin-Targeting Therapies**
*Katherine Smith, USA***09:50****Q&A****09:55****WS05.07 - Clinical and Pathologic Phenotyping of Mesotheliomas Developing in Carriers of Germline BAP1 Mutations**
*Michele Carbone, USA***10:10****WS05.08 - Young Investigator: Impact of Epigenetic Alterations in Mesothelioma: Methods of Analysis of DNA Methylation in Mesothelioma Diagnosis**
*Janah Vandenhoeck, Belgium***10:25****WS05.09 - Young Investigator: AI/Deep Learning and Transcriptomic Profile to Improve Classification and Response to Treatment**
*Nicolas Alcalá, France***10:40****WS05.10 - Panel Discussion: Diagnostic Dilemmas in Mesothelioma: Diving into the Differential**
*Françoise Galateau-Salle, France & Sonja Klebe, Australia***11:00****WS05.11 - Bench to Bedside: Impact of Genomics of Treatment of Mesothelioma**
*Thomas John, Australia***11:20****Q&A****11:25****Closing Remarks**
Arnaud Scherpereel, France

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

08:30 - 11:30 WS06.01 - 2025 IASLC CT SCREENING SYMPOSIUM
(TICKETED SESSION)

ROOM 08



Chairs: Rudolf Huber, Germany, Catherine Jones, Australia, Antoni Rosell, Spain, Betty Tong, USA, Milena Cavic, Serbia

08:30 Welcome & Introduction
Milena Cavic, Serbia

08:35 Group Work

09:00 WS06.01.01 - Introduction to Session 1: Designing an Optimal Lung Cancer Screening Program
Rudolf Huber, Germany

09:05 WS06.01.02 - Australia National Lung Cancer Screening Program
Miranda Siemienowicz, Australia

09:15 WS06.01.03 - Inclusion of Smoking Cessation in a LCS Program
Stephanie Land, USA

09:25 WS06.01.04 - SOLACE Project
Anna Kerpel-Fronius, Hungary

09:35 WS06.01.05 - Reimbursement and Cost Effectiveness
Nicole Rankin, Australia

09:45 Q&A

10:10 Break

10:20 WS06.01.06 - Introduction to Session 2: Examples of Running Lung Cancer Screening Programs
Catherine Jones, Australia

10:25 WS06.01.07 - Bunando Medical Center Tanzania
Nestory Masalu, Tanzania

10:35 WS06.01.08 - Republic of Korea
Yeol Kim, Republic of Korea

10:45 WS06.01.09 - USA Program with Breast Cancer Screening Program
Kim Sandler, USA

10:55 WS06.01.10 - Denmark Program
Michael Stegner, Denmark

11:05 Q&A

The 2025 IASLC CT Screening Symposium will continue at 13:00.

09:00 - 10:00 INDUSTRY SPONSORED SYMPOSIA

See page 228 for more information.

ROOM 10



Chair: Marco Chiappetta, Italy

10:00 Welcome & Introduction
Marco Chiappetta, Italy

10:05 WS07.01 - Unsolved Issues in Thymic Malignancies Staging Systems and What's New in the 9th TNM Edition
Enrico Ruffini, Italy

Part 1: Guidelines and Research in Thymic Malignancies: Looking for a Common Language

10:15 Moderator Introduction
Anja Roden, USA

10:20 WS07.02 - Limits of Current Guidelines on Thymic Malignancies Management
Wentao Fang, China

10:30 WS07.03 - Future Research Topics Based on New
Anja Roden, USA

Part 2: Future Guidelines: How the 9th TNM Should Change Clinical Practice

10:40 WS07.04 - Changes in Imaging Description
Edith Marom, Israel

10:44 WS07.05 - What's New in Specimen Evaluation
Malgorzata Szolkowska, Poland

10:48 WS07.06 - Surgical Approach and Indication: What Should Be Considered?
Jeffrey Velotta, USA

10:52 WS07.07 - The Oncologist Point of View
Fatemeh Ardeshir Larijani, USA


10:56 WS07.08 - Radiotherapy: When and How
Annemarie Shepherd, USA

11:00 Q&A and Open Discussion

Moderators: Marco Chiappetta, Italy Andreas Rimmer, Germany and Anja Roden, USA
Discussants: Enrico Ruffini, Italy, Wentao Fang, China, Annemarie Shepherd, USA, Edith Marom, Israel, Malgorzata Szolkowska, Poland, Jeffrey Velotta, USA, Fatemeh Ardeshir Larijani, USA

10:00 - 11:30 WS08 - PRACTICAL APPLICATION OF GENE-EDITING FOR THE VERIFICATION OF NOVEL LUNG CANCER BIOMARKERS: FROM GENE DISCOVERY TO PRE-CLINICAL AND BEYOND

ROOM 09



Chair: Paola A. Marignani, Canada

10:00 Welcome & Introduction
Paola A. Marignani, Canada

10:05 WS08.02 - Biomarker Discovery and Optimization of New Therapeutic Tools
Chiara Ambrogio, Italy

10:25 WS08.03 - scRNAseq Analysis of Primary Tumors and Machine Learning Integration
Paola Marignani, Canada

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

10:45 **WS08.04 - Detection of Early-Stage Lung Cancer**
Christian Rolfo, USA

10:55 **WS08.05 - Therapeutic Lung Cancer Biomarkers**
David P. Carbone, USA

11:05 **Panel Discussion and Q&A**

10:30 – 11:30 **INDUSTRY SPONSORED SYMPOSIUM**

See page 229 for more information.

10:30 – 11:30 **SATELLITE CME SYMPOSIUM**

See page 231 for more information.

11:30 – 13:00 **AWARDS LUNCHEON**
(LIMITED CAPACITY, FIRST COME FIRST SERVED)

ROOM 01 + 02

Host: Sandip Patel, USA

Join us for a special luncheon honoring the rising stars of the lung cancer research community. During this luncheon, we will recognize outstanding participants from programs such as the International Mentorship Program, the IASLC Academy, Education Award winners, IASLC Foundation grant recipients, and many more.

This is a moment to applaud the dedication, innovation, and promise of early career researchers who are shaping the future of lung cancer science and care. Enjoy a meal, connect with peers, and be part of a celebration of excellence and emerging talent in the global fight against thoracic cancers.

12:00 – 13:00 **INDUSTRY SPONSORED SYMPOSIUM**

See page 229 for more information.

13:00 – 14:15 **WS03.02 - EARLY CAREER INVESTIGATOR WORKSHOP - PART 2**

ROOM 03

Chair: Zhaohui Arter, USA

13:00 **Welcome & Introduction**
Zhaohui Arter, USA

13:03 **WS03.02.02 - Boosting My Career: How IASLC Grants Made a Difference**
Biagio Ricciuti, USA

13:08 **WS03.02.03 - IASLC Grant Workshop: Small Group Discussion**
Panelists: Jose Benitez, France, Roberto Ferrara, Italy, Alessio Cortellini, Italy, Tianhong Li, USA, Biagio Ricciuti, USA, Masaoki Ito, Japan, Luiz Araujo, Brazil, Celine Mascaux, France, Christina Baik, USA, Lyudmila Bazhenova, USA, Balazs Halmos, USA, Tripama Sen, USA

13:53 **Group Learning and Q&A**
Zhaohui Arter, USA

The Early Career Investigator Workshop will continue at 14:30.

13:00 – 16:00

WS06.02 - 2025 IASLC CT SCREENING SYMPOSIUM
(TICKETED SESSION) - CONTINUATION

ROOM 08

NOT FOR CME CREDIT

Chairs: Rudolf Huber, Germany, Catherine Jones, Australia, Antoni Rosell, Spain, Betty Tong, USA, Milena Cavic, Serbia

13:00 **Introduction to Session 3: Downstream Effects of Screening Implementation**
Betty Tong, USA

13:05 **WS06.02.02 - Medical Imaging (CT/PET)**
Sally Ayesa, Australia

13:15 **WS06.02.03 - Endoscopic Techniques**
Antoni Rosell, Spain

13:25 **WS06.02.04 - Radiotherapy (Non-Surgical Treatments)**
Suresh Senan, Netherlands

13:35 **WS06.02.05 - Surgical Treatments**
Chi-Fu Jeffrey Yang, USA

13:45 **Q&A**

14:10 **Break**

14:20 **Introduction to Session 4: Alternative Methods for Early Detection of Lung Cancer**
Milena Cavic, Serbia

14:25 **WS06.02.06 - Exhaled Air and Blood-Based Biomarkers**
Stephen Lam, Canada

14:35 **WS06.02.07 - Artificial Intelligence and Radiomics for Chest X-Rays and CTs**
Catherine Jones, Australia

14:45 **WS06.02.08 - Incidental Pulmonary Nodules**
Helmut Prosch, Austria

14:55 **Q&A**

15:10 **Group Discussion**

15:50 **Conclusion**

13:00 – 16:00 **WS09 - IASLC & ITONF: NURSE & AHP WORKSHOP**

ROOM 07

NOT FOR CME CREDIT

Chairs: Michelle Turner, USA, Caitlin Broderick, Australia, Katherine Kuhns, USA, Nicole Kiss, Australia, Melanie Rabbets, Australia, Mary Duffy, Australia

13:00 **Welcome & Introduction**
Michelle Turner, USA and Caitlin Broderick, Australia

13:05 **WS09.02 Welcome to: Pillar 1 Introduction, Advances in Treatment, Latest Updates & Innovations**
Katherine Kuhns, USA

13:10 **WS09.03 - Advances in Medical Markers: Latest Insights & Applications**
Michelle Turner, USA

13:25 **WS09.04 - From Trial to Treatment: Educational Support Across the Care Continuum, Bridging Knowledge Gaps for Nurses from Research to Standard of Care Application**
Amanda Kluxen, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:40 **WS09.05 - Radiation Toxicity: Advances in Management & Prevention**
Gerard Hanna, Ireland

14:05 **Q&A**
Caitlin Broderick, Australia

14:05 **WS09.06 - Welcome to: Pillar 2 Introduction, Living Well with Cancer: Managing Life Beyond Diagnosis**
Nicole Kiss, Australia

14:10 **WS09.07 - Supporting & Educating Patients Following Curative Treatments: Understanding the Risk of Recurrence**
Charlotte Smith, UK

14:25 **WS09.08 - Immunotherapy: The Silent Struggles, Coping with Long Term Toxicities**
Stephanie McDonald, USA

14:40 **WS09.09 - Taking the Fear Out of Dying: Discussions with Your Patients**
Maria Ftanou, Australia

14:55 **Networking Break**

15:15 **WS09.10 - Introduction**
Melanie Rabbets, Australia

15:20 **WS09.11 - International Comparison of Lung Cancer Screening**
Hannah Jongbloed, Australia

15:30 **WS09.12 - The Interface Between the Nurse and the Pharmacist, Dentist, Nutritionist & Psychologist**
Gisele Farias, Brazil

15:40 **WS09.13 - Microbiome Study: Key Findings & Next Steps**
Gisele Fraga, Brazil

15:50 **WS09.14 - Nurse-Led Self-Management Education to Improve Cancer Patient Treatment Adherence in Ethiopia: Mixed Methods, Experience-Based Co-design PhD Research**
Dejen Alem, Ethiopia

16:00 **WS09.15 - Summary & Close**
Mary Duffy, Australia

13:00 - 14:15 WS10 - DEBATES, DISCUSSIONS & DIDACTICS ON SCIENCE COMMUNICATIONS IN 2025

ROOM 09

Chairs: Jarushka Naidoo, Ireland and Matthew Smeltzer, USA

13:00 **Welcome & Introduction**
Jarushka Naidoo, Ireland and Matthew Smeltzer, USA

13:02 **WS10.02 - Combatting Misinformation in Science**
Solange Peters, Switzerland

13:12 **WS10.03 - Debate: Is Social Media No Longer an Appropriate Platform for Scientific Discourse? YES**

13:17

WS10.04 - Debate: Is Social Media No Longer an Appropriate Platform for Scientific Discourse? NO
Stephen Liu, USA

13:22 **WS10.05 - Discussion: Picking a Platform: Twitter/X, LinkedIn, Bluesky, TikTok, Weibo, or the Good Old-Fashioned Podium?**

Panelists: Hidehito Hironouchi, Japan, Eric Singhi, USA, Stephen Liu, USA, Solange Peters, Switzerland

13:37 **WS10.06 - Not-So-Lost in Translation: How To Break Down a Scientific Message**
Tony Mok, China

13:47 **WS10.07 - Debate: Are Print Journals Prehistoric? YES**
Ana Velazquez Manana, USA

13:52 **WS10.08 - Debate: Are Print Journals Prehistoric? NO**
Martin Edelman, USA

13:57 **WS10.09 - Discussion: How Will AI Revolutionize Science Communications**
Panelists: Tony Mok, China, Martin Edelman, USA, Fiona Hegi-Johnson, Australia, Ana Velazquez Manana, USA, Annabelle Gurwitch, USA

13:00 - 15:00 WS11 - AI USAGE FOR RADIATION ONCOLOGY: WHERE ARE WE AND WHERE WILL WE GO?

ROOM 10

Chair: Daniel Przybylsz, Brazil

Workshop Faculty: Daniel Przybylsz, Brazil, Léo Franco, Spain, Eric Talbot, USA, William Kennedy, USA

NOT FOR CME CREDIT

13:00 - 15:00 WS12 - GGO MANAGEMENT AND TREATMENT – INTRAOPERATIVE ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY (ENB) GUIDED MARKING AND MINIMALLY INVASIVE RESECTION

ROOM 12

Chairs: Stefan Watzka, Austria and Thomas Klikovits, Austria

13:00 **Welcome & Introduction**

Stefan Watzka, Austria and Thomas Klikovits, Austria

Part 1: Lectures

13:05 **WS12.02 - Diagnostic Work-up of GGOs (Pathological Correlation, Radiology, Diagnostic Principals)**
Stefan Watzka, Austria

Part 2: Lectures

13:25 **WS12.03 - Importance of Minimally Invasive Surgery for Early-Stage Lung Cancer Including GGO**
Didier Schneider, Switzerland

13:45 **WS12.04 - ENB Basics and Marking Techniques**
Thomas Klikovits, Austria

Part 2: Practical Aspects

14:05 **WS12.05 - Group 1: ENB Planning According to 2 Real-Life Cases – How We Do It**
Thomas Klikovits, Austria

14:25 **WS12.06 - Group 2: Demonstration of ENB Tools (Fiducial Marker, Injection)**
Lisa Schulte, Austria

14:45 **Q&A**

NOT FOR CME CREDIT

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:30 – 14:30 INDUSTRY SPONSORED SYMPOSIUM

See page 230 for more information.

13:30 – 14:30 SATELLITE CME SYMPOSIUM

See page 231 for more information.

14:30 – 16:00 WS03.03 - EARLY CAREER INVESTIGATOR WORKSHOP – PART 3

ROOM 03

Chair: *Ticiana Leal, USA*

14:30 Welcome & Introduction

Ticiana Leal, USA

14:33 WS03.03.02 - How to Successfully Publish Your Manuscript: Winning Over Reviewer #2

Jennifer Carlisle, USA

14:43 WS03.03.03 - Tips & Pearls for Delivering an Oral Presentation

Natasha Leigh, Canada

14:53 WS03.03.04 - Using AI Tools to Streamline Presentation Creation

Arsela Prelaj, Italy

15:03 Q&A

15:13 WS03.03.05 - Panel Discussion: Expert Insights on Publishing and Presentations

Moderator: *Ticiana Leal, USA*

Panelists: *William William Jr., Brazil, Junko Tanizaki, Japan, Vanita Noronha, USA, Kenneth O'Byrne, Australia, Tannia Soria, Ecuador*

15:48 Q&A

14:30 – 16:00 WS13 - LATAM WORKSHOP

ROOM 06

Chairs: *Lucia Viola, Colombia and Luis Raez, USA*

14:30 Welcome & Introduction

Lucia Viola, Colombia and Luis Raez, USA

14:32 WS13.02 - Implementation of EBUS and Minimal Invasive Surgery in LATAM How Far We Have Gone?

Stella Martinez, Colombia

14:42 WS13.03 - How We Can Use Artificial Intelligence To Improve Lung Cancer Screening in LATAM

Gilberto de Castro, Brazil

14:52 WS13.04 - Progress in Molecular Testing in Latin America, Where We Are Now?

Isabella Barcelos Favato, Brazil

15:02

WS13.05 - Improving Clinical Research in Latin America

Maria Clara Rodriguez, Uruguay

15:12

WS13.06 - How We Can Increase Scientific Collaborations and Publications in LATAM

Pedro Aguiar Jr., Brazil

15:22

WS13.07 - Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations

Francisco Sarmiento Neto, Brazil

15:27

WS13.08 - Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles

Maria Raquel Fernandes, Brazil

15:32

WS13.09 - Lung Cancer's Price Tag: Escalating Hospitalization Costs in Brazil Over the Past Two Decades

Jean Henri Maselli Schoueri, Brazil

15:37

WS13.10 - Abstract Discussion

Carlos Aliaga, Peru

15:47

Q&A

14:30 – 16:00 WS14 - FROM GUIDELINES TO IMPLEMENTATION IN NSCLC: PERTINENT CONSIDERATIONS OF ADHERENCE TO CONSENSUS STANDARDS OF CARE IN CLINICAL PRACTICE

ROOM 09

Chair: *Daniel Gomez, USA*

14:30

Welcome & Introduction

Daniel Gomez, USA

Part 1: Pertinent Considerations in the Development of International Guidelines

14:32

WS14.02 - NCCN Guidelines

Gregory Riely, USA

14:42

WS14.03 - ESMO Guidelines

Sanjay Popat, UK

14:52

WS14.04 - CHEST Guidelines

Douglas Arenberg, USA

15:02

WS14.05 - Themes and Differences Between Methodologies and Approaches

Daniel Gomez, USA

Part 2: The IASLC Approach of "Common Sense Oncology" - Applying Guidelines in Low-Resourced Regions and Unique Clinical Contexts

15:09

WS14.06 - Definitive Management of Patients of Special Populations

Jyoti Malhotra, USA

15:16

WS14.07 - Brain Metastases

Irina Veytsman, USA

15:23

WS14.08 - Oligometastatic Lung Cancer

Nagla Karim, USA

15:30

Q&A

SCIENTIFIC PROGRAM Saturday, September 6, 2025

Part 3: Patient and Guideline Panel Discussion and Perspective

15:35

WS14.09 - Panel Discussion

Moderator: Daniel Gomez, USA

Panelists: Gregory Riely, USA, Sanjay Popat, UK, Douglas Arenberg, USA, Nagla Karim, USA, Iriha Veytsman, USA, Jyoti Malhotra, USA, Jim Pantelas, USA

15:00 – 16:00 SATELLITE CME SYMPOSIUM

See page 232 for more information.

16:15 – 17:45

PL01 - OPENING PLENARY WITH DISTINGUISHED SERVICE AWARDS - TRANSFORMING LUNG CANCER THROUGH SOCIETAL PROGRESS

PLENARY HALL

LIVESTREAMED

NOT FOR CME CREDIT

Chairs: Noemi Reguart, Spain and Umberto Malapelle, Italy

PL01.01 - Welcome Remarks

PL01.02 - IASLC Distinguished Service Award Presentations

PL01.03 - From Smoking to Solutions: Advancing Tobacco Control for Better Lung Health in Europe

Filippos Filippidis, UK

PL01.04 - The Bridge Between Art and Medicine

Giovanna Cassese, Italy

PL01.05 - Playing for a Cause: How Sport Can Inspire Progress in Lung Cancer

Ricky Rubio, Spain

17:45 – 18:45

PRESS CONFERENCE

ROOM CC7 AB

NOT FOR CME CREDIT

17:45 – 19:15

WELCOME RECEPTION

EXHIBIT HALL

REFRESHMENTS PROVIDED

03

PROGRAM: SUNDAY

SUNDAY, SEPTEMBER 7, 2025

HOD	HOW	Highlight of the Previous Day	P	Poster
MA	OA	Hands-On Workshop	PT	Poster Tour
		Mini Oral Abstract Session	PL	Plenary
		Oral Abstract Session	WS	Workshop

08:15 – 10:30 PLO2 - PRESIDENTIAL SYMPOSIUM 1 WITH LECTURESHIP AWARD PRESENTATIONS

PLENARY HALL



Chairs: Paul Van Schil, Belgium and Heather Wakelee, USA

PL02.01 - Robert J. Ginsberg Lectureship Award for Surgery
Andrea Wolf, USA

PL.02.02 - James D. Cox Lectureship Award for Radiation Oncology
Suresh Senan, Netherlands

PL02.03 - IASLC Lectureship Award for Tobacco Control and Smoking Cessation
Lawson Eng, Canada

PL02.04 - First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival
David Planchard, France

PL02.05 Discussant
Daniel Tan, Singapore

Q&A

PL02.06 - Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Genes (ACROSS 2): Phase III Study
Jie Wang, China

PL02.07 Discussant
Jordi Reimon, Spain

Q&A

PL02.08 - Ivonescimab vs Placebo Plus Chemo, Phase 3 in Patients with EGFR+ NSCLC Progressed with 3rd gen EGFR-TKI Treatment: HARMONI
Jonathan Goldman, USA

PL02.09 Discussant
Suresh Ramalingam, USA

Q&A

PL02.10 - Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROSt+ NSCLC
Alexander Drlon, USA

PL02.11 Discussant
Anne-Marie Dingemans, Netherlands

Q&A



HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

PL02.12 - Phase 3 Trial of Crizotinib vs Observation for Surgically Resected Early-Stage ALK+ NSCLC

David Gerber, USA

PL02.13 Discussant

Jessica Lin, USA

Q&A

10:30 – 12:00 POSTER VIEWING BREAK WITH PI PRESENTERS IN ATTENDANCE

EXHIBIT HALL

REFRESHMENTS PROVIDED

NOT FOR CME CREDIT

Track 04: Screening and Early Detection

Rows: 01–06

Track 07: Early-Stage Non-small Cell Lung Cancer

Rows: 06–12

Track 11: Metastatic Non-small Cell Lung Cancer – Immunotherapy

Rows: 12–20

Track 17: Global Health, Health Services, and Health Economics

Rows: 20–28

10:45 – 11:30 NON-PROFIT PRESENTATION

See page 235 for more information.

10:45 – 11:45 ANNOUNCING THE IASLC-LANCET COMMISSION ON LUNG CANCER: A TRANSFORMATIVE GLOBAL APPROACH

ROOM 10

SPECIAL SESSION

NOT FOR CME CREDIT

Chairs: Karen Kelly, USA and Vania Wisdom, UK

10:45 Welcome & Introduction

Karen Kelly, USA and Vania Wisdom, UK

10:47

The Global Burden of Lung Cancer: An Urgent and Escalating Crisis

David J. Hunter, UK

10:57

The Power of Lancet Commissions in Shaping Global Health

Vania Wisdom, UK

11:02

Partnership for Impact – IASLC and The Lancet

Karen Kelly, USA

11:07

The Vision for the IASLC-Lancet Commission on Lung Cancer

C S Pramesh, India

11:17

Panel Discussion and Audience Questions

David J. Hunter, UK, Vania Wisdom, UK, Karen Kelly, USA, C S Pramesh, India, Mei Ling Yap, Australia, Caleb Egwuenu, Nigeria, William William, Brazil

10:45 – 11:45

PRESS CONFERENCE

ROOM CC7 AB

NOT FOR CME CREDIT

12:00 – 13:15

ES01 - IMMUNOTHERAPY PARTNERS: EXCITING AND CHALLENGING RELATIONSHIPS

Track: Metastatic Non-small Cell Lung Cancer – Immunotherapy

ROOM 08

ACCME ACCREDITED BY IASLC

Chairs: Edward Garon, USA and Anne-Marie Dingemans, Netherlands

12:00

Welcome & Introduction

Edward Garon, USA and Anne-Marie Dingemans, Netherlands

12:02

ES01.01 - Tobacco Awareness Moment: Lung Cancer Outcomes in the Setting of Smoking and Immunotherapy

Abhishek Shankar, India

12:05

ES01.02 - Dangerous Relationships: Immune Checkpoint Inhibitors and Steroids, Proton-Pump Inhibitors and Antibiotics/Probiotics

Naoki Furuya, Japan

12:17

ES01.03 - New Relationships: Bispecifics Combining (Dual) Immune Checkpoints and Other Targets

Giannis Mountziou, Greece

12:29

ES01.04 - A Unique Relationship: Microbiome and Immunotherapy

Misako Nagasaka, USA

12:41

ES01.05 - Considering Toxicity and Quality of Life Issues with Novel Immunotherapeutic Agents: The Patient's Perspective

Seamus Cotter, Ireland

12:53 Q&A

12:00 – 13:15

ES02 - USING PRECLINICAL MODELS TO TACKLE THE THERAPEUTIC CHALLENGES IN LUNG CANCER

Track: Tumor Biology – Preclinical Biology

ROOM 05

ACCME ACCREDITED BY IASLC

Chairs: Triparna Sen, USA and Montse Sanchez-Cespedes, Spain

12:00

Welcome & Introduction

Triparna Sen, USA and Montse Sanchez-Cespedes, Spain

12:02

ES02.01 - Rare Molecular Alterations in Lung Cancer

Guilherme Harada, Brazil

12:09

Discussion

12:19

ES02.02 - Leveraging Preclinical Models To Decipher Heterogeneity and Plasticity in SCLC

Esrá Akbay, USA

12:26

Discussion

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:36 ES02.03 - Identification of the HER2-ADC Sensitivity Determinant Using a 3D Co-Culture System

Ryohei Katayama, Japan

12:43 Discussion

12:53 ES02.04 - Mapping the Tumour Microenvironment in NSCLC Across Space and Time

Mihaela Angelova, UK

13:00 Discussion

13:10 Q&A

12:00 - 13:15 ES03 - SCLC: THE KNOWN AND UNKNOWN IN EVERYDAY PRACTICE WITH EXPERT INSIGHTS

Track: Small Cell Lung Cancer and Neuroendocrine Tumors

ROOM 07

Chairs: Luis Paz-Ares, Spain and Junko Tanizaki, Japan

12:00 Welcome & Introduction

Luis Paz-Ares, Spain and Junko Tanizaki, Japan

12:02 ES03.01 - Panel Discussion

Panelists: Afshin Dowlati, USA, Suresh Senan, Netherlands, Sabina Berezowska, Switzerland, Kate Sinclair, UK

12:50 Q&A

12:00 - 13:15 ES04 - JOINT IASLC - GLCC ADVOCACY SESSION: OVERCOMING CHALLENGES TO ENSURE BETTER OUTCOMES FOR PEOPLE LIVING WITH LUNG CANCER

ROOM 09

Chairs: Carolyn Aldige, USA and Kim Norris, USA

12:00 Welcome & Introduction

Jesme Fox, UK and Kim Norris, USA

12:02 ES04.01 - Reading a Clinical Trials Paper - Clinical Trial Stages and Assessing Response. What do Advocates Need to Know?

Emily Stone, Australia

12:12 ES04.02 - Success in the England Lung Cancer Screening Program. What Learnings for Advocates of Other Screening Programs in Development?

Richard Lee, UK

12:22 ES04.03 - Informing and Supporting Those on Long Term Systemic Therapies - Addressing Psychosocial Issues and Common Long Term Adverse Effects

Bernard Gaspar, Spain

12:32 ES04.04 - Stigma and Negativity in Lung Cancer. Is There Cause for Optimism?

Maureen Rigney, USA

12:42

ES04.05 - The IASLC STARS Program. Impacting a Generation of Lung Cancer Research Advocates

Andrew Clupek, USA

12:52

Q&A

12:00 - 13:15 ES05 - HOW WE DO LUNG CANCER SCREENING

Track: Screening and Early Detection

ROOM 04

Chairs: David Baldwin, UK and Douglas Wood, USA

12:00 Welcome & Introduction

David Baldwin, UK and Douglas Wood, USA

12:02 ES05.01 - Tobacco Awareness Moment: Read Out on the Smoking Cessation at Lung Examination

Jamie Ostroff, USA

12:05 ES05.02 - Screening and Early Detection of Lung Cancer in High-Risk Populations: Insights from Regions with China's Highest Lung Cancer Morbidity and Mortality Rates

Long Jiang, China

12:17 ES05.03 - Lung Cancer Screening in Individuals with a Family History of Lung Cancer

Allison Chang, USA

12:29 ES05.04 - Maximizing Benefit from Incidental Findings

Rozemarijn Vliegenthart, Netherlands

12:41 ES05.05 - The Use of Robotic Bronchoscopy: Screening and Therapy in One Procedure?

Pallav Shah, UK

12:53

Q&A

12:00 - 13:15 HOW01 - RADIATION ONCOLOGY CONTOURING WORKSHOP - LOCALLY ADVANCED NSCLC #1 (PRE-SIGN UP REQUIRED FOR CASE ASSIGNMENTS)

NOTE: DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP

ROOM 11 This session will be repeated today from 15:15 to 16:30.

Chairs: Alexander Louie, Canada and Fiona Hegji-Johnson, Australia and Hongcheng Zhu, China

12:00 Welcome & Introduction

Alexander Louie, Canada and Fiona Hegji-Johnson, Australia and Hongcheng Zhu, China

HOW01.01 - Can EBUS Results in a Seismic Shift in Radiation Volumes

Melody Qu, Canada

HOW01.02 - Management Options for Neoadjuvant ChemoIO Patients Who Do Not Proceed to Surgery

Houda Bahig, Canada

HOW01.03 - Is There Still a Role for Post-Operative Radiotherapy?

Said Al Saifi, Oman

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:00 - 13:15 MA01 - NEW DRUGS AND STRATEGIES IN LOCALLY ADVANCED NSCLC

Track: Local-Regional Non-small Cell Lung Cancer

ROOM 01

Chairs: Joe Chang, USA and Feng-Ming Kong, Hong Kong

12:00 Welcome & Introduction

Joe Chang, USA and Feng-Ming Kong, Hong Kong

12:02 MA01.01 - Surgical Outcomes and Oncological Quality of Surgery According to IASLC Criteria in NADIM II Trial

Jose Jarabo, Spain

12:07 MA01.03 - Metabolomic Analysis Identifies Histamine as a Key Predictive Factor for Perioperative Chemoimmunotherapy in NADIM II Trial

Pilar Mediavilla-Medel, Spain

12:12 Q&A

12:17 MA01.04 - Neoadjuvant PD-(L)1 Blockade in Combination with Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

Biagio Ricciuti, USA

12:25 MA01.05 - Tislelizumab Plus Chemotherapy Followed by Surgery or Radiotherapy and Adjuvant Tislelizumab in Unresectable Stage III NSCLC

Jiewei Liu, China

12:30 MA01.06 - Phase I/II Trial of Canakinumab with Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer (ChHORUS)

Narek Shaverdian, USA

12:35 Q&A

12:43 MA01.07 - Preliminary Results of the Phase I LuCa-MERIT-1 Trial: An Advanced NSCLC pt Cohort Treated with BNT116 + Cemiplimab Post CRT

Akin Atmaca, Germany

12:48 MA01.08 - Sequential Chemo-SaBR Following by Immunotherapy in Unresectable LA-NSCLC Unfit for Concurrent ChT-RT According to the START-NEW-ERA Trial

Paola Anselmo, Italy

12:53 Q&A

12:00 - 13:15 MA02 - NEW TREATMENT STRATEGIES IN OTHER THAN EGFR-POSITIVE TUMORS

Track: Metastatic Non-small Cell Lung Cancer - Target Therapy

ROOM 02

Chairs: Xiuning Le, USA and Jon Zugazagoitia, Spain

12:00 Welcome & Introduction

Xiuning Le, USA and Jon Zugazagoitia, Spain

12:02

MA02.01 - Contemporary Landscape of Acquired Resistance to Next-Generation ALK Inhibitors: Paired Pre-/Post-Treatment Biopsy Analysis

Sarah Waliqny, USA

12:07

MA02.02 - Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-small Cell Lung Cancer: The Global TRUST-II Study

Geoffrey Liu, Canada

12:12

MA02.03 - Repotrectinib in Patients with ROS1 Fusion-Positive (ROS1+) NSCLC: Long-Term Follow-Up from the Phase 1/2 TRIDENT-1 Trial

Byoung Chul Cho, Republic of Korea

12:35 Q&A

12:43

MA02.04 - Updated Efficacy, Safety, and Genomic Data in Patients with Trk Fusion Lung Cancer Treated with Larotrectinib

Jessica Lin, USA

12:30

MA02.05 - Liquid Biopsy in BRAF V600E NSCLC Treated With Dabrafenib Plus Trametinib: Final Analysis of LiBRA Study (GOIRC-03-2020)

Alessandro Leonetti, Italy

12:40

Q&A

12:48

MA02.06 - Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01

Melissa Johnson, USA

12:48

MA02.07 - Efficacy and Safety of GFH375 in Advanced Non-small Cell Lung Cancer Patients with KRAS G12D Mutation

Ziming Li, China

12:53

MA02.08 - Upfront Management of Brain Metastases (BM) in Oncogene-Addicted NSCLC Treated With Targeted Therapies: An EORTC Survey

Ana Ortega-Franco, UK

12:58 Q&A

12:00 - 13:15 OA01 - SMOKING AND BEYOND: NAVIGATING RISK FACTORS IN LUNG CANCER

Track: Risk Factors, Risk Reduction & Tobacco Control

ROOM 03

Chairs: Angeline Low, Australia and Nir Peled, Israel

12:00

Welcome & Introduction

Angeline Low, Australia and Nir Peled, Israel

12:02

OA01.01 - Genetic and Air Pollution Scores Identify Individuals at Elevated Risk in a Lung Cancer Screening Cohort

Lianne Trap, Netherlands

12:12

OA01.02 - The Mirror Study: Tumor Microenvironment (TME) in Patients with Non-small Cell Lung Cancer Exposed to Indoor Radon +/- Tobacco Smoke

Marta Garcia de Herreros, Spain

12:22

OA01.03 - Lung Cancer Among People Who Never Smoked: Global Epidemiology and Initial Identification of Early Detection Biomarkers

Hilary Robbins, France

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:32 **OA01.04 - Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk**
YiShen Chen, China

12:42 **OA01.05 - Discussant**
Mahdi Sheikh, France

12:52 **Q&A**

12:00 - 13:15 **OA02 - LATEST DIAGNOSTIC AND MANAGEMENT OPTIONS TO IMPROVE SURVIVAL OUTCOMES IN EARLY-STAGE RESECTABLE NON-SMALL CELL LUNG CANCER**

Track: Early-Stage Non-small Cell Lung Cancer

ROOM 06

Chairs: Heather Wakelee, USA and René Petersen, Denmark

12:00 **Welcome & Introduction**
Heather Wakelee, USA and René Petersen, Denmark

12:02 **OA02.01 - SKYSCRAPER-05: Phase II Study of Perioperative Tiragolumab + Atezolizumab ± Chemotherapy in Locally Advanced Resectable NSCLC**
Catherine Shu, USA

12:12 **OA02.02 - Molecular Residual Disease (MRD) Analysis from NeoADAURA: Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC**
Collin Blakely, USA

12:22 **OA02.03 - Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study**

Tetsuya Mitsudomi, Japan

12:32 **OA02.05 - Discussant**
Joshua Reuss, USA

12:42 **Q&A**

13:15 - 15:15 **Lunch Break**  **Exhibit Hall**  **LUNCH PROVIDED**

13:45 - 14:45 **HW01 - WORK-LIFE HARMONY: REDEFINING BALANCE IN THE DEMANDING FIELD OF ONCOLOGY**

ROOM 12

Chair: Sandip Patel, USA

13:45 **Welcome & Introduction**
Sandip Patel, USA

13:50 **HW01.01 - Leadership's Role in Building Work-Life Harmony: Departmental Strategies to Support Oncology Professionals**
Maria Rosario Campelo, Spain


14:05 **HW01.02 - Breaking the Myth of Perfect Balance: Navigating the Trade-offs in High-Stress Medical Careers**
Mark Awad, USA

14:20 **Q&A**

13:45 - 14:45 **INDUSTRY SPONSORED SYMPOSIA**

See page 233 for more information.

14:15 - 15:00 **POSTER TOURS**
EXHIBIT HALL/EPOSTER LOUNGE

 **NOT FOR CME CREDIT**

Note: Each Poster Tour will include 4 - 5 Posters (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).

Poster Tour: PT1.01 - Risk Factors, Risk Reduction and Tobacco Control **ePOSTER LOUNGE STATION 1**

Tour Lead: Ugo Pastorino, Italy

14:15 **PT1.01.01 - Large Language Models to Extract Smoking History from Clinical Notes in EHR to Evaluate Lung Cancer Surveillance Strategies**
TaeYoon Lee, USA

14:23 **PT1.01.02 - Temporal Analysis of Smoking Profiles in Brazil Among Lung Cancer Patients and the Impact of 25 Years of Public Policies**
Bruna Rezende, Brazil

14:31 **PT1.01.03 - IMPRINT-Lung: Single-Arm, Multi-Center Phase II Trial of Immunotherapy With Pembrolizumab for Interception of High-Risk Lung Nodules**
Jianjun Zhang, USA

Poster Tour: PT1.02 - Tumor Biology - Preclinical Biology **ePOSTER LOUNGE STATION 2**

Tour Lead: David P. Carbone, USA

14:15 **PT1.02.01 - Targeting NOX1/4-YAP/TEAD-CD47 Axis Promotes Macrophage Phagocytosis and Potentiates Radiotherapy Antitumor Efficacy in NSCLC**
Xiaorong Dong, China

14:23 **PT1.02.02 - Novel Organoid Models of Patient-Derived Lung Cancer in Decellularized Mouse Lung Tissue**
Roya Navab, Canada

14:31 **PT1.02.03 - GBC-11004: An AI-Driven Novel Kinase Target with Potential to Overcome Osimertinib Resistance in NSCLC**
Jihye Ryu, Republic of Korea

14:39 **PT1.02.04 - Mapping Gene-Environment Interactions Driving Small Cell Lung Cancer (SCLC) Initiation in Human Airway Organoids**
Andrés Marco, Spain

Poster Tour: PT1.03 - Tumor Biology - Translational Biology **ePOSTER LOUNGE STATION 3**

Tour Lead: Ucero Alvaro, Spain

14:15 **PT1.03.01 - Precision Medicine Platform to Guide the Treatment of NSCLC**
Sofia Merajver, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

- 14:23** PT1.03.02 - Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer
Jie Huang, China
- 14:31** PT1.03.03 - Drug Repurposing for Metastatic Lung Adenocarcinoma Therapy Using AI-Guided Single-Cell Gene Expression Profiles
Maria Raquel Fernandes, Brazil
- 14:39** PT1.03.04 - VIKTOR - the Virtual International Knowledgebase for Thoracic Oncology Research of the IASLC
Ferdinando Cerciello, Switzerland
- 14:47** PT1.03.05 - An AI-Based Predictive Tool for Druggable Mutations in Lung Cancer Using Nationwide Comprehensive Genomic Profiling Data
Hiroaki Ikushima, Japan
- Poster Tour: PT1.04 - Screening and Early Detection** ePOSTER LOUNGE STATION 4
Tour Lead: Chi-Fu Jeffrey Yang, USA
- 14:15** PT1.04.01 - Incidental Pulmonary Nodule Programs (IPN) Working Together with LDCT Scans and Artificial Intelligence (AI) Increase Lung Cancer Detection
Luis Raez, USA
- 14:23** PT1.04.02 - Performance of Lung Nodule and Cancer Risk Calculators in Identifying Primary Lung Cancer Across Screening and Incidental Nodule Populations
Francisco Sarmento Neto, Brazil
- 14:31** PT1.04.03 - The LEAP Study: A Biospecimen Bank for Validation of Liquid Biomarkers in a Lung Cancer Screening Cohort
Edwin Ostrin, USA
- 14:39** PT1.04.04 - Biomarker-Based Eligibility for Lung Cancer Screening - Validation of Protein-Based INTEGRAL-Risk Model in the LC3 Consortium
Mattias Johansson, France
- 14:47** PT1.04.05 - Subclassification of Abnormal Cells into Precancerous and Malignant Categories Based on 3D Cellular Imaging
Michael Meyer, USA
- Poster Tour: PT1.05 - Pulmonology and Staging** ePOSTER LOUNGE STATION 5
Tour Lead: Kwun Fong, Australia
- 14:15** PT1.05.01 - Impact of Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy on Next-Generation Sequencing
Kenya Sato, Japan
- 14:23** PT1.05.02 - Development of an AI Image Analysis System for Malignancy Classification in Rapid On-Site Cytologic Evaluation of Lung Cancer
Tetsuya Sakai, Japan
- 14:31** PT1.05.03 - Comparison Between Lymph Node Station- and Zone-Based Classification: Analysis With the 9th IASLC Node Descriptors in Surgically Resected NSCLC
Shia Kim, Republic of Korea

- 14:39** PT1.05.04 - Use of an Ultrathin Bronchoscope with a Larger Working Channel Enhances Diagnostic Yield in Cone-Beam CT-Guided Transbronchial Biopsy
Naoya Kawakita, Japan
- Poster Tour: PT1.06 - Pathology and Biomarkers** ePOSTER LOUNGE STATION 6
Tour Lead: Keith Kerr, UK
- 14:15** PT1.06.01 - ERBB2 (HER2) Fusions in Lung Cancer Are Targetable by Anti-HER2 Small Molecules and Antibody-Drug Conjugates
Marc Ladanyi, USA
- 14:23** PT1.06.02 - Distinct Bronchoalveolar Lavage Fluid Microbiome and Metabolome Profiles in EGFR-Mutated and Wild-Type Non-Small Cell Lung Cancer
Ly Wu, China
- 14:31** PT1.06.03 - Loss of MTAP Expression in Thymic Carcinomas: Insights From a Retrospective Multi-Institutional, Global Study
Anja Roden, USA
- 14:39** PT1.06.04 - Signatures of Functional CD8 T, Marginal Zone/Memory B and NK Cells in PBMC Predict Survival in NSCLC Patients Receiving Chemoimmunotherapy
Jialei Wang, China
- 14:47** PT1.06.05 - Enhancing Spread Through Air Spaces Diagnosis Using AI Diagnostician: A Multi-Center Study
Hongmei Wu, China
- Poster Tour: PT1.07 - Early-Stage Non-small Cell Lung Cancer** ePOSTER LOUNGE STATION 7
Tour Lead: Nasser Khaled Altorki, USA
- 14:15** PT1.07.01 - IASLC Multidisciplinary Recommendations for Pathological Response Evaluation of Resected Lymph Nodes After Neoadjuvant Therapy in NSCLC
Sabina Berezowska, Switzerland
- 14:23** PT1.07.02 - Neoadjuvant Ensartinib for ALK-Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC): A Multicenter, Real-World Study
Xi Zhang, China
- 14:31** PT1.07.03 - Adjuvant Osimertinib in IB-IIIB NSCLC with Uncommon EGFR Mutations (Admin): Mutation Profile and ctDNA Dynamics
Chengwu Liu, China
- 14:39** PT1.07.04 - Radiomics Model Based on Synthesized PET for Predicting Neoadjuvant Therapy Pathologic Response in NSCLC (CPT-LC-NEO Trial)
Maotao Weng, China
- Poster Tour: PT1.08 - Local-Regional Non-small Cell Lung Cancer** ePOSTER LOUNGE STATION 8
Tour Lead: Alona Zer, Israel
- 14:15** PT1.08.01 - Neoadjuvant Amonertinib Followed by Chemo-Immunotherapy in II-IIIB EGFR-TKI, Interim Analysis of a Single Arm, Phase II Study (NEOVADE)
Jun-tao Lin, China
- 14:23** PT1.08.02 - 5-Y Outcomes of Stereotactic Ablative Radiotherapy in T01 Unresectable LA-NSCLC Patients: The START-NEW-ERA Phase II Trial
Fabio Arcidiacono, Italy
- 14:31** PT1.08.03 - Chemoradiation/Immunotherapy (IO) for Stage III NSCLC: Timing of IO, and the Benefits/Selection in Elderly & Black Patients
John Varlotta, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

14:39 **PTI.08.04 - Cachexia in Patients with Unresectable Stage III NSCLC**
Cristina Muñoz-Pinedo, Spain

14:47 **PTI.08.05 - Radioresistance of NSCLC Tumors Is Mediated by Immunosuppressive Cell Populations. Strategies to Sensitize Tumors by Targeting Innate Immunity**
Sergio León, Spain

Poster Tour: PTI.09 - Metastatic Non-small Cell Lung Cancer - Local Therapies
Tour Lead: Hossein Borghaei, USA

14:15 **PTI.09.01 - Chemoradiotherapy Plus Tislelizumab in Advanced or Metastatic NSCLC: A Prospective, Multicenter, Phase II Study**
Sheng Lin, China

14:23 **PTI.09.02 - Double Lung Transplantation in Patients with Metastatic Lung-Limited Non-small Cell Lung Carcinoma (NSCLC): A Case Series**
Young Kwang Chae, USA

14:31 **PTI.09.03 - Dormant Tumor Maintenance and Immune Evasion in Induced Oligometastatic Lung Cancer**
Rui Fu, China

14:39 **PTI.09.04 - Incomplete Cryoablation Promotes Recurrence and Progression of KRAS-Driven Lung Adenocarcinoma via the NF2B-CCL20-MAPK/MEK/ERK Axis**
Zeyi Liu, China

14:47 **PTI.09.05 - Preclinical Safety Assessment of a Conformable Electrode for Bronchoscopy-Guided Radiofrequency Ablation**
Min Jee Kim, Republic of Korea

15:15 - 16:30 **WHAT DO THIS YEAR'S POLICY DEVELOPMENTS IN LUNG CANCER MEAN FOR YOU?**

ROOM 12

Chair: Helena Wilcox, UK

15:15 **Welcome & Introduction**
Helena Wilcox, UK

15:20 **IASLC Global Policy Report: A New Tool to Monitor and Inform Policy**
Andreas Charalambous, Cyprus

15:25 **Global Commitment Begins with Consensus: Aligning Efforts and Strengthening National Implementation**
Mary Bussell, USA

15:30 **The Asia Pacific Lung Cancer Consensus Statement and Priorities for the Region**
Herbert Loong, China

15:35 **Integration of Smoking Cessation Support in the Setting of Lung Cancer Screening**
Mahdi Sheikh, France

15:40 **IARC Handbooks Volume 21: Lung Cancer Screening**
Xiaoshuang Feng, France

15:45 **The Lung Health Resolution: Taking an Integrated Approach to Lung Cancer**
Yannick Romero, Switzerland

15:50 **Q&A**

16:25 **Closing Remarks**
Helena Wilcox, UK

15:15 - 16:30 **ES07 - ADVANCED EGFR MUTANT NSCLC TREATMENT OPPORTUNITIES AND LEPTOMENINGEAL DISEASE IN ONCOGENE DRIVEN NSCLC**

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy

ROOM 02

Chairs: Sewanti Limaye, India and Laura Book, USA

15:15 **Welcome & Introduction**
Sewanti Limaye, India and Laura Book, USA

15:17 **ES07.01 - Treatment Options for Common Sensitizing EGFR Mutant Advanced NSCLC?**
Jessica Menis, Italy

15:29 **ES07.02 - Treatment Option for Uncommon EGFR and EGFR ex20ins Advanced NSCLC?**
Aaron Tan, Singapore

15:41 **ES07.03 - Treatment Options for Sequencing EGFR/ALK Treatments? Mechanisms of Resistance**
Rossana Ruiz, Peru

15:53 **ES07.04 - Leptomeningeal Disease in Oncogene Driven NSCLC: Diagnostic and Treatment Opportunities**
Helena Yu, USA

16:05 **Q&A**

15:15 - 16:30 **ES08 - NAVIGATING THE SPECTRUM OF OLIGOMETASTATIC DISEASE IN NSCLC**

Track: Metastatic Non-small Cell Lung Cancer - Local Therapies

ROOM 01

Chairs: Wen-Zhao Zhong, China and Pablo Munoz Schuffenegger, Chile

15:15 **Welcome & Introduction**
Wen-Zhao Zhong, China and Pablo Munoz Schuffenegger, Chile

15:17 **ES08.01 - Decoding Oligometastatic NSCLC: Ready to Molecular Classification?**
Raphael S Werner, Germany

15:29 **ES08.02 - Understanding Multiple Classifications: Definitions and Patient Selection in Focus**
Qing Zhou, China

15:41 **ES08.03 - Tobacco Awareness Moment: Lung Cancer Outcomes in the Setting of Smoking and Radiotherapy**
Jacek Jassem, Poland

15:44 **ES08.04 - Precision Radiotherapy & Strategic Approaches in OM disease**
Chiaojung Jillian Tsai, Canada

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:56 ES08.05 - Survivorship in the Oligometastatic State
Annabelle Gurwitch, USA

16:08 Q&A

15:15 - 16:30 ES09 - WHAT ARE THE BEST PRACTICES FOR INVASIVE STAGING FOR NSCLC IN THE ERA OF CHEMO-IMMUNOTHERAPY?

Track: Pulmonology and Staging

ROOM 04

Chairs: Motoko Tachihara, Japan and Zeno Gouw, Netherlands

15:15 Welcome & Introduction

Motoko Tachihara, Japan and Zeno Gouw, Netherlands

15:17 ES09.01 - Challenges and Limitations of Nodal Staging in TNM

James Huang, USA

15:29 ES09.02 - EBUS and Optimal Staging for Clinical NO-N1 NSCLC

Tracey Leong, Australia

15:41 ES09.03 - Restaging After Neoadjuvant Therapy - PRO

Sergi Call, Spain

15:53 ES09.04 - Restaging After Neoadjuvant Therapy - CON

Sanjay Popat, UK

16:05 Q&A

15:15 - 16:30 ES10 - NAVIGATING MULTIDISCIPLINARY CARE: THE POWER OF COMMUNICATION IN A PATIENT'S JOURNEY

Track: Patient Advocacy

ROOM 03

Chairs: Caleb Egwuenu, Nigeria and Upal Basu Roy, USA

15:15 Welcome & Introduction

Caleb Egwuenu, Nigeria and Upal Basu Roy, USA

15:17 ES10.01 - Voices of Experience: A Young Patient's Key Communication Moments

Sydney Barned, USA

15:27 ES10.02 - ERAS/ Pre-Operative Assessment. Is it Really Patient-Centered?

Aki Kobayashi, Japan

15:37 ES10.03 - Patient Preferences and Discussion in Lung Cancer Screening Participation

David Chi-Leung, China

15:47 ES10.04 - Handling Difficult Conversations in Lung Cancer Care: Case Scenarios

Omagh Kestell, Ireland, Rasheda Persinger, USA

15:57 Q&A

15:15 - 16:30

ES11 - OPTIMAL MANAGEMENT OF EARLY STAGE PLEURAL MESOTHELIOMA - CASE SCENARIOS AND INNOVATIVE MANAGEMENT STRATEGIES

Track: Mesothelioma, Thymoma, and Other Thoracic Tumors

ROOM 05

Chairs: Ritu Gill, USA and Ivy Ng, Singapore

15:15 Welcome & Introduction

Ritu Gill, USA and Ivy Ng, Singapore

15:17 ES11.01 - Chemotherapy for PM-End of an Era?

Federica Grosso, Italy

15:29 ES11.02 - Innovating the Local Approach: SMART Radiotherapy

John Cho, Canada

15:41 ES11.03 - What Happens When the Diagnosis Defies the Golden Rules?

Malgorzata Szolkowska, Poland

15:53 ES11.04 - Surgery in MPM: Convincing or Conditional?

Marc de Perrot, Canada

16:05 ES11.05 - How to Navigate the Patient at the Heart of Care

Melissa Culligan, USA

16:17 Q&A

15:15 - 16:30 ES12 - VAPING TO STOP, VAPING TO START

Track: Risk Factors, Risk Reduction & Tobacco Control

ROOM 07

Chairs: Silvia Novello, Italy and Olalekan Ayo-Yusuf, South Africa

15:15 Welcome & Introduction

Silvia Novello, Italy and Olalekan Ayo-Yusuf, South Africa

15:17 ES12.01 - Other Than Cigarette: The Other Tools. Status of the Art

Enrica Capelletto, Italy

15:25 ES12.02 - eCig as Valid Aid to Stop

Rachael Murray, UK

15:33 ES12.03 - eCig and Health Outcomes: Epidemiological and Public Health Challenges

Pawan Kumar Singh, India

15:41 ES12.04 - eCig Versus Other Tools/Methods to Stop Smoking

Nicola Lindson, UK

15:49 Round Table

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:15 - 16:30 HOW02 - *REPEAT SESSION* RADIATION ONCOLOGY CONTOURING WORKSHOP - LOCALLY ADVANCED NSCLC #2 (PRE-SIGN UP REQUIRED FOR CASE ASSIGNMENTS)

NOTE: DELEGATES ARE REQUIRED TO BRING THEIR LAPTOP

ROOM 11

Chairs: Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China

12:00 Welcome & Introduction

Alexander Louie, Canada and Fiona Hegi-Johnson, Australia and Hongcheng Zhu, China

HOW02.01 - Can EBUS Results in a Seismic Shift in Radiation Volumes

Melody Qu, Canada

HOW02.02 - Management Options for Neoadjuvant ChemoIO Patients Who Do Not Proceed to Surgery

Houda Bahig, Canada

HOW02.03 - Is There Still a Role for Post-Operative Radiotherapy?

Said Al Saifi, Oman

15:15 - 16:30 MA03 - NEW ADVANCES IN CIRCULATING BIOMARKERS

Track: Pathology and Biomarkers

ROOM 06

Chairs: Ross Juergens, Canada and Ming Tsao, Canada

15:15 Welcome & Introduction

Ross Juergens, Canada and Ming Tsao, Canada

15:17 MA03.01 - Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC

Zachary Coyne, Canada

15:22 MA03.02 - Clinical Performance of a Tumor Informed Whole Genome Based ctDNA Assay for Predicting Recurrence in Early-Stage Resectable NSCLC

Gaston Becharano, USA

15:27 MA03.03 - SAVANNAH: Biomarker Concordance and Acquired Resistance to Osi+Savo in Patients with EGFRm MET-OverExp and/or Amp NSCLC

Christina Baik, USA

15:32 Q&A

15:40 MA03.04 - Comparative Analysis of Circulating Tumor DNA Monitoring Strategies in Advanced NSCLC With MET Exon 14 Skipping Treated with Ensartinib

Yang Xia, China

15:45 MA03.05 - Circulating Tumor DNA Tumor Fraction as a Precision Biomarker for Radiotherapy in Oligometastatic NSCLC

Kaushal Parikh, USA

15:50

MA03.06 - Intrathecal Pemetrexed for Lung Adenocarcinoma Leptomeningeal Metastasis: A Study on Efficacy and Liquid Proteomics

Xiaorong Dong, China

15:55 Q&A

16:03

MA03.07 - Multi-Omic Analyses of CSF Reveal Genomic Instability and Suppressed Microenvironment After TKI Resistance in Patients with Brain Metastases

Meichen Li, China

16:08

MA03.08 - Identification of Circulating microRNA Signature for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis

Haiyi Deng, China

16:13

MA03.09 - Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive-Stage Small Cell Lung Cancer

Yinghui Xu, China

16:18 Q&A

15:15 - 16:30 OA03 - UNRAVELLING TUMOR EVOLUTION AND BOOSTING IMMUNOTHERAPY EFFICACY

NOT FOR CME CREDIT

Track: Tumor Biology - Translational Biology

ROOM 08

Chairs: Ignacio Wistuba, USA and John Le Quesne, UK

15:15

Welcome & Introduction

Ignacio Wistuba, USA and John Le Quesne, UK

15:17

OA03.01 - Multiomic Single Cell Profiling Reveals Novel Evolutionary Trajectories in Lung Carcinogenesis

Huizhao Hong, China

15:27

OA03.02 - Deciphering Genomic Evolution of Metastatic Organotropism with Large-Scale Paired Primary Lung Cancers and Metastases

Wen-Fang Tang, China

15:37

OA03.03 - Rilvestomig Enhances Ex Vivo Immune Activation in Patient-Resected NSCLC Tumors Over PDX or PDX/aTIGIT Combination Therapy

Jeremy Rattiu, USA

15:47

OA03.04 - TNFSF8-Targeting CpG Peptide Vaccine Reduces ICB Pneumonitis While Boosting Cancer Immunotherapy Efficacy

Zi-Xuan Rong, China

15:57

OA03.05 - Discussant

Yi-Long Wu, China


16:07 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:15 - 16:30 OA04 - FROM AI TO PSYCHOSOCIAL SUPPORT: NEW FRONTIERS IN LUNG CANCER MULTIDISCIPLINARY CARE

Track: *Multidisciplinary care: Nursing, Allied Health and Palliative Care*

ROOM 09



Chairs: *Stephanie McDonald, USA and Juan Carlos Laguna, Spain*

15:15 Welcome & Introduction

Stephanie McDonald, USA and Juan Carlos Laguna, Spain

15:17 OA04.01 - Perceptions of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery: A Pilot Mixed Methods Study

Melissa Culligan, USA

15:27 OA04.02 - Implementation of Large Language Model and GraphRAG-Assisted Decision Support for Multidisciplinary Team Cancer Care

Su Chen, China

15:37 OA04.03 - Association of Pre- and Postdiagnosis Physical Activity, Promotion, and Maintenance with Lung Cancer Survival: A Nationwide Cohort Study

Yeon Wook Kim, Republic of Korea

15:47 OA04.04 - Resiliency Among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Phase II - RCT Supportive Care Intervention

Carolyn Presley, USA

15:57 OA04.05 - Discussant

Andreas Charalambous, Cyprus

16:07 Q&A

16:45 - 18:00 ES06 - JOINT IASLC-ESTRO SESSION: SAFETY AND SYNERGY OF RADIOTHERAPY IN EGFR AND ALK NSCLC

ROOM 09



Chairs: *Houda Bahig, Canada and Gerard Walls, UK*

16:45 Welcome & Introduction

Houda Bahig, Canada and Gerard Walls, UK

16:47 ES06.01 - Recent and Ongoing Clinical Trials

Shankar Siva, Australia

16:59 ES06.02 - Best Practices with Brain Metastases

Kevin Chua, Singapore

17:11 ES06.03 - Timing and Toxicity with Radiation and Targeted Therapies

Florence Katie Keane, USA

17:23 ES06.04 - Case-based Considerations and Controversies

Michael Tjong, Canada

17:35 Q&A

16:45 - 18:00 ES13 - HOW WELL DO YOU KNOW YOUR ADCS?

Track: *Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy*

ROOM 01



Chairs: *Alfredo Addeo, Switzerland and Francesco Cortiula, Netherlands*

16:45 Welcome & Introduction

Alfredo Addeo, Switzerland and Francesco Cortiula, Netherlands

16:47 Contestants

Ross Jeurgens, Canada, Alessandra Curioni, Switzerland, Herbert Loong, China, Leonardo Rojas, Colombia

17:35 Q&A

16:45 - 18:00 ES14 - MULTIOMIC SPATIAL BIOLOGY, LIQUID BIOPSY

Track: *Tumor Biology – Translational Biology*

ROOM 03



Chairs: *Caroline Dive, UK and Milena Cavic, Serbia*

16:45 Welcome & Introduction

Caroline Dive, UK and Milena Cavic, Serbia

16:47 ES14.01 - Patient Derived Tumor Fragments

Krijn Dijkstra, UK

16:59 ES14.02 - Multiomic Spatial Biology

Kurt Schalper, USA

17:11 ES14.03 - Tobacco Awareness Moment: Nicotine and Tumor Growth and Metastasis of Lung Cancer

Courtney Granville, USA

17:14 ES14.04 - Methylation Analysis as an Integrative Tool for Early Detection

Chaimaa Mounjid, Morocco

17:26 ES14.05 - Next Generation Liquid Biopsies

Atocha Romero, Spain

17:38 Q&A

16:45 - 18:00 ES15 - LOCAL INTERVENTIONS FOR EARLY STAGE NON-SMALL CELL LUNG CANCER

Track: *Early-Stage Non-small Cell Lung Cancer*

ROOM 08



Chairs: *Gavitt Woodard, USA and William William, Brazil*

16:45 Welcome & Introduction

Gavitt Woodard, USA and William William, Brazil

16:47 ES15.01 - Expanding the Role of Radiation Therapy

Drew Moghanaki, USA

16:59 ES15.02 - Percutaneous Ablation

Carole Ridge, UK

17:11 ES15.03 - Endobronchial Ablation

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

Joyce Chan, China

17:23 ES15.04 - Novel Interventional Bronchosopic Techniques

Thomas Gaisl, Switzerland

17:35 Q&A

16:45 - 18:00 ES16 - IMPROVING OUTCOMES FROM LUNG CANCER GLOBALLY: WHERE EVERYONE'S VOICE MATTERS

Track: Global Health, Health Services, and Health Economics

ROOM 05

Chairs: Valerie Rusch, USA and Raymond Osarogbogbon, USA

16:45 Welcome & Introduction

Valerie Rusch, USA and Raymond Osarogbogbon, USA

16:47 ES16.01 - Round Table Discussion 1: Overcoming Global Challenges to Diagnostics and Molecular Testing for Lung Cancer

Michael Boyer, Australia, Yishan Chuang, USA, Rodrigo Dientsmann, Spain, Matthew Evison, UK

17:12 ES16.02 - Key Takeaways (Panel 1)

Clarissa Mathias, Brazil

17:17 ES16.03 - Round Table Discussion 2: Improving Access to Novel Targeted and Immunotherapy Drugs for Lung Cancer in LMICs

Shankar Prinja, India, Annie Wong, New Zealand, Jill Feldman, USA

17:42 ES16.04 - Key Takeaways (Panel 2)

Navneet Singh, India

17:47 Q&A

16:45 - 18:00 ES17 - UPDATES ON LUNG CANCER PATHOLOGY

Track: Pathology and Biomarkers

ROOM 07

Chairs: Luisella Righi, Italy and Soo-Ryum Yang, Japan

16:45 Welcome & Introduction

Luisella Righi, Italy and Soo-Ryum Yang, Japan

16:47 ES17.01 - Pulmonary or Not Pulmonary? The Diagnosis of Cancer of Unknown Primary (CUP) on a Small Sample (Biopsy or Cytology)

Kenzo Hiroshima, Japan

16:59 ES17.02 - Advances in Grading of NSCLC

Andre Moreira, USA

17:11 ES17.03 - Tobacco Awareness Moment: Smoking Status and Biomarkers of Lung Cancer Prognosis

Mahdi Sheikh, France

17:14

ES17.04 - Pitfalls in the Diagnosis of Lung Cancer

Giuseppe Pelosi, Italy

17:26

ES17.05 - WHO Reporting System for Lung Cytopathology

Lukas Bubendorf, Switzerland

17:38 Q&A

16:45 - 18:00 ES18 - NAVIGATING THE CHALLENGES OF LOCALLY ADVANCED NSCLC

Track: Local-Regional Non-small Cell Lung Cancer

ROOM 04

Chairs: Juan Carlos Trujillo, Spain and Dolores Isla, Spain

16:45 Welcome & Introduction

Juan Carlos Trujillo, Spain and Dolores Isla, Spain

16:47 ES18.01 - Resectability: Defining the Indefinable in Lung Cancer Surgery

Jon Villena, USA

16:59 ES18.02 - Integrating Radiation Therapy in the Era of Neoadjuvant Immunotherapy: Strategies and Synergies

Alexander Louie, Canada

17:11

ES18.03 - Advancing Targeted Approaches in Stage III NSCLC: EGFR and Beyond

Ibiayi Dagogo-Jack, USA

17:23

ES18.04 - Raising the Bar: Optimizing Immunotherapy in Unresectable Stage III NSCLC

Francesco Passiglia, Italy

17:35 Q&A

16:45 - 18:00 OA05 - IMMUNOTHERAPY FOR SPECIAL POPULATIONS

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

ROOM 06

Chairs: Federico Cappuzzo, Italy and Jane Sui, Ireland

16:45 Welcome & Introduction

Federico Cappuzzo, Italy and Jane Sui, Ireland

16:47

OA05.01 - ASTRUM-002: First-Line Serplulimab Plus Chemotherapy With or Without

HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer

Yuankai Shi, China

16:57

OA05.04 - A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as

Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L

Solange Peters, Switzerland

17:07

OA.05 - Discussant

Hossein Borghaei, USA

17:13

OA05.02 - First-Line Atezolizumab Plus Chemotherapy in Elderly Patients with

Advanced NSCLC, IFCT-1805 Elderly: A Randomized, Multicenter, Phase 3 Trial

Céline Mascaux, France

17:23

OA05.03 - NIVIPI-Brain: Phase 2 Study of Nivolumab + Ipilimumab Combined with

Chemotherapy in NSCLC With Synchronous Brain Metastases

Ernest Nadal, Spain

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

17:33 OA05.05 - Discussant


Lizza Hendriks, Netherlands

17:39 Q&A**16:45 - 18:00 OA06 - NOVEL ADCs IN SCLC****Track: Small Cell Lung Cancer and Neuroendocrine Tumors****ROOM 02**

Chairs: Jhanelle Gray, USA and Raffaele Califano, UK

16:45 Welcome & Introduction

Jhanelle Gray, USA and Raffaele Califano, UK

16:47**OA06.01 - A First-in-Human Phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC**
Linlin Wang, China**16:57****OA06.02 - Safety and Efficacy of QLC5508 in Previously Treated Patients with Small Cell Lung Cancer: Updated Data from a Phase 1 Study**
Caicun Zhou, China**17:07****OA06.03 - Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 IDEate-Lung01 Study**
Myung-Ju Ahn, Republic of Korea**17:17****OA06.04 - Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R/R SCLC**
Lauren Byers, USA**17:27****OA06.05 - Discussant**
Tatsuya Yoshida, Japan**17:37****Q&A****16:45 - 18:15 WS15 - SYBIL: USING A DEEP LEARNING MODEL TO PREDICT LUNG CANCER RISK IN THE REAL WORLD****ROOM 10**

Chair: Lecia Sequist, USA

16:45**Welcome and Introduction**
Lecia Sequist, USA**16:50****WS15.02 - Sybil Implementation Consortium**
Raymond Osarogiagbon, USA**16:58****WS15.03 - Technical Aspects of Sybil Installation**
Florian Fintelmann, USA**17:13****WS15.04 - Real World Experience**
Mary Pasquinelli, USA**17:18****WS15.05 - Real World Experience**
Pan Chyr Yang, Taiwan**17:23****WS15.06 - Real World Experience**
William Mayfield, USA**17:28****WS15.07 - Real World Experience**
Stephen Lam, Canada**17:33****WS15.08 - Panel Discussion**

Chang Allison, USA, Peter Mikhael, USA, Jill Feldman, USA, Raymond Osarogiagbon, USA, Florian Fintelmann, USA, Mary Pasquinelli, USA, Pan Chyr Yang, Taiwan, William Mayfield, USA, Stephen Lam, Canada

18:00 - 20:30 THE BACKYARD STEPS EXPERIENCE

A charitable initiative from The Ricky Rubio Foundation during the IASLC World Conference on Lung Cancer as part of the IASLC Wellness Challenge. Let's climb the stairs to Montjuic together! Bus transfers will be provided at 18:00 from the following pick up points:

18:00**FIRA Gran Via, North Entrance, Hall 8, Meeting Point: Wellness Challenge Counter, Registration Area, Ground Floor****18:00**

Hotel Porta Fira

18:00

Hotel Melia Sarria

18:00

Hotel Nobu

18:00**INNSIDE Barcelona Apolo**

Return transfers to above listed points will be provided (except FIRA Gran Via).

For more information, visit: <https://therickyrubiofoundation.org/reto-backyard/#K18>**18:30 - 19:30 INDUSTRY SPONSORED SYMPOSIUM**

See page 234 for more information.

18:30 - 19:30**SATELLITE CME SYMPOSIUM**

See page 235 for more information.

19:30 - 22:00**FACULTY DINNER**
(BY INVITATION ONLY)



04

PROGRAM:
MONDAY



IASLC
2025 World Conference
on Lung Cancer
SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

CLOSING LUNCH

**Not So Trivial: A WCLC
Interdisciplinary Quiz Challenge**

Don't miss it!
A dynamic and engaging session where some of the field's most renowned names go head-to-head in a spirited competition. It is the perfect way to close out the Conference with great food and high energy!

Hall 6 - Plenary Hall

Tuesday, September 9 14:15 - 15:45

MONDAY, SEPTEMBER 8, 2025

HOD
HOW
MA
OA

Highlight of the Previous Day
Hands-On Workshop
Mini Oral Abstract Session
Oral Abstract Session

P Poster
PT Poster Tour
PL Plenary
WS Workshop

08:30 – 10:30 PLO3 - PRESIDENTIAL SYMPOSIUM 2 WITH LECTURESHIP AWARD PRESENTATIONS

PLENARY HALL

LIVESTREAMED

NOT FOR CME CREDIT

Chairs: Alex Adjei, USA and Caicun Zhou, China

PLO3.01 - Tsuguo Naruke Lectureship Award for Surgery

Kazuhiko Yasufuku, Canada

PLO3.02 - Heine H. Hansen Lectureship Award for Small Cell Lung Cancer

Ying Cheng, China **IN MEMORIAM**

PLO3.03 - Incoming and Outgoing IASLC President's Address

Paul Van Schil, Belgium and Caicun Zhou, China

PLO3.04 - EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC

John Varlotta, USA

PLO3.05 - Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial

Nan Bi, China

PLO3.06 Discussant

Corinne Falvre-Finn, UK

Q&A

PLO3.07 - Adjuvant Chemotherapy (CT) vs CT-immunotherapy for R0 Stage IB-IIIa NSCLC Patients (NADIM ADJUVANT): A Randomized, Phase 3 Trial

Mariano Provencio, Spain

PLO2.08 Discussant

Tina Cascone, USA

Q&A

PLO3.09 - Survival Outcome of VATS Compared to Open Lobectomy for Lung Cancer: An Individual Patient Data Meta-analysis of Randomised Trials

Jacie Law, UK

PLO2.10 Discussant

Ayumi Suzuki, Japan

Q&A

PLO3.11 - Spread Through Airways (STAS) and Prognosis in the Phase III JCOG0802/WJOG4607L Trial of Segmentectomy vs Lobectomy in NSCLC

Yasushi Yatabe, Japan

PLO3.12 Discussant

Luisella Righi, Italy

Q&A



HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

PL03.13 - Comparing 74 vs 80 as the Upper Age Limit for Lung Cancer Screening: A Multi-Centre Cohort Study
Patrick Goodley, UK

PL03.14 Discussant
Pan Chyr Yang, Taiwan

Q&A

10:30 – 12:00 POSTER VIEWING BREAK WITH P2 PRESENTERS IN ATTENDANCE

EXHIBIT HALL REFRESHMENTS PROVIDED NOT FOR CME CREDIT

- Track 02: Tumor Biology – Preclinical Biology Rows: 01-05
- Track 05: Pulmonology and Staging Rows: 05-07
- Track 06: Pathology and Biomarkers Rows: 07-17
- Track 08: Local-Regional Non-small Cell Lung Cancer Rows: 17-23
- Track 10: Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy Rows: 23-25
- Track 15: Multidisciplinary Care: Nursing, Allied Health and Palliative Care Rows: 25-28

10:45 – 11:45 HOD01 - HIGHLIGHTS OF THE DAY - SUNDAY ABSTRACTS

EXHIBIT HALL/EPOSTER LOUNGE NOT FOR CME CREDIT

- 10:45 **HOD01.01 - Lung Cancer Risk Factors and Tumor Biology**
Christian Rolfo, USA
- 10:55 **HOD01.02 - Early-Stage Non-small Cell Lung Cancer**
Pierre Emanuel Falcoz, France
- 11:05 **HOD01.03 - Metastatic Non-small Cell Lung Cancer - Immunotherapy**
Federico Cappuzzo, Italy
- 11:15 **HOD01.04 - ADCs for SCLC**
Lauren Byers, USA
- 11:25 **HOD01.05 - Presidential Symposium Abstract Highlights (Sunday)**
Martin Reck, Germany

10:45 – 11:45 PRESS CONFERENCE

ROOM CC7 AB NOT FOR CME CREDIT

10:45 – 11:45

THE WHO INTEGRATED LUNG HEALTH RESOLUTION: WHAT IT IS AND WHY IT MATTERS TO THE LUNG CANCER COMMUNITY

ROOM 10

NOT FOR CME CREDIT SPECIAL SESSION

Chair: Karen Kelly, USA

10:45 Welcome & Objectives
Karen Kelly, USA

10:47 Supporting the WHO Lung Health Resolution and Next Steps for Impact
Yannick Romero, Switzerland

10:57 Multidisciplinary Panel Discussion: Translating Policy into Practice

Panelists: Jesme Fox, UK, David Baldwin, UK, Wen-Zhao Zhong, China, Samuel Kareff, USA, Andrea Bezjak, Canada, Claudia Henschke, USA, Yasushi Yatabe, Japan, Andreas Charalambous, Cyprus

11:32 Q&A

11:42 Closing Remarks & Call to Action
Karen Kelly, USA

12:00 – 13:15 HOW03 - ROBOTIC NAVIGATIONAL BRONCHOSCOPY WORKSHOP #1

(LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11

NOT FOR CME CREDIT

This workshop will be repeated today 15:30 - 16:45.

Workshop Faculty: Thomas Gaisl, Switzerland and Gian-Marco Monsch, Switzerland

12:00 – 13:15 ES19 - HOW TO IMPROVE EFFICACY OF IMMUNOTHERAPY IN METASTATIC NSCLC?

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy ACCME ACCREDITED BY IASLC

ROOM 06

Chairs: Dellys Rodriguez-Abreu, Spain and Ola Khorsid, Egypt

12:00 Welcome & Introduction

Dellys Rodriguez-Abreu, Spain and Ola Khorsid, Egypt

12:02 ES19.01 - Combining Novel Immune Checkpoint Inhibitors Is the Way to Go
Melissa Johnson, USA

12:14 ES19.02 - Combining ICIs With ADCs Is the Way to Go

Sun-Min Lim, Republic of Korea

12:26 ES19.03 - Combining ICIs with Molecular Targeted Agents Is the Way to Go
Rafael Rosell, Spain

12:38 ES19.04 - Combining ICIs With Novel Immunotherapeutics (Vaccines, Cellular Immunotherapy)

Vamsidhar Velcheti, USA

12:50 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:00 - 13:15 ES20 - LEVERAGING OMICS TO UNDERSTAND THE BIOLOGY OF LUNG CANCER

Track: *Tumor Biology - Preclinical Biology*



ROOM 05

Chairs: *Guilherme Harada, Brazil and A El Halali, China*

- 12:00 Welcome & Introduction**
Guilherme Harada, Brazil and A El Halali, China
- 12:02 ES20.01 - Therapeutic Strategies to Tackle Specific Tumor Suppressor Gene Alteration Contexts**
Montse Sanchez, Spain
- 12:14 ES20.02 - Revealing New Vulnerabilities in Lung Adenocarcinoma Using Proteomics**
Antonio Maraver, France
- 12:26 ES20.03 - Liquid Biopsy Using ctDNA Methylation to Subtype Small Cell Lung Cancer**
Caroline Dive, UK
- 12:38 ES20.04 - The Preclinical Genomics of Lung Cancer Plasticity and Metastasis**
Triparna Sen, USA
- 12:50 Q&A**

12:00 - 13:15 ES21 - WHAT WE NEED TO KNOW ABOUT LUNG NEUROENDOCRINE NEOPLASMS (NENS): INSIGHTS FROM A MULTIDISCIPLINARY PERSPECTIVE

Track: *Small Cell Lung Cancer and Neuroendocrine Tumors*



ROOM 04

Chairs: *Claudio Martin, Argentina and José Trigo, Spain*

- 12:00 Welcome & Introduction**
Claudio Martin, Argentina and José Trigo, Spain
- 12:02 ES21.01 - NEN, NET, or NEC? Clarifying Classification Through the Pathologist's Lens**
Marina Baine, USA
- 12:14 ES21.02 - What We Need to Know About the Molecular Spectrum of NENS**
Jules Derks, Netherlands
- 12:26 ES21.03 - Defining the Role of Surgery in the Management of Thoracic NENS**
Keiju Aokage, Japan
- 12:38 ES21.04 - Advances on Systemic Therapy for Lung NENS Beyond SCLC**
Jaume Capdevila, Spain
- 12:50 Q&A**

12:00 - 13:15

ES22 - ADDING VALUE TO LUNG CANCER CARE: MULTIDISCIPLINARY TOXICITY MANAGEMENT FOR NEW THERAPIES

Track: *Multidisciplinary Care: Nursing, Allied Health & Palliative Care*



ROOM 03

Chairs: *Santiago Viteri, Spain and Caitlin Broderick, Australia*

- 12:00 Welcome & Introduction**
Santiago Viteri, Spain and Caitlin Broderick, Australia
- 12:02 ES22.01 - Antibody Drug Conjugates**
Beth Sandy, USA
- 12:14 ES22.02 - Targeted Therapies**
Gisele Fraga Moreira, Brazil
- 12:26 ES22.03 - Immunotherapy**
Jorgina Serra López, Spain
- 12:38 ES22.04 - Innovating AI for Toxicity Monitoring**
Loic Verlingue, France
- 12:50 Q&A**

12:00 - 13:15 ES23 - ENHANCING EFFICIENCY AND QUALITY IN SCREENING PROGRAMS

Track: *Screening and Early Detection*



ROOM 07

Chairs: *Jeffrey Yang, USA and Hecheng Li, China*

- 12:00 Welcome & Introduction**
Jeffrey Yang, USA and Hecheng Li, China
- 12:02 ES23.01 - Exploring What Matters to Patients in Screening and Early Detection Programs**
Satoko Yamaoka, Japan
- 12:19 ES23.02 - Radiology Standards in Nodule Management**
Anand Devaraj, UK
- 12:36 ES23.03 - How to Reach the Target Population and Maximize Uptake**
Renda Wiener, USA
- 12:53 ES23.04 - How to Run an Efficient Screening Review Meeting**
Emma O'Dowd, UK
- 13:10 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:00 - 13:15 ES24 - JOINT IASLC - ASCO SESSION: TERMINATING LUNG CANCER: HARNESSING AI TO TRANSFORM THE BATTLE TO CONQUER LUNG CANCER

ROOM 09




Chairs: Courtney Coschi, Canada and Vincenzo L'Imperio, Italy

- 12:00 Welcome & Introduction**
Courtney Coschi, Canada and Vincenzo L'Imperio, Italy
- 12:02 ES24.01 - Code Against Cancer: From Big Data to Big Impact in Lung Cancer Care**
Sandip Patel, USA
- 12:17 ES24.02 - Reading Between the Slices: AI Revolution in Radiology**
Yeon Wook Kim, Republic of Korea
- 12:27 ES24.03 - Smarter Than Your Average Slide: How AI is Rewriting the Diagnostic Playbook**
Vincenzo L'Imperio, Italy
- 12:37 ES24.04 - Smart Drugs, Smarter Science: The AI Revolution in Cancer Therapeutics**
Maria Chiara Garassino, USA
- 12:47 ES24.05 - Panning for Gold: Mining the Electronic Health Record Using AI**
Mihaela Aldea, France
- 12:57 Panel Discussion with all Speakers and Chairs**

12:00 - 13:15 MA04 - MULTI-MODAL TREATMENT OF RESECTABLE LUNG CANCER-OUTCOMES OF TARGETED TREATMENTS AND IMMUNOTHERAPIES IN EARLY-STAGE LUNG CANCER

ROOM 01



Track: Early-Stage Non-small Cell Lung Cancer

- Chairs: Enriqueta Felip, Spain and Martin Reck, Germany*
- 12:00 Welcome & Introduction**
Enriqueta Felip, Spain and Martin Reck, Germany
- 12:02 MA04.01 - No Versus Systematic Mediastinal LN Dissection for GGO-Dominant Lung Adenocarcinoma: A Multicenter, Phase III, Non-Inferiority RCT**
Yang Zhang, China
- 12:07 MA04.02 - Nautical: Clinical Outcomes and Pathologic Regression with Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC**
Jay Lee, USA
- 12:12 MA04.03 - Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA EGFR Mutated NSCLC With High Risk (APPOINT)**
Wei Zhang, China
- 12:17 Q&A**

- 12:25 MA04.04 - Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study**
Heather Wakelee, USA
- 12:30 MA04.05 - Patient-Reported Outcomes with Perioperative Nivolumab by Nodal Status in Patients with Resectable NSCLC From Checkmate 77T**
Jonathan Spicer, Canada
- 12:35 MA04.06 - Neoadjuvant Pembrolizumab: Multi-Omics Characterization of the Tumor Immune Response Reveals Distinct Mechanisms of Action**
Benedikt Niedermaier, Germany
- 12:40 Q&A**
- 12:48 MA04.07 - A Phase 2 Multicenter Umbrella Trial Assessing Tislelizumab ± Anti-TIGIT or Anti-LAG-3 mAb ± Chemotherapy in Resectable NSCLC**
Peng Zhang, China
- 12:53 MA04.08 - Perioperative Tislelizumab for Resectable Non-small Cell Lung Cancer: Final Analysis of RATIONALE-315**
Dongsheng Yue, China
- 12:58 MA04.09 - Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN**
Manuel Cobo Dols, Spain
- 13:03 Q&A**
- 12:00 - 13:15 OA07 - EXPANDING HORIZONS IN ADVANCED NSCLC INTEGRATING LOCAL THERAPY**
- Track: Metastatic Non-small Cell Lung Cancer - Local Therapies*
- ROOM 08**
- Chairs: Lilian Faroni, Brazil and Myung-Ju Ahn, Republic of Korea*
- 12:00 Welcome & Introduction**
Lilian Faroni, Brazil and Myung-Ju Ahn, Republic of Korea
- 12:02 OA07.01 - Final Analysis of Brightstar: LCT With Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC**
Yasir Elamin, USA
- 12:12 OA07.02 - Tumor Burden Metrics at Oligoprogression and Survival After SBRT in NSCLC: An Analysis of the Randomized Phase II CURB Trial**
Matthew McMillan, USA
- 12:22 OA07.03 - Stereotactic Ablative Radiotherapy in Oligo-Metastatic NSCLC Patients: START NEW ERA#OLIGO Non-Randomised Phase II Trial**
Fabio Arcidiacono, Italy
- 12:32 OA07.04 - Molecular and Early Outcomes of a Randomized Phase II Trial of Primary Tumor Resection Following EGFR TKI in Metastatic NSCLC**
Pei-Hsing Chen, Taiwan
- 12:42 OA07.05 - Discussant**
Pablo Munoz Schuffenegger, Chile
- 12:52 Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

12:00 - 13:15 OA08 - IMPROVING OUTCOMES IN EGFR AND KRAS MUTANT TUMORS, MORE IS BETTER?

Track: Metastatic Non-small Cell Lung Cancer - Targeted Therapy

ROOM 02  NOT FOR CME CREDIT

Chairs: Fabrice Barlesi, France and Stephanie Saw, Singapore

12:00 Welcome & Introduction
Fabrice Barlesi, France and Stephanie Saw, Singapore

12:02 OA08.01 - BMS-986504 in Patients with Homozygous MTAP-Deletion (Del): Clinical Results in Patients with NSCLC Enrolled in CA240-0007
Pasi A. Jänne, USA

12:12 OA08.02 - Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01
Marcelo Negrao, USA

12:22 OA08.03 - COMPEL: Osimertinib + Platinum-Based Chemotherapy in Patients with EGFRm Advanced NSCLC and Progression on 1L Osimertinib
Giulia Pasello, Italy

12:32 OA03.04 - Primary Endpoint Results from SHERLOCK: a Phase 2 Trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC
Chee Lee, Australia

12:42 OA03.05 - Discussant
Maurice Perol, France

12:52 Q&A

13:00 - 14:00 LATAM STEERING COMMITTEE MEETING
(BY INVITATION ONLY)

MEETING ROOM A

13:15 - 15:15 Lunch Break  Exhibit Hall  LUNCH PROVIDED

13:30 - 14:30 MEET THE EDITORS WITH ALEX A. ADJEI AND EMILY STONE

EXHIBIT HALL, IASLC JOURNAL LOUNGE  NOT FOR CME CREDIT

13:30 - 14:45 DE102 - INCLUSION IN ACTION: ADDRESSING HIDDEN AND EMERGING INEQUITIES IN THORACIC ONCOLOGY

ROOM 10  LUNCH PROVIDED  NOT FOR CME CREDIT

Chairs: Denis Moro Sibilot, France and Oscar Arrieta, Mexico

13:30 Welcome & Introduction
Denis Moro Sibilot, France and Oscar Arrieta, Mexico

13:32 DE102.01 - Displaced but Not Forgotten: Addressing Refugee Challenges in Thoracic Oncology Care
Amy Nolan, Ireland

13:42 DE102.02 - Lost in Translation: Removing Language Barriers to Ensure Equitable Cancer Treatment
Coral Olazagasti, USA

13:52 DE102.03 - Healing Across Beliefs: Overcoming Culture and Religious Divides in Thoracic Oncology
Om El Khair, Egypt

14:02 DE102.04 - The Geography of Disparity: Bridging the Gaps of Rural vs. Urban Thoracic Cancer Care
Jie Wang, China

14:12 Q&A

13:45 - 14:45 DE101 - NAVIGATING GENDER EQUITY IN THE DAILY LIFE OF A THORACIC ONCOLOGIST

ROOM 03  LUNCH PROVIDED  NOT FOR CME CREDIT

Chair: Julia Rotow, USA, Enric Carcereny, Spain

13:45 Welcome & Introduction
Julia Rotow, USA

13:47 DE101.01 - Is She the Right Fit for the Position? Navigating Gender Bias and Career Advancement
Pilar Garrido, Spain

13:57 DE101.02 - This is Called 'Local Politics': Navigating Gender Issues and Conflict at Work
Helena Linardou, Greece

14:07 DE101.03 - 'You Need to Be in the Operating Room. No, You Need to Be at Playground.' Navigating Gender Issues and Life Roles
Maria Teresa Ruiz Tsukazan, Brazil

14:17 DE101.04 - 'You Need to Find Your People.' Gender Factors on Mentorship, Sponsorship, and Positive Work Environment
Gerard G. Hanna, Ireland

14:27 Panel Discussion

13:45 - 14:45 INDUSTRY SPONSORED SYMPOSIA

See page 236 for more information.

HOD
HOW
MA
OA

Highlight of the Previous Day
Hands-On Workshop
Mini Oral Abstract Session
Oral Abstract Session

P
PT
PL
WS

Poster
Poster Tour
Plenary
Workshop

14:15 – 15:00 POSTER TOURS

EXHIBIT HALL/EPOSTER LOUNGE

NOT FOR CME CREDIT
Note: Each Poster Tour will include 4 – 5 Posters (8min per Poster: 3min presentation by the Poster Presenter, followed by 2min Discussion by the Poster Lead and 3min Audience Q&A).

Poster Tour: PT2.10 - Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy

Tour Lead: Rami Manochakian, USA

ePOSTER LOUNGE STATION 1

14:15 **PT2.10.01 - Incidence and Severity of Interstitial Lung Disease Associated with Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis**

Roberto Borea, USA

14:23 **PT2.10.02 - Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein-Overexpressing NSCLC: LUMINOSITY Study**

Hidehito Horinouchi, Japan

14:31 **PT2.10.03 - Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study**

Jie Wang, China

14:39 **PT2.10.04 - Efficacy and Safety of TQB2102, a Biparatopic HER2-Targeting ADC, in HER-2 Aberrant NSCLC: A Phase II Study**

Li Zhang, China

Poster Tour: PT2.11 - Metastatic Non-small Cell Lung Cancer – Immunotherapy

Tour Lead: Jin Hyoung Kang, Republic of Korea

ePOSTER LOUNGE STATION 2

14:15 **PT2.11.01 - Predictors of Response to PD-(L)1 Blockade in Patients with Oncogene-Driver Negative NSCLC Without History of Tobacco Use**

Eleonora Gariazzo, USA

14:23 **PT2.11.02 - Rescue by Radiotherapy and Anti-CTLA4/PD-1 After Failure of Anti-PD-1 Therapy in Metastatic NSCLC Patients: the RECLAIM study**

Ezgi Ulas, Netherlands

14:31 **PT2.11.03 - Phase I Study of Trametinib, Anlotinib, and Tislelizumab in KRAS-Mutant NSCLC: Safety, RP2D, and Preliminary Efficacy**

Baohui Han, China

14:39 **PT2.11.04 - Divergent Mechanisms of Hyper-Progressive Disease in Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors**

Seohee Shim, Republic of Korea

14:47 **PT2.11.05 - IF16-High Cancer-Associated Fibroblasts Impede Immunotherapy Response in NSCLC**

Leyi Lin, China

Poster Tour: PT2.12 - Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Tour Lead: Myung-Ju Ahn, Republic of Korea

ePOSTER LOUNGE STATION 3

14:15 **PT2.12.01 - Osimertinib Combined with Tegavivint Is Safe and Tolerable as First-Line Therapy in Patients with Metastatic EGFR-Mutated NSCLC**

Regan Memmott, USA

14:23 **PT2.12.02 - Effect of JIN-A02, a Novel 4Th-Generation EGFR-TKI, on Multiple EGFR Mutations in Comparison with 3Rd-Generation EGFR-TKIs**

Hee-Yeon Kim, Republic of Korea

14:31 **PT2.12.03 - Zongertinib in Patients with Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1**

Gerrina Ruitter, Netherlands

14:39 **PT2.12.04 - Osimertinib + Savolitinib in EGFRm Advanced NSCLC With MET Overexp and/or Amp Post-Progression on Osimertinib: SAVANNAH PROS**

Silvia Novello, Italy

Poster Tour: PT2.13 - Small Cell Lung Cancer and Neuroendocrine Tumors

Tour Lead: Katherine Scilla, USA

ePOSTER LOUNGE STATION 4

14:15 **PT2.13.01 - A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC**

Di Liu, China

14:23 **PT2.13.02 - Multi-Cycle Low-Dose Radiotherapy Reshapes Immunotherapy for ES-SCLC: The SPUR Phase II Trial**

Zhuoran Yao, China

14:31 **PT2.13.03 - Spatial Multiomics Profiling Reveals Distinct Tumor Microenvironment and Therapeutic Targets in EGFR-Mutant NSCLC Transformed to SCLC**

Bingnan Zhang, USA

14:39 **PT2.13.04 - Real-World Multi-Institution Analysis of Patients with Small Cell Lung Cancer Treated with Tarlatamab**

Alissa Cooper, USA

ePOSTER LOUNGE STATION 5

Poster Tour: PT2.14 - Mesothelioma, Thymoma, and Other Thoracic Tumors

Tour Lead: Sean Dullloo, UK

14:15 **PT2.14.01 - SYSTEMS-2: A Randomised Phase II Study of Radiotherapy Dose Escalation in Pleural Mesothelioma**

Iain Phillips, UK

14:23 **PT2.14.02 - Human- and AI- Whole Slide Image Assessment of Tumor Immune Microenvironment of Pleural Mesothelioma in Prediction of Patients Outcome**

Giuseppe Maggioni, Italy

14:31 **PT2.14.03 - Molecular Correlates of Response to Atezolizumab Plus Carboplatin and Paclitaxel in Patients with Thymic Carcinoma**

Yukina Shirai, Japan

14:39 **PT2.14.04 - Efficacy and Safety of Adebrelimab Plus Chemotherapy as Neoadjuvant Treatment for Unresectable Locally Advanced Thymic Carcinoma**

Ning Xu, China

14:47 **PT2.14.05 - Redefining Clinical Outcomes for Peritoneal Mesothelioma (PeM) in the Era of Immunotherapy**

Yamato Takabe, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

Poster Tour: PT2.15 - Multidisciplinary Care: Nursing, Allied Health and Palliative Care
Tour Lead: Lucia Viola, Colombia

ePOSTER LOUNGE STATION 6

14:15 **PT2.15.01 - A Randomized Controlled Trial on the Effect of Oncologist's Recommendations on Exercise, Sedentary, and Quality of Life in Patients with NSCLC**
Alice Avancini, Italy

14:23 **PT2.15.02 - Young Lung Cancer: The Psychosocial Needs Assessment**
Narijust Florez, USA

14:31 **PT2.15.03 - Examining the Role of Frailty Assessments in Older Adult with Lung Cancer to Identify Patient Vulnerabilities and Exploring Patient Outcomes**
Philip Papayanis, USA

14:39 **PT2.15.04 - Impact of Physical Exercise on Quality of Life in Patients with Advanced Lung Cancer**
Ana López Martín, Spain

Poster Tour: PT2.16 - Patient Advocacy
Tour Lead: Antoinette Wozniak, USA

ePOSTER LOUNGE STATION 7

14:15 **PT2.16.01 - Current Patient, Caregiver and Provider Attitudes Toward Use of AI in Lung Cancer Patient Navigation**
Courtney Granville, USA

14:23 **PT2.16.02 - Patients Who Reach Clinical Trials and Those Who Do Not, a Structural Analysis of Access Disparities in Japan**
Kazuo Hasegawa, Japan

14:31 **PT2.16.03 - Overcoming Lung Cancer Nihilism and Fatalism to Foster Compassion, Empathy, and Support**
Jamie Studts, USA

14:39 **PT2.16.04 - Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries**
Caleb Egwuenu, Nigeria

14:47 **PT2.16.05 - Survivorship Needs for Patients with NSCLC Treated with Oral Targeted Therapies**
Caroline Burley, USA

Poster Tour: PT2.17 - Global Health, Health Services, and Health Economics
Tour Lead: Mauricio Cuello Toledo, Uruguay

ePOSTER LOUNGE STATION 8

14:15 **PT2.17.01 - Point-Of-Care Rapid Tissue Diagnosis at Primary Consultation: Optimizing TIME to Treatment in the Neoadjuvant Era**
Biniam Kidane, Canada

14:23 **PT2.17.02 - Impact of Timely Treatment Initiation on Outcomes in Non-small Cell Lung Cancer. A Registry Based Observational Study**
Louis Irving, Australia

14:31 **PT2.17.03 - Accelerated Biological Aging Is Correlated with the Incidence and Poor Prognosis of Young Lung Cancer**
Yuxuan Liao, China

14:39 **PT2.17.04 - First Assessment of IASLC Inclusive Practices and Challenges: Results from the Diversity, Equity, and Inclusion Survey**
Narijust Florez, USA

14:47 **PT2.17.05 - Benefits of Adjuvant Alectinib in ALK+ Early-Stage Non-small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System**
Javier de Castro, Spain

14:45 – 15:30 IASLC BUSINESS MEETING

ROOM 09

REFRESHMENTS PROVIDED

NOT FOR CME CREDIT

- Welcome from the IASLC President
- CEO Report
- CSO Report
- CFO Report
- JTO & JTO CRR Report
- Passing of the Gavel

15:30 – 16:45 ES25 – ONCOGENE ADDICTED NSCLC: WORLDWIDE CASE BASED DISCUSSIONS

ACCME ACCREDITED BY IASLC

Track: Metastatic Non-small Cell Lung Cancer – Targeted Therapy

ROOM 03

Chairs: Alessandra Curioni, Switzerland and Kaushal Parikh, USA

15:30 **Welcome & Introduction**
Alessandra Curioni, Switzerland and Kaushal Parikh, USA

15:32 **ES25.01 - For ROS1 Fusion NSCLC, Is There Still a Place for Sequential Treatment Starting with Crizotinib?**
Daniel Tan, Singapore

15:47 **ES25.02 - HER2 Mutant NSCLC: ADC vs TKI, Challenges**
Pilar Garrido, Spain

16:02 **ES25.03 - BRAF and MET Mutant Tumors, How to Treat?**
Shirish Gadgeel, USA

16:17 **ES25.04 - NSCLC and KRAS G12C Mutation Second Line or in First Line?**
Helena Linardou, Greece

16:32 **Q&A**

15:30 – 16:45 ES26 – OLIGOMETASTATIC DILEMMAS: REAL-WORLD CASES, INSIGHTS, AND MULTIDISCIPLINARY SOLUTIONS

ACCME ACCREDITED BY IASLC

Track: Metastatic Non-small Cell Lung Cancer – Local Therapies

ROOM 01

Chairs: Matthias Guckenberger, Switzerland and Vanessa Costa Menezes, Brazil

15:30 **Welcome & Introduction**
Matthias Guckenberger, Switzerland and Vanessa Costa Menezes, Brazil

15:32 **Panel Discussion**
Gianluca Milanese, Italy, Hidehito Horinouchi, Japan, Mara Antonoff, USA, Gabriela Antelo, Spain, Tiffani Tyer, USA

HOD	Highlight of the Previous Day	P	Poster
HW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:30 - 16:45 ES27 - IMAGING TOOLS FOR STAGING: NEW KIDS ON THE BLOCK

Track: *Pulmonology and Staging*

ROOM 08

Chairs: *Mylene Truong, USA and Marisol Arroyo, Mexico*

15:30 Welcome & Introduction

Mylene Truong, USA and Marisol Arroyo, Mexico

15:32 ES27.01 - Tobacco Awareness Moment: Integrating Smoking Status as a Prognostic Factor in the TNM Lung Cancer Staging Criteria

Lawson Eng, Canada

15:35 ES27.02 - What's New in CT as a Staging Tool

Jonas Kroschke, Switzerland

15:47 ES27.03 - Imaging Controversies in Lung Cancer Staging

Kyongmin Sarah Beck, Republic of Korea

15:59 ES27.04 - PET/CT in Lung Cancer Staging: Challenges in Interpretation

Jeremy Erasmus, USA

16:11 ES27.05 - Systematic EBUS Staging to Guide Therapy

Daniel Steinfurt, Australia

16:23 Q&A

15:30 - 16:45 ES28 - PERSONALIZED CANCER CARE: FROM DIAGNOSIS TO SURVIVORSHIP

Track: *Patient Advocacy*

ROOM 02

Chairs: *Jill Feldman, USA and Hideo Ichimura, Japan*

15:30 Welcome & Introduction

Jill Feldman, USA and Hideo Ichimura, Japan

15:32 ES28.01 - Access to Early Detection Programs for People with an Increased Risk of Lung Cancer: Participant's Perspective

Jurg Hurter, Switzerland

15:42 ES28.02 - Elevate Patient Outreach and Advocacy: Leveraging Social Media

Eric Singhi, USA

15:52 ES28.03 - Caregiver and HCP Compassionate Fatigue Care

Shani Shilo, Israel

16:02 ES28.04 - Policy and Survivorship: Enhancing Access and Opportunities

Lauren Pretorius, South Africa

16:12 ES28.05 Patient-centred Perioperative Surveillance

Brendon Stiles, USA

16:22 Q&A

15:30 - 16:45

ES29 - THYMIC MALIGNANCIES – HOW TO MOVE THE FIELD FORWARD

Track: *Mesothelioma, Thymoma, and Other Thoracic Tumors*

ROOM 10

Chairs: *Mariana Brandao, Belgium and Nicolas Girard, France*

15:30 Welcome & Introduction

Mariana Brandao, Belgium and Nicolas Girard, France

15:32 ES29.01 - What's New on the Medical Side for Thymus

Ross Soo, Singapore

15:44 ES29.02 - Adjuvant Radiotherapy –When, Where and How?

Cengel Keith, USA

15:56 ES29.03 - Which Classification Do We Use?

Deepali Jain, India

16:08 ES29.04 - How Much Thymus and Lymph Nodes Do We Need to Get Out?

Alessandro Mariani, Brazil

16:20 Q&A

15:30 - 16:45 ES30 - LUNG CANCER AND RISK FACTORS: EXPLORING BEYOND CIGARETTE SMOKING

Track: *Risk Factors, Risk Reduction & Tobacco Control*

ROOM 04

Chairs: *Abhishek Shankar, India and Randi Williams, USA*

15:30 Welcome & Introduction

Abhishek Shankar, India and Randi Williams, USA

15:32 ES30.01 - Environmental Risk for Lung Diseases

Gianluigi De Gennaro, Italy

15:44 ES30.02 - Occupational Exposure and Risk of Airway Cancer

Laura Mezquita, Spain

15:56 ES30.03 - Rural Areas and Professional or Accidental Exposure to Pesticides

Monireh Seyyedsalehi, Italy

16:08 ES30.04 - Indoor Domestic and Professional Cooking and the Risk of Disease

Stephen Lam, Canada

16:20 Q&A

15:30 - 16:45 HOW04 - *REPEAT SESSION* ROBOTIC NAVIGATIONAL BRONCHOSCOPY WORKSHOP #2

(LIMITED CAPACITY - FIRST COME FIRST SERVED)


ROOM 11

Workshop Faculty: *Thomas Gaisl, Switzerland and Gian-Marco Monsch, Switzerland*

NOT FOR CME CREDIT

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:30 - 16:45 MA05 - PRECISION IN LUNG CANCER SCREENING

Track: *Screening and Early Detection*

ROOM 09

Chairs: *Ricardo Sales Santos, Brazil and Hilary Robbins, France*

15:30 **Welcome & Introduction**
Ricardo Sales Santos, Brazil and Hilary Robbins, France

15:32 **MA05.01 - A Systematic Approach to Appropriate Guideline-Based Management of Incidentally Detected Pulmonary Nodules the Mayo Clinic Experience**
Robert Anderson, USA

15:37 **MA05.02 - The Preliminary Results of Taiwan National LDCT Lung Cancer Screening for Smokers and Nonsmokers with a Family History of Lung Cancer**
Pan Chyr Yang, Taiwan

15:42 **Q&A**

15:50 **MA05.03 - Validation of Sybil in a Minority Population: Results from the Sybil Implementation Consortium: UIC, MGH, Baptist, Wellstar**
Mary Pasquinelli, USA

15:55 **MA05.04 - SENTINLO Systemwide Early Notification Tool for Imminent Nascent Lung Cancer**
Alexander Krule, USA

16:00 **MA05.05 - Analysis of Longitudinal Low-Dose CT Sybil Scores in Two Canadian Cohorts**
Clinton Durney, Canada

16:05 **Q&A**

16:13 **MA05.06 - Integrating Circulating Protein Biomarkers in Nodule Malignancy Prediction Model Based on Five International Lung Cancer Screening Cohorts**
Elham Khodayari Moez, Canada

16:18 **MA05.07 - Breathomics for Early Non-Invasive Detection of Lung Cancer: A Prospectively Multicenter Study Using TD-GC-MS and Portable Micro-GC**
Runchen Wang, China

16:23 **MA05.08 - Cell-Free DNA Methylation Markers in Serum and Bronchial Washing for Lung Cancer Detection: A Prospective Observational Study**
Yechan Song, Republic of Korea

16:28 **MA05.09 - Precise Diagnosis of Small Malignant Pulmonary Nodules Driven by Peripheral Single-Cell Immune Signatures: A Prospective Multi-Center Study**
Yang Xia, China


16:33 **Q&A**

15:30 - 16:45

MA06 - IMPROVING CARE JUDICIOUSLY

Track: *Global Health, Health Services, and Health Economics*

ROOM 06

Chairs: *Justin Gainer, USA and Mariano Provencio, Spain*

15:30 **Welcome & Introduction**
Lecia Sequist, USA and Mariano Provencio, Spain

15:32 **MA06.01 - Real-World Outcomes of First-Line Immunotherapy Intensification of Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)**
Xiao Wang, USA

15:37 **MA06.02 - Paradigm Shift in Lung Cancer Mortality in the USA: A Multifaceted Success Story**
Muhammad Islam, USA

15:42 **MA06.03 - Pharmacoeconomic Analysis of NADIM 2 Trial: Cost-Effectiveness of Perioperative Chemo-Immunotherapy in Resectable Stage III NSCLC**
Bartomeu Massuti, Spain

15:47 **Q&A**

15:55 **MA06.04 - Improving Preoperative ctDNA Detection in NSCLC Through Mechanistic Profiling and Multiregion-Informed Customization**
Yue He, China

16:00 **MA06.05 - Impact of Bronchoalveolar Lavage Combined with mNGS in Patients with Checkpoint Inhibitor Pneumonia: A Prospective Cohort Study**
Zhenhua Zhou, China

16:05 **MA06.06 - Overall Survival Among Patients with Oncogene Driven Lung Cancers Treated on Clinical Trials Compared to Standard Care**
Ashley Sestito, Australia

16:10 **Q&A**

16:18 **MA06.07 - Benchmarking CT Foundation Models for Survival Prediction in NSCLC Patients**
Beshoy Guirges, Italy

16:23 **MA06.08 - Is Weight-Based Pembrolizumab Dosing as Effective as Standard Fixed Dose in Advanced NSCLC?**
Ari Raphael, Israel

16:28 **MA06.09 - Assessing the Impact of Project ASCENT, a Multi-Level Lung Cancer Screening Intervention Targeting Hispanic/Latin Individuals**
Manmeet Ahluwalia, USA

16:33 **Q&A**

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

15:30 - 16:45 OA09 - NEW ADVANCES IN PATHOLOGY

Track: Pathology and Biomarkers

NOT FOR CME CREDIT

ROOM 05

Chairs: *Cristina Teixeira, Spain and Ellen Nascimento, Brazil*

15:30 Welcome & Introduction

Cristina Teixeira, Spain and Ellen Nascimento, Brazil

15:32 OA09.01 - Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project
Sanja Dacic, USA

15:42 OA09.02 - I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC
Arsela Prelaj, Italy

15:52 OA09.03 - Real-World Assessment of TROP2-NMR by Quantitative Continuous Scoring (QCS) in Non-small Cell Lung Carcinoma (NSCLC)
Fernando Lopez-Rios, Spain

16:02 OA09.04 - Discussant
Vincezo L'imperio, Italy

16:12 Q&A

15:30 - 16:45 OA10 - OPTIMIZING SYSTEMIC THERAPY: BRIDGING NEW & OLD

Track: Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy

NOT FOR CME CREDIT

ROOM 07

Chairs: *Virginia Calvo, Spain, Pieter Postmus, Netherlands*

15:30 Welcome & Introduction
Virginia Calvo, Spain, Pieter Postmus, Netherlands

15:32 OA10.01 - Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in Patients with Advanced/Metastatic NSCLC in TROPION-Lung01
Elvire Pons-Tostivint, France

15:42 OA10.02 - Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study
Meichen Li, China

15:52 OA10.03 - Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients with Locally Advanced or Metastatic EGFR Mutated NSCLC
Wenfeng Fang, China

16:02 OA10.04 - Phase II Study of Iza-Bren (BL-B01D1) Combo with Osimertinib in EGFR Mutated Locally Advanced or Metastatic NSCLC Patients
Fei Zhou, China

16:12 OA10.05 - Discussant
Antonio Passaro, Italy

16:22 Q&A

16:00 - 17:00

EDITORIAL RECEPTION
(BY INVITATION ONLY)

FIRST FLOOR - WALKWAY TO PLenary HALL

REFRESHMENTS PROVIDED

17:00 - 18:15 ES31 - ADCS: CURRENT CONTROVERSIES

Track: *Metastatic Non-small Cell Lung Cancer - Cytotoxic Therapy*

ROOM 02

Chairs: *Riyaz Shah, UK and Fiona McDonald, UK*

17:00 Welcome & Introduction
Riyaz Shah, UK and Fiona McDonald, UK

17:02 ES31.01 - Leveraging ADCs for the HER Pathways. Where Do These Compounds Fit in HER2 and EGFR Space?
Susan Scott, USA

17:14 ES31.02 - Trop2 ADCs: Is There Hope or Is All Is Lost?
Stephanie Saw, Singapore

17:26 ES31.03 - Emerging ADCs: The Next Generation
Giuseppe Banna, UK

17:38 ES31.04 - Biomarkers for ADCs: IHC and Beyond
Sewanti Limaye, India

17:50 Q&A

17:00 - 18:15 ES32 - EXPERIMENTAL DESIGN FOR DISSECTING IMMUNE EVASION, CELL PLASTICITY, AND DRUG RESISTANCE

Track: *Tumor Biology - Translational Biology*

ROOM 03

Chairs: *Deepali Jain, India and Triparna Sen, USA*

17:00 Welcome & Introduction
Deepali Jain, India and Triparna Sen, USA

17:02 ES32.01 - Lung Cancer Plasticity
Tuomas Tammela, USA

17:14 ES32.02 - Immune Evasion in Early Lung Cancer
Celine Mascaux, France

17:26 ES32.03 - The Lung Cancer Microbiome
Sara Pilotto, Italy

17:38 ES32.04 - Drug Persister Cells in NSCLC
Hironichi Ebi, Japan

17:50 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

17:00 - 18:15 ES33 - PRECISION FRONTIERS: TARGETED THERAPIES IN EARLY-STAGE LUNG CANCER

Track: *Early-Stage Non-small Cell Lung Cancer*

ROOM 08

Chairs: *Jamie Chافت, USA and Antonio Calles, Spain*

17:00 Welcome & Introduction

Jamie Chافت, USA and Antonio Calles, Spain

17:02 ES33.01 - EGFR Mutant Non-small Cell Lung Cancer

Peng Zhang, China

17:14 ES33.02 - ALK Rearranged Non-small Cell Lung Cancer

Jay Lee, USA

17:26 ES33.03 - Other Actionable Oncogenic Alterations

Erin Gillaspie, USA

17:38 ES33.04 - Managing Toxicities, Surgery and Quality of Life

Margherita Majem, Spain

17:50 Q&A

17:00 - 18:15 ES34 - NARROWING DISPARITIES FOR EFFECTIVE MANAGEMENT OF LUNG CANCER ON A GLOBAL SCALE

Track: *Global Health, Health Services, and Health Economics*

ROOM 05

Chairs: *Helena Masua, Kenya and Samuel Kareff, USA*

17:00 Welcome & Introduction

Helena Masua, Kenya and Samuel Kareff, USA

17:02 ES34.01 - Bronchoscopy and Interventional Radiology in Resource Limited Settings (Challenges and Cost Related to Tissue Acquisition, Diagnosis and Staging)

Emmet O'Brien, Ireland

17:13 ES34.02 - Cost-Effective Processing of Tissue Samples in Resource Limited Settings in the Era of Precision Oncology (Access to and Cost of Immunohistochemistry and Molecular Biomarker Testing)

Amanjit Bal, India

17:24 ES34.03 - Improving Access to Surgery in Resource Limited Settings (Availability of Minimally Invasive Surgery, Wait Times, Cost)

Tomohito Saito, Japan

17:35 ES34.04 - Advanced Radiation Therapy Technologies in Resource Limited Settings (SBRT for Early Stage, Concurrent Chemoradiation for Locally Advanced NSCLC & SCLC-LD, Palliative Thoracic/Brain/Bone Radiation for Metastatic Disease)

May Abdel Wahab, Austria

17:46 ES34.05 - Targeted and Immunotherapy Drug Access in Resource Limited Settings (Availability/Approvals/Cost/Cost-Effectiveness)

Sze-Wai Chan, South Africa

17:57 Q&A

17:00 - 18:15 ES35 - EGFR AS A BIOMARKER: PAST, PRESENT, FUTURE

Track: *Pathology and Biomarkers*

ROOM 07

Chairs: *Beatriz Bellosillo, Spain and Christian Rolfo, USA*

17:00 Welcome & Introduction

Beatriz Bellosillo, Spain and Christian Rolfo, USA

17:02 ES35.01 - The Past: Discovery of EGFR and the Advances in Approach to Diagnosis

Jaclyn LoPiccolo, USA

17:14 ES35.02 - The Present: Evolving Landscape of Treatment and Resistance to EGFR Inhibitors

Clarissa Baldotto, Brazil

17:26 ES35.03 - The Present: How Do Different Parts of the World Approach EGFR Biomarkers (Due to Population Prevalence)

Jinyong Kim, Republic of Korea

17:38 ES35.04 - The Future: The Landscape of EGFR Histology and Histological Transformation

Fernando Lopez Rios, Spain

17:50 Q&A

17:00 - 18:15 ES36 - STAGE III NSCLC: HOW FAR CAN WE PUSH THE LIMITS? BATTLE OF PERSPECTIVES

Track: *Local-Regional Non-small Cell Lung Cancer*

ROOM 09

Chairs: *Nasser Altorki, USA and Ernest Nadal, Spain*

17:00 Welcome & Introduction

Nasser Altorki, USA and Ernest Nadal, Spain

17:02 ES36.01 - Revision of Cases

Marcelo Sánchez, Spain

17:12 ES36.02 - Panel Discussion

Benjamin Solomon, Australia, Salma Jabbour, USA, Fabio Ynoe de Morales, Canada, Young Tae Kim, Republic of Korea, Paula Ugaldede, USA, Esther Conde, Spain, Julien Mazieres, France, José Sanz-Santos, Spain

17:00 - 18:15 OA11 - BEYOND TNM - NEW HORIZONS IN PROGNOSTICATION

Track: *Pulmonology and Staging*

ROOM 04

Chairs: *Anna Rita Larici, Italy and Fredrick Asirwa, Kenya*

17:00 Welcome & Introduction

Anna Rita Larici, Italy and Fredrick Asirwa, Kenya

17:02 OA11.01 - Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database

*Lawson Eng, Canada**JTO Simultaneous Publication*

17:12 OA11.02 - Molecular Alterations and Survival: Analyses from IASLC 9th Edition Staging Database

*Fred R. Hirsch, USA**JTO Simultaneous Publication*

17:22 OA11.03 - The Survival Impact of Subdividing Clinical and Pathologic N2 Descriptors in a Population-Based Surgical Cohort

Jessica Rice, USA

17:32 OA11.04 - Validation and Refinement Proposal of the Ninth Edition n Descriptor for Non-small Cell Lung Cancer Receiving Neoadjuvant Therapy

Haojie Ji, China

17:42 OA11.05 - Discussant

Masahiro Tsuboi, Japan

17:52 Q&A

17:00 - 18:15 OA12 - NOVEL CLINICAL APPROACHES AND TRANSLATIONAL INVESTIGATION IN MESOTHELIOMA

Track: *Mesothelioma, Thymoma, and Other Thoracic Tumors*

ROOM 01

Chairs: *Serap Akyurek, Turkey and Joachim Aerts, Netherlands*

17:00 Welcome & Introduction

Serap Akyurek, Turkey and Joachim Aerts, Netherlands

17:02 OA12.01 - IASLC Mesothelioma Staging Project: Impact of Molecular Alterations on Survival in a Cohort From 9Th Edition Database

Valerie Rusch, USA

17:12 OA12.02 - CCTG IND227, a Randomized Trial of Chemotherapy + Pembrolizumab in Advanced Pleural Mesothelioma: Updated Analyses

Scott Laurie, Canada

17:22 OA12.03 - Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Resectable Diffuse Pleural Mesothelioma

Joshua Reuss, USA

17:32 OA12.04 - Radiation Reprograms CDKN2A/p16 Wild Type Epithelioid Mesothelioma Towards an Immune Responsive Tumor Microenvironment


Marc De Perrot, Canada

17:42 OA12.05 - Discussant

Nicolas Girard, France

17:52 Q&A

17:00 - 18:15 OA13 - OPTIMIZING FRONT-LINE TREATMENT IN SCLC

Track: *Small Cell Lung Cancer and Neuroendocrine Tumors*

ROOM 06

Chairs: *Gabriela Fernandez, Portugal and Samuel Rosner, USA*

17:00 Welcome & Introduction

Gabriela Fernandez, Portugal and Samuel Rosner, USA

17:02 OA13.01 - Safety and Survival Update of Tarlatamab with Anti-PD-L1 as 1L Maintenance After Chemo-IO for ES-SCLC: DeLLphi-303 Ph1b Trial

Kelly Paulson, USA

17:12 OA13.02 - Global Phase 2 Randomized Trial of BNT327 (Pumitamidg; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis

John Heymach, USA

17:22 OA13.03 - RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

Aaron Mansfield

17:32 OA13.04 - Highly Proliferative (G3) Lung Carcinoids: IASLC Pathology Committee Study With Proposal for Inclusion in WHO Classification

Natasha Rekhtman, USA

17:42 OA13.05 - Discussant

Charles Rudin, USA

17:52 Q&A

18:30 - 20:00 IASLC FOUNDATION APPRECIATION RECEPTION

(TICKETED EVENT)

OFFSITE: RESTAURANT MIRABÉ

19:30 - 23:00 IASLC CELEBRATION NIGHT

(TICKETED EVENT)

OFFSITE: TIBIDABO PARK

Arrive in style on the brand-new funicular, indulge in local cuisine and drinks, and enjoy live music and entertainment. Take in breathtaking panoramic views of the city while connecting with peers and sharing a night of celebration. Don't miss this special evening filled with great company and unforgettable moments!

Transportation from various Conference hotels provided. Check your ticket for details.



05

PROGRAM:
TUESDAY



When it comes to unexplained muscle weakness and fatigue in SCLC patients

LEAVE NO STONE UNTURNED

Your patients may also have Cancer-Associated LEMS,
which can make it difficult to get out of a chair or climb stairs

LEMS=Lambert-Eaton myasthenic syndrome; SCLC=small cell lung cancer; VGCC-Ab=voltage-gated calcium channel antibody.

Visit Booth 408 to learn how a VGCC-Ab test,
both P/Q and N types, can confirm a diagnosis.^{1,2}



References: 1. Gilhus NE. *Autoimmune Dis.* 2011;2011:973808. 2. Titulaer MJ, et al. *Lancet Neuro.* 2011;10(12):1098-1107.

© 2025 Catalyst Pharmaceuticals, Inc. All Rights Reserved. CAL-0015-1 May 2025

TUESDAY, SEPTEMBER 9, 2025

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

07:00 – 08:30 AFRICA STEERING COMMITTEE MEETING
(BY INVITATION ONLY)

MEETING ROOM A

08:30 – 10:00 PLO4 - SCIENTIFIC PLENARY WITH LECTURESHIP AWARD PRESENTATIONS: FROM LEARNERS TO LEADERS: ADVANCING ONCOLOGY TRAINING FOR THE NEXT GENERATION OF THORACIC ONCOLOGISTS

PLENARY HALL

Chairs: Isabelle Opitz, Switzerland and Jarushka Naidoo, Ireland

Welcome & Introduction

Isabelle Opitz, Switzerland and Jarushka Naidoo, Ireland

PLO4.01 Clifton F. Mountain Lectureship Award for Staging
Jin Mo Goo, Republic of Korea

PLO4.02 Fred R. Hirsch Lectureship Award for Translational Research
Mary Beth Beasley, USA

PLO4.03 Daniel C. Inde Lectureship Award for Medical Oncology
Lizza Hendriks, Netherlands

PLO4.04 Data-Driven Oncology: How Big Data and AI Can Transform Lung Cancer
Arsela Prelaj, Italy

PLO4.05 Unlocking the Complete Molecular Code: The Future of Thoracic Oncology Diagnostics with Epigenetics, Fragmentomics, Proteomics, Spatial Technologies, and Bioinformatics
Victor Velculescu, USA

PLO4.06 Empowering the Next Generation of Surgical Oncologists: Leveraging Technology for Oncologic Surgical Training
Lars Konge, Denmark

Q&A

09:00 – 16:00 IASLC REVIEWER WORKSHOP
(BY INVITATION ONLY)

Chair: Yun-Sin Lim, China

MEETING ROOM C

NOT FOR CME CREDIT



HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

10:00 – 11:30 POSTER VIEWING BREAK WITH P3 PRESENTERS IN ATTENDANCE

EXHIBIT HALL REFRESHMENTS PROVIDED NOT FOR CME CREDIT

- Track 01: Risk Factors, Risk Reduction & Tobacco Control Rows: 01-06
- Track 03: Tumor Biology – Translational Biology Rows: 06-11
- Track 09: Metastatic Non-small Cell Lung Cancer – Local Therapies Rows: 11-12
- Track 12: Metastatic Non-small Cell Lung Cancer – Targeted Therapy Rows: 12-19
- Track 13: Small Cell Lung Cancer and Neuroendocrine Tumors Rows: 20-23
- Track 14: Mesothelioma, Thymoma, and Other Thoracic Tumors Rows: 23-25
- Track 16: Patient Advocacy Rows: 25-27
- Track 18: Clinical Trials in Progress Rows: 28-36

10:15 – 11:15 HOD02 - HIGHLIGHTS OF THE DAY - MONDAY ABSTRACTS

EXHIBIT HALL/EPOSTER LOUNGE NOT FOR CME CREDIT

- 10:15 HOD02.01 - Pathology
Fernando Lopez-Rios, Spain
- 10:25 HOD02.02 - Local and Systemic Therapies
Enriqueta Felip, Spain
- 10:35 HOD02.03 - Targeted Therapies
Charu Aggarwal, USA
- 10:45 HOD02.04 - Advances in SCLC, Mesothelioma and Thymic Malignancies
Rafal Dziadziuszko, Poland
- 10:55 HOD02.05 - Presidential Symposia Abstracts (from Monday)
Benjamin Besse, France

10:15 – 11:15 PRESS CONFERENCE

ROOM CC7 AB NOT FOR CME CREDIT

11:30 – 12:45 ES37 - CHALLENGING SCENARIOS FOR IMMUNOTHERAPY TREATMENT

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy ACCME ACCREDITED BY IASLC

- ROOM 02
- Chairs: *Natasha Leigh, Canada and Thanyanan Baisamut, Thailand*
- 11:30 Welcome & Introduction
Natasha Leigh, Canada and Thanyanan Baisamut, Thailand
- 11:52 ES37.01 - Immunotherapy in Auto-Immune Diseases and Organ Transplant Recipients: Can They Go Together?
Naoka Murakami, USA

- 11:44 ES37.02 - Patients Older Than 75 Years of Age or Frail (PS 2/3)
Roberto Ferrara, Italy
- 11:56 ES37.03 - Immunotherapy and Brain Metastases
Thomas John, Australia
- 12:08 ES37.04 - Is It Feasible to Restart Immunotherapy After Severe Immune-Related Toxicity?
Satoru Miura, Japan
- 12:20 Q&A

11:50 – 12:45 ES38 - WHAT PROVIDERS NEED TO KNOW TO PERSONALIZE CARE FOR RESECTABLE LUNG CANCER

Track: Early-Stage Non-small Cell Lung Cancer ACCME ACCREDITED BY IASLC

- ROOM 08
- Chairs: *Fabiana Cecere, Italy and Ricardo Terra, Brazil*
- 11:50 Welcome & Introduction
Fabiana Cecere, Italy and Ricardo Terra, Brazil
- 11:52 ES38.01 - EGFR, ALK, PD-L1 and Emerging Biomarkers
Sara Najmeh, USA
- 11:44 ES38.02 - Extent of Lung Resection After Neo-Adjuvant Treatment
Shun-ichi Watanabe, Japan
- 11:56 ES38.03 - Lymph Node Management After Induction: Challenges and Extent of Lymphadenectomy
Carlos Galvez, Spain
- 12:08 ES38.04 - Circulating Tumor DNA to Guide Management of Patients With Resectable NSCLC
Sinchita Roy Chowdhuri, USA
- 12:20 Q&A

11:50 – 12:45 ES39 - BREAKING NEW GROUND: CHALLENGING ADVANCES IN SCLC THERAPY

Track: Small Cell Lung Cancer and Neuroendocrine Tumors ACCME ACCREDITED BY IASLC

- ROOM 04
- Chairs: *Jacob Sands, USA and Susan Harden, Australia*
- 11:50 Welcome & Introduction
Jacob Sands, USA and Susan Harden, Australia
- 11:52 ES39.01 - Challenges and Perspectives in LS-SCLC
Kenneth O'Byrne, Australia
- 11:44 ES39.02 - Challenges and Novel Strategies in Advanced SCLC
Noura Choudhury, USA
- 11:56 ES39.03 - Rethinking Radiotherapy in the Era of New Standards for SCLC
Anthony Levy, France
- 12:08 ES39.04 - Choosing Wisely: Strategies for Navigating Therapeutic Options in Special SCLC Populations
Motoko Tachihara, Japan
- 12:20 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

11:30 – 12:45 ES40 – UNITING FORCES: MULTIDISCIPLINARY APPROACHES TO HOLISTIC LUNG CANCER CARE

Track: *Multidisciplinary Care: Nursing, Allied Health & Palliative Care*



ROOM 03

Chairs: *Lucia Viola, Colombia and Carlos Cabrera-Galvex, Spain*

11:30 Welcome & Introduction

Lucia Viola, Colombia and Carlos Cabrera-Galvex, Spain

11:32 ES40.01 – Finding Your Voice: Speech and Swallowing Strategies for Lung Cancer Patients

Eduardo Rios, Spain

11:44 ES40.02 – Exercise and Optimization in Patients with Lung Cancer: The Role of Physiotherapy in Enhancing Lung Cancer Patients' Quality of Life

Morten Quist, Denmark

11:56 ES40.03 – The Heart of Care: Empowering Lung Cancer Patients Through Oncology Nursing Support

Mary Duffy, Australia

12:08 ES40.04 – Living with Dignity: Palliative Care Strategies to Enhance Quality of Life in Lung Cancer

Guida Da Ponte, Portugal

12:20 Q&A

11:30 – 12:45 HOW05 – NEXT GENERATION SEQUENCING CLINICAL REPORT DECODIFICATION IN NON-SMALL CELL LUNG CANCER #1

(LIMITED CAPACITY – FIRST COME FIRST SERVED)



ROOM 11 *This session will be repeated today from 13:00 to 14:15.*

11:30 HOW05.01 – Next Generation Diagnosis in Patients with Non-small Cell Lung Cancer

Ola Khorshid, Egypt

11:50 HOW05.02 – Report Next Generation Sequencing Data for Clinical Interpretation


Christian Rolfo, USA

12:10 HOW05.03 – Hands-On Practical Training

Gianluca Russo, Italy

11:30 – 12:45 MA07 – NEW PERSPECTIVES IN PATHOLOGY BIOMARKERS

Track: *Pathology and Biomarkers*



ROOM 09

Chairs: *Fernando Lopez-Rios, Spain and Veronica Cheung, Australia*

11:30 Welcome & Introduction

Fernando Lopez-Rios, Spain and Veronica Cheung, Australia

11:31

MA07.01 – A Grading System for Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee
Mari Mino-Kenudson, USA

11:36

MA07.02 – Development and Prospective Validation of a Chromatin-Based Classification for Small-Cell Lung Cancer
Anish Thomas, USA

11:41

MA07.03 – Morphological Implication of Invasive Lung Adenocarcinoma -Analysis Employing AI Method Based on Noguchi's Classification
Hitomi Kawaii, Japan

11:46

Q&A

11:54

MA07.04 – Integration of a Molecular Prognostic Classifier Enhances Conventional Staging of Lung Adenocarcinoma
Hanie Abolfathi, Canada

11:59

MA07.05 – Lung Cancer with Spread of Tumor Through Air Spaces: Transcriptomic Biosignature of Primary Tumors and Expression Analysis Airway Tumor Clusters
Whitney Brandt, USA

12:04

Q&A

12:12

MA07.06 – Characterization of Protein Arginine Methyltransferase 5 (PRMT5) Expression in Methylothioadenosine Phosphorylase (MTAP) Deleted NSCLC
Robert Hsu, USA

12:17

MA07.07 – Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC
Benjamin Besse, France

12:22

MA07.08 – MFAP4+ Pericytes Promote Tc17-Mediated Pneumonitis Induced by the Combination of Radiotherapy & Immunotherapy
Xue Bai, China

12:27

MA07.09 – Three-Year Survival Update and Biomarker Analysis of Neoadjuvant Chemotherapy in Potentially Resectable Stage IIIA/IIIB NSCLC
Kewei Ma, China

12:32

Q&A

11:30 – 12:45

MA08 – COMMON AND UNCOMMON EGFR MUTATIONS, NEW TREATMENTS IN THE HORIZON



Track: *Metastatic Non-small Cell Lung Cancer – Targeted Therapy*

ROOM 01

Chairs: *Alessio Cortellini, Italy and Cheryl Ho, Canada*

11:30

Welcome & Introduction
Alessio Cortellini, Italy and Cheryl Ho, Canada

11:32

MA08.01 – A Multinational Phase 2 Randomized Pivotal Study of Sunvozertinib in Pretreated NSCLC with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, China

11:37

MA08.02 – Ziplertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab
Zofia Piotrowska, USA

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

11:42 MA08.03 - First-Line Subcutaneous Amivantamab Plus Chemotherapy in EGFR Exon 20 Insertion-Mutated Advanced NSCLC: Results From PALOMA-2
Sun-Min Lim, Republic of Korea

11:47 Q&A

11:55 MA08.04 - Phase 2 Interim Results of Ziplertinib in Patients with NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations
Hibiki Udagawa, Japan

12:00 MA08.05 - PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks (Q4W) Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC
Susan Scott, USA

12:05 Q&A

12:13 MA08.06 - Comparison of Asandeteritinib and Osimertinib in EGFR-Mutated NSCLC with Brain Metastases: Interim Analysis of the ESAONA Pivotal Study
Yuankai Shi, China

12:18 MA08.07 - OCELOT: A Pan-Canadian Study of Osimertinib for Patients with Treatment Naive Advanced NSCLC with Uncommon EGFR Mutations
Daniel Breadner, Canada

12:23 Q&A

11:30 - 12:45 OA14 - CANCER EVOLUTION AND DRUG RESISTANCE

Track: *Tumor Biology – Preclinical Biology*

ROOM 05

Chairs: *Yuchen Han, China and Diego de Miguel Perez, USA*

11:30 Welcome & Introduction

Yuchen Han, China and Diego de Miguel Perez, USA

11:32 OA14.01 - Glutamine Metabolic Reprogramming Drives Evolution of Lung Adenocarcinoma

Yang Wang, China

11:42 OA14.02 - DCBLD2high Tumor-Derived Retinoic Acid Orchestrates Macrophages to Drive Vascular Immunosuppression and Immunotherapy Resistance
Shangbiao Li, China

11:52 OA14.03 - Functional Characterization of Osimertinib-Induced Drug Tolerant Persisters in Lung Adenocarcinoma

Kristyna Gorospe, Canada

12:02 OA14.04 - Genetic Inactivation of the Epigenetic Regulator ATF7IP: Functional Impact in Lung Adenocarcinomas

Juan Morillas, Spain

12:12 OA14.05 - Panorama of Chromosomal Instability in 1209 Lung Cancer Genomes
Lixing Yang, USA

12:22 OA14.06 - Discussant
Roberto Bianco, Italy

12:32 Q&A

11:30 - 12:45 OA15 - GLOBAL LUNG CANCER SCREENING STRATEGIES

Track: *Screening and Early Detection*

ROOM 07

Chairs: *Long Jiang, China and Giulia Pasello, Italy*

11:30 Welcome & Introduction
Long Jiang, China and Giulia Pasello, Italy

11:32 OA15.01 - Results of the Croatian National Lung Cancer Screening Program
Miroslav Samaržija, Croatia

11:42 OA15.02 - Preliminary Results of the Singapore Lung Cancer Screening Through Integrating CT With Other Biomarkers (SOLSTICE) Study
Gillianne Lai, Singapore

11:52 OA15.03 - Female Asian Nonsmoker Screening Study (FANSS): A U.S. Based Lung Cancer Screening Program in a Non-Smoking Population
Elaine Shum, USA

12:02 OA15.04 - Discussant
David Baldwin, UK

12:12 Q&A

11:30 - 12:45 OA16 - BUILDING BRIDGES BETWEEN RESECTABLE AND UNRESECTABLE STAGE III NSCLC

Track: *Local-Regional Non-small Cell Lung Cancer*

ROOM 06

Chairs: *Giulia Veronesi, Italy and Cecile Le Pechoux, France*

11:30 Welcome & Introduction
Giulia Veronesi, Italy and Cecile Le Pechoux, France

11:32 OA16.02 - RAPID-RT: Using Rapid-Learning to Assess the Survival Impact of Limiting Dose to a New Cardiac Avoidance Area During Lung Cancer Radiotherapy
Corinne Faivre-Finn, UK

11:42 OA16.03 - Sequencing of Radiotherapy and Immunotherapy Stratifies Pneumonitis Risk: A Propensity-Matched Multicenter Study
Wei Wei, China

11:52 OA16.04 - Prognostic Value of Residual Viable Tumor in Lymph Nodes of Non-small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy
Tianxiao Han, China

12:02 OA16.05 - Discussant
Matthew Hatton, UK

12:12 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:00 - 14:15 ES41 - CHALLENGES IN ONCOGENE DRIVEN NSCLC: YOUNG PATIENTS, ECONOMIC TOXICITY, FEASIBILITY FOR DE-ESCALATING TKI

Track: *Metastatic Non-small Cell Lung Cancer - Targeted Therapy*

ROOM 08

Chairs: *Jordi Remon, France and Vanita Noronha, India*

13:00 Welcome & Introduction

Jordi Remon, France and Vanita Noronha, India

13:02 ES41.01 - Oncogene Addicted NSCLC in Young Patients: Incidence and Outcome on Targeted Therapies

Hossein Borghaei, USA

13:12 ES41.02 - Pregnancy in Oncogene Addicted NSCLC: Incidence, Feasibility and Risks

Martina Imbimbo, Italy

13:22 ES41.03 - How to Reduce Inequalities into Access to Targeted Therapies Worldwide, Financial Burden

Luis Corrales, Costa Rica

13:32 ES41.04 - Is It Feasible the De-Escalation Treatment with TKI in Oncogene Addicted NSCLC

Halmos Balaz, USA

13:42 ES41.05 - How to Explain to Your Children You Are a Patient with Lung Cancer?

Terri Conneran, USA

13:52 Q&A / Panel Discussion

13:00 - 14:15 ES42 - PATIENT AND EXPERTS DIALOGS FOR NEOADJUVANT, ADJUVANT OR PERIOPERATIVE MODALITIES FOR RESECTABLE NSCLC

Track: *Early-Stage Non-small Cell Lung Cancer*

ROOM 02

Chairs: *Kristen Marrone, USA and Yuko Oya, Japan*

13:00 Welcome & Introduction

Kristen Marrone, USA and Yuko Oya, Japan

13:02 ES42.01 - Patient Board

Yvonne Diaz, UK, Debra Montague, UK, Merel Hennink, Netherlands

13:17 ES42.02 - Neoadjuvant

Maria Rosario Campelo, Spain

13:29 ES42.03 - Adjuvant

Mary O'Brien, UK

13:41 ES42.04 - Perioperative

David Jones, USA

13:53 Discussion

13:00 - 14:15

ES43 - CONFOUNDING CASES OF PULMONARY NODULES: ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF SUBSOLID AND GROUND GLASS OPACITIES

Track: *Pathology and Biomarkers*

ROOM 07

Chairs: *Jia Luo, USA and Wei Gu, USA*

13:00 Welcome & Introduction

Jia Luo, USA and Wei Gu, USA

13:02 ES43.01 - The Radiologist: Neoplastic or Not Neoplastic?

Mathias Prokop, Netherlands

13:12 ES43.02 - The Pathologist: The Diagnostic Workflow of Lung GG or SS Nodule

Veronica Cheung, Australia

13:22 ES43.03 - The Oncologist: Multiple Primaries or Metastases?

Eduarne Arriola, Spain

13:32 ES43.04 - The Surgeon: To Resect or Not to Resect?

Andrea Billè, UK

13:42 ES43.05 - The Patient Advocate/Nurse Practitioner: Patient and Clinician Perspective on Lung Nodules

Stephanie Canty, USA

13:52 ES43.06 - The Radiation Oncologist View: How to Treat?

Sara Ramella, Italy

14:02 Q&A

13:00 - 14:15 ES44 - ADDRESSING SPECIAL CONDITIONS TO BRIDGE GAPS IN UNRESECTABLE NSCLC

Track: *Local-Regional Non-small Cell Lung Cancer*

ROOM 04

Chairs: *Monica Castro, Argentina and Dusty Donaldson, USA*

13:00 Welcome & Introduction

Monica Castro, Argentina and Dusty Donaldson, USA

13:02 ES44.01 - Tackling Cancer Cachexia in Locally Advanced NSCLC

Puneeth Iyengar, USA

13:14 ES44.02 - Optimizing the Management of Treatment-Related Pneumonitis

Samantha Aso, Spain

13:26 ES44.03 - Caring for Long-Term Survivors After Curative Chemoradiation

Nicole Rankin, Australia

13:38 ES44.04 - Novel Approaches for Patients Who Are Unfit for Concurrent Chemoradiotherapy

Andrea Filippi, Italy

13:50 Q&A

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:00 - 14:15 HOW06 - *REPEAT SESSION* NEXT GENERATION SEQUENCING CLINICAL REPORT DECODIFICATION IN NON-SMALL CELL LUNG CANCER #2

(LIMITED CAPACITY - FIRST COME FIRST SERVED)

ROOM 11



11:50 HOW06.01 - Next Generation Diagnosis in Patients with Non-small Cell Lung Cancer
Ola Khorshid, Egypt

11:50 HOW06.02- Report Next Generation Sequencing Data for Clinical Interpretation
Christian Rolfo, USA

12:10 HOW06.03 - Hands-On Practical Training
Gianluca Russo, Italy

13:00 - 14:15 MA09 - DIVING DEEP INTO DIVERSITY: OLD AND NEW RISKS FOR LUNG CANCER

Track: Risk Factors, Risk Reduction & Tobacco Control

ROOM 05



Chairs: Rachael Murray, UK and Biagio Ricciuti, USA

13:00 Welcome & Introduction
Rachael Murray, UK and Biagio Ricciuti, USA

13:02 MA09.01 - Association of Air Pollution Exposure with Lung Screening Outcomes and Lung Cancer Risk in the Taiwan TALENT Study
Rafael Meza, Canada

13:07 MA09.02 - Impact of Air Pollution and EGFR Mutation on Epigenetic Age and Lung Cancer: A Pilot Study
Anna McGuire, Canada

13:12 MA09.03 - Determining the Role of Fine Particulate Matter (PM2.5) in Lung Cancer Initiation
Peiyao Wang, Canada

13:17 Q&A

13:25 MA09.04 - Maternal Preconception Vaping of Nicotine Induces Severe Airway Remodeling in Offspring and Reduces Airway Progenitor Cells in D. Melanogaster
Leizhi Shi, Germany

13:30 MA09.05 - The Effect of Lung Cancer Screening on Smoking Behaviors - No Evidence of a 'License to Smoke' Effect
Matthew Callister, UK

13:35 MA09.06 - Impact of Smoking Cessation at Diagnosis on Overall Survival in Lung Cancer Patients: A Comprehensive Meta-Analysis
Dong Won Park, Republic of Korea

13:40 Q&A

13:48 MA09.07 - Body Roundness Index and Polygenic Risk Score Improve Lung Cancer Risk Prediction Over BMI: Prospective Analyses in the UK Biobank
Wenxuan Li, China

13:53 MA09.08 - Germline Variants in Indian NSCLC Patients with Familial Aggregation: A Prospective Cohort Study
Prabhat Malik, India

13:58 MA09.09 - Unraveling Ancestry Disparities and Intratumoral Heterogeneity in Non-small Cell Lung Cancer
Wenxiang Wang, China

14:03 Q&A

13:00 - 14:15 MA10 - LONGER FOLLOW UP AND NEW IO COMBINATIONS

Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy

ROOM 06



Chairs: Sara Goldberg, USA

13:00 Welcome & Introduction
Sara Goldberg, USA

13:02 MA10.01 - Phase II Trial of Serplulimab Plus Bevacizumab and Chemotherapy for Treatment-Naïve Non-Squamous NSCLC With Brain Metastases (SUPER BRAIN)
Hui Yu, China

13:07 MA10.02 - CAN-2409 With Continued Immune Checkpoint Inhibitor (ICI) in Patients with Stage III/IV NSCLC With Inadequate Response to ICI
Charu Aggarwal, USA

13:12 MA10.03 - Efficacy and Safety of Cadonilimab Plus Pulocimab in NSCLC Patients Who Progressed Following Prior Immunotherapy: A Phase 1b/2 Study
Yulong Zheng, China

13:17 Q&A

13:25 MA10.04 - Low-Pass Wgs Reveals Clonal Evolution of CNAs Associated with Response to the First-Line Immunotherapy or Chemoimmunotherapy in NSCLC Patients
Marcin Nicos, Poland

13:30 MA10.05 - Phase I/II Study of Nivolumab and Ipilimumab with Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC
Mehmet Altan, USA

13:35 MA10.06 - IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration
Federico Cappuzzo, Italy

13:40 Q&A

13:48 MA10.07 - Impact of Myeloid Growth Factor Support on Outcomes in RELATIVITY-104: Insights from Clinical and Preclinical Data in NSCLC
Vamsidhar Velcheti, USA

13:53 MA10.08 - Anti-PD-1 Re-Challenge After Immune Priming by CTLA-4 Inhibition and Immune Boosting Through Radiotherapy in Advanced NSCLC: The RAD-IO Trial
Daphne van der Geest, Netherlands

HOD	Highlight of the Previous Day	P	Poster
HOW	Hands-On Workshop	PT	Poster Tour
MA	Mini Oral Abstract Session	PL	Plenary
OA	Oral Abstract Session	WS	Workshop

13:58 MA10.09 - Cemiplimab Plus Chemotherapy vs Chemotherapy in Advanced NSCLC: 5-Year Results from Phase3 EMPOWER-Lung 3 Part 2 Trial
Ana Baramidze, Georgia

14:03 Q&A

13:00 - 14:15 MA11 - INNOVATIVE THERAPEUTIC STRATEGIES AND MOLECULAR INSIGHTS IN SCLC AND NEUROENDOCRINE TUMORS

Track: *Small Cell Lung Cancer and Neuroendocrine Tumors*

ROOM 01

Chairs: *Tatiane Montella, Brazil and Julio Oliveira, Portugal*

13:00 Welcome & Introduction
Tatiane Montella, Brazil and Julio Oliveira, Portugal

13:02 MA11.01 - Phase 1 Study of DLL3-Targeted CAR-T Cells Armored with dnTGFBR2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers
Adam Schoenfeld, USA

13:07 MA11.03 - Tifemalimab Plus Toripalimab and Chemotherapy as a First-Line Therapy in ES-SCLC: A Phase Ib/II Study
Ziming Li, China

13:12 Q&A

13:20 MA11.04 - Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results from the Phase 3 IMforte Study
Martin Reck, Germany

13:25 MA11.05 - Comparative Outcomes of Lobectomy and Sub-Lobar Resections in Pulmonary Carcinoids: A Multicentre Retrospective Cohort Study
Michal Dziedzic, Poland

13:30 MA11.06 - Multiomic Profiling of Inter-Lesion Heterogeneity in Small Cell Lung Cancer: A Multicenter Rapid Research Autopsy Program
Zsolt Megyesfalvi, Austria

13:35 Q&A

13:43 MA11.08 - Longitudinal Circulating Tumor DNA Dynamics Predict Therapeutic Efficacy in ES-SCLC Treated with Immunotherapy
Chunxia Su, China

13:48 MA11.09 - Circulating Tumor DNA Refines Consolidation Immunotherapy for Limited-Stage SCLC
Nan Bi, China

13:53 MA11.10 - IFITM3 Enhances Immunotherapy Sensitivity Through MHC-I Regulation in Small Cell Lung Cancer
Xinyu Liu, China

13:58 Q&A

NOT FOR CME CREDIT

13:00 - 14:15 OA17 - BALANCING COST, CARE AND PATIENT CHOICE IN REAL WORLD JOURNEY AND RESEARCH

Track: *Patient Advocacy*

ROOM 09

Chairs: *Barbara Melosky, Canada and Thomas Stinchcombe, USA*

13:00 Welcome & Introduction
Barbara Melosky, Canada and Thomas Stinchcombe, USA

13:02 OA17.01 - Stigma and Psychological Distress in Patients with Lung Cancer: A Possible Role of EMDR (Eye Movement Desensitization and Reprocessing) Therapy
Annamaria Catino, Italy

13:12 OA17.02 - Knowledge and Shared Decision Making - a European Experience
Debra Montague, Switzerland

13:22 OA17.03 - The Patient Voice on Required Research Biopsies: Results of a Survey Study Exploring the Perspective of Patients with Lung Cancer
Faith Abodunrin, USA

13:32 OA17.04 - Financial Toxicity in Patients Who Received Targeted Therapy for Lung Cancer
Caroline Burley, USA

13:42 OA17.05 - Discussant
William William Jr, Brazil

13:52 Q&A

13:00 - 14:15 OA18 - THE BEST ROAD: REDUCING DISPARITIES AND IMPROVING EARLY DETECTION RATES

Track: *Global Health, Health Services, and Health Economics*

ROOM 03

Chairs: *Verna Vanderpuye, Ghana and George Oblitas, Peru*

13:00 Welcome & Introduction
Verna Vanderpuye, Ghana and George Oblitas, Peru

13:02 OA18.01 - Improving Lung Cancer Outcomes Through Policy a Global Perspective on Risk Reduction, Early Detection, Care and Survivorship
Andreas Charalambous, Cyprus

13:12 OA18.02 - Emerging Disparities in Lung Cancer Burden in the Americas: A GLOBOCAN-Based Projection to 2050
Gabriela Carmona De Souza, Brazil

13:22 OA18.03 - Cost Effectiveness of Australian Lung Cancer Screening Eligibility Criteria: A Comparison Study
Chellan Kumarasamy, Australia

13:32 OA18.04 - Sociodemographic and Healthcare Factors Associated with Enrollment in a Clinical Trial Integrating Tobacco Cessation and Lung Cancer Screening
Efrén Flores, USA

13:42 OA18.05 - Discussant
Cecilia Pompili, UK

13:52 Q&A

SCIENTIFIC PROGRAM Tuesday, September 9, 2025

14:15 – 15:45

CLOSING LUNCH - NOT SO TRIVIAL: A WCLC INTERDISCIPLINARY QUIZ CHALLENGE

PLENARY HALL

Quizmaster: Stephen Liu, USA

Don't miss it! A dynamic and engaging session where some of the field's most renowned names go head-to-head in a spirited competition. It is the perfect way to close out the Conference with great food and high energy!



LUNCH PROVIDED



NOT FOR CME CREDIT

ON-DEMAND

HOD03 - HIGHLIGHTS OF THE DAY - TUESDAY ABSTRACTS

HOD03.01

Tumor Biology

Cristina Teixido, Spain

HOD03.02

Screening

Pan Chyr Yang, Taiwan

HOD03.03

Local-Regional NSCLC

Lilian Faroni, Brazil

HOD03.04

Patient Advocacy and Global Health

Jia Luo, USA

Purchase Your Tickets at the Registration Desk by **September 7.**

SEPT
08

TIBIDABO
BARCELONA

19:30 – 23:00

IMPORTANT: Please ensure you have a copy of your e-ticket to gain access. Your e-ticket has been emailed to you from: wclc2025-registration@icsevents.com.

INCLUDED WITH YOUR TICKET:

- Bus Transfers from Key Locations
- Round-trip Funicular Rides
- Spanish Cuisine and Beverages
- Exclusive Access to Select Park Rides
- Live Entertainment
- Panoramic Views of Barcelona

IASLC

CELEBRATION
NIGHT

Tibidabo, Barcelona



IASLC | 2025 World Conference
on Lung Cancer
SEPTEMBER 6-9, 2025 | BARCELONA, SPAIN

WCLC 2025'S GOT TALLENT

THANK YOU TO OUR AMAZING PERFORMERS!

PERFORMING AT THE
OPENING PLENARY:

- ANDREAS RIMMER**, GERMANY
- HENRY PARK**, USA
- SANTIAGO VITERI**, SPAIN
- TOM JOHN**, AUSTRALIA
- SANJAY POPAT**, UK

PERFORMING AT THE
CLOSING LUNCH:
DAVID LEE, USA

IASLC | 2026 World Conference
on Lung Cancer
SEPTEMBER 12 - 15, 2026 | SEOUL, REPUBLIC OF KOREA

WANT TO BE ON STAGE IN SEOUL?

Watch out for the WCLC 2026 Call for Talent on wclc.iaslc.org



06

POSTERS & EPOSTERS

Each poster has a unique number that provides important information when and where it will be presented. Poster Number Format: **P1.04.11**

Example: **P1.04.11**

P1

04

11

DAY OF PRESENTATION

- P1:** Sunday, September 7
- P2:** Monday, September 8
- P3:** Tuesday, September 9

TOPIC NUMBER

- 04:** This poster belongs to the track 'Screening and Early Detection'

POSTER NUMBER

- 11:** This is the 11th poster in this track

Sunday, September 7, 2025 – P1 Posters

Presenters in Attendance: **10:30 – 12:00**

- Track 04:** Screening and Early Detection
- Track 07:** Early-Stage Non-Small Cell Lung Cancer
- Track 11:** Metastatic Non-small Cell Lung Cancer – Immunotherapy
- Track 17:** Global Health, Health Services, and Health Economics

- Rows: 01 - 06
- Rows: 06 - 12
- Rows: 12 - 20
- Rows: 20 - 28

Monday, September 8, 2025 – P2 Posters

Presenters in Attendance: **10:30 – 12:00**

- Track 02:** Tumor Biology – Preclinical Biology
- Track 05:** Pulmonology and Staging
- Track 06:** Pathology and Biomarkers
- Track 08:** Local-Regional Non-small Cell Lung Cancer
- Track 10:** Metastatic Non-small Cell Lung Cancer – Cytotoxic Therapy
- Track 15:** Multidisciplinary Care: Nursing, Allied Health and Palliative Care

- Rows: 01 - 05
- Rows: 05 - 07
- Rows: 07 - 17
- Rows: 17 - 23
- Rows: 23 - 25
- Rows: 25 - 28

Tuesday, September 9, 2025 – P3 Posters

Presenters in Attendance: **10:00 – 11:30**

- Track 01:** Risk Factors, Risk Reduction & Tobacco Control
- Track 03:** Tumor Biology – Translational Biology
- Track 09:** Metastatic Non-small Cell Lung Cancer – Local Therapies
- Track 12:** Metastatic Non-small Cell Lung Cancer – Targeted Therapy
- Track 13:** Small Cell Lung Cancer and Neuroendocrine Tumors
- Track 14:** Mesothelioma, Thymoma, and Other Thoracic Tumors
- Track 16:** Patient Advocacy
- Track 18:** Clinical Trials in Progress

- Rows: 01 - 06
- Rows: 06 - 11
- Rows: 11 - 12
- Rows: 12 - 19
- Rows: 19 - 23
- Rows: 23 - 25
- Rows: 25 - 27
- Rows: 27 - 36



POSTERS

SUNDAY, SEPTEMBER 7, 2025

10:30 – 12:00 Presenters in Attendance

TRACK 04: SCREENING AND EARLY DETECTION

- P1.04.01** Stage Shift and Then Some – St. Elizabeth Healthcare’s Notable Journey, 50,000 Screens Later
Michael Gieske, USA
- P1.04.02** Performance of AI Vs. Radiologists in the 4-IN-THE-LUNG-RUN Lung Cancer Screening Trial: Annual Follow-Up Results
Margolein Heuvelmans, Netherlands
- P1.04.03** Comorbidities and Social Factors in Lung Cancer Screening Eligibility: Insights from the Colaas and Lc65 Cohorts in Switzerland
Louis Gros, Switzerland
- P1.04.04** Effect of Social Determinants of Health on Lung Cancer Screening Uptake in the U.S.
Elizabeth Seitz, USA
- P1.04.05** Diminishing Eligibility for Lung Cancer Screening According to Standardized Screening Guidelines
Janet Song, USA
- P1.04.06** AI Performance for Lung Nodule Growth in UK Lung Cancer Screening: Expert Consensus and Histological Validation
Michael Davies, UK
- P1.04.07** Projection of the Lung Cancer Screening Eligible Population in Argentina from 2000 to 2050
M. Victoria Salgado, Argentina
- P1.04.08** Program Guidelines for Australia’s National Lung Cancer Screening Program: A Robust and Consultative Development Approach
Nicole Rankin, Australia
- P1.04.09** Size Distribution and Short-Term Progression of New Nodules From the 4ITLR Lung Cancer Screening Trial
Margolein Heuvelmans, Netherlands
- P1.04.10** Lung Cancer Screening Completion Rates as Predicted by Social Deprivation
Randi Williams, USA
- P1.04.11** New Nodule Lung Cancer in the UK Lung Cancer Screening Trial: Characteristics and Comparison with NELSON
Michael Davies, UK
- P1.04.12** Smoking Duration Lung Screening Criteria (Potter Criteria) Captures More Underrepresented Individuals at Risk for Lung Cancer
Teri Hill, USA
- P1.04.13** The Impact of Reconstruction Kernel and Hounsfield Unit Threshold on Emphysema Quantification from Lung Cancer Screening Data
Hailan Liu, Netherlands
- P1.04.14** Age, Risk Thresholds and Cost-Effectiveness: Evaluating Lung Cancer Screening Using the PLCom2012 Model
Megha Sikarwar, Germany
- P1.04.15** Lung Cancer Screening in Switzerland: Baseline Results from the Vaud Pilot Project
Cédric Bongard, Switzerland
- P1.04.16** Real-World Outcomes of Lung Cancer Screening and High-Risk Lung-RADS 4 Nodules at VA Northern California Health Care System
Cristhlean Ochoa, USA

- P1.04.17** Poor Utilization of Lung Cancer Screening Among Cancer Survivors in the USA
Alexis Chidi, USA
- P1.04.18** Diagnosis of Sub-Cm Lung Nodules with Deep Learning Segmentation and Radiomics-Based Machine Learning Classifiers
Ian Janzen, Canada
- P1.04.19** Evaluating the Impact of Electronic Reminders on Lung Cancer Screening
Carolyn Chang, USA
- P1.04.20** Barriers to Lung Cancer Screening Among Overdue Patients: a Quality Improvement Initiative
Sania Choudhary, USA
- P1.04.21** Molecular Profiles of Clinical and Radiological Features in Pre-Invasive Lung Adenocarcinoma
Yi-Duo Lin, China
- P1.04.22** The Relationship Between Nodular Pleural Tail Sign and Metastasis or Recurrence of Peripheral Lung Cancer
Anle Yu, China
- P1.04.23** Real-World Predictive Performance of Lung-RADS in the Evaluation of Part-Solid Nodules
Seulgi You, Republic of Korea
- P1.04.24** TabPFN Empowered the Ternary Classification of Histological Subtypes in Stage IA LUADs Based on AI Analyzed Histogram Features
Guotian Pei, China
- P1.04.25** Incidental Findings from the Annual Follow-Up in the 4-In-The-Lung-Run Lung Cancer Screening Trial
Carlijn van der Aalst, Netherlands
- P1.04.26** The Impact of Brain MRI Surveillance on Survival Outcomes in Initially CNS Metastasis-Free Non-small Cell Lung Cancer
Seong-Eun Kim, Republic of Korea
- P1.04.27** Radiologic Features Identification of Pathologic Tumor Invasion in Pure Ground-Glass Nodules
Yeqing Zhu, China
- P1.04.28** Correlation Between Dosimetric Parameters and Radiation-Induced Pulmonary Toxicity in Lung Cancer Radiotherapy
Luisa Assunção, Brazil
- P1.04.29** Female Asians Who Never Smoked with Lung Adenocarcinomas (FANSA) Have Unique Survival Outcomes: An ILCCO Analysis
Zachary Coyne, Canada
- P1.04.30** Screening of Paraptosis-Related Prognostic Genes in Lung Adenocarcinoma by Bioinformatics Analysis and Experimental Validation
Tao Zhang, China
- P1.04.31** Implementation of a Lung Cancer Risk Prediction Algorithm: Early Findings from the Lungflag™ Pilot at Geisinger Health System
Matthew Facktor, USA
- P1.04.32** Moving Forward in Early Detection: The ACS/NLCRT Best Practice Guide for Building Lung Cancer Early Detection Programs
Carey Thomson, USA
- P1.04.33** Sybil Pilot for Incidental Pulmonary Nodules
Renelle Myers, Canada
- P1.04.34** AI Powered Incidental Pulmonary Nodule Program Demonstrates High Lung Cancer Detection Rate: Canadian IDEAL Study
Renelle Myers, Canada
- P1.04.35** Impact of Lung Cancer Screening Eligibility Criteria on Participants’ Characteristics and Healthcare Resources
Maria Cabrera, Spain

- P1.04.36** LungFlag™ Risk Prediction Validation on Canadian Ever Smokers Pre-Classified as High Risk for Lung Cancer
Sukhinder Atkar-Khattara, Canada
- P1.04.37** Systematic Enrollment for Lung Cancer Screening Ensures Rapid Stage Shift of Diagnosed Lung Cancers at a Population Level
Tanel Laisaar, Estonia
- P1.04.38** The Coincidental Findings of Lung Nodules With AI-Assisted Chest X-Rays in the Tuberculosis Screening Project
Prakitip Susilparat, Thailand
- P1.04.39** Markov Model Approach to Optimize Lung Cancer Screening and Early Detection in Patients with Smoking Associated Diseases
Clarisse Buton, France
- P1.04.40** Improving Lung Cancer Risk Prediction in Asbestos Exposed Individuals: The AQC Ensemble Model
Chellan Kumarasamy, Australia
- P1.04.41** Survival Differences Following Surveillance Detected Vs. Symptom Detected Recurrence in Patients with Lung Cancer
Nadia Moss, Netherlands
- P1.04.42** Circulating Tumor Cells Combined with Solid Nodular Ratio to Predict High-Risk Pathological Subtypes of Stage IA Lung Adenocarcinoma
Bingyu Rao, China
- P1.04.43** Evaluating the Role of Digital Tomosynthesis in Lung Cancer Screening: A Cost-Effective Alternative to Annual LDCT in Resource-Limited Settings
Natthaya Triphuridet, Thailand
- P1.04.44** Clinical Efficiency of Repeat CT-Guided Transthoracic Needle Biopsy of Peripheral Lung Lesions
Sofya Samsonik, Russian Federation
- P1.04.45** Multi-Center Validation of a Circulating 9-microRNA Signature for Lung Cancer Early Detection
Fabrizio Bianchi, Italy
- P1.04.46** Predicting Malignancy in Ground-Glass Opacity Using Multivariate Regression and Deep Learning Models: A Proof-Of-Concept
Abed Agbarya, Israel
- P1.04.47** Breathomics Meets Deep Learning: A Novel Approach for Early Detection of Lung Cancer
Annamaria Catino, Italy
- P1.04.48** Rapid Intra-Operative Detection of Visceral Pleural Invasion in Non-small Cell Lung Cancer Using Label-Free Multiphoton Microscopy
Suyi Chen, China
- P1.04.49** Targeting VEGFR3 Nir Fluorescent Probe for Identification of NSCLC Metastatic Lymph Nodes an Exploratory Study on Surgical Navigation
Lintong Yao, China
- P1.04.50** Fluorescein-Free Confocal Laser Endomicroscopy for Intraoperative Diagnosis of Pulmonary Nodules: A Comparative Study with Frozen Section
Jiawei Xie, China
- P1.04.51** Exploring the Potential of Multimodal Cough Analysis as a Pre-Screening Tool for Non-small Cell Lung Cancer Detection
Arsela Prelai, Italy
- P1.04.52** A Clinically Applicable and Generalizable Deep Learning Model for Segmenting Anterior Mediastinal Tumors Across Multiple Institutions
Hirokazu Watanabe, Japan
- P1.04.53** Potential for AI as First Reader in Lung Cancer Screening
Giovanni Leuzzi, Spain

TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

- P1.07.01** Wearable-Based Evaluation of Tubeless Thoracic Surgery for Early-Stage Lung Cancer
Runchen Wang, China
- P1.07.02** Septum-Guided Segmentectomy vs Lobectomy for Deeply Located cT1aN0M0 Non-small Cell Lung Cancer
Qing Wang, China
- P1.07.03** Effectiveness of a Generalizable AI Based Automated Workflow Recognition Model in Multiple Approaches to Lung Resection
Seiyu Ohtani, Japan
- P1.07.04** MRD Combined with Radiological Tumor Volume as Tool to Identify Resected NSCLC Patients at High Risk of Recurrence
Roberta Minari, Italy
- P1.07.05** Real-World Biomarker Testing and Treatment Initiation in Patients with Resected Early-Stage NSCLC (eNSCLC) in the US and UK
Samantha Reiss, USA
- P1.07.06** Impact of Mediastinal Lymph Node Dissection/Sampling on Survival in Frozen Section-Upgraded Invasive Lung Adenocarcinoma
Yu Xing Huang, China
- P1.07.07** The Presence of STAS Leads to Poor Prognosis After Sublobar Resection in Stage I NSCLC: Results from an Individual Patient Data Metanalysis
Filippo Tommaso Gallina, Italy
- P1.07.08** Comparing Outcomes of Different Surgical Methods for Small-Sized NSCLC With VPI- A Population-Based Study
Xu-Heng Chiang, Taiwan
- P1.07.09** Real-World Efficacy of an AI-Driven 3D Reconstruction System on Pulmonary Surgery
Jiayi Geng, China
- P1.07.10** Prognostic Impact of Resection Margin Distance in Patients with Completely Resected Stage INSCCL After Lobectomy
Shia Kim, Republic of Korea
- P1.07.11** AI-Based 3D Reconstruction in Lung Surgery
Sayazana Kassahun, Germany
- P1.07.12** Independent Risk Factors for Occult Lymph Node Metastasis in cIA Left Upper Lobe Lung Adenocarcinoma: A Nomogram-Based Prediction Model
Weijie Zhu, China
- P1.07.13** Impact of TP53 Co-Mutation in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Tatsuya Masuda, Japan
- P1.07.14** Exploring the Effect of Surgical Resection on Quality of Life in Older Adults for Stage IA Non-small Cell Lung Cancer
Jiafang Zhang, USA
- P1.07.15** Oncologic Outcomes of Sublobar Versus Lobar Resection for Clinical Stage IA Pure Solid Non-small Cell Lung Cancer
Sumin Shin, Republic of Korea
- P1.07.16** The Association Between Sarcopenia and Postoperative Outcomes and Survival in Lung Cancer Patients Who Underwent Curative Resections
Isabel Emmerick, USA
- P1.07.17** A Neglected Dimension in Lung Cancer Surgery: Sleep Disorders Before and After Anatomical Resection
Riccardo Orlandi, Italy
- P1.07.18** Peri-Operative Immune Cell Profiling in Lung Cancer Resection: A Longitudinal Study
Laura Staunton, Ireland
- P1.07.19** Prospective Cohort Study on Stage 1A Non-small Cell Lung Cancer in Older Adults (>80 Years): Prevalence, Surgical Treatment, and Complications
Louis Gros, Switzerland

- P1.07.20** Feasibility of Limited Resection in Invasive Mucinous Adenocarcinoma of the Lung
Haun Kim, Republic of Korea
- P1.07.21** Lobectomy Versus Multi-Segmentectomy for Left Upper Lobe Lung Cancer: A Propensity Score-Matched Analysis
Naoki Takeno, Japan
- P1.07.22** LANTERN: AI Model for Postoperative Complications Prediction for NSCLC Lung Resection: Prospective Multicentric Study and Extern Validation
Filippo Lococo, Italy
- P1.07.23** Impact of Pulmonary Resection on Early Postoperative Cardiac Function
Toshimasa Okazaki, Japan
- P1.07.24** Radicality of Lymphadenectomy in NSCLC Resection: Impact on Survival. Results from the Spanish Video-Assisted Thoracic Surgery Group (GEVATS)
Carne Obiols, Spain
- P1.07.25** Trajectories of Synchronous Subsolid Nodules in Patients with Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study
Seyoung Jung, Republic of Korea
- P1.07.26** Applicability of Artificial Intelligence Based Tumor Segmentation in Planning for Sublobar Resection in Lung Cancer: A Meta-Analysis
Prosenjit Das, India
- P1.07.27** A Newly Developed 3D Simulation System for the Preoperative Planning for Central-Located Lung Cancer
Fengwei Li, China
- P1.07.28** Segmentectomy vs Lobectomy for Clinical Stage IA1-2 NSCLC and Upstaging Due to Pathologic Visceral Pleura Infiltration
Hafsa Kaman, Germany
- P1.07.29** Prediction of Postoperative Pulmonary Function and Blood Flow Redistribution Using SPECT/CT in Patients Undergoing Lobectomy
Deog Gon Cho, Republic of Korea
- P1.07.30** Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-Mucinous Lung Adenocarcinoma After Surgery
Hyo Kyen Park, Republic of Korea
- P1.07.31** Adjuvant Immunotherapy for Clinically Node-Negative Non-small Cell Lung Cancer
Giorgio Caturegli, USA
- P1.07.32** Prognostic Value of Consolidation-To-Tumor Ratio in Stage IA Solid Predominant Non-Mucinous Adenocarcinoma
Yura Ahn, Republic of Korea
- P1.07.33** Sublobar Resection Versus Lobectomy in Peripheral NSCLC After Neoadjuvant Chemotherapy: A Retrospective Study
Qing Liang, China
- P1.07.34** Toxicity Profile for Connective Tissue Disease Patients Treated with Lung Stereotactic Body Radiation Therapy
Gregory Videtic, USA
- P1.07.35** Stereotactic Body Radiation Therapy for Medically Inoperable Stage I/II EGFRm NSCLC: Global, Multicenter, Retrospective Study
Steven Lin, USA
- P1.07.36** A Three-Genes Signature Predicting Local Recurrence in Stage I-III NSCLC Patients Treated with Radiation Therapy
Victor Lee, USA
- P1.07.37** Using Tissue and Blood to Find Oncogenic Drivers Upfront in Patients with Lung Cancer Evaluated for Neoadjuvant Therapy-LEADER
Jules Lin, USA
- P1.07.38** Neoadjuvant Irupinalkib in Resectable ALK/ROS1 Fusion-Positive NSCLC: Updated Results of the Exploratory Neo-INFINITY Study
Guodong Zhang, China
- P1.07.39** Pooled Efficacy and Safety Profile of Neoadjuvant Therapies in Operable EGFR-Mutant Non-small Cell Lung Cancer: A Meta-Analysis
YunChu Wei, China
- P1.07.40** Detection of ctDNA Prior to Neoadjuvant Osimertinib Treatment Correlates with Decreased EFS in EGFR-Mutated NSCLC
Tyiesha Brown, USA
- P1.07.41** Exhaled Breath Analysis in Patients with Resectable NSCLC Treated with Neoadjuvant Immune Checkpoint Inhibitors
Kristof Cuppers, Belgium
- P1.07.42** Multi-Temporal Imaging and CT-to PET Translation Based Predictive Model on Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer Patients
Minjian Li, China
- P1.07.43** Clinico-Genomic Correlates of Pathologic Response to Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage NSCLC
Edoardo Garbo, USA
- P1.07.44** Multicenter Assessment of Clinical-Radiomic Predictors for Pathologic Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy
Mengzhe Zhang, China
- P1.07.45** Transforming Outcomes with Neoadjuvant Chemo-Immunotherapy in Operable Non-small Cell Lung Cancer (NSCLC): A Propensity-Matched Analysis
Nehemias Guevara Rodriguez, USA
- P1.07.46** Adjuvant Systemic Therapy for Resected Stage IB-IIA NSCLC (AJCC 8Th Edition): A Real-World Cohort Study from SEER Database
Changtai Zhao, China
- P1.07.47** Early Treatment Discontinuation of Osimertinib in the Adjuvant Setting: Insights from the ADAURA Study
Christian Grohé, Germany
- P1.07.48** Furmonertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Stage IB-IIA NSCLC with High-Risk Pathological Factors
Xiao-Long Li, China
- P1.07.49** Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Adenocarcinoma: A Multicenter CREGYT-03 ALK Study
Akira Hamada, Japan
- P1.07.50** Aumolertinib as Adjuvant Therapy in EGFRm Stage I-III NSCLC with High-Grade Histological Patterns: 3-Year Dfs Rate Updated
L. Wang, China
- P1.07.51** Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data from the Italian ATLAS Registry
Maria Lucia Reale, Italy
- P1.07.52** Clinicopathologic Risk Score to Guide Adjuvant Chemotherapy in Stage IB NSCLC: Toward Integration of AI-Assessed Tumor Immune Signatures
Jeongmin Seo, Republic of Korea
- P1.07.53** Aumolertinib as Adjuvant Therapy in I-III EGFRm NSCLC: Also Effective in Patients with Multiple Prognostic Risk Factors
Gian Xue, China
- P1.07.54** The Effect of Adjuvant EGFR-TKI Therapy on the Prognosis of Pathological Stage I Invasive Lung Adenocarcinoma with Sensitive EGFR Mutation
Zetao Liu, China
- P1.07.55** Molecular Profiling of Neo-Adjuvant IO Disclosures Residual Cancer Cells in pCR NSCLC: A Single Cell Analysis of CTONG 1804
Si-Yang Liu, China

- P1.07.56** Combining Lymph Nodes and Tumor Radiomics Enhances Immunotherapy Efficacy Prediction in Non-small Cell Lung Cancer
Weijie Zhan, China
- P1.07.57** Alterations in the Gut Microbiota and Metabolites in Patients with Liver Injury Induced by Third-Generation EGFR-Targeted Drugs
Jia-Xuan Li, China
- TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY**
- P1.11.01** First-Line Nivolumab Plus Ipilimumab in Combination with Chemotherapy for Metastatic NSCLC: Real World Data in Italy
Francesco Agustoni, Italy
- P1.11.02** Impact of Prophylactic Use of Cardioprotective L-Carnitine on First-Line Chemioimmunotherapy in Advanced NSCLC: A Cohort Study
Cheng Han, China
- P1.11.03** Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer with Rhabdoid Features: A Single-Center Retrospective Analysis
May-Lucie Meyer, Switzerland
- P1.11.04** Prediction of Overall Survival in Lung Cancer Patients with Different Organ Metastases: A SEER Population-Based Cohort Study
Kang Qin, USA
- P1.11.05** Efficacy and Multi-Omics Insights of Immune Checkpoint Inhibitors in NSCLC With Leptomeningeal Metastasis
Li-Bo Tang, China
- P1.11.06** Risk Factors and Prognosis of Immune Checkpoint Inhibitor-Induced Pneumonia in Lung Cancer with Interstitial Lung Disease
Tsukasa Ueda, Japan
- P1.11.07** Impact of Radiotherapy and Immune Checkpoint Inhibitor Combination in Advanced NSCLC: Real-World Data (RWD) Analysis
Joaquim Bosch-Barrera, Spain
- P1.11.08** Peripheral Inflammatory Biomarkers Predict Immunotherapy Retreatment Outcomes in Advanced NSCLC
Jiaxin Zhong, China
- P1.11.09** SBRT Combined with Tislelizumab and Granulocyte-Macrophage Colony-Stimulating Factor in Advanced NSCLC Progressing on Immunotherapy
Guangxian You, China
- P1.11.10** Serum Neopterin and Mortality in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Martina Spisarova, Czech Republic
- P1.11.11** Survival Impact of Pneumonitis in Older Patients with Non-Squamous NSCLC Treated with Pembrolizumab and Pemetrexed: Insights from CJLSG1901
Yoshihito Kogure, Japan
- P1.11.12** Impact of Body Composition on Immunotherapy Response in Non-small Cell Lung Cancer
Xin Zheng, China
- P1.11.13** A Phase II Study of Camrelizumab Plus Docetaxol in Advanced NCSLC Pre-Treated with Immune Checkpoint Inhibitors and Chemotherapy
Jin Zhou, China
- P1.11.14** Depth of Response to Immunotherapy Is Associated with Survival Outcomes in Oligoprogressive NSCLC: A Real-World Data Analysis
Daniel Gomez, USA
- P1.11.15** PD-(L)1 Inhibitors for Treatment of Locally Advanced or Metastatic NSCLC in Asian and Non-Asian Patients: A Meta-Analysis
Nicolas Girard, France

P1.11.16

Gut Microbiota: Associations Between Composition and Response to Immunotherapy in Non-small Cell Lung Cancer
Gisele Moreira, Brazil

P1.11.17

PD-(L)1 Inhibitors Rechallenge in Patients with Advanced NSCLC Previously Treated with Immunotherapy: A Systematic Review and Meta-Analysis
Daniele Marinelli, Italy

P1.11.18

Real-World Characterization of Response Kinetics in Patients with Metastatic NSCLC Receiving First-Line Immunotherapy
Melina Marmarelli, USA

P1.11.19

Real-World Outcomes of Nivolumab Plus Ipilimumab in Elderly NSCLC Patients (≥75): A Retrospective Analysis
Soichiro Minami, Japan

P1.11.20

Camrelizumab-Based Therapy-Induced RCEP in Advanced NSCLC Patients: A Pooled Analysis of Two Phase III Registration Trials
Caicun Zhou, China

P1.11.21

Target Lesion Necrosis Percentage as a Predictor for Response to Immune Checkpoint Inhibitors in NSCLC: A Retrospective Analysis
Arijun Narula, India

P1.11.22

Extracellular Vesicle-Derived lncRNA Signatures in Serum for Diagnosis and Prognosis of Checkpoint Inhibitor-Related Pneumonitis
Yilin Yang, China

P1.11.23

Co-Culturing LCOs and Lymphocytes Derived from Pleural Effusion Potentially Implement Personalized Immunotherapy
Xu-Hui Guan, China

P1.11.24

Real-World Evidence of Primary Resistance to First-Line Chemo-Immunotherapy in Advanced Lung Adenocarcinoma
Marianna Peroni, Italy

P1.11.25

Genomic Characterizers, Survival and Prognostic Analysis of Advanced NSCLC With Kirsten Rat Sarcoma Mutations With Brain Metastases
Yi Chen, China

P1.11.26

Temporal Optimization of Radiotherapy-Immunotherapy Synergy for NSCLC Brain Oligo-Metastases: Prospective Assessment of Prognosis Outcomes
Xiaomei Gong, China

P1.11.27

Optimal Immunotherapy Regimen for STK11 or KEAP1 Mutant Metastatic Non-small Cell Lung Cancer
Natalie Shammass, USA

P1.11.28

Nomogram and Effectiveness of Bone-Modifying Agents in Advanced Driver-Negative NSCLC: A Retrospective Real-World Study
Lingyun Zhang, China

P1.11.29

ICIs Plus Paditaxel-Based Chemotherapy Is an Optional Treatment for Transformed SCLC After EGFR-TKI
Yuyan Wang, China

P1.11.30

The Efficacy of Immunotherapy for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations
Jiaxin Zhong, China

P1.11.31

Dynamic Monitoring of Circulating Tumor Cells and Single-Cell Sequencing Predict Therapeutic Efficacy in Advanced Lung Cancer
Chao Zhao, China

P1.11.32

Quality of Life Outcomes from the Phase 3 Study of Atezolizumab + Bevacizumab and Chemotherapy (ATTLAS, KCSG-LU19-04) in EGFR/ALK- Mutated NSCLC
Eun Joo Kang, Republic of Korea

P1.11.33

The Role of Rhannose Derived from Gut Microbiome in Modulating the Efficacy of Non-small Cell Lung Cancer Immunotherapy
Xu Han, China

- P1.11.34** First-Line Camrelizumab Plus Chemotherapy in 3004 Patients with Advanced Non-Squamous NSCLC: A Nationwide Retrospective Study
Zhonghui Wei, China
- P1.11.35** RATIONALE-303: Long-Term Outcomes with Tislelizumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Kirsha Naicker, UK
- P1.11.36** Strengthening Real World Evidence Generation Through an Expanding Multicenter Canadian Lung Cancer Registry
Paul Wheatley-Price, Canada
- P1.11.37** Impact of Immunotherapy on Overall Survival in Advanced Non-small Cell Lung Cancer: A Real-World Evidence Analysis
Enric Carcereny, Spain
- P1.11.38** Measuring the Effect of Age and Ethnicity on Outcomes in Patients with Advanced Lung Cancer Treated with Immunotherapy: A New Zealand Analysis
Annie Wong, New Zealand
- P1.11.39** The BLP Score: A Tool for Non-small Cell Lung Cancer Patients with Brain Metastases
Marcus Skribeik, Sweden
- P1.11.40** The Hidden Impact of Creatinine Clearance Estimation Method on Pemetrexed-Based Chemioimmunotherapy in NSCLC With Low PD-L1 Expression
Naoya Nishioka, Japan
- P1.11.41** Intralesional Dual Blockade of IL-6 and PD-L1 Reprograms CAF Dynamics and the Tumor Microenvironment in Malignant Pleural Effusion
Ping Zhan, China
- P1.11.42** Dual Immune Checkpoint Blockade With CTLA-4 and PD-(L)1 Inhibitors in NSCLC: A Reconstructed Patient Data Meta-Analysis
Alessandro Di Federico, Italy
- P1.11.43** Analysis of Characteristics and Predictive Factors for Long-Term Benefit of Immunotherapy in Advanced NSCLC
Wei Song, China
- P1.11.44** Efficacy and Safety of Immunotherapy as First-Line Treatment in Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma
Huiwen Yang, China
- P1.11.45** Real-World Prognosis of Non-Squamous NSCLC Patients with Liver, Bone, or Brain Metastases Treated with Frontline Therapies
Mona Cai, USA
- P1.11.46** RATIONALE-303: Post-Hoc Analysis of Tislelizumab Monotherapy in Previously Treated Non-small Cell Lung Cancer with Metastases
Kirsha Naicker, UK
- P1.11.47** Clinical Outcomes of Immune Checkpoint Inhibitors Treatment for Postoperative Recurrence in Non-small Cell Lung Cancer
Yoshito Imamura, Japan
- P1.11.48** Scoreit - Is IC3 Similarly Predictive as TC3 for Single Agent PD-1/PD-L1 Immune Checkpoint Inhibition in Metastatic NSCLC (mNSCLC)
Nadine Olejnik, Germany
- P1.11.49** The Impact of the Lung Microbiome on Checkpoint Inhibitor Pneumonitis: Early Findings from the Australian TRACKER Lung Cancer Biobank
Senthuran Shivakumar, Australia
- P1.11.50** Survival Outcomes in Advanced Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An NCDB Analysis
Muskan Agarwal, USA
- P1.11.51** Effects of Immune Checkpoint Inhibitors on the Pulmonary Circulation in Lung Cancer Patients
Xia Yang, China
- P1.11.52** Impact of Disease Progression on Pros in Patients Receiving Cemiplimab/Chemotherapy Versus Chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2
Konstantin Penkov, Russian Federation
- P1.11.53** Organ-Specific Survival in Metastatic NSCLC Patients Treated with Chemo-Immunotherapy: A Machine Learning-Based Retrospective Analysis
Kang Qin, USA
- P1.11.54** Lack of Durable Response to ICI Therapy in Advanced NSCLC: The Role of Circulating Lazy T Cells
Arianna Palladini, Italy
- P1.11.55** Identifying Patients Cured from Metastatic Non-small Cell Lung Cancer (mNSCLC) With Anti-PD-(L)1 Therapy
Natalie Vokes, USA
- P1.11.56** Distinct Predictive Effects of PD-L1 Tps on Immunotherapy Outcomes and Immunophenotype in Squamous Versus Non-Squamous NSCLC
Valentina Santo, USA
- P1.11.57** Association Between CD274 (PD-L1) Gene Expression and PD-L1 Immunohistochemistry in Non-small Cell Lung Cancer Specimens
Richard Huang, USA
- P1.11.58** Efficacy of First-Line Treatment in Driver-Negative Non-small Cell Lung Cancer with Liver Metastases: A Bayesian Network Meta-Analysis
Lingyun Zhang, China
- P1.11.59** Effect of IFNG Expression Levels on Real-World Survival Outcomes in Patients with Metastatic Non-small Cell Lung Cancer Receiving Immunotherapy
Michael Rossi, USA
- P1.11.60** Interstitial Lung Abnormalities and MUC5B Polymorphism in Immune Checkpoint Inhibitor Pneumonitis
Mehmet Altan, USA
- P1.11.61** Effects of Probiotic Duration and Type on Immunotherapy Efficacy in Non-small Cell Lung Cancer with or Without Antibiotics
Weichi Luo, China
- P1.11.62** Deep Learning Histopathology Model for PD-L1 (TPS) and Immunotherapy Outcome Prediction in Non-small Cell Lung Cancer
Masoud Tafavvoghi, Norway
- P1.11.63** Shifts of Mutational Signatures Reveal Response Variability to Pembrolizumab-Based Immunotherapy in NSCLC Patients
Natalia Galant, Poland
- P1.11.64** Vision Foundation Model to Predict Immunotherapy Treatment Response in Lung Cancer Patients
Daniel Gomez, USA
- P1.11.65** Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONI-2 by Tumor PD-L1 Expression Level
Lei Wang, China
- P1.11.66** Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights from the APOLLO11 Study
Vanja Miskovic, Italy
- P1.11.67** VEGFR1/PD-L1 CAR-T Cell Treatment of Solid Tumor-Derived Malignant Pleural Effusion/Ascites
Dan Li, China
- P1.11.68** Multi-Omic Profiling Identifies Key Factors Associated with Response to Ivonescimab (AK112) in Non-small Cell Cancer
Haowei Wang, China
- P1.11.69** Efficacy of Immunotherapy ± Chemotherapy in Metastatic NSCLC with KRAS, STK11, or KEAP1 Mutations: A Network Meta-Analysis
Skylar Taylor, USA

- P1.11.70** Immune Cell Infiltration and Spatial Associations in the Tumor Microenvironment Following Dual ICI or ICI-Chemotherapy
Natalie Vokes, USA
- P1.11.71** RMT in Non Small Cell Lung Cancer
Amit Kulkarni, USA
- P1.11.72** Phase II Study of Combination Azacitidine and Entinostat and Nivolumab in Patients with Metastatic Non-small Cell Lung Cancer
Kristen Marrone, USA
- P1.11.73** Tiragolumab Plus Atezolizumab and Bevacizumab in Immunotherapy-Refractory, Pd-L1+, Advanced Non-Squamous Non-small Cell Lung Cancer
Joshua Reuss, USA
- P1.11.74** Phase Ib Study of Golubicitinib Plus Anti-PD-1 in Anti-PD-1 Treated Advanced NSCLC: Dose-Escalation Safety Using BOIN Design
Hua Zhong, China
- P1.11.75** A Phase 2 Study of PCSK9 Inhibitor, Aflrocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC
Ezi'afa Oduah, USA
- P1.11.76** Bevacizumab Plus Serplulimab and Chemotherapy for EGFR-TKI-Resistant Non-Squamous Non-small Cell Cancer: A Phase2Study
Qiming Wang, China
- P1.11.77** A Comprehensive Analysis of Front-Line Regimens for Stage IV Non-Squamous Non-small Cell Lung Cancer: A 13-Year Experience
Naveen Rehman, USA
- P1.11.78** NAI, An IL-15 Superagonist, A New Class Of Lymphocyte Stimulating Agent (LSA) Prolongs OS in NSCLC By Reversing Lymphopenia
Sandeep Reddy, USA
- P1.11.79** A Meta-Analysis on Anti-PD-1/L1 With or Without Anti-VEGF Plus Chemotherapy in EGFR-Mutant or ALK-Rearranged NSCLC Progressing on TKIs
Rogelio Jr. Velasco, Philippines
- P1.11.80** Tumor-Derived Complement Factor B Drives Tumor Growth and Anti-PD-1 Resistance in STK11-Mutant Lung Adenocarcinoma
Edwin Yau, USA
- P1.11.81** Low-Dose Nivolumab With Platinum Doublet Chemotherapy in Patients with Advanced Central Squamous Cell Lung Cancer (SCAR)
Pawan Singh, India
- P1.11.82** Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-Resistant aNSCLC: Improvement in PFS
Victor Zaporozhan, USA
- P1.11.83** Ivonescimab Versus Pembrolizumab for PD-L1-Positive NSCLC: A Subgroup Analysis of HARMONI-2 by Tumor Histology
Anwen Xiong, China
- P1.11.84** Phase II Trial of Tiselimab Combined With Anlotinib and 2-Cycle Chemotherapy as First-Line Treatment for Advanced NSCLC
Wen-Jun Tang, China

TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

- P1.17.01** Sociodemographic Factors in Access to Robotic-Assisted Oncologic Lung Resection, a USA (US) National Cancer Database Analysis
Isabel Emmerick, USA
- P1.17.02** Socioecological Factors Associated with Lung Cancer Clinical Trial Enrollment: Real-World California Cancer Registry Data
Angel Arizpe, USA

- P1.17.03** Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) Biomarker Testing Disparities and Outcomes: A Population-Based Study
Surbhi Singhal, USA
- P1.17.04** Prioritizing Lung Cancer Screening in Middle-Income Countries: A Feasibility-Need Framework to Guide Implementation
Harmida Petrovic, France
- P1.17.05** Evolution of Neoadjuvant Treatment for Non Small Cell Lung Cancer (NSCLC) in Brazil: An Analysis from the Brazilian Lung Cancer Registry
Ricardo Terra, Brazil
- P1.17.06** Who Gets a Biopsy? Disparities in Histological Confirmation and Survival Among Lung Cancer Patients
Damien Urban, Israel
- P1.17.07** Comparing Baseline Characteristics of NSCLC Patients Receiving Radiotherapy in Real-World Practice and Clinical Trials
Gerard Walls, UK
- P1.17.08** Routine Self-Administration of a Nursing Demographic Survey to Patients Starting TKIs Identifies At-Risk Individuals
Halley Vlahos, Canada
- P1.17.09** The Impact of Out-Of-Pocket Costs, Travel Distances and Clinic Visits on Quality of Life for Patients on TKIs
Kezia Rafique, Canada
- P1.17.10** Treating Without Guidelines: Management and Outcomes of Lung Cancer During Pregnancy
Nehemias Guevara Rodriguez, USA
- P1.17.11** Clinical and Molecular Characterization of Lung Cancer in Never-Smokers Identified Through an Incidental Nodule Program
José Fernando Moura, Brazil
- P1.17.12** Unwarranted Variation in Lung Cancer Care in Perth, Western Australia: A Lung Cancer Clinical Quality Data Platform Report
Jessica Nash, Australia
- P1.17.13** Biomarker Testing Timeliness for Patients with Lung Cancer
Bingfao Xiang, USA
- P1.17.14** Regional Disparities in Late-Stage Lung Cancer Outcomes in Sweden - Insights from Population-Based Data
Anders Berglund, Sweden
- P1.17.15** Social Vulnerability and Survival Outcomes in Stages I-II Lung Cancer: A Predictive Nomogram-Based Analysis
Priscila Berenice Costa, Brazil
- P1.17.16** Racial and Ethnic Disparities in Receipt of Guideline Concordant Treatment for Early-Stage NSCLC in Los Angeles County
Albert Farias, USA
- P1.17.17** Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC
Ana Velazquez Mahana, USA
- P1.17.18** Victorian Lung Cancer Registry Impacts on Multi-Disciplinary Lung Cancer Meeting Presentation
Tom John, Australia
- P1.17.19** Impact of Race and Ethnicity on the ENGAGE-Derived Lung Cancer Screening Recommendations: Implications for Risk Assessment
Iakovos Toumazis, USA
- P1.17.20** Optimal Lung Cancer Outcomes for People from Rural and Remote Areas: An Overview of the Problem and a Research Program to Reduce Disparities
Anna Ugaldé, Australia

- P1.17.21** Gender Disparities in Remote Patient Monitoring: Analysis From 973 Lung Cancer Patients Treated Across 42 Sites in France and Belgium
Claudia Parisi, France
- P1.17.22** Concordance of HER2 Protein Overexpression by IHC and ERBB2 Gene Amplification by NGS in Lung Cancer
Samrat Yeramaneni, USA
- P1.17.23** Role of Lung Microbiome on Precise Diagnosis of Patients with Checkpoint Inhibitor Pneumonia: Result from a Prospective Cohort Study
Zhenhua Zhou, China
- P1.17.24** Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes
Joyce Chen, USA
- P1.17.25** Cost-Effectiveness of Initial Pan-TRK IHC Followed by RNA-NGS for NTRK Fusion Detection in Patients with NSCLC in China
Yuchen Han, China
- P1.17.26** Evaluation of Large Language Models for Clinical Decision Support in Lung Cancer Treatment: ChatGPT-4.5 Vs. DeepResearch Vs. AvOmd
Jiyon Lyu, Republic of Korea
- P1.17.27** Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics from CT Scans
Chandana Adhikarla, USA
- P1.17.28** Developing a Multifaceted Implementation Strategy to Increase Clinical Trial Accruals in Thoracic Oncology
Kadi Dick, USA
- P1.17.29** Access to Novel Therapies for the Treatment of NSCLC in 18 EU Member States
Urška Janžič, Slovenia
- P1.17.30** Deep Learning-Based Lung Tumor Segmentation for Survival Prediction in NSCLC Patients
Beshoy Guirges, Italy
- P1.17.31** Feasibility of Integrating AI-Assisted Lung Cancer Screening in High Tuberculosis Burden Settings
Vincent Balanag, Philippines
- P1.17.32** Comparing ChatGPT's and Google Gemini's Responses to Lung Cancer Questions
Chanwoo Kim, Republic of Korea
- P1.17.33** Addressing Educational Gaps in Lung Cancer Care: Insights Based on Global Practice Setting and Experience
Michelle Worst, USA
- P1.17.34** Assessing the Outcome of 10-Year Lung Cancer Survivors and the Necessity of Long-Term Postoperative Surveillance
Satoshi Shiono, Japan
- P1.17.35** Patient Navigation and the Opportunity to Improve Experiences and Outcomes of Lung Cancer Care
Jessica Hooper, UK
- P1.17.36** Perspectives on Health-Related Quality of Life Among Physicians and Patients with ALK-Positive NSCLC in China
Yan Huang, China
- P1.17.37** Providing Equal Access to Lung Cancer MDT Consultation Through Digital Innovation
Xinghua Cheng, China
- P1.17.38** A Two-Layer MDT Model as the Standard of Care for Lung Cancer - a Good MDT Example with High-Volume Patients in Central Western China
Zhen He, China
- P1.17.39** Clinical Predictive for Early Mortality in Stage IV Lung Cancer Without Targetable Mutations from Country with High Smoking Prevalence
Anas Zayed, Jordan
- P1.17.40** Impact of Remote MDT Through a Digital Platform: Insights From 70 Patient Follow-Ups
Xiaojuan Zhang, China
- P1.17.41** Bridging Gaps in Lung Cancer Care: The Quantitative Impact of Inter-Hospital Remote MDT Consultations in China
Wen Gao, China
- P1.17.42** Canadian Consensus Recommendations for Multi-Disciplinary Team Meetings in Lung Cancer Care
Marcos Gallego-Lorente, Spain
- P1.17.43** Association Between Pretreatment Emotional Distress and EGFR-TKI Therapeutic Response in EGFR-Mutant Non-small Cell Cancer
Zhang Yang, China
- P1.17.44** Multiomic Interaction Among Host and Tumor Immunity for Chemo De-Escalation. People Phase II Trial, First Line Pembrolizumab in Low PD-L1 NSCLC
Cecilia Silvestri, Italy
- P1.17.45** Multidisciplinary Digital Platform for Independent Adjudication of ILD/Pneumonitis Related to T-DXd Treatment
William Nassib William Jr, Brazil
- P1.17.46** The Best Care One-Lung Program; a Pathway for Lung Cancer Screening in Primary Care
Christian Finley, Canada
- P1.17.47** Safety and Efficiencies of Specialist Lung Cancer Nurse-Enabled Pulmonary Nodule Management: An Australian Demonstration
Vanessa Brunelli, Australia
- P1.17.48** Characteristics and Associated Survival of Patients Diagnosed with Non-small Cell Lung Cancer in Western Kenya
Atundo Muringa, Kenya
- P1.17.49** Real-World Outcomes with IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US
Kristin Sheffield, USA
- P1.17.50** Correlation Between Clinical and Pathological Stage in Resected NSCLC
Giordano Cittolin Santos, USA
- P1.17.51** Real World Outcomes of Metastatic Mucinous Adenocarcinoma of Lung
Dhauna Karam Prasad, USA
- P1.17.52** Real-World Treatment and Survival in KRASG12C-Mutated Locally Advanced/Metastatic Non-small Cell Lung Cancer in England
Alastair Greystoke, UK
- P1.17.53** Real-World Experience With EGFR-Positive NSCLC in Resource-Limited Settings: A Decade-Long Single Center Study from Jordan
Kamal Al-Rabi, Jordan
- P1.17.54** Long-Term Outcomes from Pembrolizumab in Patients with Advanced PD-L1 =50% NSCLC and Poor PS: A Transformer-Based AI Approach
Alessio Cortellini, Italy
- P1.17.55** Transforming Prognostication: A 5-Year Follow-Up Study to Unravel Prognostic Predictors Across Age Groups in NSCLC Using Transformer-Based AI
Leonardo Brunetti, Italy
- P1.17.56** Clinical Features and Outcomes of Lung Cancer in Young Patients
Bingfei Xu, China
- P1.17.57** Estimates of Clinical Endpoints in Matched Patients Between the French Cancer Cohort (FCC) and Durvalumab Stage III NSCLC Eap
Icherak Charakaoui, France
- P1.17.58** Real-World (RW) Study of Biomarker Testing Patterns Among Patients with Early-Stage Resected NSCLC in the USA
Sandip Patel, USA

- P1.17.59** Real-World Uptake of Immunotherapy for Stage III-IV Non-small Cell Lung Cancer: Insights from the National Cancer Database (2016-2021)
Brittany Morguelan, USA
- P1.17.60** Characterizing Multi-Timepoint Lung Cancer Progression with Dynamic Bayesian Network, Structural Equation Modeling and Random Forest Model
Wei Liu, China
- P1.17.61** Rebiopsy in Oncogene-Driven Lung Cancer: Real-World Practices in ALK, EGFR, and ROS1 Cohorts in the Australian AURORA Longitudinal Cohort Study
Susan Harden, Australia
- P1.17.62** Real-World Insights on Treatment Patterns and Outcomes in ROS1 NSCLC: An Australian Multicenter Study (AURORA)
Malinda Itchins, Australia
- P1.17.63** Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis
Ling-I Hsu, USA
- P1.17.64** Acinar Cell Lung Carcinoma: A Unique Subtype of NSCLC Adenocarcinoma, Insights from the AACR Project Genie Database
Anas Zayed, Jordan
- P1.17.65** Age-Associated Incidence of Somatic Mutations and Survival Outcomes in Non-small Cell Lung Cancer
Sarah Sertich, USA
- P1.17.66** Impact of Concurrent Tissue and Liquid Comprehensive Genomic Profiling (CGP) on Receipt of First-Line (1L) Therapy in a NSCLC
Jonathan Riess, USA
- P1.17.67** A Large-Scale Network Study on Impact of Immune Checkpoint Therapy in Metastatic Non-small Cell Lung Cancer: The iCan mNSCLC Study-A-Thon
Ilkka Ilonen, Finland
- P1.17.68** Real-World Validation of Other Disease Morbidity After Lung Cancer Surgery Using a Japanese Database in Reference to JCOG0802/WJOG4607L
Takeuchi Taihei, Japan
- P1.17.69** A Real-World Study of Advanced ALK-Fusion NSCLC Patients Receiving First-Line ALK-TKI Therapy with Telehealth Care
Di Zheng, China
- P1.17.70** Clinicomolecular Characteristics and Treatment Patterns in Stage IV NSCLC: A Retrospective Study from Southwestern Ontario
M. Sara Kuruvilla, Canada
- P1.17.71** Treatment Changes Over 12 Months of Observation for ALK and EGFR-Positive NSCLC - Results From a Real-World Study
Upal Basu Roy, USA
- P1.17.72** Clinical and Dosimetric Predictors for Post-Radiotherapy Lung Cancer Recurrence: A Model for Resource-Limited Settings
Renne Aguiar, Brazil
- P1.17.73** Misperception of Unintentional Weight Loss and Anorexia More Prevalent in Lung Cancer Among Other Solid Tumors in a Mexican Cohort
Saul Campos-Gomez, Mexico
- P1.17.74** Bridging Data Gaps in Brazilian Lung Cancer Surgery Care: The Evolution of the Brazilian Lung Cancer Registry (RBCP)
Maria Tzukazan, Brazil
- P1.17.75** Realizing Digital Transformation in Health: Findings from the TRANSITION Project
Andreas Charalambous, Cyprus
- P1.17.76** Facilities and Workforce Available for Thoracic Oncologic Care and Research in Nigeria, a Low-Middle Income Country (LMIC)
Kelechi Okonta, Nigeria
- P1.17.77** Lung Cancer Consensus: Uniting for a Healthier World
Mary Bussell, USA
- P1.17.78** Living Systematic Review Linked to Guidelines and Regulatory Approvals as a Treatment Decision Support Tool in NSCLC
Anna Forsythe, USA
- P1.17.79** Assessing Radiotherapy Access and Patient Experience in Lung Cancer Treatment: A Survey on Financial and Logistical Challenges
Divya Khosla, India
- P1.17.80** Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK+ Non-small Cell Lung Cancer (NSCLC) in Spain
Rocío Gordo, Spain
- P1.17.81** Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling
Iakovos Toumazis, USA
- P1.17.82** Lung Cancer's Price Tag: Escalating Hospitalization Costs in Brazil Over the Past Two Decades
Jean Henri Maselli Schoueri, Brazil
- P1.17.83** Implementation of Lung Cancer Screening by Family Physicians in the U.S.: Results of a National Survey
Ella Kazerooni, USA

POSTERS (P2):

MONDAY, SEPTEMBER 8, 2025

i Presenters in Attendance: 10:30 – 12:00

TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY

- P2.02.01** Characterizing UPPI Expression in Non-Tumor Cells of Lung Cancer and its Clinical Implications
Yin Li, China
- P2.02.02** R-Loop-Associated DNA Damage Facilitates Chemosensitivity of NSCLC
Hongcheng Chen, China
- P2.02.03** Ferroptosis-Induced SUMO2 Lactylation Counteracts Ferroptosis by Enhancing ACSL4 Degradation in Lung Adenocarcinoma
Guangyao Shan, China
- P2.02.05** CXCL12/CXCR4 Axis Mediates M2 Monocyte Polarization-Induced Immune Resistance in NSCLC Liver Metastasis
Qi Wang, China
- P2.02.06** Functional Impact of Missense Mutations Affecting Immune Response Genes in Human Cancer
Cristina Diaz, Spain
- P2.02.07** Targeting SLC4A7 Reprograms the Acidic Tumor Microenvironment to Overcome Immunotherapy Resistance in NSCLC
Hao Qin, China
- P2.02.08** A Unique VEGFA-Expressing CAF Subpopulation Emerges in TKI-Resistant Lung Cancer to Mediate Immunotherapy Sensitization and Adverse Outcomes
Jingze Wang, China
- P2.02.09** Early-Stage Lung Adenocarcinoma: PLVAP-Driven Regulation of the Tumor Microenvironment
Dawei Yang, China
- P2.02.10** Emotional Distress Following Lung Cancer Surgery and Tandospirone Dual Benefits for Chemotherapy
Xichun Qin, China
- P2.02.11** SRC Activation Drives Acquired Pemetrexed Resistance in Non-small Cell Lung Cancer and Is Targetable by Dasatinib
Jeongmin Seo, Republic of Korea
- P2.02.12** hUC-MSC-Derived Exosomes Mitigates Immune Checkpoint Inhibitor-Associated Lung Injury by Suppressing GSDME-Mediated Pyroptosis
Zekun Chenli, China
- P2.02.13** Macrophages Exhibit Enhanced Cholesterol Efflux in Early-Stage Lung Adenocarcinoma
Dawei Yang, China
- P2.02.14** Urolithin A Alleviates Radiation Pneumonitis by Activating PINK1-PRKN-Mediated Mitophagy
Xiaomei Gong, China
- P2.02.15** Drug Tolerance and Persistence to EGFR Inhibitor Treatment Are Mediated by an ILK-SFK-YAP Signaling Axis in Lung Adenocarcinoma
Rocky Shi, Canada
- P2.02.16** Identification of Deruxtecan-Induced Methylome Signature in NSCLC Cell Lines
Arjan Gower, USA
- P2.02.17** GNAZ as a Tumor Suppressor Marker Inhibits Tumor Development Through Interaction with the KIF11 Protein
Shuning Kong, China
- P2.02.18** Crosstalk Between Oncogenic Signaling Pathways and Immune Checkpoint Proteins in Pleural Mesothelioma
Muhammad Hashim, Austria
- P2.02.19** SIN3A/MIR22HG/Beclin1 Axis Regulates Both Autophagy and Ferroptosis in Lung Adenocarcinoma
Xiaobi Huang, China
- P2.02.20** Targeting BTN1A1 in Pd-D-L1-Negative NSCLC: A Clinically Actionable Immune Checkpoint for Docetaxel-Based Combination Therapy
Stephen Yoo, USA
- P2.02.21** CTNNB1 Activates LINC01426 to Promote Metabolic Reprogramming in Lung Adenocarcinoma Cells by Regulating NFAT5 Nuclear Translocation
Qiyu Fang, China
- P2.02.22** Analysis of FGF19 in Lung Squamous Cell Cancer Tissue and Cell Models
Lukas Koszik, Austria
- P2.02.23** Screening of Autophagy Related Genes in Lung Squamous Cell Carcinoma and Study of Their Mechanisms of Action
Simiao Lu, China
- P2.02.24** Zongertinib Has Activity Against NRG1 Fusion Positive Tumor Cells
Yuji Shibata, USA
- P2.02.25** Elevated SGO2 Expression in Lung Adenocarcinoma Promotes Migration and Invasion by Regulating MAD2, Correlating with Poor Prognosis
ChuanDong Zhu, China
- P2.02.26** Establishment of a HER2 Overexpressing Lung Squamous Cell Carcinoma Cell Line Sensitive to Targeted and Cytotoxic Therapies
Satoshi Suzuki, Japan
- P2.02.27** Osimertinib Increases Expression of HER2 and Combination With T-DXd, a HER2-Directed ADC, Enhances Its Efficacy in PDX Models of EGFR Mutant NSCLC
Nicolas Floch, UK
- P2.02.28** Proteasome Inhibitor Causes Proteotoxic Death and Reshapes TME in LKB1-Deficient NSCLC by Blocking Er-Stress Repair Addiction
Zhong-Yi Dong, China
- P2.02.29** CXCR2 Inhibitor Plus KRAS G12C Inhibitor Remodels Immunosuppressive Tumor Microenvironment in KRAS G12C-Mutant NSCLC?
Jiuwei Cui, China
- P2.02.30** Targeting MTA2 Lactylation as a Therapeutic Strategy to Overcome Chemoresistance in Lung Adenocarcinoma
Ren Shencheng, China
- P2.02.31** The Changes of Macrophage in EGFR Mutant TKI-Resistant Patients with Lung Cancer
Shuxin Zhu, China
- P2.02.32** Homeostatic Dysregulation of Systemic CD8+ T Cell Compartment in Lung Cancer Patients
Ju Sik Yun, Republic of Korea
- P2.02.33** Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer
Yan-Pei Zhang, China
- P2.02.34** Synergistic Antitumor Effect of an XPO1 Inhibitor and/or Sotorasib With V-ATPase Inhibitors Pretreatment in KRAS G12C NSCLC
Jessica González, Spain
- P2.02.35** Association of Intratumoral Microbiota Composition with Tertiary Lymphatic Structure of Lung Adenocarcinoma
Weijie Zhan, China
- P2.02.36** Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers
Jianjun Zhang, USA

- P2.02.37** ERBB3-BCAR4 is a Recurrent and Oncogenic Fusion in Lung Adenocarcinoma Cases That Lack Other Driver Alterations
Kevin Levine, USA
- P2.02.38** Single-Cell RNA-Sq Reveals Potential Mechanism of RUNX3 Reshaping TME in NSCLC
Xiaohui Chen, China
- P2.02.39** Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect with Omeprazole Pretreatment in KRAS G12C NSCLC
Mengxin Zhou, Spain
- P2.02.40** Multiomics Assessment of Lung Adenocarcinoma Subtypes Defined Through Tumor Purity-Adjusted DNA Methylation
Deborah F. Nacer de Oliveira, Sweden
- P2.02.41** Feasibility of Flow Super RCA for KRAS Mutation Detection in Liquid Biopsies of Advanced Lung Adenocarcinoma: Pilot Study
Luis Posado-Dominguez, Spain
- P2.02.42** Effect of MTHFR Gene Mutation on the Efficacy of Tyrosine Kinase Inhibitor Treatment in Lung Cancer Patients
Wenmei Su, China
- P2.02.43** Multi-Omic Approach Elucidates the Underlying Mechanism of HA-Coated Neohesperidin Nanoparticles Against Lung Cancer
Ruchi Pandey, India
- P2.02.44** Research on the Mechanism of Gut Microbiota Promoting NSCLC Distant Metastasis Through Its Metabolite Testosterone
Chen-Guang Liu, China
- P2.02.45** Modulated Electro-Hyperthermia Enhances Tumor Cell Susceptibility to Gamma Delta T Cell-Mediated Cytotoxicity and Tumor Infiltration
Chi Chiu, Taiwan
- P2.02.46** V-AtPase Inhibitors Enhance the Effect of Tepotinib (c-Met Inhibitor) or RMC-6236 (Pan-Ras(ON) Inhibitor) in KRAS-Mutant NSCLC
Kevin València-Claa, Spain
- P2.02.47** Hypoxia-Driven SERBP1-SLC25A5-ND6 Axis Regulates Mitochondrial Metabolic Reprogramming to Promote Metastasis in Non-Small Cell Lung Cancer
Chuanyong Mu, China

TRACK 05: PULMONOLOGY AND STAGING

- P2.05.01** The Role of Robotic-Assisted Bronchoscopy and Endobronchial Ultrasound in Diagnosing and Staging Pulmonary Carcinoid
Shreya Podder, USA
- P2.05.02** Evolution and Survival Impact of Endobronchial Ultrasound (EBUS) Adequacy in Two Population-Based Lung Cancer Cohorts
Matthew Smeltzer, USA
- P2.05.03** Minimizing Atelectasis in ENB: A Propensity-Matched Study of Laryngeal Mask Ventilation Strategy
Yuan Xu, China
- P2.05.04** Electromagnetic Navigation-Guided 3D Conformal Microwave Ablation for High-Risk Peripheral Pulmonary Nodules
Yawei Liu, Yawei Liu, China
- P2.05.05** Prediction of Distant Metastasis Using CT/PET-Based Radiomics in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Ayah Al-Bzour, Jordan
- P2.05.06** Mature Results of a High-Precision Clinical Protocol for Staging Non-small Cell Lung Cancer (NSCLC) of the Left Lung
Lucia Cabanillas-Parades, Spain

- P2.05.07** The Effect of Adrenal Gland Metastasis on the Course of Lung Cancer
Guntulu Ak, Turkey
- P2.05.08** Discordance Between Clinical and Pathological Invasive Size in Early Stage Non-small Cell Lung Cancer
Taeyoung Yun, Republic of Korea
- P2.05.09** Proposed Modification of Clinical T Categorization for Early-Stage Lung Adenocarcinoma: A Data-Driven Multicenter Quantitative Analysis
Bing-yu Rao, China
- P2.05.10** Prognostic Factors in IIb-IIIB Patients with Nodal Involvement Underwent Surgery for NSCLC
Marco Chiappetta, Italy
- P2.05.11** Prognostic Impact of Organ-Specific Metastasis in Non-small Cell Lung Cancer
Woo Kyung Ryu, Republic of Korea
- P2.05.12** Lymph Node Pathologic Grading Strategy: Under the Backdrop of the IASLC Grading System for Invasive Lung Adenocarcinoma
Chaoqiang Deng, China
- P2.05.13** MIA With Pleural or Pericardial Effusion Have Worse Survival Than Those with Pleural or Contralateral Lung Metastasis When Receiving EGFR-TKIs
Xiang Chen, China
- P2.05.14** Clinical Versus Pathological T Staging in Lung Adenocarcinoma: Discrepancies and Prognostic Implications
Libing Yang, China
- P2.05.15** Management-Oriented Classification of Lung Neuroendocrine Tumors Based on a French Surgical Cohort of 1,915 Patients from the EPITHOR Database
Romain Vergé, France
- P2.05.16** Comparative Discriminative Performance of Number-Based and 9th Edition N Classifications in NSCLC: Exploring Statistically Valid Cut-offs
Donghee Kim, Republic of Korea
- P2.05.17** European Single-Center Validation of the 9Th TNM Staging System in Over 3,300 Surgically Treated NSCLC Patients
Inna Schott, Germany

TRACK 06: PATHOLOGY AND BIOMARKERS

- P2.06.01** Prognostic Value of a Combined Model Using CT and PET/CT Parameters for Predicting STAS in Stage I Lung Adenocarcinoma
Kyongmin Beck, Republic of Korea
- P2.06.02** Invading Through External Elastic Lamina Is Predictive of Poorer Outcomes in Pulmonary Non-Mucinous Invasive Adenocarcinoma
ChiHung Chiang, Taiwan
- P2.06.03** Diagnostic Performance of Frozen Section in Determining Histological Patterns and Spread Through Air Spaces in Lung Adenocarcinoma
Haojie Ji, China
- P2.06.04** Artificial Intelligence-Led Characterisation of Lethal Morphologies in Lung Adenocarcinoma
Kai Rakovic, UK
- P2.06.05** Diagnosis of the Novel IASLC Grading System Using Intraoperative Frozen Section: A Prospective Multi-Center Trial
Fangqiu Fu, China
- P2.06.06** Bronchiolar Adenoma with Malignant Transformation? New Insights Based on Morphologic, Immunophenotypic, and Genomic Analysis of 13 Cases
Yan Huang, China
- P2.06.08** ERBB2 Mutations in Non-small Cell Lung Cancer – Findings from a Large UK Cohort
David Moore, UK
- P2.06.09** Clinical, Racial, and Genetic Differences in Non-small Cell Lung Cancer Between Young a

- P2.06.10** Older Patients in the AACR Project Genie Database
Kamal Al-rabi, Jordan
- P2.06.11** Prognostic Impact of TP53 Co-Mutations with EGFR vs KRAS in Advanced Non-small Cell Lung Cancer: A cBioPortal Analysis
Divya Chukkalore, USA
- P2.06.12** Factors Impacting Receiving EGFR Test Results Before Initial Treatment Among Stage IV Non-small Cell Lung Cancer Patients
Jeffery Scott, MD, USA
- P2.06.13** TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes
Mark Kris, USA
- P2.06.14** Actionable Mutation Profiles and Survival Outcomes in Invasive Mucinous Adenocarcinoma of the Lung
Jongwoo Kim, USA
- P2.06.15** Adoption of a 50-Gene Targeted Next Generation Sequencing Hotspot Panel in Non-small Cell Lung Cancer in a Tertiary Institution in Singapore
Kenneth Sooi, Singapore
- P2.06.16** Genomic Alterations in Lung Cancers Associated with Fibrosing Interstitial Lung Diseases in a French Multicentric Cohort
Edouard GUENZI, France
- P2.06.17** Identification of Molecular Signatures Linked to Early-Stage Lung Adenocarcinoma with STAS Using Spatial Transcriptomics
Kazuya Hisamatsu, Japan
- P2.06.18** Cellular Heterogeneity and Tertiary Lymphoid Structure Dynamics Predict Overall Survival in Immune Checkpoint Therapy-Treated NSCLC Patients
James Wingrove, USA
- P2.06.19** Computational Modeling of Comprehensive Genomic Profiling to Predict Chemotherapy Benefit in Advanced NSCLC
Charu Aggarwal, USA
- P2.06.20** A Multi-Source Pathology-Based Model for Gene Mutation and Recurrence Risk Prediction in Lung Cancer
Huan Li, China
- P2.06.21** Assessment of Molecular Testing in Stage IV Non-small Cell Lung Cancer Patients Across American Oncology Network
Jeffery Scott, MD, USA
- P2.06.22** Differential Gene Expression and Pathway Analysis of Invasive Mucinous Adenocarcinoma
Jongwoo Kim, USA
- P2.06.23** Pathological Characterization of Molecularly Screened Diffuse Pleural Mesothelioma
Giorgia Impalà, Italy
- P2.06.24** CDKN2A Deletion Is an Independent Predictive Biomarker for Immunotherapy Response in Patients with Advanced NSCLC
Hyo Sup Shim, Republic of Korea
- P2.06.25** Primary Pulmonary Neuroendocrine Immunophenotype Carcinoma Harboring Driver Gene Mutation/Fusions: Neuroendocrine Neoplasm?
Bingxia Zhang, China
- P2.06.26** Clinical Implications of TROP2 Expression in Lung Adenocarcinomas
Kazuya Takamochi, Japan
- P2.06.27** The Clinicopathological Characteristics and Prognostic Analysis of SMARCA4-Deficient Non-small Cell Lung Cancer
Jing Zhang, China
- P2.06.28** Unlocking the Genetic Link: Exploring Germline EGFR T790M Mutations in NSCLC and Implications for Targeted Treatment and Familial Screening
Sahana Shiggaon, USA

- P2.06.28** GPC3 Upregulation After Neoadjuvant Chemioimmunotherapy Associates with Adverse Outcomes and Tumor Heterogeneity in Squamous NSCLC
Linqiang Jiang, China
- P2.06.29** Bridging Histopathology and Molecular Profiling: AI-Powered Virtual Multiplex Immunofluorescence Staining for LUAD Prognosis
Yu Lei, China
- P2.06.30** ITGBL1: A Predictive Biomarker for IPF-LUSC Comorbidity Risk in Lung Transplant Candidates
Zhanglin Yang, China
- P2.06.31** Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical Impact and Prognostic Insights from Histopathology
Shugo Takahashi, Japan
- P2.06.32** Impact of piR_004530 Reactivation in Lung Cancer: Implications for Recurrence and Survival of Lung Squamous Cell Carcinoma Patients
Yangyi He, Spain
- P2.06.33** Prognostic Significance and Therapeutic Potential of LILRB4 in MDSC-Mediated Immunosuppression in NSCLC
Sakiko Kumata, Japan
- P2.06.34** Tumor Heterogeneity Based Prognostic Score: What the Specimen Tells Us in the Intelligent Era?
Ziling Huang, China
- P2.06.35** Extracellular Vesicle RNA Diversity in Lung Adenocarcinoma: Driving Immunosuppression and Metastasis
Shen Lao, China
- P2.06.36** Proteomic Atlas Reveals Organ-Specific Metabolic and Functional Shifts in Preclinical ICB-Related Pneumonitis and Colitis
Zi-Xuan Rong, China
- P2.06.37** NGS Testing in Lung Cancer Within the Catalan Precision Oncology Program: The ICO-HUB Comprehensive Cancer Center Experience
Miguel Mosteiro Lamas, Spain
- P2.06.38** BTN1A1 and Nuclear YAP1 Co-Expression as Predictive Biomarkers for Nelmastobart Efficacy in Lung Cancer: Findings from a Phase 1 Trial
Stephen Yoo, USA
- P2.06.39** Predicting Relapse and TKI Response Using DNA and RNA EGFR VAF in EGFR-Mutant Lung Adenocarcinoma
Hsuan-Yu Chen, Taiwan
- P2.06.40** Integrated Molecular Analysis of Advanced NSCLC Depicts Molecular Signatures Associated with Tyrosine Kinase Inhibitors Efficacy
Paolo Bironzo, Italy
- P2.06.41** Real-World Data and Utility of Newly Proposed Grading System from IASLC for Invasive Lung Adenocarcinoma in Japan
Kyoshiro Takegahara, Japan
- P2.06.42** NSD3 Overexpression Predicts Prognosis and Immune Cell Infiltration Patterns in Lung Squamous Cell Carcinoma: A Bioinformatics Analysis
Wei Wang, China
- P2.06.43** Estimating Tumour Microenvironment Cellular States from Bulk RNAseq Produces Biomarkers of Clinical Outcome Across Stages
Marcelo Hurtado, France
- P2.06.44** More Than a Mutation: Prevalence of HER2 Overexpression, Amplification, and Mutations by Histology in NSCLC
Jennifer Marks, USA
- P2.06.45** A Novel Predictive Gene Signature for Liver Metastasis (LM) in NSCLC Using a Comprehensive Linked Clinical-Molecular Database
Simon Papillon-Cavanagh, USA

- P2.06.46** Multi-Omics Analysis Reveals Genomic Features Associated with Combination Immunotherapy Benefit in Advanced NSCLC
Lailing Li, China
- P2.06.47** AXI Receptor Shedding and EMT in Lung Adenocarcinoma: Prognostic Implications Based on STAS
Shuji Mishima, Japan
- P2.06.48** Histology-Specific Genomic and Immune Predictors of Resistance to Neoadjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
Tae Hee Hong, Republic of Korea
- P2.06.49** Spatial Metabolomic Profiling Reveals Dynamic Metabolic Reprogramming During Lung Squamous Cell Carcinoma Evolution
Hao Qin, China
- P2.06.50** Transcriptomic Profiling Identifies a Prognostic and Predictive Immune Signature in Patients (Pts) With Lung Squamous Cell Carcinoma (LUSC)
Avah Al-Bzour, Jordan
- P2.06.51** Tumour Tissue Extracellular Vesicle (EV) Biomarkers of Lung Cancer in Patients With or Without Heavy Smoking Histories
Kwun Fong, Australia
- P2.06.52** Survival and Mutational Differences of GPER and Estrogen Receptor (ER) in NSCLC
Robert Hsu, USA
- P2.06.53** TP53 Mutations Drive Therapeutic Resistance in ALK-Rearranged Lung Adenocarcinoma
Meng-Min Wang, China
- P2.06.54** miR-Roring IFN-Gamma Pathway Activity as a Predictive Tool for Immunotherapy Response in Non-small Cell Lung Cancer
Roberto Cuttano, Italy
- P2.06.55** Association Between Pathologic Necrosis and Postoperative Recurrence in Stage IA Non-small Cell Lung Cancer
Yongfei Fan, China
- P2.06.56** Enhancing Lung Cancer Diagnosis and Early Recurrence Risk Detection via Bedside Atomic Force Microscopy
Jordi Alcaraz, Spain
- P2.06.57** TIM-1+ B Cells Promote Immune Suppression and Predict Poor Prognosis in Lung Adenocarcinoma
Junxu Wen, China
- P2.06.58** Predictive Value of Tumor Microenvironment Biomarkers in Neoadjuvant Immunotherapy Combined with Chemotherapy for Locally Advanced NSCLC
Xu Wang, China
- P2.06.59** Multi-Level Screening of MET Aberrations in Treatment-Resistant Non-small Cell Lung Cancer: A Report From LC-SCRUM-TRY
Tetsuro Taki, Japan
- P2.06.60** Multimodal Diagnostic Model for Intraoperative Diagnosis and Surgery Strategy in Stage Ia LUAD (SuImage V2): A Prospective, Multicentric Study
Lintong Yao, China
- P2.06.61** ASPIRATION: Australian Nationwide Cohort Study to Assess Impact of Comprehensive Genomic Profiling in Metastatic Lung Cancer
Nick Pavlakis, Australia
- P2.06.62** Integrin- $\beta 6$ Modulates the Tumor Microenvironment and Serves as a Prognostic Marker in Lung Squamous Cell Carcinoma
Fawzi Abu Rous, USA
- P2.06.63** The Role of the Lower Airway Microbiome in Predicting Treatment Response to Immunotherapy in Patients With Non-small Cell Lung Cancer
Anna McLean, Australia
- P2.06.64** Fusion Transcript Burden Is Associated with Clinical Outcomes in Patients with Resected NSCLC
Jeffrey Borgia, USA
- P2.06.65** An Ensemble Approach to Predict Three-Class PD-L1 Expression From H&E Whole-Slide Images
Vanja Mišković, Italy
- P2.06.66** Novel Predictive Spatial Biomarker in NSCLC: Discriminant of Niches Unlocking Treatment Sensitivity (DONUTS)
Michael Fotheringham, Canada
- P2.06.67** Retrospective Analysis of 124 LCNEC Tumors with Targeted Expression Profiling of 111 Samples Identifies Candidate Chemo-Sensitivity Biomarker
David Severson, USA
- P2.06.68** Enhancing Precision Medicine in NSCLC - The Importance of Tumor Metabolic Spatial Profiling in Immunotherapy Biomarker Discovery
Ken Bloom, Israel
- P2.06.69** Metabolite Enrichment Patterns Correlate with Race, Gender and BMI in Lung Cancer Patients
Joshua Pothen, USA
- P2.06.70** Concurrent Tissue and ctDNA-Based Genomic Profiling in Advanced Lung Cancer: A Prospective, Single-Institution Study
Saurav Verma, Canada
- P2.06.71** Clonal Hematopoiesis and Its Association with Lung Cancer Incidence and Immunotherapy Response: A Meta-Analysis
Dhruv Bansal, USA
- P2.06.72** Impact of Peripheral Electrolyte on Equilibrium Between Immunotherapy Toxicity and Survival in Advanced NSCLC Treated With PD-L1 Blockade
Ning Gao, China
- P2.06.73** Cerebrospinal Fluid Biomarkers in Patients with Leptomeningeal Metastasis of Lung Cancer
Xiaoxing Gao, China
- P2.06.74** Detection of Actionable Biomarkers in Liquid Biopsy from Non-small Cell Lung Cancer Patients Using NGS-Based Assays
Sergi Clavé, Spain
- P2.06.75** Liquid Biopsy NGS Accelerating Treatment Decision-Making in Non-small Cell Lung Cancer
Suset Almuinas de Armas, USA
- P2.06.76** Molecular Profiling of Lung Cancer Brain Metastases: Analysis Between Liquid Biopsy and Brain Metastasis Tissue Results
Rupesh Kotecha, USA
- P2.06.77** A Perioperative Circulating Tumor DNA Model for Landmark Detection in Non-small Cell Lung Cancer
Jia-Tao Zhang, China
- P2.06.78** Using a Personalized, Tumor-Informed Circulating DNA (ctDNA) to Monitor Treatment Outcomes in Lung Cancer Patients
Daniel Rosas, USA
- P2.06.79** Deciphering Genomic and Transcriptomic Heterogeneity in Circulating Tumor Cells at Diagnosis in Small Cell Lung Cancer: CTC-CPC Study
Charles Ricordel, France
- P2.06.80** Development of a Proteomics-Based Machine Learning Model for Diagnosing and Predicting Lung Cancer: Insights From the UK Biobank
Xiao Chen, China
- P2.06.81** Circulating Tumour Cells, Spread Through Air Space and Lymph-Nodal Micrometastasis in Surgically Resected Early-Stage NSCLC
Pietro Bertoglio, Italy

- P2.06.82** Cell Free DNA Dynamics in Exhaled Breath Condensate to Predict Outcomes to Immune Checkpoint Inhibition in Advanced NSCLC
David O Reilly, Ireland
- P2.06.83** Multimethod Circulating Tumor DNA Profiling for Minimal Residual Disease Monitoring in Early-Stage Non-small Cell Lung Cancer
Glan Cui, China
- P2.06.84** Tracking Ctc Phenotypes in SCLC Liquid Biopsies as a Diagnostic and Therapy Response Assessment Tool
Loukia Karacosta, USA
- P2.06.85** Clinical Utility of a "Plasma 1st Approach" for Molecular Diagnosis Using ctDNA in Advanced Lung Cancer, NHS England Pilot
Oliver Kennedy, UK
- P2.06.86** Development and Validation of Peripheral Blood 5-Protein Signature Predicting the Efficacy of Immunotherapy in Advanced NSCLC
Lei Cheng, China
- P2.06.87** Reversible Smoking-Dependent Hg980 Increase, a Path to Identifying NSCLC-Negative Individuals: An Incentive to Quit Smoking?
Alexandre Prieur, France
- P2.06.88** ctDNA and WBC DNA Sequencing Through MSK-ACCESS Powered with SOPHIA DDM to Define Tumor and Clonal Hematopoiesis TP53 Variants in Lung Cancer
Florian Klemm, Switzerland
- P2.06.89** DYNAMALK: DYNAMIC ct-DNA in ALK+ NSCLC Under the Australasian Thoracic Cancers Longitudinal Cohort Biobank Study (AURORA)
Malinda Itchins, Australia
- P2.06.90** The Role of ctDNA Tumor Fraction in Advanced NSCLC and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study
Aya El Helali, China
- P2.06.91** Plasma Proteomic Profiling Identifies DHX9 as a Predictive Biomarker for Chemioimmunotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer
Lina Chen, China
- P2.06.92** Host-Derived Biomarkers of Inflammation and Body Composition Predict Immunotherapy Outcomes in Advanced NSCLC
Andrea De Giglio, Italy
- P2.06.93** Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis
David Gandara, USA
- P2.06.94** Integrating AI-Based Risk Stratification, LDCT, and Liquid Biopsy for Early Detection of Lung Cancer in High-Risk Individuals
Sewanti Limaye, India
- P2.06.95** Deep Learning-Based Prediction of Immunotherapy Efficacy in Non-small Cell Lung Cancer: Automated Tumor and Muscle Evaluation
Taichi Miyawaki, Japan
- P2.06.96** Exploration of the Heterogeneity of HER2 Expression in Potential Candidates for Antibody-Drug Conjugate in Non-small Cell Lung Cancer
Dongmei Lin, China
- P2.06.97** Monitoring the Risk of Second Primaryes Through Blood miRNA Testing: Follow-Up of the BioMILD Lung Cancer Screening Trial
Gabriella Sozzi, Italy
- P2.06.98** Deep Learning-Based 18F-FDG PET/CT Radiomics Model for Predicting Pathological Response to Chemioimmunotherapy in NSCLC
Ao Li, China

TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

- P2.06.99** Tumor-Associated Neutrophil Infiltration Predicts Benefit From Combination Chemioimmunotherapy in Non-small Cell Lung Cancer
Claire Norman, Canada
- P2.06.100** Initial Biomarker Results from the Phase 2A Study of AFM24 With Atezolizumab in Patients with Advanced/Metastatic NSCLC
Hye Ryun Kim, Republic of Korea
- P2.06.101** Neuroendocrine-Like Subtype or TMB-High Predicts Long-Term Survival Benefit from Sequential Thoracic Radiotherapy and ICI in ES-SCLC
Linlin Wang, China
- P2.06.102** Prevalence and Concordance Analysis of MET Amplification/Overexpression in a Phase 1 Study of Davutamig (REGN5093) in a NSCLC
Dimple Modi, USA
- P2.08.01** Double Lung Transplantation in Patients with Recent History of Malignancy
Young Kwang Chae, USA
- P2.08.02** Long Term Prognosis Following Wedge Resection in Peripheral = ctTlb Non-small Cell Lung Cancer Patients Without Pulmonary Dysfunction
Taeyoung Yun, Republic of Korea
- P2.08.03** Different Grades of Visceral Pleura Invasion in Lung Adenocarcinomas Correlate with Aggressiveness and Poor Prognosis
Stylianos Korasidis, Italy
- P2.08.04** Open Versus Thoracoscopic Versus Robotic Sleeve Lobectomy for Central Non-small Cell Lung Cancer: A Network Meta-Analysis
Haifeng Shen, China
- P2.08.05** Robotic-Assisted Versus Video-Assisted Sleeve Lobectomy for Central Non-small Cell Lung Cancer: A Multicenter Cohort Study
Haifeng Shen, China
- P2.08.06** Clinical Significance of Tertiary Lymphoid Structures in Surgically Resected Stage II-III Lung Adenocarcinoma
Taiyo Nakamura, Japan
- P2.08.07** Lymph Node Yield and Survival Among Lung Cancer Patients Treated with Neoadjuvant Systemic Therapy
Giorgio Caturegli, USA
- P2.08.08** Treatment Options and Prognosis for Lung Cancer in Elderly Patients (80 Years Old)
Mari Shimoda, Japan
- P2.08.09** Surgical Resection After Induction Therapy in Initially Unresectable Driver Mutation-Negative Stage III Non-small Cell Lung Cancer (NSCLC)
Hao Guo, China
- P2.08.10** Perioperative Outcomes of Extended Sleeve Resection at Our Institution
Chiaki Kanno, Japan
- P2.08.11** Management of High-Grade Endobronchial Pre-Invasive Lesion: To Treat or Not to Treat?
Illa Smesseim, Netherlands
- P2.08.12** Salvage Stereotactic Ablative Radiotherapy for Loco-Regional Recurrence After Initial Surgery According to the START NEW ERA Phase II Trial
Paola Anselmo, Italy
- P2.08.13** Radiation Dose to the Heart and Cardiac Substructures Associated with Adverse Cardiac Events in Locally-Advanced Non-small Cell Lung Cancer
Christopher Kelsey, USA
- P2.08.14** Tumor Volume Changes During Stereotactic Body Radiotherapy for Lung Tumors Under MRI Guidance
Chukwuka Eze, Germany

- P2.08.15** Cardiac Prioritized Planning in Locally Advanced Non-small Cell Lung Cancer: Comparison of Modern RT Techniques
Serap Akyurek, Turkey
- P2.08.16** National Real-World Data on the Treatment of Locally Advanced NSCLC With Chemoradiotherapy and Adjuvant Durvalumab
Martina Vrankar, Slovenia
- P2.08.17** Differential Cardiac Dose Evaluation and the Need of Planning Risk Volume (PRV) Margin for the Heart
Karthick Raja M, India
- P2.08.18** Evaluation of Target Volume Delineation Variability in NSCLC Radiotherapy
Lilian Faroni, Brazil
- P2.08.19** Proton Beam Therapy for Lung Cancer in Patients with Interstitial Lung Disease: Initial Experience From the UK
Caroline Maguire, UK
- P2.08.20** VMAT vs IMRT Technique in Locally Advanced Lung Cancer Radiotherapy Treatment Pulmonary Toxicity and Dosimetric Evaluation
Slavica Maric, Bosnia and Herzegovina
- P2.08.21** Mapping Early Failure After CRT and Durvalumab in NSCLC: Insights from a Real-World Cohort
Maja Lisik-Habib, Poland
- P2.08.22** In Field Progression Rates Following Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer
Drew Moghanaki, USA
- P2.08.23** Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy with Durvalumab in PD-L1 High LA-NSCLC
Steven Lin, USA
- P2.08.24** Radiation Dose to the Circulating Blood Is Associated with Poor Overall Survival in Patients with Locally Advanced Non-small Cell Lung Cancer
Narek Shaverdian, USA
- P2.08.26** Randomized Phase II Trial of Adjuvant Radiochemotherapy, Concurrent Versus Sequential, in Resected pN2 NSCLC. ARCCS Trial
Paolo Borghetti, Italy
- P2.08.27** Impact of CD73 on Immune Evasive Contexture and Clinical Outcomes in Lung Adenocarcinoma in Neoadjuvant Immunotherapy
Minxing Chen, China
- P2.08.28** Impact of Neoadjuvant Chemoimmunotherapy vs Chemotherapy in Stage III NSCLC: Real-World Analysis from Spanish ReSECT Database
Xavier Vallo, Spain
- P2.08.29** Phase 2 Trial of Neoadjuvant Tislelizumab Combined with Chemotherapy for Newly Diagnosed Stage III Unresectable NSCLC
Zhe Wu, China
- P2.08.30** IA-Based Prediction in NSCLC Patients Undergoing Neoadjuvant Radiochemotherapy
Claudia Tacconi, Italy
- P2.08.31** Clinical and Imaging Characteristics Associated With Pathologic Response After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC
Dong Young Jeong, Republic of Korea
- P2.08.32** Single Cell Transcriptomic Analysis Reveals Tumor Immune Remodeling and Epithelial Cells Gene Signature After Neoadjuvant Immunotherapy
Yutao Liu, China
- P2.08.33** Quantitative Pathological Analysis of the Surgical Specimens of NSCLC After Neoadjuvant Immunotherapy
Yui Kaburkai, Japan
- P2.08.34** Serplulimab in Neoadjuvant Therapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective Single-Arm Study
Jian Zeng, China
- P2.08.35** PD-L1 as a Predictive Biomarker in EGFR-Mutated Non-small Cell Lung Cancer with Neoadjuvant Immunotherapy
Yi-Fan Qi, China
- P2.08.36** Survival Outcomes in Locally Advanced NSCLC Patients Converted to Resectable Disease by Neoadjuvant Therapy
Ozden Altundag, Turkey
- P2.08.37** Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Real-World Evidence From a Spanish Multicenter Cohort
Karla Medina Sanchez, Spain
- P2.08.38** Identifying Risk Factors for Recurrence in Non-small Cell Lung Cancer Patients with PCR After Neoadjuvant Immunotherapy
Dongmei Lin, China
- P2.08.39** Targeting CHCHD3-cGAS to Remodel Immunosuppressive Microenvironment in Lung Adenocarcinoma: Mechanism and Clinical Translation
Mengzhe Zhang, China
- P2.08.41** The Influence of Perioperative Chemoimmunotherapy on Surgery for Resectable Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Shaoyi Chen, China
- P2.08.42** Impact of Delayed Initiation of Adjuvant Chemotherapy on Overall Survival Among Patients with Non-small Cell Lung Cancer
Esin Naimoglu, USA
- P2.08.43** Perioperative Adebrelimab Plus Chemotherapy in Patients with Resectable Stage II-III NSCLC: 4-Year Update From a Phase 1b/3 Trial
Yi-Long Wu, China
- P2.08.44** Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-small Cell Lung Cancer: A Real-World Study
Jin Kang, China
- P2.08.45** Immune Gene Guided Multi-Scale Pathomic Signature in H&E-WSI Predict Neoadjuvant Immunotherapy Response in NSCLC
Shaowei Wu, China
- P2.08.46** COPD Reshape the Tumor Microenvironments of NSCLC and Potentiate Antitumor Efficacy of Anti-PD-1 Therapy
Xiaoke Chen, China
- P2.08.47** Lymphocyte Recovery and Risk for Immune Pneumonitis After Chemoradiation in Locally Advanced NSCLC
Monika Satoskar, USA
- P2.08.48** Pacific Real-World Experience at Hospital Doce De Octubre
Mariana Ternes, Spain
- P2.08.49** Effect of the Immunological Circadian Rhythm on Treatment of Locally Advanced Non-small Cell Cancer with Immunotherapy
Ester Oliva-Poch, Spain
- P2.08.50** Tislelizumab with Chemotherapy as Neoadjuvant Therapy for Unresectable Stage III Lung Cancer: A Single-Arm, Phase II Trial
Xianming Hou, China
- P2.08.51** Outcomes from a Phase II Study of Hypofractionated Chemoradiation and Consolidation Immunotherapy in Locally-Advanced NSCLC
Gregory Vlach, USA
- P2.08.52** Optimizing Lung Cancer Radiation Therapy: Integrating Immunotherapy and Targeted Therapy for Enhanced Clinical Outcomes
Thais Dias, Brazil

- P2.08.53** Safety Results of DEDALUS Trial: Sequential CT-10, Hypofractionated RT and Consolidation IO in Unresectable Stage III NSCLC
Francesco Agustoni, Italy
- P2.08.54** Contemporary Treatment Patterns and Outcomes in Stage III NSCLC in the Immunotherapy Era
Houda Bahig, Canada
- P2.08.55** Comprehensive Analysis of Baseline Genomic Features and Plasma ctDNA Dynamics in Unresectable Locally Advanced NSCLC
Xiaoxing Gao, China
- P2.08.56** Sequencing of Chemoimmunotherapy in Resectable Locally Advanced NSCLC: Single Center Experience
Pranay Adavelly, USA
- P2.08.57** Small Volume Segmental Lung Autotransplantation for Treatment of Central Lung Cancer: One Case Report
Jinbao Xie, China
- P2.08.58** Advancing Care in NSCLC: Evaluating the Impact of New Treatment Modalities on Patient Outcome at the LTZ of the Comprehensive Cancer Center Zurich
Jorune Pikellis, Switzerland
- P2.08.59** SCGB1A1 Enhances Radioimmunotherapy Efficacy and Mitigates Pulmonary Toxicity via Dendritic Cell Functional Reprogramming
Yan-Pei Zhang, China
- P2.08.60** Telomere Length and Survival in Patients with Locally Advanced Unresectable Lung Cancer: Is There a Relationship?
Alfredo Martín-Muñiz, Spain

TRACK 10: METASTATIC NON-SMALL CELL LUNG CANCER – CYTOTOXIC THERAPY

- P2.10.01** Maintenance Pemetrexed/Pembrolizumab vs Maintenance Pembrolizumab Alone in Advanced Non-Squamous Non-small Cell Lung Cancer
Garth Strohbehn, USA
- P2.10.02** Developments in Treatment of Non-small Cell Lung Cancer and Their Implications for National Practice, Register-Lung National Registry Study
Mahmut Gümüs, Turkey
- P2.10.03** Long-Term Pemetrexed Administration Poses Risk of Renal Function Decline
Tomoki Tamura, Japan
- P2.10.04** Real-World Evidence on the Efficacy of TSI in Patients with Advanced Non-small Cell Lung Cancer
Chih-Yu Yeh, Taiwan
- P2.10.05** Real-World Efficacy of Second-Line Carboplatin Plus Pemetrexed in EGFR-Mutant NSCLC: an International, Multicentre Analysis
Martin Igor Gómez-Randulfe Rodríguez, UK
- P2.10.06** Docetaxel in NSCLC: A Multi-Centre Real World Evidence Analysis in the Immunotherapy Era
Christopher Theriault, Canada
- P2.10.07** Combined Immunoscore for Predictive Stratification of Unresectable Non-small Cell Lung Cancer
Oussama Aazzane, Morocco
- P2.10.08** Antibody-Drug Conjugates Versus Docetaxel for Previously Treated Advanced NSCLC: Systematic Review and Meta-Analysis of RCTs
Saqib Khan, Canada
- P2.10.09** Single-Cell RNA Sequencing Reveals Subtype-Specific Resistance Mechanisms to TROP2-Targeted ADCs in Non-small Cell Lung Cancer
Osama Younis, Jordan

- P2.10.10** Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery with Clinically Validated Tumor Selective Linker Payload
Hwanhee Oh, Republic of Korea
- P2.10.11** Single-Cell RNA Sequencing Identifies ALCAM and GPNMB as Therapeutic Targets for ADC Development in Squamous Cell Carcinoma of the Lung
Osama Younis, Jordan
- P2.10.12** Trastuzumab Deruxetecan in Patients from China with Pretreated HER2-Mutant NSCLC: Final Results from the DESTINY-Lung05 Study
Buhai Wang, China
- P2.10.13** Sunvozertinib Combined with Bevacizumab in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertion Mutations
Yongfeng Yu, China
- P2.10.14** Individualized Neoadjuvant Therapy With Unusual Radiotherapy Enhancement (INATURE) a Phase II Randomized Study
Feng-Ming (Spring) Kong, China
- P2.10.15** Mechanistic Study of Osimertinib Combined with Sitravatinib to Overcome Acquired Osimertinib Resistance in Non-small Cell Lung Cancer
Xiang Wang, China
- P2.10.16** Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: Updated Results of a Real-World Study
Liyun Jiang, China
- P2.10.17** Dual PARG-TOPI Inhibition Exacerbates DNA-Protein Crosslinks and Replication Stress: A Promising Strategy for Enhancing Topii-ADC Efficacy
Reeja Maskey, USA

TRACK 15: MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH AND PALLIATIVE CARE

- P2.15.01** Expedited Diagnostics Coordination Leads to Expedited Care in Advanced Stage Lung Cancer
Robert Anderson, USA
- P2.15.02** Communication Needs of Patients with Advanced Lung Cancer Receiving Immunotherapy: Results of a Qualitative Study
Matthias Villalobos, Germany
- P2.15.03** Predictive Value of LIPI Score in the Response to Immunotherapy in Very Elderly Patients with Advanced Non-small Cell Cancer
Alejandro Olivares Hernández, Spain
- P2.15.04** End-Of-Life Systemic Therapy and Survival in Metastatic Lung Cancer: A Territory-Wide Real-World Study of 24,608 Patients
Feng-Ming Kong, China
- P2.15.05** A Shared Decision Aid for First-Line Treatments of ALK+ Advanced Non-small Cell Lung Cancer: A Patient-Centered Approach
Thomas Stinchcombe, USA
- P2.15.06** Best Practices and Process Variations of Lung Cancer Multi-Disciplinary Teams: Insights from Europe and Israel
Helena Linardou, Greece
- P2.15.07** Effect of Message Framing in a Digital Lung Cancer Screening Decision Navigation Intervention: A Three-Arm Randomized Controlled Trial
Feifei Huang, China
- P2.15.08** Effects of a Decision Support Intervention for Patients with Advanced Lung Cancer: RCT- Results and Document Analysis
Matthias Villalobos, Germany
- P2.15.09** Long-Term Survival in Malignant Pleural Effusion: Validation of the LENT and PROMISE Scores
So Yeon Kim, Republic of Korea

- P2.15.10** Improving Patient-Reported Outcome Symptom Monitoring Using Bayesian Networks
Cindy Verberkt, Netherlands
- P2.15.11** Non-Cancer-Related Mortality in Lung Cancer Patients: The Role of Comorbidities in a 7-Year Retrospective Case-Control Study
Zamira Fernanda Gomez Giraldo, Colombia
- P2.15.12** Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients with Lung Cancer
Jorgina Serra López, Spain
- P2.15.13** Patient Self Management Education and Cancer Treatment Adherence in Low Middle Income Africa: A Systematic Scoping Review
Dejen Tsegaye, Australia
- P2.15.14** Improving Access and Recruitment to Clinical Trials for Lung Cancer Using the Lung I-Act Tool: A Mixed Methods UK Wide Pilot Study
Christopher Dodd, UK
- P2.15.15** Impact of Palliative Care in Patients with Non-small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis
Rohit Singh, USA
- P2.15.16** ECOMO as a Procedural Bridge for Malignant Airway Obstruction in Lung Cancer
Hyeon Jun Cho, Republic of Korea
- P2.15.17** Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline
Lauren Curry, Canada
- P2.15.18** Quality of Life for Lung Cancer Survivors
Asha Kodan, USA
- P2.15.19** Assessment of NSCLC Treatments and Correlation with Hypogonadism in Male Patients with NSCLC
Richard Chahine, USA
- P2.15.20** Influence of Preoperative Mental Health on the Postoperative Outcome and Quality of Life After Anatomic Lung Resection
Uyen-Thao Le, Germany
- P2.15.21** Feasibility and Preliminary Efficacy of Multimodal Prehabilitation in Patients with NSCLC Receiving Neoadjuvant Therapy
Raquel Sebío-García, Spain
- P2.15.22** A Nutritional Strategy to Mitigate Toxicities and Optimize Dose Intensity in Patients with Lung Cancer: The Nutricare Study
Carolyn Presley, USA
- P2.15.23** Uncertainty in Illness, Symptom Severity and Hope in Advanced Lung Cancer Patients Undergoing Immunotherapy
Yeur-Hur Lai, Taiwan
- P2.15.24** A National Survey of Lung Cancer Survivorship Care at USA Cancer Centers from the American Cancer Society
Matthew Schabath, USA
- P2.15.25** Trilaciclib's Myeloprotection in TL Advanced Solid Tumors: Lung Cancer Data Analysis
Huijing Feng, China
- P2.15.26** Frequency of Adverse Events Reported Digitally by Patients with Advanced NSCLC: Analysis From CLIMEDIN, a HeCOG Study
Paris Kosmidis, Greece
- P2.15.27** Symptom Screening Using the Patient-Generated Subjective Global Assessment Adds Value to Routine Clinical Review
Chris Smith, UK
- P2.15.28** Lorlatinib-Associated Dyslipidemia: A Multicenter, Retrospective Analysis and Implications for Future Cardiovascular Disease
Fei Xu, China

- P2.15.29** Understanding the Psychosociological Burden of ALK+ NSCLC: Findings from the French Study «Living With ALK+ Cancer»
Jacques Cadranet, France
- P2.15.30** Impact of an Incidental Pulmonary Nodule Course Series on the Professional Development of Under-Resourced Multidisciplinary Teams
Holly Sanders, USA
- P2.15.31** Integrating Biomarker Testing in Early-Stage Lung Cancer with a Nurse-Led Multidisciplinary Approach Using the 4R Oncology Model
Raymond Liu, USA
- P2.15.32** Early Lung Cancer Detection and Multidisciplinary Care
Raymond Osarogagbon, USA
- P2.15.33** A Comparative Study of the Significance of GPT-Enabled Counseling and Management of Pulmonary Nodules
Dawei Yang, China
- P2.15.34** Prompting and Medical Expertise Influence Large Language Model in Clinical Data Extraction: Findings from the APOLLO 11 Trial
Laura Mazzeo, Italy

TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

- P3.01.01** Asian-Americans with Tobacco Use History Are Less Often Eligible for Screening Than White Individuals with Lung Cancer
Julie Barba, USA
- P3.01.02** Association Between Age and Lung Cancer Risk: Evidence from Lung Lobar Radiomics
Yuwei Li, China
- P3.01.03** Night Shift Work and Lung Cancer Risk: A Prospective Cohort Study with Mediator Analysis from the UK Biobank
Yi Feng, China
- P3.01.04** Bootstrap-Based Mediation Mendelian Randomization Unveils Gut Microbiota-Driven Metabolic-Immune Networks in Lung Cancer
Ying-Long Peng, China
- P3.01.05** Decoding the Sleep Enigma: A Proteomic Mediation Analysis Linking Healthy Sleep Patterns to Lung Cancer Risk
Yi Feng, China
- P3.01.06** Lung Cancer in Incidentally Detected Pulmonary Nodules: Stratified Analysis by Smoking History and Nodule Morphology
Filippe Moura de Gouvêa, Brazil
- P3.01.07** Socioeconomic Inequalities and Lung Cancer Outcomes: Evidence from an Integrated EHR Database and State Cancer Registry Data
Tae Yoon Lee, USA
- P3.01.08** Impact of Reproductive Factors on Lung Cancer Risk in Women: A Prospective Analyses in the UK Biobank
Ximin Gao, China
- P3.01.09** Survival Determinants and Socio-Demographic Disparities in Early Onset Lung Cancer in Young Adults: Insights from AI Modeling
Maroun Bou Zerdan, USA
- P3.01.10** Income, Tumour Stage, and Treatment in Patients with Non-small Cell Lung Cancer: A Population-Based Study in the Netherlands
Anouk Eijkelboom, Netherlands
- P3.01.11** Lung Cancer in Young Patients Under 45 Years: Clinical Characteristics, Histology and Molecular Profile
Parvin Akhmedov, Russian Federation

POSTERS (P3):

TUESDAY, SEPTEMBER 9, 2025

i Presenters in Attendance: 10:00 - 11:30

- P3.01.12** Associations Between Respiratory Diseases and Lung Cancer Risk, With New Insights into Acute Infections
Qiu Zhong, China
- P3.01.13** Lung Cancer Characteristics and Survival Among Smokers, Former Smokers, and Never Smokers Within an Australian Lung Cancer Registry
Susan Harden, Australia
- P3.01.14** The Rising Toll: Global Burden and Future Projections of Tracheal, Bronchus, and Lung Cancer in Women, 1990-2050
Jaimini Patoliya (Desai), India
- P3.01.15** Quantifying the Burden of Lung Cancer Attributable to Behavioral Risk Factors in OECD Countries Over Three Decades
Vatsaikumar Jetani, UK
- P3.01.16** Global Burden of Lung Cancer Attributed to High Fasting Plasma Glucose: A Benchmarking Analysis of G20 Countries (1990-2021)
Vatsaikumar Jetani, UK
- P3.01.17** Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the UK From 1990-2021
Prashant Gupta, India
- P3.01.18** The Journey to a Lung Cancer Diagnosis: Reports from the LEAD Study
Lauren Kiehl, USA
- P3.01.19** Gender Differences in Lung Cancer Diagnosis, Treatment Patterns and Outcomes: A Systematic Literature Review
Nagla Fawzy Abdel Karim, USA
- P3.01.20** Lung Cancer Risk Factors in 35,530 People from the UKLS Trial Who Have Never Smoked
Lucy Shire, UK
- P3.01.21** Lifting the Smoke Screen: A Real-World Comparative Study of Lung Cancer in Never-Smokers Versus Ever-Smokers
Pragadeesh Thamarai Selvan, India
- P3.01.22** Deep Learning-Based CT Analysis Enhances Lung Cancer Risk Prediction in Never Smoking Women
Alexis Chidi, USA
- P3.01.23** The Impact of PM2.5 Exposure on the Genome of Patients with Lung Adenocarcinoma Who Have Never Smoked
Peiyao Wang, Canada
- P3.01.24** Economic Burden of Radon Attributable Non-small Cell Lung Cancer: A Cost Analysis
David Griffin, Canada
- P3.01.25** Residential Radon and Molecular Alterations in Non-small Cell Lung Cancer
Virginia Calvo, Spain
- P3.01.26** Respiratory Hazard Index Is Associated with Lung Cancer Development in Underrepresented Lung Cancer Screening Individuals
Frank Weinberg, USA
- P3.01.27** Environmental Carcinogenesis in Lung Cancer: Sodium Arsenite-Induced PML Dysregulation and LINE-1 Activation
Kennedy Whelan, Canada

- P3.01.28** Household Air Pollution and Mitochondrial DNA Fragmentation
Elizabeth Francis, USA
- P3.01.29** Identifying Long Term Air Pollution Exposure for Lung Cancer Risk in Canada
Renelle Myers, Canada
- P3.01.30** The Relationship of Particulate Matter 2.5 and Mortality Rate of Patients with Lung Cancer and Lag Time Effect in Northern Thailand
Busyamas Chewaskulyong, Thailand
- P3.01.31** Physical Characterization of PM2.5 - Effects on Cellular Uptake, Dispersion, and Lung Cell Interactions
Isabella Mendoza Montealegre, Canada
- P3.01.32** Association of Long-Term Exposure to Fine Particulate Matter, Ozone, and Greenness with Lung Cancer Risk
Jin Hwa Lee, Republic of Korea
- P3.01.33** Global Trends in Tracheal, Bronchus, Lung Cancer Burden from Household Air Pollution
Shen Lao, China
- P3.01.34** Associating Pollution-Related Anthracotic Pigments Within Normal Lung Tissue with Lung Cancer Characteristics
Lucas Fung, Canada
- P3.01.35** Air Pollution and Lung Cancer Risk by Smoking Status: Findings from the UK Biobank
Alpamyss Issanov, Canada
- P3.01.36** Feasibility of Implementing a Virtual Nursing-Led Smoking Cessation Clinic for Patients with Cancer
Sun Choi, Canada
- P3.01.37** Time-Dependent Analysis Reveals the Dual Role of Smoking in Non-small Cell Lung Cancer Immunotherapy
Ying-Long Peng, China
- P3.01.38** Effect of Smoking Cessation Duration on Lung Cancer Incidence: A Nationwide Retrospective Cohort Study in Korea
Myeoung Geun Choi, Republic of Korea
- P3.01.39** From Nodule-Free to Nodule-Positive: Blood Biomarkers Bridge Smoking and Lung Cancer Risk
Wenjun Ye, China
- P3.01.40** 10 Years Post Implementation of a Smoking Cessation (SC) Program in Regional Cancer Centres in Ontario, Canada: Successes and Ongoing Challenges
William Evans, Canada
- P3.01.41** Impact of Smoking Status on Survival and Radiation Toxicity in Lung Cancer Patients Receiving RT
Gustavo Cunha, Brazil
- P3.01.42** Transitions in Cigarette and E-Cigarette Use in the PATH Study: A Multistate Transition Model Analysis of US Adults by Race and Ethnicity
Rossana Torres Alvarez, Canada
- P3.01.44** Comparison of Age-Adjusted Charlson Comorbidity Index and Modified Frailty Index as a Postoperative Prognostic Indicator for Lung Cancer
Masaya Yatsukura, Japan
- P3.01.45** Restrictive Lung Function and Smoking Increase Lung Cancer Risk in Tuberculosis Survivors: A Cohort Study
Yun-Gyoo Lee, Republic of Korea
- P3.01.46** Characterization of Patients with Lung Cancer Not Meeting Lung Cancer Screening Criteria: Identifying a High-Risk Group Beyond Tobacco Smoking
Juan Carlos Laguna, Spain
- P3.01.47** Presentation and Validation of Three Engage Variants of the PLCom2012 Lung Cancer Risk Prediction Model
Rafael Meza, Canada

- P3.01.48** Familial Lung Cancer and Hereditary Patterns in NSCLC - Implications for Risk Redefinition
Sulin Wu, USA
- P3.01.49** A Pro-Mitotic Gene Expression Module in Small Airways Links COPD Severity to Non-small Cell Lung Cancer
Vanessa das Gracas Pereira de Souza, Canada
- P3.01.50** Association Between Chronic Lung Diseases and Lung Cancer: A Bidirectional Two-Sample Mendelian Randomization Study
Weijie Zhu, China
- P3.01.51** Evidence Synthesis of Non-Screen-Eligible Cohorts and Implications for Lung Cancer Advocacy
Leah Fine, USA
- P3.01.52** Unseen Risks: Rethinking Lung Cancer Screening for Hispanic Communities
Coral Olazagasti, USA
- P3.01.53** Germline EGFR Mutations Are Enriched in the Southeast USA and Associated with High Penetration of Non-small Cell Lung Cancer
Jenny O'Brien, USA

TRACK 03: TUMOR BIOLOGY – TRANSLATIONAL BIOLOGY

- P3.03.01** Rb Inactivation as a Hallmark of Squamous Transformation in EGFR-Mutant Lung Cancers
Mark Jeng, USA
- P3.03.02** WEE1 as the Target for Circumvention of ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutated Lung Cancer
Seiji Yano, Japan
- P3.03.03** Mechanisms of Osimertinib Tolerance in Mutant EGFR Lung Cancer PDX Models
Nhu-An Pham, Canada
- P3.03.04** Aggressive Lymph Node Dissection Is Linked to Poor Survival and Impaired Anti-Tumor Immunity in Non-small Cell Lung Cancer
Melek Agkoc, Turkey
- P3.03.05** Proteomic Analysis of Pleural Mesothelioma
Tetsuzo Tagawa, Japan
- P3.03.06** Integrated Bulk and Single-Cell Transcriptomics Reveals Immune Ecotype Heterogeneity in EGFR-Mutated Lung Adenocarcinoma
Shu Xian Zhang, China
- P3.03.07** Characterization of Live Cell Repository for Tumor Derived Pleural Mesothelioma Cells and Cancer Associated Fibroblasts
Mayura Meerang, Switzerland
- P3.03.08** Patient-Derived Tumour Organoids Recapitulate Keratinizing Lung Squamous Cell Carcinomas
Christina Cahill, Ireland
- P3.03.09** Synonymous Mutations in PDGFRA Exons 12 and 18 Correlate with Reduced Survival and Serum Iron Levels in Non-small Cell Lung Cancer
Xiaowei He, China
- P3.03.10** Establishment of Patient-Derived Organoids From EBUS-TBNA Cytological Samples in Lung Cancer Patients
Melissa Acosta-Plascencia, Spain
- P3.03.11** Anlotinib Exerts a Protective Effect on Radiation Lung Injury Through the Regulation of the Immune Microenvironment Mediated by M2c Macrophages
Huajyu Wang, China
- P3.03.12** YAP-Driven Modulation of HER3-Mediated Adaptive Resistance to RET Inhibitors in RET-Altered Cancer
TADAAKI YAMADA, Japan

- P3.03.13** HLA II Genetics Shapes Lung Cancer Immunosurveillance
Ezekiel Oluwoyide, USA
- P3.03.14** PCSK9-Mediated Immune Escape as a Mechanism of Acquired Resistance to PD-1/PD-L1 Blockade
Guang-Ling Jie, China
- P3.03.15** Investigating Mechanisms of Resistance in EGFR-Mutated Non-small Cell Lung Cancer Through High Resolution Transcriptomics
Eva Cabrera San Millan, Italy
- P3.03.16** CXCR2+ Neutrophils Influence Immunotherapy Efficacy in NSCLC Patients with KL Subtype
Xuefei Li, China
- P3.03.17** Intermittent Caloric Restriction Synergizes With KRAS(OFF) Inhibitors in Preclinical Models of KRASG12C Lung Adenocarcinoma
Edoardo Garbo, Italy
- P3.03.18** Single-Cell Transcriptomic Analyses of Lung Immune Cells Reveal That MITF-Driven Plcb1HighMacrophages Induce Radiation-Induced Lung Injury
Huan Zhang, China
- P3.03.19** SFRP2highCAFs Trigger CD8+T Cell Apoptosis to Sustain Abscopal Resistance to Radioimmunotherapy in Lkb1-Mutant Lung Tumors
Yujie Zeng, China
- P3.03.20** Citrullinated Vimentin Is an Effective Target for CAR T Cells in Non-small Cell Lung Cancer
Jenny O'Brien, USA
- P3.03.21** Aptamer-Drug Conjugates for Leptomeningeal Carcinomatosis and Cancer-Associated Cachexia in Lung Cancer
Emily Lin, Taiwan
- P3.03.22** Tumor Treating Fields (TTFields) Downregulate DNA Repair and Show Efficacy in Small Cell Lung Carcinoma Preclinical Models
Tisdrey Torres, USA
- P3.03.23** Circular RNA Vaccine Synergizes with Anti-PD-1 to Augment Therapeutic Efficacy in Lung Cancer
Shaoyi Chen, China
- P3.03.24** Oxidock: Optimizing Lung Cancer-Targeted Therapy Through Oxygen-Responsive Molecular Docking
Arnab Pemmatalu, USA
- P3.03.25** A Combination Therapy Strategy That Targets Both KRAS-G12C and GSK3 for Non-small Cell Lung Cancer
Xian Gong, China
- P3.03.26** Ir-Metal Framework Loaded with Radiation-Responsive Anti-Angiogenic Prodrugs for Enhanced Radiotherapy Efficacy
Qin Zhang, China
- P3.03.27** The TXNRD1-IGF2BP3 Axis Promotes EGFR-TKI Resistance and Identifies a Therapeutic Vulnerability in NSCLC
Mengwei Yang, China
- P3.03.28** Tumor Treating Fields (TTFields) Concomitantly with Anti-PD-1 and Cisplatin in a Mouse Model of Non-small Cell Lung Cancer
Anat Klein-Goldberg, Israel
- P3.03.29** IAM1363 Is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Zhongdong Huang, USA
- P3.03.30** Activation of EGFR Signaling Mediated by PTPRR Methylation Causes Resistance to KRAS Inhibitor Sotorasib
Hiroaki Kanemura, Japan

- P3.03.31** Transcriptomic Profiling Identifies a Prognostic and Predictive Inflammatory Signature in Patients with Lung Adenocarcinoma
Ayah Al-Bzour, Jordan
- P3.03.32** Multi-Omic Characterization of ALK Fusion LUADs Reveals Overactivation of DNA Replication as a Contributor to ALK TKI Resistance
Esther Redin, USA
- P3.03.33** Clinical and Genomic Landscape of BRAF-Mutant NSCLC Patients from the AACR GENIE BPC Cohort
Sandra Ortiz-Cuaran, France
- P3.03.34** Assessment of Minimal Residual Disease Using Liquid Biopsy in Patients with EGFR-Mutated Lung Cancer Treated with Osimertinib
Celia Delahaye, France
- P3.03.35** Association of Intestinal Flora and Metabolites with Bone Metastasis in Patients with Non-small Cell Lung Cancer
Jia-Xuan Li, China
- P3.03.36** Whole Genome Doubling Drives Genomic Instability and Poor Postoperative Outcomes in Stage I Driver-Negative Lung Adenocarcinoma
Masahiro Torasawa, Japan
- P3.03.37** Target Lipid Metabolism in Immune Microenvironment: Immunotherapy Sensitization and Combinatorial Strategies for NSCLC With Liver Metastases
Yujia Fang, China
- P3.03.38** Oncolytic Virus Effectively Delivers CD47 Blockade to Suppress Tumour Growth in Preclinical NSCLC Models
Kelsie Thu, Canada
- P3.03.39** Deep Learning Based Multiplex Imaging Platform for High Throughput ADC Targets Expression Quantification and Biomarker Discovery in NSCLC
Kenneth Bloom, Israel
- P3.03.40** PRMT9 mRNA Stabilized by IGF2BP1 in an m6A-Dependent Manner Promotes Proliferation and Metastasis of Lung Adenocarcinoma Cells
Jing-Hua Chen, China
- P3.03.41** FOXO3A Regulates NSCLC Radiotherapy Resistance Through PINK1/Parkin Pathway of Protective Mitophagy
Shilan Luo, China
- P3.03.42** Immune-Related Gene Expression Profiling and ALK-TKI Efficacy for Patients With ALK-Rearranged Non-small Cell Cancer
Takashi Kurosaki, Japan
- P3.03.43** Gut Klebsiella Pneumoniae Drives Lung Cancer Progression by Modulating Macrophage HPGDS and Suppressing the PGJ2-PPAR γ Signaling Pathway
Zixuan Hu, China
- P3.03.44** High Frequency of SMARCA4 Inactivating Mutations in Advanced NSCLC and Their Association with Low PD-L1 Expression
Maria Saigi Morgui, Spain
- P3.03.45** KRAS Mutations Shape an Oxidative, Immune-Cold Tumor Microenvironment Driving Chemo-Immunotherapy Resistance in Advanced NSCLC
Victor Seguí, Spain
- P3.03.46** Phenotyping Double Negative B Cells in Non-small Cell Lung Cancer
Liam Neilson, UK
- P3.03.47** Study of Genomic Intra-Tumor Heterogeneity and Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Pablo Navajas-Chocarro, Spain
- P3.03.48** Fluorescence Lifetime Imaging in Fixed NSCLC Samples Demonstrate Differences Between Tissue Compartments
Alexander Hunt, UK

- P3.03.49** Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Cells Harboring RET Fusions
Eva Pros, Spain
- P3.03.50** cIRCCAMSAPI Induce Osimertinib Resistance in Lung Adenocarcinoma by Downregulating the Degradation Level of HSPA1A
Wenmei Su, China
- P3.03.51** FLT3LG Improve Therapeutic Sensitivity to Anti-PD-1 Therapy by Modulating Immune Cell Infiltration in NSCLC
Sida Qin, China
- P3.03.52** XPO1 Inhibition Reduces Tumor Growth Potential by Inhibiting WNT Signaling Pathway in Lung Squamous Cell Carcinoma
Vidushi Durani, USA
- P3.03.53** WISP3 Drives NSCLC Progression by Upregulating SDCBP via the TGF- β Signaling Pathway
Guanghui Gao, China
- P3.03.54** Influenza's Silent Warriors: Unveiling Lung Tumor Cell Assassination Through Macrophage Reprogramming via SAA4-MLKL Axis
Öznur Cetin, Germany

TRACK 09: METASTATIC NON-SMALL CELL LUNG CANCER – LOCAL THERAPIES

- P3.09.01** Validation of Lung Specific-Graded Prognostic Assessment Score in NSCLC with Brain Metastases from India
Sarath S, India
- P3.09.02** Stereotactic MR-Guided Adaptive Radiotherapy (SMART) for Ultracentral Non-small Cell Lung Cancer (NSCLC)
Crispin Hiley, UK
- P3.09.03** Efficacy of Radiotherapy in Patients with Oligo-Progressive Non-small Cell Cancer - A Retrospective Analytical
Tamar Barkan, Israel
- P3.09.04** Macrophage CD38 Expression as a Predictive Biomarker for the Abscopal Effect in Lung Cancer Undergoing Radiotherapy-Immune Therapy
Yuanjun Wu, China
- P3.09.05** Prognostic Value of TNM 9th Lymph Node Classification and Pathological Node Count in NSCLC Patients
Yoriko Sakata, Japan
- P3.09.06** Primary Tumor Resection Confers Survival Benefit in cMOs/Mla Lung Adenocarcinoma
JiaYuan Tian, China
- P3.09.07** Local MDT Improve the Survival of Leptomeningeal Metastasis in NSCLC With EGFR Mutation From the CLM-Tree Registry
Weiping Hong, China
- P3.09.08** Tumor Treating Fields for Patients with Metastatic Non-small Cell Lung Cancer: Real World First Experience
Rupesh Kotecha, USA
- P3.09.09** Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-small Cell Lung Cancer
Daisuke Morimaga, Japan
- P3.09.10** Safety and Efficacy of Co-Ablation System Therapy in Patients with Lung Cancer: A Single Arm Cohort Study
Shengxiang Ren, China

TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

- P3.12.01** Phase II Trial of First-Line Double-Dose Firmonertinib in Locally Advanced or Metastatic NSCLC With EGFR L858R (FIRM Study)
Meiqi Shi, China

- P3.12.02** Real-World Outcomes in Patients with NSCLC and Leptomenigeal Disease
Muskan Agarwal, USA
- P3.12.03** Retrospective Analysis of Age, EGFR Mutation Type, and TP53 Co-Mutation on Survival Outcomes in EGFR-Mutant Non-small Cell Lung Cancer
Eric Singhi, USA
- P3.12.04** Taltretinib, a Next Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models
Hritisha Patel, USA
- P3.12.05** Patterns of EGFR Mutations and Real-World Experience of Therapeutic Interventions - a Community Oncology Study
Kunal Jobanputra, India
- P3.12.06** Pralsetinib (Phase 1/2 ARROW Trial) Compared With Best Available Therapy (External Control) in Pretreated RET Fusion+ NSCLC
Domenico Galetta, Italy
- P3.12.07** Rezivertinib in EGFR-Mutated NSCLC Patients with CNS Metastases: CNS Efficacy from Phase 3 RAZOR Study
Jirong Peng, USA
- P3.12.08** Weight Gain Induced by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-small Cell Lung Cancer: A Meta-Analysis and a Meta-Regression Study
Lorenzo Belluomini, Italy
- P3.12.09** Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study
Ryota Saito, Japan
- P3.12.10** Adapting RECIST for Real-World Data: Independent Imaging Read Methodology Over Successive Treatments in a NSCLC Data Registry
S. Peter Eggleton, Germany
- P3.12.11** Aumolertinib Plus Chemotherapy as First - Line for Ps 2 - 3 Advanced NSCLC with EGFR Mutations: A Phase 2 Subgroup Analysis
Yan Wei Li, China
- P3.12.12** Clinical Pharmacologic Characteristics of Taltretinib
Lyudmila Bazhenova, USA
- P3.12.13** Long-Term Real-World Outcomes of Sotorasib in Second-Line and Beyond Treatment of KRAS G12C-Mutated Advanced NSCLC
Enriqueta Felip, Spain
- P3.12.14** Clinical Effectiveness and Safety of Tepotinib in Patients from Germany with MET Exon14 Skipping NSCLC: A Case Series
Frank Griesinger, Germany
- P3.12.15** Activity and Tolerability of MET TKIs in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database
Maria Lucia Reale, Italy
- P3.12.16** Reduced Survival in Black Patients With EGFR-Mutant NSCLC
Karen Reckamp, USA
- P3.12.17** A Phase II Study of Firmonertinib Combined with Apatinib as First-Line Therapy in NSCLC Patients with EGFR Uncommon Mutations
Hai-Yan Xu, China
- P3.12.18** Vebreltinib Plus EGFR-TKI in EGFR-Mutated NSCLC With MET Amplification and/or Overexpression After Failure on EGFR-TKI: A Retrospective Study
HaiBo Wang, China
- P3.12.19** Optimizing Treatment Sequencing to Maximize Survival in ALK+ Advanced Non-small Cell Lung Cancer: A Modeling Study
Hannah Le, USA
- P3.12.20** VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients
- P3.12.21** Biomarker Analysis and Final Efficacy of Lorlatinib in Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Benjamin Solomon, Australia
- P3.12.22** A Phase II Study of Sunvozertinib Combined with Anlotinib in Treatment-Naïve NSCLC with EGFR Sensitive Mutations and Co-Mutations (WU-KONG32)
Yongchang Zhang, China
- P3.12.23** Tepotinib Efficacy in Poor Performance Status and Elderly Patients with MET Exon 14 Skipping NSCLC: A RELA-MET Subanalysis
Kazuhiro Nishiyama, Japan
- P3.12.24** Real-World Treatment of Osimertinib Monotherapy Versus Combination Therapy in Stage IV Non-small Cell Lung Cancer Patients
Edgardo Santos, MD, USA
- P3.12.25** First-Line HX07 Plus Serplulimab with or Without Chemotherapy in Squamous Non-small Cell Lung Cancer: A Phase 2 Study
Yilong Wu, China
- P3.12.26** Adding Gefitinib to Target Acquired C797S Mutation After Progression on First-Line Osimertinib in EGFR-Mutant Advanced NSCLC
Zi-Ji Mao, China
- P3.12.27** Resistance Mechanisms of Novel Targeted Therapies to EGFR Exon 20 Insertion Mutation-Positive Non-small Cell Lung Cancer
Bin-Chi Liao, Taiwan
- P3.12.28** Association of PD-L1 Expression with Clinical Outcome in Advanced NSCLC With ALK Rearrangement
Nattanit Suriyaphan, Thailand
- P3.12.29** Effectiveness and Treatment Patterns in Patients with First-Line 2G ALK TKI Across the Esme French Real-World Cohort
Girard Nicolas, France
- P3.12.30** Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features
Laura Masfarré, Spain
- P3.12.31** Rezivertinib in Advanced NSCLC Patients With EGFR T790M Mutation via Tissue/Plasma Samples: Pooled Analysis of 2 Clinical Studies
Yanqiu Zhao, China
- P3.12.32** Long-Term Survival Outcome After First-Line Osimertinib Monotherapy in Advanced/Metastatic NSCLC: Results From LC-SCRUM-Asia
Hiroki Izumi, Japan
- P3.12.33** The Primary Endpoint: Analysis of RELAY-Effusion; a Phase II Study of Ramucirumab Plus Erlotinib in EGFR-Mutated NSCLC With Pleural Effusion
Naoko Katsurada, Japan
- P3.12.34** Real-World Study in Patients With ALK+ Metastatic Non-small Cell Lung Cancer (mNSCLC) Treated with First-Line (1L) Lorlatinib
Shirish Gadgeel, USA
- P3.12.35** Real-World Clinical Outcomes of Osimertinib in Patients with Recurrent EGFR Mutated Lung Adenocarcinoma: A Multicenter Study
Ichidai Tanaka, Japan
- P3.12.36** Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan
Yasuhiro Mihashi, Japan
- P3.12.37** First-Line Lazertinib with or Without Local Ablative Radiotherapy in Oligo-Metastatic EGFR-Mutant NSCLC
Jii Bum Lee, Republic of Korea
- P3.12.38** Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations

- P3.12.39** *Xiuning Le, USA*
Long-Term Overall Survival in Advanced EGFRm NSCLC Treated With 1L Osimertinib: Results From the US, Japan, Germany and China
Jorge Nieva, USA
- P3.12.40** Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: =3-Years Follow-Up of VISION
Enriqueta Felip, Spain
- P3.12.41** Factors Associated with Clinical Outcomes in Patients with HER2-Mutant NSCLC Treated with Sevabertinib (BAY 2927088)
Xiuning Le, USA
- P3.12.42** Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC
Misako Nagasaka, USA
- P3.12.43** A Phase II Study of Sunvozertinib Combined with Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations
Hai-Yan Xu, China
- P3.12.44** A Retrospective Study of the Effect of Cumulative Smoking Dose on Clinical Course in People with EGFR-Mutated NSCLC Treated with Osimertinib
Takanori Ito, Japan
- P3.12.45** Aumolertinib for Treatment-Naive EGFR-Mutant NSCLC Patients With Brain Metastases: Updated Efficacy Data From the ARTISTRY
Xiaojuan Zhang, China
- P3.12.46** Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in EGFRm Advanced NSCLC: The COCOON Global RCT (*ATO SIMULTANEOUS PUBLICATION*)
Byoung Chul Cho, Republic of Korea
- P3.12.47** A Phase II Study of Sunvozertinib Combined with Chemotherapy in EGFR-TKIs Resistant EGFRm Advanced NSCLC Patients (WU-KONG36)
Felifei Na, China
- P3.12.48** Efficacy and Safety of Savolitinib in Advanced or Metastatic METex14 NSCLC Patients with or Without Prior Immunotherapy
Yongfeng Yu, China
- P3.12.49** Clinical Significance of a Genomic Screening Platform of Non-small Cell Lung Cancer in Asia-Pacific: LC-SCRUM-AP
Muthukumarani Thiagarajan, Malaysia
- P3.12.50** A Prognostic Model Based on a Concurrent Gene Mutational Signature for EGFR Mutant NSCLC with TKI Treatments
Qi Wang, China
- P3.12.51** Patient-Derived Organoids as Preclinical Models for Drug Resistance in NSCLC
Nikolina Radulovich, Canada
- P3.12.52** Aumolertinib Plus Anlotinib in Advanced EGFR-Mutant NSCLC With TP53 Co-Mutation: A Single-Arm, Phase II Study
Zhansheng Jiang, China
- P3.12.53** High-Dose Furmonertinib Plus Bevacizumab in EGFR-Mutant NSCLC With CNS Metastases After Resistance to Third-Generation EGFR-TKIs
Li Kun Chen, China
- P3.12.54** Predicting Osimertinib-Induced Pneumonitis in EGFR-Mutated NSCLC Using Multi-Modal Machine Learning Model
Kyujiro Nibuya, Japan
- P3.12.55** Efficacy of Vebreltinib in Advanced NSCLC Patients with MET Exon 14-Skipping: Post-Hoc Analysis of KUNPENG Study
Jin-Ji Yang, China
- P3.12.56** Medication Adherence to Osimertinib in Patients Diagnosed with Metastatic Non-small Cell Lung Cancer

- P3.12.57** *Daniel Rosas, USA*
Phase I/II Study of FHND9041 in T790M-Positive Advanced NSCLC Patients Progressed After Prior EGFR-TKI Therapy
Dechuang Yuan, China
- P3.12.58** Initial Results from Phase 1/2 Study of the RET-Selective Inhibitor Vepafestinin in Patients with RET-Abserrant Solid Tumors
Kiyotaka Yoh, Japan
- P3.12.59** A Phase Ib/II Study of Vebreltinib Plus Tiselimuzumab in Patients With MET-Amplified and PD-L1-Positive Locally Advanced or Metastatic NSCLC
Zhijie Wang, China
- P3.12.60** The Combination of USP24-i101-Astemizole Sensitizes the Cytotoxicity of Taxol and Gefitinib in Drug-Resistant Lung Cancer
Jan-Jong Hung, Taiwan
- P3.12.61** Retrospective Multicenter Study Within the German Network Genomic Medicine Lung Cancer on RET Fusions as Resistance in EGFR-Mutant Lung Cancer
Cornelia Kropp-Sanchen, Germany
- P3.12.62** First-Line Osimertinib ± Platinum-Pemetrexed Chemotherapy for EGFR-Mutated Advanced NSCLC: FLAURAZ Non-Asian Country Cohort
Pasi A. Jänne USA
- P3.12.63** MTA Ploss Is Frequent and Potentially Targetable with PRMT5 Inhibitors in Oncogene-Driven NSCLC
Mihaela Aldea, USA
- P3.12.64** Frontline Treatment Duration in MET-Amplified NSCLC After Third-Generation EGFR-TKI Failure: SACHI Study Insights
Lijuan Chen, China
- P3.12.65** First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURAZ Clinical Outcomes by EGFRm Subtype
Samreen Ahmed, UK
- P3.12.66** Overcoming Osimertinib Resistance in EGFR+ NSCLC: PI3K Inhibitor Combined with Osimertinib Restores Drug Sensitivity
Lin Jiang, China
- P3.12.67** Redefining Tolerability: A Head-To-Head IPD Toxicity Comparison of Amivantamab+Lazertinib vs Osimertinib+Chemotherapy in EGFR-Mutant NSCLC
Blerina Resuli, Germany
- P3.12.68** Regulating Autophagy Will Be a Potential Key Point in Overcoming EGFR TKI Resistance in Non-small Cell Lung Cancer
Seoree Kim, Republic of Korea
- P3.12.69** Updated Efficacy and Safety of Tiletrectinib in Chinese Patients with ROS1+ Non-small Cell Lung Cancer: Phase 2 TRUST-I Study
Wei Li, China
- P3.12.70** Development of a Bispecific Antibody That Safely and Effectively Targets EGFR and B7H3 in NSCLC
Xinxin Zhi, China
- P3.12.71** Efficacy and Safety of Pralsetinib in Patients with Advanced Ret Fusion-Positive NSCLC: Phase 1/2 ARROW Study Final Data
Aaron Mansfield, USA
- P3.12.72** FIN-EGFR/CNS: Real World Survival and Patient Characteristics of EGFR Mutated NSCLC Patients With Cns Metastases in Finland
Maria Silvonieni, Finland

TRACK 13: SMALL CELL LUNG CANCER AND NEUROENDOCRINE TUMORS

- P3.13.01** Effect of Patient Management System and Medical Resources on Outcomes of SCLC Treated with Chemo-ICI

- P3.13.02** The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma
Yuta Yamana, Japan
Michal Dziedzic, Poland
- P3.13.03** Proteomic Profiling of Small Cell Lung Cancer Patients Reveals Blood-Based Prognostic Proteins
Kristina Boettiger, Austria
- P3.13.04** Consolidation Thoracic Radiotherapy After Chemoimmunotherapy in ES-SCLC: A Multicentric Retrospective Analysis
Federico Monaca, Italy
- P3.13.05** First-in-Human Study of 225Ac-ABD147 for SCLC and LCNec Post-Chemotherapy: Pharmacokinetics, Biodistribution and Safety Insights
Sean Carlin, USA
- P3.13.06** Comprehensive Assessment of the Tumor Microenvironment of Resected Small Cell Lung Cancer
Andréanne Gagné, Canada
- P3.13.07** Real-World Implementation of Immunotherapy for Stage III-IV Small Cell Lung Cancer: Insights from the National Cancer Database (2016–2021)
Brittany Morguelan, USA
- P3.13.08** Autologous Vax-NK/HCC Consolidation Therapy in ES-SCLC
In-Jae Oh, Republic of Korea
- P3.13.09** Surface Targeting Strategies to Overcome Heterogeneity Associated with Treatment Resistance in Small Cell Lung Cancer (SCLC)
Allison Stewart, USA
- P3.13.10** Real-World Outcomes of Prophylactic Cranial Irradiation (PCI) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the US
Samantha Reiss, USA
- P3.13.11** HER2- and TROP2-Directed Antibody Drug Conjugates Show Potent Antitumor Activities in Small Cell Lung Cancer
Bingnan Zhang, USA
- P3.13.12** Multi-Institution Analysis Evaluating Safety, Efficacy and ctDNA Dynamics Following Tarlatamab in ES-SCLC and LCNec Patients
Graeme Fenton, USA
- P3.13.13** A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
Tina Roy, USA
- P3.13.14** Lab Data-Based Prediction for Clinical Efficacy of Immunotherapy in ES-SCLC Using Statistical and Machine Learning Models
Shuichiro Hara, Japan
- P3.13.15** First-Line Immunotherapy in ES-SCLC Patients with ECOG PS =2: Real-World Evidence From the ASTRUM-005R Trial
Lih Wu, China
- P3.13.16** Survival Outcomes with Carboplatin Versus Cisplatin and the Impact of COVID-19 on Platinum Choice in SCLC in the Netherlands
Ilias Houda, Netherlands
- P3.13.17** A Comparative Analysis of TNM 8 and TNM 9 Classification Systems in Small Cell Lung Cancer
Asaf Dan, Sweden
- P3.13.18** Immunotherapy Pooled Analysis in 1L Extensive-Stage Small Cell Lung Cancer
Judith Pérez-Granado, USA
- P3.13.19** High Throughput Drug Screening for Small Cell Lung Cancer Based on Machine Learning and Organoid Platforms
Xiaoyi Feng, China

P3.13.20

Integrative Spatial Analysis Reveals Ferroptosis Heterogeneity and Novel Therapeutic Vulnerabilities in Small Cell Lung Cancer
Chaoqiang Deng, China

P3.13.21

Refining Patient Selection for Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer: A Multicenter Cohort Study
Hye In Lee, Republic of Korea

P3.13.22

Efficacy and Safety of Surufatinib, Durvalumab in Combined with Chemotherapy as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Ying Hu, China

P3.13.23

Copy Number Gain of MYC-Paralogs Represents Proliferative Phenotype and Poor Prognosis in Resected Small Cell Lung Cancer
Yan Ju, China

P3.13.24

Longitudinal Plasma Proteomics Identifies Predictive Biomarkers for Anti-PD-L1 Therapy in SCLC
Guang-Ling Jie, China

P3.13.25

Comprehensive Immune Microenvironment Profile of EGFR-Mutant Non-small Cell Lung Cancer Transformation Towards Small Cell Lung Cancer
Yu Hui, China

P3.13.26

Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes
Henry Park, USA

P3.13.27

Toripalimab Consolidation After Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase II, Randomized Controlled Study
Pengxin Zhang, China

P3.13.28

Survival Outcomes in Advanced Large Cell Neuroendocrine Carcinoma of the Lung in Immunotherapy Era: An NCDB Analysis
Kim Chul, USA

P3.13.29

Somatostatin Receptor Expression and First-Line Somatostatin Analog Therapy: A Comparative Analysis in Thoracic Neuroendocrine Neoplasms
Mariia Vorobeva, Russian Federation

P3.13.30

Whole Exome Sequencing Analysis of Somatic Mutations in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia
Hui Yu, USA

P3.13.31

Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates from Jazz EMERGE 402
Balazs Halmos, USA

P3.13.32

Real-World Outcomes of Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lutetium Lu 177 DOTATATE (Lutathera)
Giuseppe Maiocco, USA

P3.13.33

Clinical Outcomes and Single-Cell Map of Neoadjuvant Immunochemotherapy for Stage II-IIIb LS-SCLC: A Real-World Study
Chen Huang, China

TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

P3.14.01

Global Trends in Asbestos Related Mesothelioma Mortality From 1990 to 2021
Kyle Edwards, USA

P3.14.02

Clinical Implications of BAP1 Status in Pleural Mesothelioma (PM)

- Susana Cedres, Spain*
P3.14.03 Loss of MHC Class I and II Defines an Immune Excluded Subtype in Pleural Mesothelioma
Jasper van Genugten, Netherlands
- P3.14.04** High-Volume Surgical Centers for Pleural Mesothelioma Are Associated with Lower Perioperative Mortality
Darren Bryan, USA
- P3.14.05** Survival Outcomes of Sequential Therapies in Malignant Pleural Mesothelioma: A Real-World Analysis of Second-Line Treatments
Michele Maffezzoli, UK
- P3.14.06** Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey
Giulia Pasello, Italy
- P3.14.07** Recent Studies on Mesothelioma as a Model to Understand the Interaction of Gene and Environment (G X E)
Haining Yang, USA
- P3.14.08** Genetically Defined Mouse Models of Malignant Pleural Mesothelioma Recapitulate Human MPM Phenotypes and Response to Therapy
Pooyeh Farahmand, UK
- P3.14.09** Sex-Based Differences in Mesothelioma: Insights from the ICO Cancer Registry
Jesús Brenes, Spain
- P3.14.10** Ultrasound Detection of Effusion and Neoplasia in Genetically Defined Mouse Models of Mesothelioma
Xinya Hong, UK
- P3.14.11** Real-World Outcomes and Toxicity of First-Line Dual Immunotherapy in Unresectable Pleural Mesothelioma
Beatriz Jimenez Munariz, Canada
- P3.14.12** Pseudo-Senescence Induced by Palbociclib Does Not Sensitize Pleural Mesothelioma Cells to Combinations with Classical Senolytics
Iswarya Sreeram, Spain
- P3.14.13** Sex and Histology Related Profile of Gut Microbiota (GM) in Pleural Mesothelioma (PM): Preliminary Results of a Prospective Observational Study
Federica Grosso, Italy
- P3.14.14** Ten-Year Longitudinal Analysis of Mesothelioma Incidence: A Nationwide Cohort Study Based on the 2012 Korean Health Screening Registry
Kwanyong Hyun, Republic of Korea
- P3.14.15** Thymic Cancer in France: A Comprehensive Analysis of Incidence Based on French National Healthcare Data
Alvaro López Gutiérrez, France
- P3.14.16** Prospects of Applying convolutional Neural Network Models for Surgical Videos in Clinical Practice
Shuning Kong, China
- P3.14.17** Oncological Outcomes of Complete Versus Limited Thymectomy in Stage I Thymic Epithelial Tumors
Riccardo Taje, Italy
- P3.14.18** The Role of Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis
Giovanni Leuzzi, Italy
- P3.14.19** The Role of Tumors Size in Different Thymic Tumors Histology: Results Form the ESTS Thymic Database
Marco Chiappetta, Italy
- P3.14.20** MTAP Deficiency in Thymic Epithelial Tumors
Jennifer Marks, USA

P3.14.21 Single-Nucleus RNA Sequencing Reveals Key Pathways and Prognostic Markers in Thymic Carcinoma
Xuehan Gao, China

P3.14.22 Outcomes to Systemic Standard-Of-Care Therapies in Patients With MTAP-Deleted Advanced Non-small Cell Lung Cancer
Julian Huang, USA

P3.14.23 The Mechanism of Immunotherapeutic Resistance in Pulmonary Sarcomatoid Carcinoma
Haoyue Guo, China

P3.14.24 Tracheal Resection Surgery: Comparison of Continuous Vs. Interrupted Suture of the Membranous Wall in a Series of 162 Cases
Pablo Pagliarunga, Argentina

TRACK 16: PATIENT ADVOCACY

P3.16.01 Lung Cancer Patients' Understanding of and Involvement in Their Treatment and Care: Insights from a Global Patient Experience Survey
Jesme Fox, UK

P3.16.02 Cancer Patients' Advocacy and Policy Impact in Japan, How 3,623 Voices Halted a National Cost-Sharing Reform
Kazuo Hasegawa, Japan

P3.16.04 Lung Cancer Treatment in Brazil: The Gap Between Incorporation and Real-World Access
Luciana Holtz de Camargo Barros, Brazil

P3.16.05 Exploring Quality of Life in Oncogene Addicted NSCLC Patients and Their Caregivers
Massimiliano Cini, Italy

P3.16.06 The Saving Lungs Behind the Chair Model Is Increasing Lung Cancer Awareness in US Black Communities
Sydney Barnes, USA

P3.16.07 Canadian Action Plan for Lung Cancer - Patient Perspective
Angus Pratt, Canada

P3.16.08 Feasibility of Engaging Latino Individuals in a Lung Cancer Screening Study Through Mychart
Arlette Chavez Iniguez, USA

P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers
Nabanita Mandal, India

P3.16.10 Co-Designing a Resource to Reduce Stigma in Lung Cancer Screening
Kathleen McFadden, Australia

P3.16.11 A Pulmón - Lunging It: Climbing Mountains and Breaking Barriers in Lung Cancer Advocacy
Santiago Viteri, Spain

P3.16.12 Analysis of the Nationwide Database on the Penetration Rate of Lung Cancer Biomarker Tests in Japan
Takayuki Takahama, Japan

P3.16.13 Using Group Concept Mapping to Identify Research Priorities by Patient and Caregiver Stakeholders Affected by Lung Cancer
Jamie Ostroff, USA

P3.16.14 The Influence of Deprivation on Lung Cancer Care Experiences in Urban, Rural, and Coastal Areas: A Qualitative IPA Study
Samuel Cooke, UK

P3.16.15 Giving Back - Co-Creation of Data Dashboard to Share Survey Results with Patients and Caregivers
Bellinda King-Kallimanis, USA

P3.16.16 The Development of a Patient Education Lung Cancer Nodal Staging Video Toolkit: American Cancer Society National Lung Cancer Roundtable

- P3.16.17** *Jeffrey Velotta, USA*
Understanding the Awareness of Treatment, Clinical Trails, Biomarkers and Unmet Needs of Chinese NSCLC Patients: A Mixed-Methods Study in China
Xiyuyu Cai, China
- P3.16.18** Beyond Clinical Outcomes: A Qualitative Exploration of Wellbeing Among People Living with Onco-Driven Lung Cancer
Virginia Harrison, UK
- P3.16.19** Multilevel Assessment of ChatGPT-4o in Radiation Oncology for Lung Cancer Patient Education
Chukwuka Eze, Germany
- P3.16.20** Improving Lung Cancer Screening Uptake in 20 Disadvantaged New York Counties: Early Findings from a Demonstration Project
Angela Gonnella, USA
- P3.16.21** The Role of Neighborhood Deprivation in Lung Cancer Diagnosis and Treatment
Brittney Nichols, USA
- P3.16.22** Frontline Insights in US Payer Barriers Impacting Patient Access and Participation in Comprehensive Lung Cancer Screening Programs
Angela Barry, USA
- P3.16.23** Facilitators to Patient Advocacy Group-Led Engagement of Diverse, Community, Clinical Sites in Multiple Research Types
Andrew Clupek, USA

TRACK 18: CLINICAL TRIALS IN PROGRESS

- P3.18.01** Sex-Based Differences in STAS Positivity and Survival in Stage I Lung Adenocarcinoma: Is Female Prognosis Still Better Despite STAS?
Süleyman Güneş, Turkey
- P3.18.02** Sex-Based Differences in Immunotherapy Response via Blood Biomarkers in NSCLC: Interim Results from the ALICE Study
Melis Aykac-Bicer, Germany
- P3.18.03** Implementation Study of Lung Cancer Screening Combined with a Smoking Cessation RCT in the Flemish Region: The ZORALCS- and TAMIRO-Stop-Study
Charlotte Theuns, Belgium
- P3.18.04** MRDSEEKER (JCOG2111A): A Prospective Study to Evaluate MRD and Its Association with Prognosis in Curative-Intent NSCLC
Ken Masuda, Japan
- P3.18.05** Enrollment Update for the CSP #2005 Phase III Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study [VALOR]
David Harpole, USA
- P3.18.06** Phase 1b Study of a Novel Fluorescent Imaging Agent, LS301, for Lung Cancer Surgery to Localize Tumors and Assess Margins
Nick Staten, USA
- P3.18.07** Immunotherapy Combined with Radiotherapy as Neoadjuvant Therapy in Resectable NSCLC: A Single Arm, Phase II Clinical Study
Buhai Wang, China
- P3.18.08** Alectinib as Adjuvant Therapy in Resected ALK-Positive NSCLC: A Prospective Multicenter Cohort Study in China
Chang Chen, China
- P3.18.09** SUNRAY-02: A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC After Definitive Therapy
Ernest Nadal, Spain
- P3.18.10** Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage IA3 EGFRm NSCLC With High Risk Factors
Baiqin Zhao, China
- P3.18.11** Adding Certolizumab to Neoadjuvant Chemotherapy - Control of Immune-Related Adverse Events and Prevention of Surgical Delays
Paul Paik, USA
- P3.18.12** ARIAN, Adjuvant Treatment With Sacituzumab and ZimberelimAb in Resected Patients: A Phase III Study - Trial in Progress
Mariano Provençio, Spain
- P3.18.13** Atezolizumab +/- Tiragolumab Before and After Chemoradiation for Unresectable Stage III Non-small Cell Lung Cancer (AFT-57)
Helen Ross, USA
- P3.18.14** Quick Start Durvalumab: A Phase II Pilot Study of Early Durvalumab Initiation Following Chemoradiation in Unresectable Stage II-III NSCLC
Stephanie Brinton, USA
- P3.18.15** Neoadjuvant and Adjuvant Chemotherapy in Resectable Stage II-IIIa NSCLC: Interim Results of a Prospective Cohort Study
Yuan Xu, China
- P3.18.16** CROWD: Chemoradiotherapy with Surgery Followed by Consolidation Durvalumab for Initially Unresectable Stage III NSCLC
Ilias Houda, Netherlands
- P3.18.17** Neoadjuvant Chemotherapy with Immunosensitizing Radiation for Borderline Resectable Non-small Cell Lung Cancer (NeoRADjuvant)
Samuel Rosner, USA
- P3.18.18** Predictive Role of Respiratory Function Tests on Lung Toxicity in Stage III NSCLC Under Chemo-Radiotherapy and Durvalumab: Preludio Trial
Giuseppe Viscardi, Italy
- P3.18.19** The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial 2 (SPRINT2)
Nitin Ohri, USA
- P3.18.20** PELAGOS: Integrating Surgery and Radiotherapy in EGFR-Mutant N3-Stage III NSCLC After Conversion Therapy
Ailin Li, China
- P3.18.21** Durvalumab (D) and Chemotherapy Followed by Either Surgery + D or Chemoradiotherapy + D in Borderline Resectable Stage III NSCLC
Yu Wang, China
- P3.18.22** TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-small Cell Lung Cancer
Angelica D'Aiello, USA
- P3.18.23** Management of Synchronous Oligometastatic NSCLC with Surgical Resection of the Primary Tumor: Preliminary Results from the Prospective Trial
Pavel Karakovich, Belarus
- P3.18.24** A Multicenter, Open Label, Dual Cohort Study: The Efficacy and Safety of Vinorelbine Combined with a First-Line Treatment for Metastatic NSCLC
Xiao Fu, China
- P3.18.25** Phase 2 Study of Carboplatin Plus Nab-Paclitaxel Rechallenge for NSCLC With Interstitial Lung Disease: TORG2442/CASTLE Study
Taku Itoh, Japan
- P3.18.27** An Exploratory Clinical Study of TROP2 ADC SHR-A1921 Combined with Adebrelimab for Advanced NSCLC After Failure of First-line Standard Therapy
Chunxia Su, China
- P3.18.28** KEYMAKER-U01 Substudy 01G: Pembrolizumab+Patritumab Deruxtecant±Chemotherapy in Previously Untreated Stage IV NSCLC
Melissa Johnson, USA
- P3.18.29** NAPISTAR 1-01: An International Phase I/II Trial of the Novel ADC TUB-040 in Advanced/Metastatic NSCLC Adenocarcinoma
Alexander Starodub, USA

- P3.18.30** A Phase II Clinical Study of Tafolcicimab Combined with Sintilimab in the Treatment of Advanced NSCLC Who Failed the Previous Immunotherapy
Mengqiang Xie, China
- P3.18.31** Phase II Study of CBDCA + Nab-PTX + Tremelimumab+Durvalumab for TTF-1 Negative Advanced non-sq NSCLC (WJOG17223L, TURNING)
Motoko Tachihara, Japan
- P3.18.32** Tislelizumab Combined with Bevacizumab and Nab-Paclitaxel as Second-Line Therapy for PD-1/L1 Inhibitor-Resistant Advanced NSCLC
Liping Lin, China
- P3.18.33** Intraleural Anti-PD-1 Antibody for the Treatment of Advanced Non-small Cell Lung Cancer with Malignant Pleural Effusion
Ping Zhan, China
- P3.18.34** TACTI-004, a Phase 3 Trial of Efficlimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1st Line NSCLC
Martin Sebastian, Germany
- P3.18.35** ARTEMIDE-Lung02: A Phase 3 Global Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for 1L Metastatic Squamous NSCLC
T. Hiltermann, Netherlands
- P3.18.36** Peripheral Immune and Hormonal Signatures Associated with Sex Differences in NSCLC Response to Checkpoint Inhibition
Susanne Hermann, Germany
- P3.18.37** A Phase 3 Trial of First-Line MK-3475A (Subcutaneous Pembrolizumab) for Stage IV NSCLC with PD-L1 TPS =50%
Balazs Halmos, USA
- P3.18.38** Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC with PD-L1 TC <50%
Melissa Johnson, USA
- P3.18.39** PRESERVE-003: A Phase 3 Study of Gotitobart Versus Docetaxel in Metastatic NSCLC After Progression on PD-(L)1 Inhibitors
Tianhong Li, USA
- P3.18.40** KRAS Peptide Vaccine Combined with Chemotherapy, Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-small Cell Lung Cancer
Kristen Marrone, USA
- P3.18.41** A Phase II Study of Second-Line Cadonilimab, Bevacizumab and Docetaxel in Patients with Advanced NSCLC
Jian Chun Duan, China
- P3.18.42** Camrelizumab Combined with Chemotherapy and Local Consolidative Therapy for Untreated Oligometastatic NSCLC With PD-L1 Expression <50%
Li-Ping Lin, China
- P3.18.43** A Phase II Study of IDH1 Inhibitor Combined with Serplulimab and Docetaxel in Previously Treated Advanced NSCLC (ChiCTR2400086196)
Shili Zhang, China
- P3.18.44** Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Patients with Non-small Cell Cancer
Maojing Guan, China
- P3.18.45** A Multi-Cohort, Phase II Study of SHR0302 Combined With PD-1/PD-L1 Inhibitor for Treatment Naïve or Acquired Resistant to Immunology NSCLC
Xinyu Zhang, China
- P3.18.46** Ivonescimab Plus Platinum-Doublet Chemotherapy as First-Line Therapy for Locally Advanced/Metastatic SMARCA4-Deficient NSCLC
Yuan Liang, China
- P3.18.47** ATTEND: Randomized Phase III Trial of Tislelizumab and Chemotherapy with or Without Diphenhydramine in Advanced Non-small Cell Lung Cancer
Liang Liu, China
- P3.18.48** Phase II Clinical Trial of Trifluciclib in Combination With PD-1 Inhibitor and Chemotherapy as First-Line Treatment for (NSCLC)
Fei Li, China
- P3.18.49** Efficacy and Safety of Tislelizumab Combined with Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy
Wang Xie, China
- P3.18.50** Tislelizumab with Chemotherapy Followed by Surgery and Radiotherapy in Stage III-N3 Unresectable NSCLC (HURRICANE)
Allin Li, China
- P3.18.51** Anlotinib Combined With PD-1 Blockade and Platinum Doublet Chemotherapy for PSC as First Line Treatment
Yongsheng Wang, China
- P3.18.52** Phase 3 Trial ResQ201A of NAI Plus Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced or Metastatic NSCLC Resistant to ICI Therapy
Leylah Drusbosky, USA
- P3.18.53** Phase 3 Clinical Trial ResQ201A of N-803 (NAI), Tislelizumab and Docetaxel Vs. Docetaxel Monotherapy for Advanced NSCLC Resistant to ICI Therapy
Sandeep Reddy, USA
- P3.18.54** Increasing the Dosing Interval of Osimertinib in Patients With EGFR-Mutated Advanced NSCLC (OSI-SAVE Study Design)
Maalike van den Bos, Netherlands
- P3.18.55** A Phase II Study of Reprotractinib in ROS1-Positive Non-small Cell Lung Cancer Patients with Active Brain Metastasis - REPOSE
Thorsten Fliederer, Austria
- P3.18.56** EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study (ERIS): A National Phase III Trial from the Swedish Lung Cancer Study Group
Maria Planck, Sweden
- P3.18.57** Phase 1/2 Clinical Trial of JIN-A02, a 4th Generation EGFR-TKI in EGFR Mutant Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)
Sun-Min Lim, Republic of Korea
- P3.18.58** Trastuzumab Deruxtecan + Pembrolizumab as First-Line Treatment in HER2-Overexpressing, PD-L1 TPS <50% NSCLC (DESTINY-Lung06)
William William Jr., Brazil
- P3.18.59** Resistance Mechanisms and Sequential Therapies Following 1st Line Lorlatinib in ALK+ NSCLC: A Real-World Study (LORES CTONG2501)
Ziming Li, China
- P3.18.60** The COALA (Cure Oncogene-Addicted Lung Adenocarcinoma) Network: A Nationwide Consortium to Improve Lung Cancer Outcome
Julien Mazieres, France
- P3.18.61** KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC
Jarushka Naidoo, Ireland
- P3.18.62** TRUST-III: Phase 3 Head-To-Head Study of Taletrectinib vs Crizotinib in Patients with ROST+ Non-small Cell Lung Cancer
Caicun Zhou, China
- P3.18.63** Phase 1 Study of FHND5071, a Novel Selective RET Inhibitor, in RET Fusion-Positive Advanced NSCLC
Dechuang Yuan, China
- P3.18.64** Phase 1 Study to Evaluate the Safety and Tolerability of CVHNL-C Plus Pembrolizumab in Patients with Squamous NSCLC
Benjamin Besse, France
- P3.18.65** Trial in Progress - RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) Vs. Docetaxel in Patients with Previously Treated RAS Mutant NSCLC
Ferdinandos Skoulidis, USA

- P3.18.66** Preliminary Safety and PK of the MET-TKI Do-2 in Advanced Solid Tumors with MET Aberrations: Phase I Study
Timothy Perera, Belgium
- P3.18.67** First-in-Human Phase I/II Trial of PFL-002/VERT-002 in Locally Advanced or Metastatic Solid Tumors Including NSCLC With MET Alterations
Julien Mazieres, France
- P3.18.68** First-in-Human Trial of PFL-241/STX-241 in Patients with Locally Advanced or Metastatic NSCLC Resistant to EGFR Tyrosine Kinase Inhibitors
Gerrina Ruiter, Netherlands
- P3.18.69** Efficacy and Safety of Befotertinib Plus Icotinib in Advanced NSCLC With Uncommon EGFR Mutations: A Phase II Study (Icombine)
Xue Hou, China
- P3.18.70** Combination of Osimertinib and Carotuximab for Advanced, EGFR-Mutated Non-small Cell Lung Cancer Patients
Karen Reckamp, USA
- P3.18.71** CA240-0007: BMS-986504 With Anti-PD-1 or Chemotherapy as Treatment for Advanced Solid Tumors with Homozygous MTAP Deletion
Konstantinos Leventakos, USA
- P3.18.72** Liquid Biopsy Guided Addition of Chemotherapy with TKI in Advanced EGFR Mutated NSCLC (LIQUIACT)
Prabhat Malik, India
- P3.18.73** A Phase 1b/2 Study of Gocatamig and Ifmatamab Deruxtecan for Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Pedro Rocha, Spain
- P3.18.74** BNT324-01: A Phase 1b/2 Trial of BNT324/DB-1311 (B7H3 ADC) With BNT327 (PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC)
Adam Schoenfeld, USA
- P3.18.75** Tislelizumab in Combination With EP/EC Chemotherapy and Sequent Anlotinib Followed by Radiotherapy as First-Line Treatment for ES-SCLC
Zhen Tian Liu, China
- P3.18.76** Efficacy and Safety of Cross-Line Adebreliamab Combined with Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer
Hongbo Wu, China
- P3.18.77** Efficacy and Safety of Adebreliamab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH)
Yudong Wang, China
- P3.18.78** A Prospective Study of Lurbinectedin Plusivonescimab Assecond-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Fei Zhou, China
- P3.18.79** Contralateral Esophageal-Sparing Technique Reduces High-Grade Esophagitis in Locally Advanced Small Cell Lung Cancer
Min Hu, China
- P3.18.80** A Phase 3 Study of Sacituzumab Govitecan in Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
Afshin Dowlati, USA
- P3.18.81** A Phase II Study of First-Line Sintilimab Combined with Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM
Xinyu Wu, China
- P3.18.82** Towards Harmonization of Clinical Care and Promoting Research for Thymic Epithelial Tumors: THETIS (THYMIC Cancers NETWORK in Switzerland)
Ambrogio Gagliano, Switzerland
- P3.18.83** Efficacy and Safety of Ivonescimab Plus Chemotherapy for Recurrent/Metastatic Thymic Carcinoma: A Phase II Study (iThyme)
Xue Hou, China
- P3.18.84** A Randomized Comparative Effectiveness Trial of Perioperative Physical Activity in Older Adults with Lung Cancer and Their Family Caregivers
Dan Raz, USA
- P3.18.85** A Personalized Nutrition and Physical Exercise Intervention to Enhance Early-Stage NSCLC Outcomes: The STARLIGHT Study
Alice Avancini, Italy
- P3.18.86** Efbemalenograstim Alpha Prophylaxis for Intermediate-Risk FN Chemotherapy in NSCLC: A Multicenter Exploratory Study
Mengjie Li, China
- P3.18.87** EVEREST-2: Phase 1/2 Study of Logic-Gated Tmod CAR T A2B694 in Lung Cancer and Other Tumors Expressing MSLN With HLA-A*02 LOH
Salman Puneekar, USA



EPOSTER LISTINGS

ePosters will be available for viewing at the **ePoster stations** in the **Exhibit Hall** during **Exhibit Hall Opening Hours** and on the **Mobile App**.

Download the official **WCLC 2025 Mobile App** to view all ePosters.



Available on the
Google Play
App Store

Supported by: Nuvalent

TRACK 01: RISK FACTORS, RISK REDUCTION & TOBACCO CONTROL

- EP.01.01** Exercise Training Modalities in Patients with Lung Cancer: A Protocol for Systematic Review and Network Meta-Analysis
Yu Zhang, China
- EP.01.02** Long-Term Survival After Curative Surgery for Stage I-III NSCLC Patients in British Columbia, 2005-2021: A Population-Based Study
Yixian Chen, Canada
- EP.01.03** Young Patients with Non-small Cell Lung Cancer in Poland - a Comprehensive Epidemiological, Molecular and Prognostic Analysis
Magdalena Knetki-Wroblewska, Poland
- EP.01.04** Features, Demographics and Treatment Profiles of Primary Lung Cancer Cases in Nigeria: The Largest Single Centre Report in West Africa
Maruf Adewole, Nigeria
- EP.01.05** Mapping the Clinical Pathways in Lung Cancer: Evaluating the Inspire Program in the Brazilian Public Healthcare System
Robson Prudente, Brazil
- EP.01.06** Clinical Characteristics, Molecular Profile and Survival Outcomes in Young Lung Cancer Patients from Western India
Udip Maheshwari, India
- EP.01.07** Lung Cancer in Young: A Descriptive Study from Thoracic Oncology Clinic in Northern India
Samruddhi Chougale, India
- EP.01.08** Lung Cancer in Elderly Patients: Insights from a Community Oncology Setting in Western India
Pradip Kendre, India
- EP.01.09** NSCLC Epidemiology and Survival in Denmark, Finland, and Norway: A Decade of Real-World Insights from the LANDSCAPE Study
Aslaug Helland, Norway
- EP.01.10** Young Onset Lung Cancer: Clinical, Pathologic and Molecular Profile from a Tertiary Care Centre in India
Kenil Borda, India
- EP.01.11** Impact of Demographics and Smoking on Driver Gene Mutations Development in Non-small Cell Lung Cancer (NSCLC)
Tasneem Khallad, Jordan
- EP.01.12** A Causal Machine Learning Approach for the Prediction of Immune-Related Adverse Events in Lung Cancer Patients Receiving Immunotherapy
Fergus Reid, UK
- EP.01.13** Lung Cancer Burden in Latin America and the Caribbean, 1990-2021: A Comprehensive Analysis
Prashant Gupta, India
- EP.01.14** Pulmonary Pure Ground-Glass Nodule Follow-Up During Pregnancy and Lactation: A Case Report
Baolei Liang, China
- EP.01.15** Gender Disparities in Survival Outcomes of "Minimally Invasive Lung Squamous Cell Carcinoma"
Yucheng Ma, China
- EP.01.16** Differential Effect of Neoadjuvant Therapy in Locally Advanced Non-small Cell Lung Cancer Based on Sex
Henry Park, USA
- EP.01.17** Association Between Cigarette Smoking History and Germline Rare Variant Burden in a Cohort of Lung Cancer Patients
Stella Aslibekyan, USA
- EP.01.18** Family History of Lung Cancer in Lung Cancer in Never-Smokers, a Matched Case-Control Study
Hyun Seok Kwak, Republic of Korea
- EP.01.19** Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study from Greece
Georgia Gomatou, Greece
- EP.01.20** Non-Smoking Lung Adenocarcinoma: Implications for Predominant Growth Patterns, Tumor Heterogeneity and Prognosis
Erik Rolf, Germany
- EP.01.21** Mapping Persistent and Irreversible Arsenic Effects on Lung Epithelium Using Integrated Transcriptome and Methylation Analysis
Melis Erkan, Canada
- EP.01.22** The Effectiveness of Offering Repeated Co-Located, Opt-Out Smoking Cessation Support Within Lung Cancer Screening
Rachael Murray, UK
- EP.01.23** Tobacco Smoking, Quit Attempts and Vaping Among an Online Sample of South African Cancer Survivors
Lekan Ayo-Yusuf, South Africa
- EP.01.24** Determinants Influencing Smoking Cessation Implementation in an Oncology Setting: Canadian Healthcare Provider Perspectives
William Evans, Canada
- EP.01.25** Identifying Effective Strategies to Support Smoking Cessation in Ontario Cancer Care Settings: A Consensus-Building Approach
Lawson Eng, Canada
- EP.01.26** Achievements and Future Directions of Tobacco Control in Lung Cancer Prevention in China
Xiuyi Zhi, China
- EP.01.27** Gender and Tobacco Use Status Shape Support for Endgame Strategies in India
Durre Aden, India
- EP.01.28** Changes in Respiratory Function in a Patient Undergoing Two Lung Resections
Nanami Hiraiwa, Japan
- EP.01.29** Association of the Cholesterol-Modified Prognostic Nutritional Index with the Survival After Lung Resection for Elderly Patients With NSCLC
Yuuki Matsui, Japan
- EP.01.30** Beyond Smoking: Exploring Risk Factors for Lung Cancer in Women
Muhammad Islam, USA
- EP.01.31** Vaping, Smoking and Lung Cancer in Adults Under Age 50: A Case-Control Study
Marisa Bittoni, USA

TRACK 02: TUMOR BIOLOGY – PRECLINICAL BIOLOGY

- EP.02.01** Investigating the MET Exon 14 Interactome in Lung Adenocarcinoma
Sarah Anna Okun, Canada
- EP.02.02** YB-1 Is a Survival Factor for Mesothelioma-Associated Fibroblasts
Marc Pinós, Austria
- EP.02.03** Investigating the Therapeutic Potential of DUSP4/6 Inhibition in Lung Adenocarcinoma
William Lockwood, Canada
- EP.02.04** Identification of a Novel Immunotherapy Target in EGFR-Mutant Lung Cancer Resistant to Immune Checkpoint Inhibitors
Kiichi Nitani, Japan
- EP.02.05** Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method
Junjue Yi, Republic of Korea
- EP.02.06** Natural Multiple Serine Synthase Inhibitors Modulate Tumor Microenvironment Polarization and Inhibit the Growth of Lung Cancer
Menghan Liu, China
- EP.02.07** Enhancing Alectinib Efficacy in ALKPositive Non-small Cell Lung Cancer by Targeting Mtor
Sofia D Merajver, USA
- EP.02.08** Exploratory Effect of Cisplatin on Autophagic Pathway in Human Lung Adenocarcinoma Cell Line
Diksha Diksha, India
- EP.02.09** Deciphering CD47-Mediated Platelet-Tumor Crosstalk and Its Role in NSCLC Metastasis
Asa Lau, Canada
- EP.02.10** Fumarate and Ass1 in KRAS-Mutant NSCLC: The Influence of Cetuximab in Combination with KRAS G12C Inhibitors (Sotorasib and Fulzasorb)
Daniel Olmo González, Spain
- EP.02.11** Clinical and Biological Significance of Cystathionine Gamma-Lyase in Pulmonary Adenocarcinoma
Yoko Kataoka, Japan
- EP.02.12** Identifying Acquired Resistance Mechanisms to Sotorasib in G12C Lung Adenocarcinoma (LuAD) Cell Lines (CL)
Marc Cucurtull Salameo, Spain

TRACK 03: TUMOR BIOLOGY – TRANSLATIONAL BIOLOGY

- EP.03.01** Identification and Validation of Recurrence-Associated Proteins in Stage I Lung Adenocarcinoma
Kei Suzuki, USA
- EP.03.02** An Integrating Multiomic Approach to Chart the Tumor Immune Microenvironment Associated to Immunotherapy Response in Non-small Cell Lung Cancer
Riccardo Taje, Italy
- EP.03.03** Tumor Heterogeneity Consisting of SCLC With RB1 Exon 19 Deletion and L718V Mutation-Positive Adenocarcinoma in EGFR-TKI Resistant Lung Cancer
Sho Kakuto, Japan
- EP.03.04** PD-L1-Regulated c-Met Phosphorylation Contributes to MET Amplification in EGFR Mutation NSCLC
Derek De-Rui Huang, Taiwan
- EP.03.05** The Study on the Mechanism of OM-85 in Regulating the Immune Microenvironment in Early-Stage Lung Adenocarcinoma
Dawei Yang, China
- EP.03.06** Blocking JNK Signaling as a Strategy to Fight EGFR-Driven Lung Cancer
Leizhi Shi, Germany

EP.03.07 The Role of Tumour Intrinsic Inflammasome Mutations in Lung Adenocarcinoma
Daniel Gough, Australia

EP.03.08 Tumor Treating Fields (TTFields) Concomitant with Antiangiogenic Therapy in Non-small Cell Lung Cancer in Vivo Model
Anat Klein-Goldberg, Israel

EP.03.09 A New Treatment Approach for Non-small Cell Lung Cancer
Amila Suraweera, Australia

EP.03.10 Evaluating the Role of the Blood-Brain Barrier in Intracranial Response Rates for Metastatic Lung Cancer
Tsu-Yu Unice Chang, Canada

EP.03.11 Peritumoral B Lymphocyte Mediated Immune Response Is Associated with Survival in Patients with Non-small Cell Lung Cancer
Akif Turna, Turkey

EP.03.12 Sex-Specific Blood-Based Immune Signatures Predict Response to First-Line Immunotherapy in Advanced NSCLC: A Prospective Translational Study
Amanda Tufman, Germany

EP.03.13 LIF Is Associated with Poor Prognosis and Participates in Lung Cancer Growth and Implantation in Preclinical Models of NSCLC
Cristina Muñoz-Pinedo, Spain

EP.03.14 Single-Cell Transcriptome Analysis Revealed an Activated Tumor Immune Microenvironment in KRAS Mutant NSCLC
Hao Wang, China

EP.03.15 Chemotherapy Upregulates PD-L1 Expression via cGAS-STING Pathway in Non-small Cell Lung Cancer
Maryam Khalil, Canada

EP.03.16 Cell-Specific Fluorescence Lifetime Values in Live Non-small Cell Lung Cancer Cells
Ava Russell, UK

EP.03.17 Altered Immune Profile in Lung Cancer Patients with Pneumonitis
Po Hao Feng, Taiwan

TRACK 04: SCREENING AND EARLY DETECTION

EP.04.01 Current Status of Lung Cancer Screening in Latin America
Lucia Viola, Colombia

EP.04.02 Fully-Automated Classification of Parenchymal Low Attenuation-Clusters as Indicators of Pulmonary Emphysema in Lung Cancer Screening
Hailan Liu, Netherlands

EP.04.03 Uptake and Impact of a Framework to Support Implementation of Low-Dose Computed Tomography (LDCT) Screening for Lung Cancer
Helena Wilcox, UK

EP.04.04 A Relative Perspective on Whether Risk-Based Lung Screening Eligibility Prioritize People with Higher Competing Mortality
Xiaoshuang Feng, France

EP.04.05 Lung Cancer Diagnosis Among Screening Participants in the Multi-Health-System Philadelphia Lung Cancer Learning Community
Julie Barta, USA

EP.04.06 Health Beliefs and Adherence to Lung Cancer Screening in a Diverse, Real-World Population
Sheena Bhalla, USA

EP.04.07 Participant and Provider Experiences in an Indigenous Focused Trial of Lung Cancer Screening in Aotearoa New Zealand
Kate Parker, New Zealand

EP.04.08 Building Policy Recommendations Using an Implementation Framework for Low-Dose Computed Tomography Screening
Helena Wilcox, UK

- EP.04.10** Evaluating Primary Care Practice's LCS Smoking History Accuracy for Maori Patients - Implications for a Future Lung Cancer Screening Programme
Sue Crengle, New Zealand
- EP.04.11** Feasibility of AI-Assisted Mobile Low-Dose CT Screening in Underserved Communities in China
Weisheng Chen, China
- EP.04.12** Outcome of Lung RADS Category 4 in Lung Cancer Screening Population at Tertiary Hospital, Single Center Study
Soo-Youn Ham, Republic of Korea
- EP.04.13** Emphysema on Baseline CT Predicts COPD and Cardiovascular Death After 25 Years in Lung Cancer Screening
Jessica González, Spain
- EP.04.14** Pilot Lung Cancer Screening Program and "Lung Health Check" in Lleida: Preliminary Results
Anna Sánchez Cucó, Spain
- EP.04.15** Determinants of Lung Cancer Screening Intention Among Adults Eligible for Lung Cancer Screening
Hermine Poghosyan, USA
- EP.04.16** Piloting Lung Cancer Screening: Tumor Detection Rate, Psychological Distress and Incidental Findings
Kathrin Chiffi, Switzerland
- EP.04.17** Radiomics Predicts IASLC Grades of Invasive Pulmonary Adenocarcinoma by Distinguishing High-Grade Patterns and Predominant Subtypes
Sunyi Zheng, China
- EP.04.18** Preoperative Prediction of Grade 3 Invasive Non-Mucinous Adenocarcinoma Using Semiconductor 18F-FDG-PET/CT: A Diagnostic Accuracy Study
Hirotsugu Notsuda, Japan
- EP.04.19** Radiologic Characteristics of Solitary Pulmonary Capillary Hemangioma
Yeqing Zhu, China
- EP.04.20** Exploring Diffusion-Weighted Magnetic Resonance Imaging in Lung Cancer Screening
Krista Dollár, USA
- EP.04.21** Imaging Manifestations in 4 Cases of Invasive Pulmonary Adenocarcinoma with Indolent Growth
Anle Yu, China
- EP.04.22** Internal Validation of the IASTO-PDPI Lung Cancer Risk Level at Indonesia's National Respiratory Center, Persahabatan Hospital
Rachel Arintonang, Indonesia
- EP.04.23** Prediction of STAS Positivity in Non-small Cell Lung Cancer
Burcu Kılıc, Turkey
- EP.04.24** Initial Experience with Cancer Screening Center: Model to Improve Lung Cancer Screening Uptake
Kei Suzuki, USA
- EP.04.25** Integrated Biological and Imaging Assessment for Pulmonary Nodule Malignancy: A Real-World Study with Large Cohort Modeling and Validation
Zihao Li, China
- EP.04.26** A Case Series on Video Fiber Optic Bronchoscopy in the Diagnosis of Non-small Cell Lung Cancer (NSCLC) Subtype: Squamous Cell
Setu Saxena, India
- EP.04.27** Enhancing Lung Cancer Screening: A Comparative Evaluation of Predictive Models for Malignancy in Pulmonary Nodules
Fabian Doerr, Germany
- EP.04.28** TD-GC-MS-Based Breath Analysis for Early Diagnosis of Lung Cancer
Kahraman Emri, Turkey

- EP.04.29** Tobacco-Related Atheromatous Disease as Eligibility Criteria for Lung Cancer Screening: A Prospective Evaluation
Elsa Armand, France
- EP.04.30** Second Primary Lung Cancer in Surgically Treated Breast Cancer Patients: Association or Incidental Finding?
Sara Ricciardi, Italy
- EP.04.31** Nomogram for Predicting Lung Cancer-Free Survival in Patients with Persistent Pulmonary Nodules
Jianjun Zhang, USA
- EP.04.32** The Impact of Symptom Monitoring on Survival Among Patients with Lung Cancer: a 4-Year Follow-Up of the SYMPRO-Lung Study
Marloes Hassing, Netherlands
- EP.04.33** Exhaled Breath Analysis Using Infrared Spectroscopy Combined with Machine Learning Algorithms for Lung Cancer Diagnosis
Kahraman Emri, Turkey
- EP.04.34** Preliminary Results of Added Benefit of Blood-Based Biomarkers in a Lung Cancer Screening Program
Kathrin Chiffi, Switzerland
- EP.04.35** Innovative Intraoperative Technique for Rapid Tumor Identification in Lung Cancer Through Spectral Characterization: A Promising Exploration
Ming Li, China
- EP.04.36** Evaluation of the Utility of msignal® for Lung Cancer Screening in a Rural Region of Northern Japan (Hokkaido Region)
Masato Aragaki, Japan
- EP.04.37** An Observational Study Evaluating the Benefits of AI-Assisted Lung Cancer Screening Using Chest X-Rays in Bangkok, Thailand
Chuleekorn Soudorn, Thailand
- EP.04.38** A Computational Framework for Estimating Transportability in Cancer Screening Trials
Aviona Conti, USA
- EP.04.39** Lung Cancer Early Screening via cfDNA Fragmentome Profiling
Yongsheng Wang, China
- EP.04.40** Preoperative Prediction of Occult Lymph Node Metastasis in Clinical Stage I NSCLC Using CT Radiomics, PET, and ctDNA
You Jin Oh, Republic of Korea
- EP.04.41** Detecting Minimal Residual Disease (MRD) in Lung Cancer Using an Epigenetic-Based Liquid Biopsy Approach
Ari Raphael, Israel
- EP.04.42** Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research
Michael Kammer, France
- EP.04.43** Chest X-Ray Analysis with Artificial Intelligence Software Aids in the Early Diagnosis of Lung Cancer- a Case Series
Deniz Koksal, Turkey

TRACK 05: PULMONOLOGY AND STAGING

- EP.05.01** Use of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Molecular Characterization of Non-small Cell Lung Cancer
Estrella Caballeria Lamelas, Spain
- EP.05.02** Evaluation of ROSE Utility in Multiplex Gene-Panel Testing Using Samples From EBUS-GS for Lung Cancer
Yukihiko Nakamura, Japan
- EP.05.03** Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction
Youjun Deng, China

- EP.05.04** SUVmax Predicts Pathologic Complete Response and Survival in Lung Cancer Patients Undergoing Neoadjuvant Treatment
Akif Turna, Turkey
- EP.05.05** Invasive Mediastinal Staging of NSCLC Using Vamla: Results and Perspectives
Yury Esakov, Russian Federation
- EP.05.06** Should We Screen Patients with Stage IV Non-small Cell Lung Cancer for Brain Metastases at Diagnosis?
Anouk Goudsmit, Belgium
- EP.05.07** Prognostic Impact of Double Positive in EGFR Mutation and PD-L1 Expression in Resected pNOMO G2-3 Adenocarcinoma
Masaaki Ito, Japan
- EP.05.08** Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging cNO-N1 Non-small Cell Lung Cancer
L. Cabanillas-Paredes, Mexico

TRACK 06: PATHOLOGY AND BIOMARKERS

- EP.06.01** Tumor-Infiltrating Lymphocytes as Predictors of Chemotherapy Response in Non-small Cell Lung Cancer: A Retrospective Cross-Sectional Study
Aline Caldart, Tregnago, Brazil
- EP.06.02** Clinical Significance and Preoperative Prediction of High-Grade Subtypes in Early-Stage Lung Adenocarcinoma
Masashi Mikubo, Japan
- EP.06.03** Mucoepidermoid Carcinoma of the Lower Respiratory Tract with Few to None Intermediate/Squamous Cells: A Challenging Tumor Series
Giuseppe Pelosi, Italy
- EP.06.04** Extrnodal Extension in Lung Adenocarcinoma: Pathological Insights and its Role as an Independent Prognostic Factor
Shunta Tsuchida, Japan
- EP.06.05** Extensive-Stage Small Cell Lung Cancer Compared with Metastatic Extrapulmonary Small Cell Cancers- a Retrospective Study
Parikshit Padhi, USA
- EP.06.06** Characterization of SMARCA4 and SMARCA2 Alterations in Early-Stage Pulmonary Adenocarcinomas
Andréanne Gagné, Canada
- EP.06.07** Clinicopathologic and Genomic Landscape of Lung Cancer Arising in Interstitial Lung Disease: An Expanded Cohort Analysis
Sehui Kim, Republic of Korea
- EP.06.08** Mutation Spectrum of EGFR Mutations in South Indian Population Identified by Next Generation Sequencing and Real TIME PCR
Vijayalakshmi Ramshankar, India
- EP.06.09** Integrated Clinical, Radiological and Molecular Profile of Lung Cancer Patients from an Incidental Nodule Detection Program
Francisco Sarmento Neto, Brazil
- EP.06.10** Hypoxia-Induced Cancer Stemness, Metastasis, Angiogenesis and Immune Modulation in Lung Adenocarcinoma
Qian Wang, USA
- EP.06.11** Comprehensive Genomic Profiling in Lung Cancer Management: Insights from North Sweden
Mikael Johansson, Sweden
- EP.06.12** Kita-Kyusyu Lung Cancer Antigen-1 Positive Is Associated with Pathological High-Grade in Lung Adenocarcinoma
Yasuto Kondo, Japan

- EP.06.13** Molecular Alterations in Octogenarians with Early-Stage Lung Cancer: A Real-World Study
Jeffrey Zhu, USA
- EP.06.14** Decreased Expression of DAAAM2 Is Correlated with Poor Prognosis and Tumor Immune Microenvironment in Lung Adenocarcinoma
Weibin Liu, China
- EP.06.15** Reflex Next Generation Sequencing Testing in NSCLC: Overcoming Barriers to Equitable Molecular Profiling in an Urban Healthcare Network?
Brianna Graham, USA
- EP.06.16** Immunophenotyping of the Molecular Subtypes of Small Cell Lung Cancer and Its Correlation with Prognostic and Therapeutic Implications
Sunil Pasricha, India
- EP.06.17** Immunological and Genetic Profile and Efficacy of Immunotherapy in NSCLC Patients with Mutations in KRAS and STK11 Genes
Michal Gil, Poland
- EP.06.18** Is There Any Association Between EGFR Alterations and PD-L1 Expression in NSCLC a Single Center Experience
Sevinci Balli, Turkey
- EP.06.19** The Relationship Between PD-L1 Expression and Tumor Microenvironment in Lung Squamous Cell Carcinoma
Naoki Yanagawa, Japan
- EP.06.20** Stage-Dependent Increase in EGFR Mutation Rates in Early-Stage Lung Cancer at National Taiwan University Cancer Center
Tzu-Ning Kao, Taiwan
- EP.06.21** Genomic and Demographic Predictors of Survival in Patients with ALK Fusion NSCLC: Insights from a Single-Center Cohort
Karen Reckamp, USA
- EP.06.22** Genomic Insights Into ALK-Rearranged NSCLC: A Comprehensive Study
Warisa Khatoon, India
- EP.06.23** Comprehensive Genomic Profiling as a Key Determinator in Clinical Staging and Treatment Planning
Robert Auber, USA
- EP.06.24** Update of Mutation Status and PD-L1 Expression in Lung Cancer
Norma Pilnik, Argentina
- EP.06.25** Analysis of LAT1 Protein Expression and Clinical Characteristics of Patients with Primary Lung Cancer
Hayato Koba, Japan
- EP.06.26** Resectable Lung Cancer with KRAS Mutation May Have Less Lymphatic Metastasis
Chikara Nakagami, Japan
- EP.06.27** Challenges in Implementing Targeted Panel NGS for Biomarker Testing in Non-small Cell Lung Carcinoma in Resource-Constrained Settings
Aruna Nambirajan, India
- EP.06.28** Circadian CLOCK Expression in Non-small Cell Lung Cancer
Masaaki Inoue, Japan
- EP.06.29** Prognostic Impact of Lepidic Growth in Intermediate and High-Grade Lung Adenocarcinoma
Benedikt Niedermaier, Germany
- EP.06.30** Single-Cell RNA Sequencing Reveals a Subset of F5J1P1 Cancer Cells and Verified Its Value of Prognosis in Lung Adenocarcinoma
Shirong Zhang, China
- EP.06.31** Prognostic Impact of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Expression in Non-small Cell Lung Cancer
Amna Almuttrafi, Saudi Arabia

- EP.06.32** Elevated SERPINA3 Expression in Bronchoalveolar Lavage Fluid Predicts Poor Prognosis in Non-small Cell Lung Cancer
Joon Kim, Republic of Korea
- EP.06.33** Unique Features of the Tumor-Microenvironment in PL3 Non-small Cell Lung Cancer and Their Association with Post-Operative Outcomes
Ei Miyamoto, Japan
- EP.06.34** Retrospective Analysis of Genomic Testing and Survival Outcomes in Lung Cancer Patients from Western India
Udip Maheshwari, India
- EP.06.35** Role of PD-L1 Expression and TP53 Mutation as a Prognostic Factor in Early Stage NSCLC
Jana Panikvics, Switzerland
- EP.06.36** Non-small Cell Lung Cancer with Diffuse Coexpression of TTF-1 and P40: A Clinicopathologic and Molecular Study of 19 Cases
Jielu Lin, China
- EP.06.37** Clinical and Pathological Features of a High Altitude-Peruvian Population with Metastatic EGFR Mutated Lung Cancer
Jorge Zegarra Cárdenas, Peru
- EP.06.38** HLA-DQB1 Predicts Immunotherapy Response in NSCLC Through Augmented TCR Signalling
Yaxian Yang, China
- EP.06.39** Better Prediction of Resistance to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: Immunoresist Project
Basil Bertrand, France
- EP.06.40** The Role of Histology and Metabolic Parameters in Predicting Spread Through Air Spaces
Filippo Lococo, Italy
- EP.06.41** CD200 as a Novel Prognostic Biomarker in Early-Stage Lung Adenocarcinoma Immune Microenvironment
Luning Mao, China
- EP.06.42** Clinical Characteristics and Treatments of Patients with Advanced Non-Squamous NSCLC KRAS-Mutated with or Without STK11
Edyta Urbanska, Denmark
- EP.06.43** Using Artificial Intelligence to Leverage Phenotypic, Genomic and Proteomic Correlations in Lung Carcinoma Patients with MET Alterations
Susana Hernandez, Spain
- EP.06.44** Tertiary Lymphoid Structures in the Tumor Micro Immune Environment of EGFR Positive Lung Cancer Are Associated Prognosis
Hikaru Yamaguchi, Japan
- EP.06.45** Heterogeneity of Tumor Microenvironment and PD-L1 Expression in NSCLC and Tumor Draining Lymph Nodes After Solid Organ Transplantation
Zhaoping Yu, Germany
- EP.06.46** Frequent Co-Existence of RBMT0 Mutation in Patients with Non-Squamous NSCLCs Harboring EGFR Point Mutations
Kenichi Suda, Japan
- EP.06.47** A Ten-Gene DNA Damage Repair-Related Signature for Predicting Prognosis and Treatment Response in Non-small Cell Lung Cancer
Huixia Li, Hong Kong
- EP.06.48** Complementary Role of IHC in ALK Fusion Detection: A Validation Study of NSCLC NGS-Based Screening in Seven Laboratories
Sergi Clavé, Spain
- EP.06.49** Analysis of EGFR Mutations Using Highly Sensitive Digital Droplet PCR for EGFR Mutation-Positive NSCLC
Shinnosuke Takemoto, Japan
- EP.06.50** Development of a Novel AI-Augmented Small Cell Lung Cancer (SCLC) Algorithm for Accurately Classifying Cell Types From H&E
Kenneth Bloom, USA

- EP.06.51** Development of Novel IHC Assay for PD-L1 Detection in Non-small Cell Lung Cancer
Fangru Lian, USA
- EP.06.52** TTF-1 Negativity Predicts Poor Outcomes in Advanced Non-Squamous NSCLC Also in the Immunotherapy Era: A Multicenter Cohort and Meta-Analysis
Leonardo Brunetti, Italy
- EP.06.53** c-MET Expression in Non-Squamous NSCLC: Molecular Correlation and Interobserver and Intersample Concordance on Scoring
Mariiko Muto-Ishizuka, USA
- EP.06.54** The Landscape of Actionable Genomic Alterations in Non-small Cell Lung Cancer: A Single Institution Quality Improvement Initiative
Ahmed AL Lawati, Canada
- EP.06.55** Racial Differences in ERBB2 Mutations in Lung Adenocarcinoma: Insights From a Multi-Cohort Study
Ya-Hsuan Chang, Taiwan
- EP.06.56** Genomic and Immune Characteristics Linked to Second-Line Combination Immunotherapy Outcome in EGFR-Mutated Advanced NSCLC
Lailing Li, China
- EP.06.57** Molecular Analysis of Driver Negative Lung Cancer for Rearrangements and Fusions Using a New HIC Sequencing Assay
Alex Hastie, USA
- EP.06.58** CEACAM5 as a Biomarker for Differentiating Ground-Glass Opacities from Other Lung Cancers
Gavitt Woodard, USA
- EP.06.59** DNA+RNA-NGS Testing in NSCLC Patients with Primary Resistance to First-Line Non-Targeted Therapy and Negative Driver Genes (Dream Study)
Baohui Han, China
- EP.06.60** Exploring the Role of the Oral Microbiome in Saliva Sputum Bronchoalveolar Fluid and Tissue Tumor in Lung Cancer a Systematic Review
Jairo Zuluaga León, Colombia
- EP.06.61** FGFR-2: A Prognostic Biomarker and Potential Therapeutic Target in NSCLC
Martin Barr, Ireland
- EP.06.62** Based on Labyrinth Microfluidic Chip in Evaluating Therapeutic Efficacy for Leptomeningeal Metastasis of Lung Cancer
Liang Xue, China
- EP.06.63** New Approaches for Enhancing the Efficacy of “Liquid Biopsy” in Non-small Cell Lung Cancer
Pavel Karatkevich, Belarus
- EP.06.64** ISET CTC-DNA Shows Higher Sensitivity than ctDNA in Early Stage Lung Cancer Patients
Patrizia Paterlini, France
- EP.06.65** Mosaic Chromosomal Alterations and the Risk of Incident Lung Cancer: A Systematic Review and Meta-Analysis
Dhruv Bansal, USA
- EP.06.66** Prediction of Immune-Related Adverse Events by Human Leukocyte Antigen (HLA) and Other Biomarkers in Patients with Non-small Cell Lung Cancer
Pablo Flores-Paco, Spain
- EP.06.67** Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated with HER2 ADC: Preliminary Results from the RESOLUTION Trial
Chunxia Su, China
- EP.06.68** Clonal Hematopoiesis (CH)-Derived Mutations Detected in Non-small Cell Lung Cancer (NSCLC) Liquid Biopsies (LBX)
David Kozono, USA
- EP.06.69** Real-World Utilization of Tissue-Free ctDNA Monitoring in Patients with Lung Cancer on Targeted Therapies +/- Chemotherapy
Amaya Gasco, USA

- EP.06.70** Development and Clinical Application of Ultra-Sensitive Digital EV Assay Targeting GLUT1 for Early Diagnosis of Non-small Cell Lung Cancer
Taketo Kato, Japan
- EP.06.71** Clinical Application of Expert Software Based on Tumor Biomarkers to Stratify LC-Risk in a Hospital Thoracic Tumor Committee
Antonio Barco Sánchez, Spain
- EP.06.72** Lung Cancer EGFR Mutation Prediction via cfDNA Fragmentome Profiling
Yongsheng Wang, China
- EP.06.73** Co-Driver Mutations in Fusion-Positive NSCLC: Liquid Biopsy Insights From 2,369 Patients
Laila Roisman, Israel
- EP.06.74** Clinical Validity of Repeated CTCs and CAM-L Enumeration in Treatment Monitoring of Metastatic Non-small Cell Lung Cancer
Marco Siringo, Italy
- EP.06.75** Identifying Emergent Resistance Alterations in Patients with Advanced NSCLC Using Plasma Genotyping (DISCOVER)
Scarlet Berenice Urtecho Suarez, Canada
- EP.06.76** Real-World Use of Tissue-Free ctDNA Monitoring in Patients with Lung Cancer Receiving Immunotherapy and/or Chemotherapy
Amaya Gasco, USA
- EP.06.77** Exploring the Impact of Peripheral Immune Landscape on Immunotherapy Outcomes in Non-small Cell Lung Cancer
Ester Munera, Spain
- EP.06.78** T Lymphocyte Subpopulations as Predictive Biomarkers in Non-small Cell Lung Cancer Patients Treated with Anti-Pd(L1) Inhibitors
Teresa Moran-Bueno, Spain
- EP.06.79** Liquid Biopsy Shortens Time to Diagnosis and Treatment Selection: Primary Results from the International LIST Study
Fabrice Barlesi, France
- EP.06.80** Immunological Markers of Prognosis in Lung Cancer: T-Cell Subpopulations and Their Correlation with Clinical Outcomes
Federica Biello, Italy
- EP.06.81** Observational Study of Concordance Between Tissue-Based ODXTT CDx and In-House Plasma OPA Gene Analysis in NSCLC Patients
Kenitaro Nakanishi, Japan
- EP.06.83** Prognostic Impact of PD-L1 Expression in a Swiss Cohort of EGFR-Mutant Non-small Cell Lung Cancer Patients Treated with First-Line Osimertinib
Alexandra Schuler, Switzerland
- EP.06.84** Impact of Preoperative Brain Natriuretic Peptide Levels on Postoperative Outcomes in Lung Cancer Patients
Shinya Otsuka, Japan
- EP.06.85** Real-World Performance of NGS Panels in Detecting Actionable Genomic Alterations in NSCLC
Marina Quero Vilà, Spain
- EP.06.86** Evaluating Sustainment of Results in Quality Improvement Focused on Molecular Testing in Non-small Cell Lung Cancer Patients
Mike Gart, USA

TRACK 07: EARLY-STAGE NON-SMALL CELL LUNG CANCER

- EP.07.01** Prediction of Pathologic Low-Grade Malignant Adenocarcinoma in Radiologically Invasive C-Stage IA Non-small Cell Lung Cancer Measuring >2-3 Cm
Makoto Endo, Japan
- EP.07.02** Development and Validation of a High-Speed and High-Throughput 3D Reconstruction Algorithm in Pulmonary Vasculature and Nodules Localization
Zihao Chen, China
- EP.07.03** Lung Cancer: Artificial Intelligence, Biometrics and Modeling of Alive Supersystems for Best Management
Oleg Kshivets, Russian Federation
- EP.07.04** Pathological Investigation of Bronchial Stump and Bronchopleural Fistula After Anatomical Pulmonary Resection for Lung Cancer
Hiromasa Arai, Japan
- EP.07.05** Oncologic Outcomes of Segmentectomy Versus Lobectomy in Early-Stage Lung Adenocarcinoma with High-Risk Pathologic Features
Zhifei Li, China
- EP.07.06** Preserved Ratio Impaired Spirometry Are Associated with Poor Postoperative Outcomes in Clinical Stage I Non-Small Lung Cancer
Toshio Shiotani, Japan
- EP.07.07** Prognostic Analysis and Molecular Characteristics of Bubble-Like Appearance-Type Lung Adenocarcinoma
Kotaro Murakami, Japan
- EP.07.08** Quantifying Resection Margins in Lung Cancer Patients Undergoing Sublobar Resection Using CT-Based 3D Reconstruction
Mong-Wei Lin, Taiwan
- EP.07.09** Preliminary Results of One-Stop Shop: Results From the First Twenty-One Tumor Resections Compared to a Stage-Matched Control Group
Gian-Marco Monsch, Switzerland
- EP.07.10** Analysis of Residual Lung Volume After Segmentectomy Using 3DCT and Risk Factors for Decline in Postoperative Pulmonary Function
Selyu Ohtani, Japan
- EP.07.11** Comparison of Robotic Assisted Thoroscopic Lobectomy and Video-Assisted Thoroscopic Lobectomy for Early Stage Non-small Cell Lung Cancer
Tomoyoshi Takenaka, Japan
- EP.07.12** The Impact of Quantification Parameters and Clinicopathologic Characteristics on the Prognosis of Stage Ia Invasive Lung Adenocarcinoma
Zetao Liu, China
- EP.07.13** Thoracoscopic Combined Anatomical Sublobar Resection for Deep Intersegmental Small-Sized Non-small Cell Lung Cancer
Yungang Sun, China
- EP.07.14** Contemporary Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-small Cell Lung Cancer
Drew Moghanaki, USA
- EP.07.15** Model Navigated Anchor Based Responsive CT Hybrid Surgery for Intraoperative Localization and Resection for Small Pulmonary Nodules
Xining Zhang, China
- EP.07.16** Minor Ground-Glass Opacity Differences Were Associated with Prognostic Variation in Solid-Predominant Clinical Stage IA Lung Adenocarcinoma
Pei-Hsing Chen, Taiwan
- EP.07.17** Patient Characteristics, Surgical Outcomes, and Treatment Decisions in Early-Stage Resected NSCLC in Canada
Anna McGuire, Canada

- EP.07.18** Optimizing Intraoperative Lymph Node Dissection in Stage I NSCLC: A Risk-Stratified Approach Based on CNN Model Predictions
Yuanyuan Fu, China
- EP.07.19** Temporal Advances of Surgical Outcomes in Posterior Segment Ectomy for Primary Lung Cancer
Ryota Kiriyama, Japan
- EP.07.20** Evolution of Overall Survival (OS) After Good Quality Curative-Intent Lung Cancer Surgery in a Population-Based Cohort
Meredith Ray, USA
- EP.07.21** The Efficacy of the 'Lung Partial Resection Prior to Lobectomy Method' as a No-Touch Isolation Technique in Lung Cancer Surgery
Hiroyuki Adachi, Japan
- EP.07.22** Major Lung Resections for Non-small Cell Lung Cancer: Does Postoperative Pneumonia Remain a Life-Threatening Complication?
Konstantinos Grapatsas, Germany
- EP.07.23** Single Port Robot and Navigational Bronchoscopy During Single Episode of Anesthesia: Less Is More
Patrick Ross, USA
- EP.07.24** Study on Complex Segmentectomy Cases at Our Institution
Takuya Nagashima, Japan
- EP.07.25** Real-World Treatment Patterns and Outcomes of Stage I-III Resectable Non-small Cell Lung Cancer (NSCLC) in Portugal
Marta Soares, Portugal
- EP.07.26** A Novel Thoracic Localization Technique: Combining Intracorporeal Radiopaque Marker Suturing and Intraoperative Cone-Beam CT
Tzu-Ning Kao, Taiwan
- EP.07.27** Unravelling Sublobar Resections: Real-World Outcomes after Wedge vs Segmentectomy and Recurrence Risk Factors
Sara Fra, Spain
- EP.07.28** Real-Time Image-Guided Indocyanine Green Fluorescedual-Visualization Technique for Thoracoscopic Segmentectomy
Feng Shao, China
- EP.07.29** Single-Port Robotic Anatomical Lung Resection Using the Novel Chinese SPI000 Robotic System: Initial Experience
Shengcheng Lin, China
- EP.07.30** Preop-Intraop Consistency in Thoracic Surgery: MRMCM Reanalysis of Surgical Planning Accuracy
Heng Zhao, China
- EP.07.31** A Comparative Analysis of Sublobar Versus Lobar Resection for Early-Stage Non-small Cell Lung Cancer in Octogenarian Patients
Sangil Yun, Republic of Korea
- EP.07.32** Initial Experience with Robot-Assisted Thoracic Surgery for Anatomical Lung Resection: A Case Series of 40 Patients from a Japanese Regional Hospital
Toshiyuki Shima, Japan
- EP.07.33** The Pictorial Fit Frail Scale as a Preoperative Risk Stratification Tool in Lung Resection Patients
Desiree Steimer, USA
- EP.07.34** A Study of Lung Cancer Patients Who Survived for More Than 5 Years After Incomplete Resection
Fumihiko Hoshi, Japan
- EP.07.35** Comparative Analysis of Anterior and Posterior Approaches in Robotic Pulmonary Resection
Atsushi Osoegawa, Japan

- EP.07.36** Introduction of Dural-Port Robot Assisted Thoracoscopic Lung Dissection - Aiming for Reduce-Port RATS That Anyone Can Do
Hiroki Numanami, Japan
- EP.07.37** An Initial Experience of Resectable Non Small Cell Lung Cancer from a Tertiary Care Center
Sonal Raikwar, India
- EP.07.38** Immune Checkpoint Inhibitors May Not Fully Mitigate the Adverse Prognostic Impact of PD-L1 Expression in Early Lung Cancer
Ken Onodera, Japan
- EP.07.39** Simply the Best: Analysis Of 1000+ Patients Comparing Single-Fraction to Three-Fraction Lung SBRT for Early-Stage Inoperable Lung Cancer
Gregory Videtic, USA
- EP.07.40** Efficacy of Re-Irradiation with SABR of Lung Cancer After Primary SABR: A Single Centre Experience
Nagendran Balaramal, UK
- EP.07.41** Individualized SBRT for Ultra-Central NSCLC Achieves Optimal Tumor Control with Minimal Toxicity
Di Liu, China
- EP.07.42** Stereotactic Body Radiation Therapy Versus Surgery in Early-Stage Non-small Cell Lung Cancer: How Does Comorbidity Impact?
Arturo Navarro-Martin, Spain
- EP.07.43** The Role of FDG-PET/CT SUVmax in Predicting Treatment Outcomes and Progression Risk in SBRT for ES-NSCLC
Gloria Guardia, Spain
- EP.07.44** Perioperative Treatment Patterns and Clinical Outcomes in Early-Stage NSCLC: A Real-World Study (Peri-R-02)
Hua Zhong, China
- EP.07.45** Single-Cell Analysis Revealed the Characteristics of Tumors with Different Responses to Neoadjuvant Chemo Immunotherapy in Stage II-III NSCLC
Minglei Zhuo, China
- EP.07.46** Clinical and Radiologic Factors Associated with Surgical Eligibility After Neoadjuvant Chemoimmunotherapy in Stage II-III NSCLC
Junghee Lee, Republic of Korea
- EP.07.47** Real-World Implementation of Neoadjuvant Chemo-Immunotherapy in Resectable Non-small Cell Lung Cancer
Michael Shackcloth, UK
- EP.07.48** The Impact of Sarcopenia on Neoadjuvant Chemoimmunotherapy in Earlier Stage Resectable NSCLC
Daniele Marinelli, Italy
- EP.07.49** Neoadjuvant Sunvozertinib for Early-Stage NSCLC Patients with EGFR Exon 20 Insertion Mutation: A Case Series
Jinfeng Chen, China
- EP.07.50** Real-World Treatment Strategy and Postoperative Prognosis for Clinical Stage II/III NSCLC: A Multicenter Study
Taichi Matsubara, Japan
- EP.07.51** Long-Term EGFR-TKI as Neoadjuvant Therapy Effectively Achieved Depth of Pathological Response
Yuan Da Cheng, China
- EP.07.52** PD-L1 Tumor Expression Changes in Non-small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy and the Relation with Pathologic Response
Mateusz Polaczek, Poland
- EP.07.53** Impact of Subcutaneous Fat on the Relative Dose Intensity of Adjuvant Chemotherapy in Patients with Non-small Cell Lung Cancer
Ikki Takada, Japan

- EP.07.54** Lymphatic Permeation as a Key Risk Factor for Recurrence in Pathological Stage IIA NSCLC Under the 9th TNM Classification
Yujin Kudo, Japan
- EP.07.55** Adjuvant Sunvozertinib for Early-Stage NSCLC Patients with EGFR Exon 20 Insertion Mutation: A Case Series
Xiaohan Chen, China
- EP.07.56** Efficacy and Safety of Postoperative Adjuvant Chemotherapy and Atezolizumab and Osimertinib Maintenance Therapy for NSCLC at Our Hospital
Masahide Ota, Japan

TRACK 08: LOCAL-REGIONAL NON-SMALL CELL LUNG CANCER

- EP.08.01** Surgery for Resectable Lung Cancer with Radiographic Disease Control After Chemoinmunotherapy: A Retrospective Cohort Study
Bingbing Lu, China
- EP.08.02** A Study of Patients with Lung Cancer Complicated with IPF Who Underwent Partial Pulmonary Resection
Madoka Toyoda, Japan
- EP.08.03** Surgical Outcomes in Induction and Perioperative Chemoimmunotherapy Trials: A Meta Analysis
Pietro Bertoglio, Italy
- EP.08.04** Reducing Medication Burden and Accelerating Recovery Through Tubeless Thoracic Surgery: A Large-Scale Real-World Study
Zihao Liu, China
- EP.08.05** Minimally Invasive Approaches for Pancoast Tumor Resection: A Comparative Analysis of Surgical Techniques and Outcomes
Fumiaki Watanabe, Japan
- EP.08.06** Survival Analysis and Nomogram for Postoperative Pulmonary Sarcomatoid Carcinoma Patients: SEER Database Analysis and External Validation
Zixuan Hu, China
- EP.08.07** The Role of Surgery After Neoadjuvant Immunotherapy in NSCLC: Refining the Multimodal Paradigm
Alejandra Libreras Niño, Spain
- EP.08.08** Complex Tracheobronchial Reconstruction for Locally Advanced T4N2M0 Non-small Cell Lung Cancer Using Three-Dimensional Models
Sergew Yeskov, Belarus
- EP.08.09** Aggravation of Tumor Necrosis After Transbronchial Biopsy in Lung Cancer: A Fatal Complication Despite Rescue Surgery
Shiho Hattori, Japan
- EP.08.10** N3 Stage May no Longer Be Considered Unresectable in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer: A Case Series
Hao Guo, China
- EP.08.11** Multimodality Approach for Locally Advanced Lung Cancer, When Is Surgery Most Beneficial in a Resource-Constrained Environments
Riad Abdel Jellil, Jordan
- EP.08.12** Occult Lymph Nodal Metastasis in Sub-Centimeter Lung Cancer: A Report of Seven Cases and Review of Literature
Xiao Wang, China
- EP.08.13** Machine Learning Prediction of Overall Survival in Stage III Unresectable NSCLC: Data Analysis from a Single Center Prospective Cohort
Sara Ramella, Italy
- EP.08.14** Adaptive Radiotherapy in Locally Advanced Lung Cancer - a Single-Centre Retrospective Study
Anil Tibdewal, India

- EP.08.15** Predicting Locations of In-Field Failure Leading to Proton Re-irradiation for NSCLC
Mitin Ohri, USA
- EP.08.16** Impact of Pathological Subtypes and Radiation Dose on Survival in Lung Cancer: A Retrospective Analysis from a Single Institution
Thais Dias, Brazil
- EP.08.17** Patterns of Recurrence and Eligibility for Salvage Therapy After Curative Intent Treatment for Unresectable Stage III NSCLC
Eric Bhang, Canada
- EP.08.18** Concurrent Chemoradiotherapy (ConCRT) in Locally Advanced (LA) Non-small Cell Lung Cancer (NSCLC) in the Durvalumab Era
Haris Charalambous, Cyprus
- EP.08.19** Timing and Predictors of Lymphopenia in Lung Cancer Patients Undergoing Proton and Photon Chemoradiotherapy
Robert Press, USA
- EP.08.20** Comparative Survival Post-Radiotherapy in Small Vs. Non-small Cell Lung Cancer: Revisiting Prognostic and Dosimetric Factors
Renne Aguiar, Brazil
- EP.08.21** Sequential Radiotherapy Following Induction Immunochemotherapy/Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Yanhua Yang, China
- EP.08.22** Treatment Patterns and Clinical Outcomes in South Korean Patients with Unresectable Stage III EGFRm NSCLC Undergoing CRT
Jii Bum Lee, Republic of Korea
- EP.08.23** EMS to Lung Cancer Patients Receiving Platinum Doublet Concomitant Chemoradiotherapy
Anneyuko Saito, Japan
- EP.08.24** Pattern of Care in Locally Advanced NSCLC in India
Aswin Ravi, India
- EP.08.25** CRT Patterns and Short-Term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)
Marina Chernykh, Russian Federation
- EP.08.26** Blood Inflammatory Biomarkers Dynamics in Neoadjuvant Chemoimmunotherapy vs Chemotherapy Alone in Non-small Cell Lung Cancer
Marc Boada, Spain
- EP.08.27** Exploration of Targeted Sequential Surgery Combined Therapy for R0S1-Rearranged Non-small Cell Lung Cancer
Linqiang Jiang, China
- EP.08.28** Referral Rates to Medical Oncology Before Lung Cancer Surgery: A Quality Improvement Study in the Era of Perioperative Chemoimmunotherapy
Juliet Meir, USA
- EP.08.29** Pathologic Response After Neoadjuvant Chemoradiotherapy Versus Chemoimmunotherapy in Resected Stage III-N2 Non-small Cell Lung Cancer
Junghee Lee, Republic of Korea
- EP.08.30** The Outcome of Preoperative Therapy for Resectable NSCLC Patients with EGFR PACC Mutations
Wanpu Yan, China
- EP.08.31** Phase II Trial and Correlative Genomic Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-Mutant Non-small Cell Cancer
Chao Zhang, China
- EP.08.32** Real-World Outcome of Neoadjuvant-Intent Therapy vs Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer
Yasmin Fakhari Tehrani, USA
- EP.08.33** A Real-World Study of Resectable NSCLC Following Neoadjuvant Immunotherapy: Should Postoperative Adjuvant Immunotherapy Be Recommended?
Ming Li, China

- EP.08.34** To Resect or Not to Resect: The Evolving Landscape of Definitive Therapy for Stage III NSCLC: Implications for Service Demand in Ireland
Conor Moloney, Ireland
- EP.08.35** Accurate Pathologic Response Assessment of Lung Squamous Cell Carcinoma Treated with Neoadjuvant Immunotherapy
Shaoling Li, China
- EP.08.36** Vabretinib as Neoadjuvant Therapy in Three Cases of MET Exon 14 Skipping Mutation-Positive NSCLC: A Case Series
Yifei Zhou, China
- EP.08.37** Treatment Strategies for Unresectable Stage IIIA Lung Cancer After Neoadjuvant Therapy
Paula Rodriguez Hernaez, Spain
- EP.08.38** Real-World Data of Adjuvant Therapy with Aumolertinib for EGFR-Mutated NSCLC Patients
Honggang Liu, China
- EP.08.39** Adjuvant Therapy with Furmonertinib Significantly Reduces the Recurrence Rate in Lung Cancer Patients with Exon 20 Insertion Mutations
Jialu Chen, China
- EP.08.40** Immunotherapy Extended Survival in Patients with Recurrent Pulmonary Pleomorphic Carcinoma Following Surgery
Wakako Nagase, Japan
- EP.08.41** Tislelizumab Combined with Chemotherapy for Conversion Therapy in Stage III-N3 Non-small Cell Lung Cancer: A Phase 2, Single-Arm Trial
Kai MA, China
- EP.08.42** A Prognostic Marker for Consolidation Therapy with Durvalumab After Concurrent Chemoradiotherapy in NSCLC: The Utility of Serum CYFRA 21-1
Masahiro Ito, Japan
- EP.08.43** Surgical Stress After Lung Cancer Surgery Triggers the Outgrowth of Distant Metastases
Yo Kawaguchi, Japan
- EP.08.44** The Prognosis of NSCLC Patients Who Received Neoadjuvant Immunotherapy
Bolun Zhou, China
- EP.08.45** Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 ≥50%: A Systematic Review and Meta-Analysis
Guilherme Franceschini Machado, Brazil
- EP.08.46** Neoadjuvant Immunotherapy Improves Recurrence-Free Survival in Resectable Non-small Cell Lung Cancer - a 10-Year Institutional Experience
Gavit Woodard, USA
- EP.08.47** Consolidation Immunotherapy Impact in Non-small Cell Lung Cancer: A Descriptive Analysis
Manuel Quintana Déniz, Spain
- EP.08.48** PD-L1 Expression and Efficacy of Durvalumab Consolidation in Stage III EGFR-Mutant Non-small Cell Lung Cancer: A Multicenter Real-World Study
Insu Kim, Republic of Korea
- EP.08.49** Accurate Pathologic Response Assessment of Lung Adenocarcinoma Treated with Neoadjuvant Targeted Therapy
Shaoling Li, China
- EP.08.50** Excellent Response to Osimertinib-Based Regimens in Choroidal Metastasis in Patients with EGFR Exon 19 Deleted Non-small Cell Lung Cancer a Case Series
Natalie Shammas, USA
- EP.08.51** Impact of KRAS Mutations on Outcomes in Stage III Non-small Cell Lung Cancer Treated with Chemoradiation and Durvalumab
Nikhil Mankuzhy, USA
- EP.08.52** Is Attraction to Surgery Even Less in a Real-World Setting After Neoadjuvant Chemo-Immunotherapy for Non-small Cell Lung Cancer?
Raphael Werner, Switzerland

TRACK 09: METASTATIC NON-SMALL CELL LUNG CANCER – LOCAL THERAPIES

- EP.09.01** Feasibility of High Pressure Continuous Positive Airway Pressure to Reduce Respiratory Motion in Thoracic Irradiation
Sarit Appel, Israel
- EP.09.02** Consolidative Hypofractionated RT for Oligometastatic NSCLC
Bong Kyung Bae, Republic of Korea
- EP.09.03** Survival and Neurotoxicity of WBRT Vs. SRS in Individuals with Brain Metastases from Lung Cancer: Retrospective Study
Gustavo Cunha, Brazil
- EP.09.04** Duration of Systemic Therapy in Patients with Metastatic EGFR-Mutated NSCLC and Brain Metastases: First Vs. Third Generation TKIs
Alex Louie, Canada
- EP.09.05** Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-small Cell Lung Cancer Patients: A Retrospective Study
Haiyu Zhou, China
- EP.09.06** Consolidative High-Dose Thoracic Radiotherapy in NSCLC Without Progression After First-Line Systemic Therapy with ICIs
Marco Galaverni, Italy
- EP.09.07** Cardiac Dosimetry and Clinical Outcomes in Individuals with Lung Cancer Undergoing Thoracic Radiotherapy: Retrospective Study
Gustavo Cunha, Brazil
- EP.09.08** Outcomes of SBRT in the Management of Adrenal Metastases from Lung Cancer - Retrospective Data from Tertiary Cancer Centre of India
Memtombi Ngasepam, India
- EP.09.09** Evaluation of Radiotherapy Use in Patients with Metastatic Solid Tumors: An Analysis of Real-World Data
Sofia Mendes, Brazil
- EP.09.10** Salvage Surgery After Nonoperative Treatment of Initially Unresectable Stage IIIB-IV Non-small Cell Lung Cancer
Raphael Werner, Switzerland
- EP.09.11** Prognostic Impact of Nodal Downstaging After Neoadjuvant Therapy on Survival in Oligometastatic Non-small Cell Lung Cancer
Nina Steinmann, Switzerland
- EP.09.12** Pleurodesis in cMOsM1a Lung Adenocarcinoma with Pleural Metastasis: Impact on Pleural Effusion Control and Survival Outcomes
JiaYuan Tian, China
- EP.09.13** Prognostic Analysis of Patients with Incidentally Diagnosed Pathological Stage IVA Non-small Cell Lung Cancer After Anatomical Resection
Ryotaro Matsuyama, Japan
- EP.09.14** Efficacy and Safety of Intrathecal Pemetrexed in NSCLC Patients with Leptomeningeal Metastases: A Retrospective Study
Tianli Zhang, China
- EP.09.15** CT-Guided Microwave Ablation as an Alternative Treatment for Non-Surgical Lung Cancer Patients: A Clinical Evaluation of Benefits and Risks
Chung-Yu Chen, Taiwan
- EP.09.16** Airway Stenting for the Treatment of Airway Stenosis in Advanced Lung Cancer; a Study of 20 Patients with Advanced Lung Cancer
Akaya Tsuji, Japan
- EP.09.17** Permanent Local Control After Orbital Cryoablation for Ocular Metastasis from Lung Cancer
Muriá Mederos Alfonso, Switzerland

TRACK 10: METASTATIC NON-SMALL CELL LUNG CANCER – CYTOTOXIC THERAPY

EP-10.01 Retrospective Study of Pemetrexed Monotherapy for Non-small Cell Lung Cancer Patients by Renal Function
Taisaku Koyanagi, Japan

TRACK 11: METASTATIC NON-SMALL CELL LUNG CANCER – IMMUNOTHERAPY

EP-11.01 The Challenge of Immunotherapy in Advanced Lung Cancer Patients With HIV: A Systematic Review of Case Reports
Tindara Franchina, Italy

EP-11.02 Four Year-Experience with Immunotherapy in First Line Treatment of Advanced Lung Cancer in Patients with High and Very High Expression of PD-L1
Silvia Sequero, Spain

EP-11.03 First Line Chemo-Immunotherapy Prognostic Factors Predicting Non-small Cell Lung Cancer Overall Survival
Riccardo Ronga, Italy

EP-11.04 Camrelizumab-Induced Immune-Related Toxic Epidermal Necrolysis in Lung Adenocarcinoma: A Case Report and Literature Review
Man Sun, China

EP-11.05 Prognostic Value of Hb/RDW and Its Correlation with Immune-Inflammatory Profile in NSCLC Receiving First-Line Immunotherapy
Federica Pecci, Italy

EP-11.06 First-Line Immunotherapy for PD-L1 ≥50% Advanced NSCLC vs EGFR-TKIs in EGFR-Mutant NSCLC: A Retrospective Single-Center Study
Shun Futamura, Japan

EP-11.07 Type2 Diabetes Mellitus Affect Prognosis and Immune Checkpoint Inhibitor Treatment Efficacy for Advanced Non Small Cell Lung Cancer
Yasuhiro Kato, Japan

EP-11.08 Comparison of Efficacy and Safety of Combination Therapy with Atezolizumab and Chemotherapy in Non-small Cell Lung Cancer
Taichi Isobe, Japan

EP-11.09 Predictive Value of Markers of Systemic Inflammation in Patients with Advanced NSCLC Treated With First-Line Immune Checkpoint Inhibitors
Katarina Lujic, Serbia

EP-11.10 Clinicopathologic Features, Genetic Characteristics and Prognostic Analysis of Advanced Non-small Cell Lung Cancer. Not Otherwise Specified
Xiheng Yu, China

EP-11.11 Real World Outcomes of First-Line Pembrolizumab with or Without Chemotherapy in Patients with Non-small Cell Lung Cancer
Surein Arulananda, Australia

EP-11.12 Real-World Impact of Immune Checkpoint Inhibitors in Elderly Patients with Advanced NSCLC: A Retrospective Cohort Study from South Korea
Eun Young Heo, Republic of Korea

EP-11.13 ICI Rechallenge in Non Small Cell Lung Cancer: A Retrospective Analysis of Efficacy and Prognostic Factors
Solchiro Minami, Japan

EP-11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis from a Prospective Real-World Study
Jing Zheng, China

EP-11.15 Bimodal Onset and Pan-Cancer Uniformity of Immune-Mediated Liver Injury: A Retrospective Cohort Study
Xiaoke Chen, China

EP-11.16 Immunotherapy Rechallenge of Advanced NSCLC Patients Who Progressed on 3rd-Generation of EGFR-TKI and Immunotherapy Sequentially
Shuyi Hu, China

EP-11.17 Promising Effect of Nivolumab with Carboplatin, Paclitaxel, and Bevacizumab in EGFR-Mutant NSCLC Following EGFR-TKI Therapy
Akane Narumi, Japan

EP-11.18 Non-small Cell Lung Cancer Metastases to Adrenal Glands Are Not Differentially Sensitive to Immune Checkpoint Inhibitors
Charles Soutif, Belgium

EP-11.19 Efficacy and Safety of Continuing Tislelizumab After Progression of First-Line Tislelizumab in Patients with Advanced NSCLC
Boyu Qin, China

EP-11.20 Real World-Outcomes of Advanced Non-Squamous NSCLC Patients Treated with First-Line Chemo-Immunotherapy According to KRAS Status
Fabiana Perrone, Italy

EP-11.21 Efficacy of Immunotherapy in EGFR-Mutant NSCLC After Tyrosine Kinase Inhibitors: Real World Analysis at a Tertiary Oncology Center in Hong Kong
Gin Wai Gerry Kwok, Hong Kong

EP-11.22 Efficacy and Safety of Atezolizumab Plus Bevacizumab-Based Therapy in Non-small Cell Lung Cancer: A Meta-Analysis of Clinical Trials
Dipesh Rohita, USA

EP-11.23 Sex-Based Differences in Immune Toxicity Without Survival Trade-Off in Immune-Checkpoint Inhibitor Therapy for Lung Cancer
Amanda Tufman, Germany

EP-11.24 A CT Based Tumor Microenvironment Specific Radiomics Signature for Predicting the Efficacy of Checkpoint Inhibitor Therapy in Advanced NSCLC
Haiyu Zhou, China

TRACK 12: METASTATIC NON-SMALL CELL LUNG CANCER – TARGETED THERAPY

EP-12.01 Real-World Data of ROS-1 Positive NSCLCs- Mutational Heterogeneity, Clinical Characteristics and Its Outcomes
Kunal Jobanputra, India

EP-12.02 Efficacy and Safety of Firmoneitinib for EGFR Exon 21 L858R Mutation-Positive NSCLC Patients with Brain Metastases
Haichuan Su, China

EP-12.03 Study on the Effects of Anlotinib Combined with PD-1 Antibody in Lung Cancer Rats and Its Impact on the PLGF/Flt-1 and TGF-β1 Pathways
Shugeng Tang, China

EP-12.04 Efficacy of EGFR TKIs of a Rare but Sensitive Subtype of EGFR L833V/H835L Mutation in Advanced NSCLC
Yue-Li Sun, China

EP-12.05 The Effect of a Dutch Breakfast on the Exposure of Alectinib Using a Microtracer Approach: A Proof-Of-Concept Study
Ma Ida Mohrmaed Ali, Netherlands

EP-12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC
Lei Wang, China

EP-12.07 Using Online Continuing Medical Education to Identify Ongoing Gaps in Global Clinicians' Understanding of HER2-Altered NSCLC
Michelle Worst, USA

EP-12.08 A Real-World Study of the Efficacy and Safety of Firmoneitinib for Patients with Non-small Cell Lung Cancer with EGFR Uncommon Mutations
Min Li, China

- EP.12.09** Third-Generation EGFR-TKIs in T790M-Negative NSCLC After First/Second-Generation EGFR-TKI Failure: A Retrospective Study
Xiaobi Huang, China
- EP.12.10** Clinical Investigators' (CIs) Preferences for First-Line Therapy of ALK-Positive Metastatic Non-small Cell Lung Cancer
Neil Love, USA
- EP.12.11** Prognostic Impact of Metastatic Tumor Burden in Patients with EGFR-Mutated Lung Cancer: Real-World Data from a Single Center
Silvia Sequero López, Spain
- EP.12.12** Efficacy of Lazertinib in Treatment-Naive Patients for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
Hyun Seok Kwak, Republic of Korea
- EP.12.13** Gradually or Locally Progressed NSCLC Patients Benefit from Aumolertinib in Post-1L Dose-Escalation Treatment
Jun Li, China
- EP.12.15** Predictive Value of Gastrin for the Absorption of pH-Dependent Small-Molecule Inhibitors in Patients With NSCLC
Niels Heersche, Netherlands
- EP.12.16** Prolonged Survival in Oligometastatic ALK-Positive NSCLC: Impact of Local Ablative Therapy in a Multimodal Treatment Approach
Caroline Kamali, Sweden
- EP.12.17** NNMT as a Therapeutic Target in EMT-Associated Osimertinib Acquired Resistance in EGFR-Mutant Lung Adenocarcinoma
Wei Wang, China
- EP.12.18** Osimertinib-Associated Asymptomatic Depigmented Skin Macules in a Mexican Cohort
Seul Campos-Gomez, Mexico
- EP.12.19** Efficacy of Aumolertinib in Patients with Advanced NSCLC for Uncommon EGFR Exon 19 Deletion Mutations
Yifan Yang, China
- EP.12.20** A RealWorld Study: Clinical Molecular Characteristics and Prognostic Factors of NSCLC with MET Alteration
Xiao Fu, China
- EP.12.21** The Impact of Afatinib and Osimertinib Plasma Concentrations on Treatment Toxicities, Quality of Life, and Effectiveness in Patients With NSCLC
Sheng-Kai Liang, Taiwan
- EP.12.22** Clinical Treatment Outcomes of Erlotinib in Metastatic Non-small Cell Cancer Harboring Uncommon EGFR Mutations
Chalita Lagampan, Thailand
- EP.12.23** Disease Burden and rWPFS as a Surrogate Endpoint for rWOS in NTRK+ NSCLC and Other Advanced/Metastatic Solid Tumors
Carlos Flores Avile, USA
- EP.12.24** Common vs Uncommon EGFR Mutations in NSCLC and the Potential Prognostic Role of Neutrophil-To-Lymphocyte Ratio
Javier Baena Espinar, Spain
- EP.12.25** Demographic Influences on Treatment Preferences in Advanced EGFR+ mNSCLC: A Qualitative Analysis of Patient Perspectives on Osimertinib
Rena Seeger, Canada
- EP.12.26** Multi-Omics Decipher the Molecular Landscape of EGFR+ Non-small Cell Lung Cancer Patients Following Osimertinib Treatment
Per Hydring, Sweden
- EP.12.27** Effect of PD-L1 Expression Level on Clinical Outcomes of Stage IV EGFR Mutant Lung Cancer Patients Treated with Osimertinib
Jonathan Lee, USA

- EP.12.28** Real-World Clinical Outcomes in Chinese Patients with Advanced EGFR-Mutated NSCLC on First-Line Third-Generation EGFR-TKIs Treatment
Xinlin Mu, China
- EP.12.29** Association Between Tepotinib-Induced Edema and Clinical Outcomes in Patients with MET Exon 14 Skipping NSCLC
Takayuki Kobayashi, Japan
- EP.12.30** Real-World Outcomes of Full and Reduced Dose Capmatinib and Tepotinib Treatment for MET Exon 14 Skipping Mutation NSCLC
Joseph Fuchs, USA
- EP.12.31** Dual Target Drug Discovery for EGFR and PIK3CA in Lung Adenocarcinoma Using Machine Learning and Molecular Simulation Techniques
Simiao Lu, China
- EP.12.32** Targeted Therapy Utilization in Patients with Stage IV Non-small Cell Lung Cancer Harboring Actionable Mutations
Eduardo S. Santos, MD, USA
- EP.12.33** Retrospective Analysis of Adenocarcinoma of Lungs from Medical Oncology Clinic in Eastern India
Kiran Yidagur Gangadharaiiah Lokesh, India
- EP.12.34** Long-Term Control of Leptomeningeal Disease in NSCLC With EGFR Mutations: A Case Series
Estelamari Rodriguez, USA
- EP.12.35** Insights on Treatment Experience from Patients With ALK+ NSCLC Treated With 1st-Line Brigatinib, Lorlatinib and Alectinib
Christopher Danes, USA
- EP.12.36** Data Visualization of Treatment Patterns in Adults with BRAFV600E Mutant mNSCLC in Real-World Settings
David Planchard, France
- EP.12.37** Targeted Treatment of NSCLC With? BRAF Fusions: A Systematic Review
Saurav Verma, Canada
- EP.12.38** Firmoneertinib(160mg) Combined with Chemotherapy as First-Line Treatment for Advanced NSCLC Patients with EGFR Mutations and Cns Metastases
Lailing Li, China
- EP.12.39** Dynamic Evolution of Genomic and Microenvironment Landscape in ALK-Positive Non-small Cell Lung Cancer
Jiani Wu, China
- EP.12.40** Clinical Efficacy and Safety Analysis of Osimertinib Versus Aumolertinib in Real-World Treatment of EGFRm Advanced NSCLC
Hui Qiao, China
- EP.12.41** FUTURE Trial: First-Stage Data of Initial Firmoneertinib 160mg in EGFR+/PD-L1+ Locally Advanced or Metastatic NSCLC (Simon's Two-Stage Design)
Hui Yu, China
- EP.12.42** Durable Response to ROSI-Tkis in Metastatic Squamous NSCLC With EZR-ROSI Fusion
Edyta Urbanska, Denmark
- EP.12.43** Long Progression-Free Survival with Sunvozertinib in EGFRm NSCLC Patients After Third-Generation EGFR TKI Failure: Case Series
Mengxing You, China
- EP.12.44** The Efficacy of Capmatinib in Treating NSCLC Patients with MET Amplification in a Multi-Center Real-World Setting
Ning Yan, China
- EP.12.45** Concurrent ROS1-Rearrangements of Brain Metastasis in EGFR-Mutation Lung Adenocarcinoma
Ching Min Tseng, Taiwan

- EP.12.46** Efficacy of Sunvozertinib in Advanced NSCLC With HER2 Exon 20 Insertion After Prior Treatment Failure: A Real-World Case Series
Dongying Liu, China
- EP.12.47** Persistent Response of Sunvozertinib in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutation
Hui Han, China
- EP.12.48** Identifying Optimal First-Line Treatment Strategy for Advanced-Stage EGFR Mutant NSCLC: A Network Meta-Analysis
Du Feng, China
- EP.12.49** Osimertinib Distribution in Brain Metastases from Patients with Metastatic Non-small Cell Lung Cancer
Geerten Veerman, Netherlands
- EP.12.50** Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor as an Effective Subsequent Line: A Case Series from Kuwait
Abdulaziz AlJassim, Kuwait
- EP.12.51** Clinical Landscape and Future Perspectives of Targeted Protein Degradation Therapies in Lung Cancer
Man Sun, China
- EP.12.52** A High-Fat Meal Optimizes the Pharmacokinetic Profile of DO-2, a Novel MET-Kinase Inhibitor for NSCLC
Daan Lanser, Netherlands
- EP.12.53** Case Report Response to Treatment with Erdafitinib in a Patient with FGFR2 Mutation in Adenocarcinoma Lung Cancer
Grezia Siancas, Peru
- EP.12.54** Real-World Use of Targeted Therapy Combinations to Manage Secondary Oncogenic Addition in Non-small Cell Cancer
Clara Morin, France
- EP.12.55** Aumolertinib Combined with Metronomic Oral Vinorelbine in Advanced EGFR-Mutant NSCLC
Zhen Tian Liu, China
- EP.12.56** IPD Meta-Analysis of Intracranial Efficacy: Can CNS Data Refine First-Line Choices in EGFR-Mutant NSCLC?
Berlina Resuli, Germany
- EP.12.57** Ensartinib Exhibits Potential Synergistic Effects with Radiotherapy in ALK-Positive Non-small Cell Lung Cancer
Buhai Wang, China
- EP.12.58** Feasibility of Aumolertinib Followed by SRT in EGFR+ NSCLC Patients with Intracranial Oligo-Progression: A Phase II, Prospective Study
Jiayan Chen, China
- EP.12.59** Calcium Channel Blockers and Irreversible EGFR TKIS: Opportunities Missed?
Jo Monssen, Norway
- EP.12.60** Multiple Primary Lung Cancer with Driver Gene Mutations: Is Targeted Therapy Always the Optimal Choice?
Zi-Rui Ren, China
- EP.12.61** Prognostic-Predictive Modeling in Advanced Non-small Cell Lung Cancer: A Review of Biomarkers Using AI, ML and DL
Saqib Khan, Canada
- EP.12.62** Identification of Optimal Candidates for the FLAURAZ2 Regimen in EGFR-Mutated NSCLC Based on PFS2 Analysis
Yuya Murase, Japan
- EP.12.63** Combining Chemotherapy with Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experience Combining Chemotherapy and Osimertinib Beyond Progression in EGFR-Mutant NSCLC: A Case-Based Experience
Ana Cardena-Gutiérrez, Spain

- EP.12.64** Real-World Effectiveness of First-Line Osimertinib in EGFR-Mutated NSCLC: Interim Results From the French POSITHES Study
Florian Guisier, France
- EP.12.65** Factors Impacting Targeted Therapy Use in Stage IV Non-Small Cell Lung Cancer Patients With Infrequent Actionable Mutations
Mike Gart, USA

TRACK 13: SMALL CELL LUNG CANCER AND ENDOCRINE TUMORS

- EP.13.01** Survival Analysis of Malignant Pleural Effusion in Small Cell Lung Cancer: A Single-Center Retrospective Analysis
Ping Zhan, China
- EP.13.02** Incidence and Characteristics of Small Cell Lung Cancer at the National Respiratory Center of Persahabatan Hospital, Indonesia in 2023-2024
Kiki Widayastuti, Indonesia
- EP.13.03** A Single-Center Experience with Tarlatamab in Relapsed/Refractory Advanced Small Cell Lung Cancer and Neuroendocrine Carcinomas
Yunan Nie, USA
- EP.13.04** Patients with Limited Stage Small Cell Lung Cancer Detected Through Lung Cancer Screening May Have Improved Survival
Juhi Gor, USA
- EP.13.05** Twice Daily Hyperfractionated vs Once Daily Normofractionated Chemo-Radiotherapy in LS-SCLC: A Monocentric Experience
Anna Cappelli, Italy
- EP.13.06** Immunotherapy for ES-SCLC Comorbid with COPD: A Real-World Retrospective Study
Ping Zhan, China
- EP.13.07** Association of Gut Microbiota and Metabolites with Thalidomide-Induced Antiemetic Efficacy in Small Cell Lung Cancer Patients
Qiang-Guo Sun, China
- EP.13.08** Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated with Inferior Survival
David Billing, USA
- EP.13.09** Neoadjuvant Chemotherapy Versus Chemotherapy for LS-SCLC
Liwei Yang, China
- EP.13.10** Superior Vena Cava Syndrome in Extensive Stage (ES)-SCLC: A Marker of Aggressive Disease but Also a Window for Achieving Prolonged Survival?
Matteo Fila, Italy
- EP.13.11** Real-World Survival Data Over 25 Years in Extensive-Stage Small-Cell Lung Cancer: The Impact of Immune Checkpoint Inhibitors
Ryo Arivasa, Japan
- EP.13.12** A Retrospective Study of the Efficacy of Chemotherapy for Extended-Stage Small Cell Lung Cancer in Elderly Patients
Yoshihiro Taguchi, Japan
- EP.13.13** Treatment Outcome in Limited Stage Small Cell Lung Cancer: National Retrospective Study
Martina Vrankar, Slovenia
- EP.13.14** Real-World Data Analysis of Treatment Pattern and Prognosis of Patients with Limited-Stage Small Cell Lung Cancer in Japan
Seiji Niho, Japan
- EP.13.15** Outcome and Safety of Lurbinectedin as Compassionate Use in SCLC: A Retrospective Multicentric International Study
Daniela Scattolin, Italy
- EP.13.16** Safety and Efficacy of Chemotherapy in Stage IV Small Cell Lung Cancer: A Single-Center Retrospective Analysis
Arne Peeters, Belgium

- EP.13.17** Efficacy of First-Line Chemioimmunotherapy with Durvalumab or Atezolizumab in SCLC - Experiences from Practice of Two Polish Oncology Centers
Aleksandra Lomza-Laba, Poland
- EP.13.18** Retrospective Evaluation of the Prognostic Impact of Anti-PD-L1 Antibodies in ECOG-PS 2-3 Patients with Extensive-Stage SCLC
Kosuke Sakai, Japan
- EP.13.19** 30-Year Review of Real-World Outcomes in Small Cell Lung Cancer at Hospital Clinic of Barcelona
Luisa Delgado, Spain
- EP.13.20** Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes from a Single-Institution Retrospective Study
João Basílio, Portugal
- EP.13.21** Extended Follow-Up of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: Real-World Multicenter Study
Yechan Song, Republic of Korea
- EP.13.22** Survival and Treatment Patterns in Limited Disease-SCLC: Real World Data from the Swedish National Lung Cancer Registry
Johan Isaksson, Sweden
- EP.13.23** Tislelizumab Plus Sitravatinib or Anlotinib as Maintenance Therapy in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Yun Fan, China
- EP.13.24** ES-SCLC Outcomes Following SBRT and/or Thoracic Consolidation After Induction Systemic Therapy
Helen Gandler, USA
- EP.13.25** Real-World Treatment Patterns in ES-SCLC Highlight Continued Unmet Medical Need in the Era of New Therapies: ESSENCE Study
Helen Ross, USA
- EP.13.26** Gut Microbiota and Metabolites as Potential Biomarkers for Immunotherapy Efficacy in Patients with Extensive-Stage Small Cell Lung Cancer
Meixi Lin, China
- EP.13.27** Co-Targeting SFKs and DNA Damaging Chemotherapy Drugs as a Novel Therapeutic Strategy in SCLC
Nerea Otegui, Spain
- EP.13.28** Assessment of Clinical Characteristics and Outcomes of Brazilian ES-SCLC Patients on First Line Durvalumab + Chemotherapy
Mauro Zukin, Brazil
- EP.13.29** Safety and Efficacy of DLL3 CAR-T Cells Armored With dnTGFBR2 in a Patient with Recurrent Small Cell Lung Cancer
Zhonglin Hao, USA
- EP.13.30** Real-World Analysis of Treatment Patterns in Limited-Stage Small Cell Lung Cancer: Implications for Clinical Practice
Yan Xu, China
- EP.13.32** Multi-Institutional Real-World Experience of Early Tarlatamab-Related Toxicities for Extensive Stage Small Cell Lung Cancer
Estelamari Rodriguez, USA
- EP.13.33** Treatment Timeliness and Impact on Survival in Extensive Stage Small Cell Lung Cancer
Tom John, Australia
- EP.13.34** Meta-Analysis of First-Line Immunotherapy in ES-SCLC: Does ECOG PS =2 Affect Survival Outcomes
Xinmin Yu, China
- EP.13.35** Sequential Atezolizumab Regimens (Chemo Followed by Anlotinib) for ES-SCLC: Real-World Data
Xiaojun Qian, China

- EP.13.36** Induction Immunotherapy Followed by Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer
Letong Yang, China
- EP.13.37** Immunotherapy Plus Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
Chia Ching Lee, Singapore
- EP.13.38** Real-World Comparison of Carboplatin-Etoposide vs Cisplatin-Etoposide in ES-SCLC
Deepro Chowdhury, Canada
- EP.13.39** Factors Associated with Refusal of Chemoradiotherapy in Stage I-III Small Cell Lung Cancer and Their Effect on Survival
Yagni Patel, USA
- EP.13.40** Trial of Chemotherapy in Patients with Relapsed Small Cell Lung Cancer Combined with Allopurinol and Mycophenolate (CLAMP)
Brendan Knapp, USA
- EP.13.41** Expression of PD-L1 and Alternative Immune Checkpoints (ICs) and Their Impact on Outcomes in Small Cell Lung Cancer (SCLC)
Mumtu Lalla, USA
- EP.13.42** Self-Oxygenating PROTAC Microneedles for Spatiotemporally-Tunable Protein Degradation and Enhanced Small Cell Lung Cancer Therapy
Meng Hou, China
- EP.13.43** The Prognostic Factors Related with the Organ Specific Metastasis on Survival in ES-SCLC; TROD 08-16 Study
Serap Akyurek, Turkey
- EP.13.44** Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Neuroendocrine Neoplasms of the Lung (NEN-L)
Haichuan Hu, USA
- EP.13.45** Efficacy and Prognostic Significance of Immunotherapy in Postoperative Recurrent and Advanced Large Cell Neuroendocrine Carcinoma
Hua Zhong, China
- EP.13.46** Novel Prognostic Markers in Pulmonary Neuroendocrine Tumors (Carcinoid Tumors)
Somagattu Sushmitha, India
- EP.13.47** The Subtle Signals of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): A Clinical Characterization
Catherine Meador, USA
- EP.13.48** Natural Killer (NK) Cell Heterogeneity in Small Cell Lung Cancer: Implications for Chemotherapy Response
Caterina De Rosa, Italy
- EP.13.49** Prognosis of Perioperative Therapy in Primary Limited-Stage Small-Cell Lung Cancer
Geyun Chang, China

TRACK 14: MESOTHELIOMA, THYMOMA, AND OTHER THORACIC TUMORS

- EP.14.01** Chemotherapy Plus Bevacizumab and Immunotherapy Prolonged the Survival of Unresectable Malignant Mesothelioma Patients in First-Line
Yuyan Wang, China
- EP.14.02** Overall Survival and PD-L1 Expression Analysis of Patients with Pulmonary Mesothelioma
Yoko Yonemori, Japan
- EP.14.03** Glutamine Dependency of Pleural Mesothelioma
Silvia Plans Marin, Spain
- EP.14.04** Mapping the Pleural Mesothelioma: Incidence, Treatment Patterns and Outcomes from Endemic Pocket in Southern Rajasthan, India
Ashish Jakhethiya, India

- EP.14.05** Predictive Factors of Postoperative Long-Term Survival in Patient with Pleural Mesothelioma
Masaki Hashimoto, Japan
- EP.14.06** Survival Analysis in Malignant Pleural Mesothelioma
Heves Sürmeli, Turkey
- EP.14.07** Applying Multi Criteria Decision Analysis in Health Care Decision Making in Egypt
Ahmed Nagy, Egypt
- EP.14.08** Gender Difference as a Prognostic Factor in Non-Epithelioid Pleural Mesothelioma: Survival Analysis in the Retrospective SONENT Study
Federica Grosso, Italy
- EP.14.09** Comparison Between Epithelioid Type and Biphasic Type in Pleurectomy/Decortication for Pleural Mesothelioma
Kazunori Okabe, Japan
- EP.14.10** Role of CT Assessed in the Evaluation of Sarcopenia in Patient with Malignant Pleural Mesothelioma. Results From an Observational Study
Federica Grosso, Italy
- EP.14.11** Comparison of Short Term Surgical Outcomes for Thymectomy with Various Minimally Invasive Approaches: A Single Center Experience
Yohan Bae, Republic of Korea
- EP.14.12** Immune Profiles and Clinicopathological Insights in Thymomas: A Comprehensive Analysis
Ashmita Sukla, India
- EP.14.13** Utility of Visual Assessment of PET/CT for Differentiating Malignancy in Thymic Epithelial Tumors
Momoko Asami, Japan
- EP.14.14** Cyclophosphamide/Pegylated Liposomal Doxorubicin/Cisplatin as First-Line Treatment for Patients with Advanced Thymic Epithelial Tumors
Ying Liang, China
- EP.14.15** Patterns of Failure and Long-Term Outcomes in Patients with Thymoma Treated with Surgery and Radiation Therapy
Oded Icht, Canada
- EP.14.16** Clinical Characteristics, Surgical Risks, and Long-Term Prognosis of Good's Syndrome: A Retrospective Analysis of 108 Thymoma Cases
Shinya Otsuka, Japan
- EP.14.17** Clinical Outcomes of Patients with Advanced Thymic Malignancies Treated with Carboplatin/Pemetrexed Vs. Pemetrexed Alone
Melina Marmarelis, USA
- EP.14.18** Post-Thymectomy Myasthenia Gravis: A Multicenter Retrospective Study on Clinical Characteristics and Outcomes
Francesco Guerrera, Italy
- EP.14.19** A Single Institution Retrospective Analysis of Mediastinal Tumor Resections Utilizing Robotic-Assisted Surgery
Yuichiro Ueda, Japan
- EP.14.20** Whole-Exome Sequencing Study of Thymic Epithelial Tumors
Wen Gao, China
- EP.14.21** Real-World Clinical Outcomes of Patients with Masaoka Stage IV Thymic Carcinoma Treated with Carboplatin and Paclitaxel
Mikako Nakamura, Japan
- EP.14.22** Intrathoracic Radiotherapy in the Treatment of Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma Metastases
Jennifer Ma, USA
- EP.14.23** Distinct Mechanical Responses in PSP Reveal AKT1 Mutation and Mechanical Tension Synergy in EMT
Xichun Qin, China

- EP.14.24** Report of Four Cases of Primary Pulmonary Sarcoma Experienced at Our Hospital
Yoshiyuki Mishina, Japan
- EP.14.25** The Initial Outcome of Single Port Robotic Surgery for Mediastinal Tumors With 16 Cases
Daisuke Ito, Japan
- EP.14.26** Novel Bioengineered Drugs with Immunotherapies for Malignant Pleural Effusion
Ping Zhan, China
- EP.14.27** mTOR Inhibitor as Treatment in Pulmonary Epithelioid Hemangioendothelioma, a Case Series
Rene Leteller Farias, Chile
- EP.14.28** Three-Dimensional Reconstruction of the Sternum: A Novel Approach for Improved Surgical Outcomes
Ashish Jakhetiya, India
- EP.14.29** A Case Study of Multiple Nodular Lesions in the Anterior Mediastinum Detected on Preoperative Imaging
Keisuke Fujimoto, Japan
- EP.14.30** Clinicopathological Features and Diagnostic Challenges of Pulmonary Lymphoma: A Retrospective Review of 21 Cases
Tae-Jung Kim, Republic of Korea
- EP.14.31** Incidence Trends and Survival Outcomes of Pulmonary Langerhans Cell Histiocytosis: A National Cancer Study Using SEER
Janani Arunachalam, USA

TRACK 15: MULTIDISCIPLINARY CARE: NURSING, ALLIED HEALTH AND PALLIATIVE CARE

- EP.15.01** Anorexia, an Underreported Adverse Event, Predicts Mortality in Lung Cancer Patients
Aline Barreto, Brazil
- EP.15.02** Therapeutic Efficacy of Traditional Chinese Medicine Heat Patch Therapy for People with Lung Cancer
Ya-Ning Chang, China
- EP.15.03** Why Are Patients with Non-small Cell Lung Cancer in Stage I-IIIA Considered Inoperable? A Registry Study from Denmark
Thomas Budolfson, Denmark
- EP.15.04** Lung Function Before and After Development of Checkpoint Inhibitor Pneumonitis: Insights for Risk Assessment and Recovery
Senthuran Shivakumar, Australia
- EP.15.05** Wearable Devices and ePROs for Perioperative Continuous Monitoring in Thoracic Surgery
Qul Zhong, China
- EP.15.06** Bridging the Gap: Co-Designing Tools to Improve Equity in Lung Cancer Screening Care Pathways
Ambreen Sayani, Canada
- EP.15.07** Living with Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact
Tanvi Reddy, India
- EP.15.08** The Lived Experience of Dyspnea and Quality of Life Before and After Lung-Sparing Surgery
Melissa Culligan, USA
- EP.15.09** Clinical Decision Flowchart for Optimizing the Use of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: Real-World Data
Gisele Fraga, Brazil
- EP.15.10** Do Enhanced Recovery After Lung Cancer Surgery Programs Risk Putting Primacy of Caring at Stake?
Malene Missel, Denmark

- EP.15.11** Patterns of Care and Outcomes in Patients with Advanced Lung Cancer in a Hospital Palliative Care Unit: A Single-Center Retrospective Study
Rita Leporati, Italy
- EP.15.12** Virtual Personalized Exercise Program for Subjects with Lung Cancer: A Feasibility Study
Melissa Neumann, USA
- EP.15.13** Pilot Study of Exercise Program and Monitoring by a Lung Cancer Patient Navigator During Chemoradiotherapy for Stage III Lung Cancer
Puey Ling Chia, Singapore
- EP.15.14** Empowering Lung Cancer Care: The Role of AI Chatbots to Promote Exercise Oncology
Tindara Franchina, Italy
- EP.15.15** Lived Experiences and Needs of People Living Long-Term with Metastatic Non-small Cell Cancer: A Qualitative Study
Robin Urquhart, Canada
- EP.15.16** Patient's Understanding of Follow-Up Post Curative Primary Lung Cancer Surgery
Peter Barton, UK
- EP.15.17** The Role of Pneumonia in Mortality Among Hospitalized Patients with Advanced Lung Cancer
Xiaofang Gao, China
- EP.15.18** Characteristics and Clinical Outcomes of Hispanic Patients with Thoracic Malignancies Requiring ICU Admission: A Single Center Experience
Stella Isabel Martinez Jaramillo, Colombia
- EP.15.19** Patients with Advanced-Stage Lung Cancer in Intensive Care Unit, a Retrospective Observational Study Assessing Their Prognosis
Sebahat Ocak, Belgium

TRACK 16: PATIENT ADVOCACY

- EP.16.01** Is Follow Up for Lung Cancer Surgery Evidence Based Within the UK - a Critical Review of Protocols
Peter Barton, UK
- EP.16.02** Lung Cancer Patients' Involvement and Support Preferences and Needs: Insights from a Global Patient Experience Survey
Karen Clayton, UK
- EP.16.03** Characterization of a Real-World Data Set of EGFR+ NSCLC Patients
Brittney Nichols, USA
- EP.16.04** Relationship Between Telomere Length and Pulmonary Toxicity in Patients with Locally Advanced Unresectable Lung Cancer
Alfredo Marin-Muñiz, Spain
- EP.16.05** Expectations and Quality of Life of Lung Cancer Patients During the Care Process
Erika Pataki, Hungary
- EP.16.06** Health Literacy Leads to Health Equity: a Best Practice Approach from a Lung Cancer Organization
Maureen Rigney, USA
- EP.16.07** Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter
Maureen Rigney, USA
- EP.16.08** Preliminary Study of Culturally Adapted Approaches to Enhance Lung Cancer Education for Hispanic/Latino Populations
Matthew Reiss, USA

TRACK 17: GLOBAL HEALTH, HEALTH SERVICES, AND HEALTH ECONOMICS

- EP.17.01** Identifying Barriers to Timely Initiation of Oral Anti-Cancer Medication in Patients with Non-small Cell Lung Cancer
Courtney Granville, USA
- EP.17.02** Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry
Louis Irving, Australia
- EP.17.03** Disparities in Lung Cancer Treatment for Older Adults
Roshni Kailar, USA
- EP.17.04** Social Vulnerability as a Determinant of Disparities in Lung Cancer Management and Survival
Priscila Berenice Costa, Brazil
- EP.17.05** Association of Social Vulnerability with Prognosis of Lung Cancer in Japan
Yoshitaka Seki, Japan
- EP.17.06** Evolving Trends in Lung Cancer Epidemiology in India: A Shift in Patterns and Clinical Insights
Ulhas Batra, India
- EP.17.07** Using COM-B Behavioural Change Framework to Implement Lung Cancer Pathway for Primary Care Physicians
Zulfiqar Otty, Australia
- EP.17.08** Ready or Not: Assessing Provider and Facility Preparedness for Bispecific Therapy in Extensive Stage-Small Cell Lung Cancer
Joelle Fathi, USA
- EP.17.09** Pulmonary Nodule Burden in Melbourne: A Snapshot Pre-Australian Lung Cancer Screening Rollout
Chui Lyn Leong, Australia
- EP.17.10** Opportunities and Challenges of Lung Cancer Diagnosis, Care and Treatment in Western Kenya
Atundo Murunga, Kenya
- EP.17.11** Integrating Prevention and Screening of Tobacco-Related Diseases Including Lung Cancer Screening: Results of a Pilot Program
Maya Lemonnier, France
- EP.17.12** Utility of CT Scans & Blood Tests After Maintenance Durvalumab Post Chemort in Stage III NSCLC Patients
Amelia Muñoz-Lerma, Spain
- EP.17.13** Healthcare Professionals' Perceived Barriers and Facilitators of Risk-Stratified Follow-Up Care in Lung Cancer
Nadia Moss, Netherlands
- EP.17.14** Concordance Between Clinical and Radiological Diagnoses of Pneumonitis: Retrospective Cohort Review from Regional Health Service in Australia
Diwanshu Dua, Australia
- EP.17.15** Tackling the Lung Cancer Crisis in Canada: Co-Creating a National Strategy to Reduce Lung Cancer Mortality by 30% Action Plan?
Christian Finley, Canada
- EP.17.16** Improved Concordance to Clinical Practice Guideline: Analysis Of Multidisciplinary Team Discussed Patients with Stage III Lung Cancer
Xinghua Cheng, China
- EP.17.17** Availability of PD-L1 and NGS Results at Initial Medical Oncology Consultation in Patients with Non-small Cell Lung Cancer
Jacqueline Martin, Canada
- EP.17.18** Refining Lung Cancer Diagnosis Through Multidisciplinary Team Collaboration
Xiaojuan Zhang, China

- EP.17.19** Quality Control and Analysis of Standardized Diagnosis and Treatment of Lung Cancer
Zhen He, China
- EP.17.20** Natural Language Processing in Rapid Evaluation of Suspicious Lung Findings: Impact on Lung Cancer Outcomes
Elizabeth Dudnik, Israel
- EP.17.21** A Digital Health Solution for Monitoring Pulmonary Symptoms in Cancer Treatment
Garry Beran, UK
- EP.17.22** The Burden of Lung Cancer in Nigeria's Capital City: Findings from the Population Based Cancer Registry
Victoria Igbinomwanhia, Nigeria
- EP.17.23** Demographic Profile and Patient Journey of Early-Stage NSCLC Patients in a Brazilian Public Reference Center: A Real-World Study
Ricardo Terra, Brazil
- EP.17.24** Clinicopathological Features of Lung Cancer: A Study from a Tertiaryreferral Center in Georgia
Anna Geguchadze, Georgia
- EP.17.25** The Transition of Treatment Choice for First-Line Treatment for Advanced or Recurrent NSCLC and the Patients' Characteristics
Yuki Akazawa, Japan
- EP.17.26** Survival in Advanced NSCLC Patients With PD-L1 =50% Treated with ICIs: A Multicenter, Retrospective Real-World Study in Georgia
Ana Tsereteli, Georgia
- EP.17.27** Real-World Impact on Overall Survival of High-Cost Targeted and Immunotherapies in Lung Cancer Patients Under Chile's DAC Program
Rene Letelier Farias, Chile
- EP.17.28** Duration of Systemic Therapy in Patients with Metastatic EGFR-Mutated NSCLC and Brain Metastases: First vs Third Generation TKIs
Alex Louie, Canada
- EP.17.29** Real-World Effectiveness of Immunotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration
Chulamas Horugsa, Thailand
- EP.17.30** Rising Incidence of Early Onset Thoracic Malignant Tumors: Real-World Data from Two Hospitals in Brazil
Beatriz Miyamura, Brazil
- EP.17.31** Temporal Trends and Prognostic Factors in Lung Cancer Patients: Analysis Of a 25-Year Cohort of 2,488 Cases
Bruna Rezende, Brazil
- EP.17.32** Real-World Disease Impact in First-Line Treated Patients with Advanced Non-small Cell Lung Cancer With PD-L1 Expression =50%
Dwight H. Owen, USA
- EP.17.33** Evolving Treatment Patterns in Early-Stage Non-small Cell Lung Cancer in the USA
Jhanelle Gray, USA
- EP.17.34** Real-World Survival Outcomes in Non-small Cell Lung Cancer: Insights from UK Ehr--Derived Data
Amit Samani, UK
- EP.17.35** Treatment-Associated Interstitial Lung Disease in Extensive-Stage Small Cell Lung Cancer
Gregory Callip, USA
- EP.17.36** Disparities in Survival Outcomes of Primary Pulmonary Diffuse Large B-Cell Lymphoma: A SEER Database Analysis
Janani Arunachalam, USA
- EP.17.37** Assessing the Hidden Risk From 1990-2021: Radon-Attributable TBL Cancer Burden Across the European Union
Joy Doshi, UK
- EP.17.38** Intersecting Determinants of NSCLC Outcomes in Brazil: The Roles of Histology, Socioeconomic Status, and Healthcare Sector Disparities
Fabio Ynoe de Moraes, Canada
- EP.17.39** Carbon Footprint of Lung Cancer Management and Impact of Lung Cancer Screening Implementation
Valentin Héluain, France

IT'S NOT A RACE. IT'S A CAUSE.

The Backyard Steps Experience

A charitable initiative from The Ricky Rubio Foundation during the IASLC World Conference on Lung Cancer.



THE RICKY RUBIO FOUNDATION

LET'S CLIMB THE STAIRS OF MONTJUIC TOGETHER!



Where?
Montjuic Main Stairs
Barcelona



When?
September 7, 2025
18:00 – 20:30



Bus transfers will be provided at **18:00** from the following pick up points:

18:00 **FIRA Gran Via, North Entrance, Hall 8**
(Meeting Point: Wellness Challenge Counter, Registration Area, Ground Floor)

18:00 **Hotel Porta Fira**

18:00 **Hotel Melia Sarria**

18:00 **Hotel Nobu**

18:00 **INSIDE Barcelona Apolo**

Return transfers to above listed points will be provided (except FIRA Gran Via).

For more information, please visit: therickyrubiofoundation.org/reto-backyard/#K18

DOWNLOAD THE
**IASLC WELLNESS
CHALLENGE APP**
TO PARTICIPATE



07

GENERAL INFORMATION

Exhibit Hall Floorplan

GENERAL INFORMATION

The Exhibit Hall is located at Hall 8.1 on the first floor.

EXHIBIT HALL FEATURES

- ☑ Delegate Lounges
- ☑ IASLC Lounges & Booth
- ☑ Podcast Studio
- ☑ Meeting Pods
- ☑ Exhibitor Lounge
- ☑ Food & Beverage (F&B)
- ☑ Poster Tours and ePoster Lounge



Exhibitors By Name

1Cell.AI	421	British Thoracic Oncology Group (BTORG)	Tabletop #6
AbbVie Oncology	103	Caris Life Sciences	107
Accord Healthcare	419	Catalyst Pharmaceuticals, Inc.	408
AECaP Asocación Española de Afectados de Cáncer de Pulmón	Tabletop #2	Daiichi Sankyo, Inc.	102
ALCMI	Tabletop #1	Eli Lilly and Company	402
American Association For Cancer Research (AACR)	108	Genmab	304
Amgen	403	Gilead Oncology	305
Annalise.ai	210	Global Lung Cancer Coalition (GLCC)	Tabletop #5
AstraZeneca	303	Gradient Bioconvergence (GBCC)	411
Bayer	203	IASLC	101
BioNTech	106	ImmunityBio	209
Boehringer Ingelheim	301	Japan Lung Cancer Society (JLCS)	Tabletop #3
Bristol Myers Squibb	409		

Johnson & Johnson	302	Pfizer Oncology	202
KRAS Kickers	Tabletop #3	PharmaMar	406
Median Technologies	420	Medicine	105
Miconvey	412	Qure.ai	206
MSD	401	Regeneron	425
Natera	207	Revolution Medicines	104
National Comprehensive Cancer Network (NCCN)	Tabletop #4	Roche	404
Nuvalent, Inc.	413	Scanlan International	423
Nuvation Bio	201	Summit Therapeutics	204
Oncology Frontier 肿瘤瞭望	211	Takeda	405
Oncoscope-AI	407	The Ricky Rubio Foundation	Tabletop #7
Personalis, Inc.	424	The White Ribbon Project	Tabletop #8
PEXA AB	212	Thermo Fisher Scientific	205

Exhibitors By Booth Number

IASLC	101	Roche	404
Daiichi Sankyo, Inc.	102	Takeda	405
AbbVie Oncology	103	PharmaMar	406
Revolution Medicines	104	Oncoscope-AI	407
Medicine	105	Catalyst Pharmaceuticals, Inc.	408
BioNTech	106	Bristol Myers Squibb	409
Caris Life Sciences	107	Gradient Bioconvergence (GBCC)	411
American Association For Cancer Research (AACR)	108	Miconvey	412
Nuvation Bio	201	Nuvalent, Inc.	413
Pfizer Oncology	202	Accord Healthcare	419
Bayer	203	Median Technologies	420
Summit Therapeutics	204	ICell.AI	421
Thermo Fisher Scientific	205	Scanlan International	423
Qure.ai	206	Personalis, Inc.	424
Natera	207	Regeneron	425
ImmunityBio	209	ALCMI	Tabletop #1
Annalise.ai	210	AECaP Asociación Española de Afectados de Cáncer de Pulmón	Tabletop #2
Oncology Frontier 肿瘤瞭望	211	KRAS Kickers	Tabletop #3
PEXA AB	212	National Comprehensive Cancer Network (NCCN)	Tabletop #4
Boehringer Ingelheim	301	Global Lung Cancer Coalition	Tabletop #5
Johnson & Johnson	302	British Thoracic Oncology Group (BTOG)	Tabletop #6
AstraZeneca	303	The Ricky Rubio Foundation	Tabletop #7
Genmab	304	The White Ribbon Project	Tabletop #8
Gilead Oncology	305	Japan Lung Cancer Society (JLCS)	Tabletop #9
MSD	401		
Eli Lilly and Company	402		
Amgen	403		

Thank You TO ALL WCLC 2025 CONFERENCE SUPPORTERS

DIAMOND LEVEL




Johnson & Johnson

GOLD LEVEL



SILVER LEVEL



BRONZE LEVEL



Conference App Supporter – Nuvalent

Connecting Changemakers Lounge – Merck Healthcare

Driving Discovery Lounge – Roche

Patient Advocacy Lounge Supporter – Johnson & Johnson

Podcast Onsite Studio Supporter – Merck Healthcare

Poster Session Supporter – Johnson & Johnson

BOOTH 421



1Cell.AI, based in Foster City, California, is at the forefront of precision oncology, driving personalized cancer therapy with its innovative single cell multi-omics platform combining cutting-edge molecular science with advanced AI technology. This platform delivers real-time information allowing for the comprehensive analysis of individual cancer cells across multiple molecular levels, including genomics, transcriptomics, proteomics, and epigenomics. This technology provides deep insights into tumor heterogeneity, enabling the identification of rare cell populations that may drive metastasis or resistance to therapy, and tailoring treatments to improve patient outcomes.

1cell.ai

BOOTH 103

At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody, and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

abbvie.com/oncology

BOOTH 419

Headquartered in the United Kingdom, Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care. Our approach is agile and inventive, we're driven to think differently by continuing to explore and deliver high quality medicines designed to benefit patients' lives worldwide.

accord-healthcare.com

TABLETOP #2



The Spanish Association of Lung Cancer Patients (Asociación Española de Afectados de Cáncer de Pulmón AEACaP) is a non-profit organization established in December 2008 to support individuals diagnosed with lung cancer. As Spain's sole association dedicated exclusively to this disease, AEACaP offers free psychological support, legal advice, and guidance on medical consultations to patients and their families. The organization also promotes research to improve treatment options and quality of life, conducts informational activities to raise awareness, and advocates for equal access to healthcare services across all regions.

affectadoscancerdepulmon.com

TABLETOP #1



ALCMI is a nonprofit international consortium comprised of 25 of the world's premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

alcmi.org

BOOTH 108



The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through: Research, Education, Communication, Collaboration, Science Policy and Advocacy, and Funding for Cancer Research. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

aacr.org

BOOTH 403

Amgen harnesses the best of biology and technology to make people's lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what's known today. With roots in the biotech revolution, we are one of the world's leading independent biotech companies.

amgen.com

BOOTH 210



Annalise.ai, Harrison.ai's radiology AI solution, empowers clinicians to deliver more accurate and efficient radiology results throughout the imaging workflow. The comprehensive AI solutions detect up to 124 findings on chest X-rays and up to 130 findings on non-contrast head CT scans and can be customised for a wide range of care settings. The solutions are clinically available in 40+ countries and deployed at 1000+ sites in Australia, APAC, US, UK, EU and the Middle-East. Their CT Chest solution will be launching in Europe in 2026.

annalise.ai

BOOTH 303



AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

astrazeneca.co.uk

BOOTH 203



Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company's approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.

bayer.com

BOOTH 106

BIONTECH

BioNTech is a global immunotherapy company pioneering novel therapies for cancer. Its diversified oncology portfolio consists of complementary therapeutic modalities, including mRNA immunotherapies, next-gen immunomodulators and targeted therapies.

biontech.com/int/en/home.html

BOOTH 301



**Boehringer
Ingelheim**

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

boehringer-ingelheim.com

BOOTH 409



Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients' lives through science.

bms.com

TABLETOP #6



The British Thoracic Oncology Group (BTOG) is the multi-disciplinary group for healthcare professionals involved with thoracic malignancies throughout the UK. BTOG's mission is to support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information, and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care. The vision is to contribute to achieving survival rates equal to the best in the world.

btog.org

BOOTH 107



Caris Life Sciences® is a leading next-generation AI TechBio company and precision medicine pioneer actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (DNA, RNA and proteins), and the application of AI and machine learning algorithms, Caris has created the large-scale, multi-modal database and computing capability needed to analyze and unravel the molecular complexity of disease.

carislife.com

BOOTH 408



Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.

catalystpharma.com

BOOTH 102



With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

daiichisankyo.com

BOOTH 402



Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

lilly.com

BOOTH 304

Genmab 25

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. Genmab's proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

genmab.com

GENERAL INFORMATION

Exhibitor Descriptions

BOOTH 305



Oncology

Gilead Oncology is working to transform how cancer is treated. We are innovating with next generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody drug conjugates and small molecules to cell therapy based approaches, we are creating new possibilities for people with cancer.

global.askgileadmedical.com

TABLETOP #5



The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

lungcancercoalition.org

BOOTH 411

gradient
bioconvergence

Gradient Bioconvergence (GBCC) is an organization developing patient-derived cancer organoids (PDOs) in a global scale. We have built Asia's largest repository of PDOs with next-generation sequencing of over 700 models from patients with lung, gastric, colorectal, pancreas, and ovarian cancer. In addition, we are developing co-culture systems with autologous immune cells. Our PDO models are available for drug evaluation services. Based on our genomic and drug response data, we are discovering and validating novel oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC has established brain organoids from hiPSCs for drug evaluation and disease modeling.

gradientbio.com

BOOTH 209



ImmunityBio develops therapies and vaccines to defeat cancers and infectious diseases, going beyond checkpoint inhibitors to bolster the immune system to deliver durable, safe protection. ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer, T- and memory T cells for long-duration response.

anktiva.com

TABLETOP #9



Founded in 1960, the Japan Lung Cancer Society (JLCS) is the largest professional organization in Japan devoted to lung cancer research, prevention, diagnosis, treatment, and advocacy. With more than 7,500 members, including physicians, researchers, and allied health professionals, the JLCS promotes multidisciplinary collaboration and advances science through annual meetings, educational programs, and publications. The society actively fosters international exchange—particularly with the IASLC and other global partners—to share knowledge and improve patient outcomes worldwide. The JLCS remains committed to reducing the burden of lung cancer and, ultimately, to realizing a world free from the disease.

haigan.gr.jp

Exhibitor Descriptions

GENERAL INFORMATION

BOOTH 302

Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

innovativemedicine.jnj.com/emea

TABLETOP #3



The KRAS Kickers mission is to connect people to current research, resources, and community to kick cancer's KRAS! KRAS kickers members engage with leading doctors, researchers, and advocates to learn about new developments and clinical trials, connect to resources, build community, and share their stories to give hope to all with a KRAS biomarker.

kraskickers.org

BOOTH 420



Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD) for the early diagnosis of lung and liver cancers. Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies.

mediantechnologies.com

BOOTH 412



Miconvey Technologies Co., Ltd., guided by the mission of "All Efforts For Health", is a national high-tech enterprise specializing in minimally invasive surgical instruments. As a subsidiary of Hemony Pharmaceuticals Group, Miconvey has established a comprehensive system encompassing research & development, manufacturing, and sales. Its core products include ultrasonic scalpel systems, manual and powered staplers, and endoscopy. Miconvey's products have obtained multiple international certifications, including China NMPA, EU CE, U.S. FDA, and Korea KFDA, with a business footprint in over 50 countries and regions worldwide.

miconvey.com

BOOTH 401



At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest, development programs in the industry across more than 30 tumor types.

msd.com

BOOTH 207



Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual's tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions.

natera.com/oncology

BOOTH 413



Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

nuvalent.com

BOOTH 201



Nuvation Bio is a late clinical-stage, global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.

nuvationbio.com

BOOTH 211



Oncology Frontier is a leading Chinese medical media platform dedicated to delivering timely, cutting-edge oncology updates worldwide. Covering around 100 international and domestic academic conferences annually, we conduct over 3,000 interviews with key opinion leaders. Our mission is to keep Chinese healthcare professionals informed of global advances in oncology by fostering academic exchange on latest research, innovative technology, and clinical practice between Chinese and international experts. At WCLC 2025, we will host MEET WCLC Daily Highlights Program to enhance awareness of Chinese research and engagement of Chinese oncologists in IASLC and the WCLC community.

ioncol.com

BOOTH 407



Oncoscope-AI is a comprehensive medical decision-support tool developed by a team of oncology scientists and AI experts. The software conducts daily Cochrane-level literature reviews supported by an agentic system of large language models, extracting 32 key variables from each relevant oncology publication into a structured database. 100% human reviewed and cross-checked, the results data are integrated with treatment paths from national guidelines and cross-linked with FDA and clinical trial registries. Designed for oncology professionals, the intuitive, interactive platform offers individual and institutional subscription options delivering real-time clinical data, empowering oncologists to make timely informed treatment decisions that improve patient outcomes.

oncoscope-ai.com

BOOTH 424



At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

personalis.com

BOOTH 212



PEXA delivers a unique non-invasive sampling platform from the small airways, enabling biomarker discovery where lung diseases begin. Actively used by leading research groups in Lung Cancer studies, PEXA also offers strategic opportunities for pharma and diagnostic companies. Potential applications include early detection, screening, and supporting drug and diagnostic development.

pexa.se

BOOTH 202



Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives.

pfizer.com

BOOTH 406



PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

pharmamar.com

BOOTH 105



Predicine is a global molecular insights company committed to advancing precision medicine in oncology. Predicine is developing proprietary technologies for cfDNA and ctRNA liquid biopsy to enable minimally invasive molecular diagnoses for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and disease progression. Predicine's portfolio includes blood, urine, tissue based NGS assays designed for globally harmonized use in clinical trial, companion diagnostic (CDx) development, and commercialization. Through its business operations in Silicon Valley, Houston, Chicago and Shanghai, Predicine is partnering and collaborating with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale.

predicine.com

BOOTH 206



Qure.ai is a health-tech company that uses Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient detection, measurement and tracking of Lung Cancer to support clinicians and hospital administrators. We empower healthcare by helping to diagnose conditions early, prioritize treatment planning and ultimately improve the quality of patient life.

qure.ai

BOOTH 425



Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center.

regeneron.com

BOOTH 104



Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

revmed.com

BOOTH 404



Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

roche.com

BOOTH 423



Since 1921, the Scanlan family has been dedicated to hand-crafting the world's finest surgical instruments. Explore our Scanlan® LEGACY Needle Holders and Forceps, showcasing the revolutionary Scan-It™ handle design. Our comprehensive range includes Scanlan® VATS instruments such as D'Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps, and Khan Decortication Grasper. Join us on our continued journey of excellence in surgical solutions.

scanlaninternational.com

BOOTH 204



Summit is a biopharmaceutical oncology company focused on resolving serious unmet medical needs. Summit's compound, ivonescimab, is a novel, potential first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit's Phase III NSCLC trials include HARMONI (enrolled: NCT06396065), HARMONI-3 (enrolling: NCT05899608), HARMONI-7 (enrolling: NCT06767514). Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's NMPA.

smmmtx.com

GENERAL INFORMATION

Exhibitor Descriptions

BOOTH 405



At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.

takedaoncology.com

TABLETOP #4



National
Comprehensive
Cancer
Network®

The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

nccn.org

TABLETOP #7



The Ricky Rubio Foundation is a non-profit organization dedicated to fighting lung cancer through awareness, research, and patient support. With 4/1/2002, we turn the law into a message: a clothing collection that raises awareness of every patient's right to molecular diagnosis. We also proudly join the Wellness Challenge to promote physical activity as a powerful ally in recovery and long-term wellbeing. Because personalized treatment starts with awareness—and movement.

therickyrubiofoundation.org

TABLETOP #8



The White Ribbon Project is a grassroots movement changing public perception of lung cancer by promoting the truth that anyone with lungs can get lung cancer. Founded by survivor Heidi Nafman-Onda and her husband Dr. Pierre Onda, it builds community, raises awareness, and advocates for issues important to the lung cancer community such as lung cancer screening, biomarker testing, and research funding. Thousands of handmade white ribbons have been shared worldwide to bring hope, connection, and urgency to this silent epidemic.

thewhiteribbonproject.org

BOOTH 205

ThermoFisher
SCIENTIFIC

Thermo Fisher Scientific is the world leader in serving science. We provide a comprehensive suite of solutions for precision oncology, spanning early development through commercial strategy, encompassing companion diagnostics. Our leading clinical research services enable customers to accelerate innovation and increase development productivity. Our advanced next-generation sequencing technology, OncoPrint™ Solutions, enables laboratories everywhere to deliver genomic profiling from solid tumors and hematological cancers in as little as one day.

thermofisher.com/oncogene

IASLC



STEP IT UP FOR RESEARCH



IASLC WELLNESS CHALLENGE 2025

Barcelona

GREAT PRIZES AWAIT AND EVERY STEP COUNTS!

i Visit the Wellness Challenge Desk at Registration



DOWNLOAD THE IASLC
WELLNESS CHALLENGE
2025 APP

INDUSTRY SPONSORED SYMPOSIA SATURDAY, SEPTEMBER 6, 2025

09:00 - 10:00 IS01: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: PREPARING NSCLC FOR THE FUTURE OF DIAGNOSTIC BIOMARKER TESTING

ROOM 04

Chair: Charu Aggarwal, USA

09:00 **Welcome and Introduction**
Charu Aggarwal, USA

09:05 **Where Are We Now? The Current State of Biomarker Testing in NSCLC**
Sandip Patel, USA

09:20 **Navigating the Emerging Biomarker Approaches in NSCLC**
Charu Aggarwal, USA

09:35 **Bridging the Gap: Multidisciplinary Strategies for Redefining Biomarker Testing**
Fernando Lopez-Rios, Spain

09:50 **Panel Discussion and Q&A**
All Faculty



09:00 - 10:00 IS02: INDUSTRY SPONSORED SYMPOSIUM BY ELI LILLY AND COMPANY: PRECISION STARTS EARLY: THE EVOLVING ROLE OF BIOMARKER TESTING IN EARLY-STAGE NSCLC

ROOM 05

Chair: Sonja Loges, Germany

09:00 **Welcome & Opening Remarks**
Sonja Loges, Germany

09:05 **The Clinical Impact of Comprehensive Biomarker Testing in Early-Stage NSCLC**
Sara Pilotto, Italy

09:20 **Implementing Comprehensive Biomarker Testing in Early-Stage NSCLC - Facing the Challenge**
Paul Hofman, France

09:35 **Panel Discussion and Q&A**
All Faculty

09:55 **Closing Remarks**
Sonja Loges, Germany



10:30 - 11:30

IS04: INDUSTRY SPONSORED SYMPOSIUM BY DAIICHI SANKYO AND MSD: EMPOWERING CLINICIANS IN SCLC MANAGEMENT: KEY INSIGHTS ON DIAGNOSIS, TREATMENT, AND EMERGING STRATEGIES

ROOM 05

Chair: Antonio Calles, Spain

10:30 **Welcome and Introduction**
Antonio Calles, Spain


10:33 **Epidemiology, Risk Factors and Molecular Genetics of SCLC**
Antonio Calles, Spain

10:43 **Current Treatment Modalities and Challenges**
Alfredo Addeo, Switzerland

10:53 **Future Directions in SCLC Research**
Charles M Rudin, USA

11:03 **Open Discussions**
All Faculty

11:28 **Closing Remarks**
Antonio Calles, Spain



12:00 - 13:00 IS05: INDUSTRY SPONSORED SYMPOSIUM BY ABBVIE: WHAT SEZ6 SAYS ABOUT SMALL CELL LUNG CANCER (SCLC) AND NEUROENDOCRINE NEOPLASMS (NENS)

ROOM 04

Chair: Ernest Nadal, Spain

12:00 **Welcome and Introduction**
Ernest Nadal, Spain

12:05 **SEZ6 Lights the Way: A Lineage Marker in SCLC and NENS**
Daniel Morgensztern, USA

12:25 **Emerging Landscape of SEZ6-directed Therapeutics for SCLC and NENS**
Anne Chiang, USA

12:50 **Panel Discussion**
All Faculty



12:00 - 13:00 IS06: INDUSTRY SPONSORED SYMPOSIUM BY PFIZER: SUSTAINED CLINICAL BENEFIT IN 1L ALK+ ANSCLC: HOW TO OPTIMISE OUTCOMES FOR OUR PATIENTS

ROOM 05

 LIVESTREAMED  SNACKS PROVIDED  NOT FOR CME CREDIT

Chair: Tony Mok, China

12:00 **Welcome and Introduction**
Tony Mok, China

12:03 **Achieving Sustained Clinical Benefit: Advances in the 1L ALK+ aNSCLC Treatment Landscape**
Tony Mok, China

12:19 **Patient Cases: Optimising Outcomes for Patients With ALK+ aNSCLC**
Justin Gainor, USA and Maria Rosario Campelo, Spain

12:49 **Patient Cases: Discussion and Q&A**
All Faculty

12:59 **Summary and Close**
Tony Mok, China

13:30 - 14:30 IS08: INDUSTRY SPONSORED SYMPOSIUM BY ACCORD HEALTHCARE: RECENT DEVELOPMENTS IN THE FIRST-LINE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

ROOM 04

 LUNCH PROVIDED  NOT FOR CME CREDIT

Chair: Simon Ekman, Sweden

13:30 **Introduction**
Simon Ekman, Sweden

13:38 **Existing Immune Checkpoint Inhibitors in ES-SCLC**
Silvia Novello, Italy

13:58 **New Immune Checkpoint Inhibitors in ES-SCLC**
Francesco Grossi, Italy

14:18 **Questions and Answers**
All Faculty

14:28 **Wrap-up**
Simon Ekman, Sweden

SATELLITE CME SYMPOSIA

SATURDAY, SEPTEMBER 6, 2025

10:30 - 11:30 IS03: SATELLITE EBAC/CME SYMPOSIUM BY ANSWERS IN CME ON BEHALF OF DAIICHI SANKYO, INC.: RESHAPING THE MANAGEMENT OF METASTATIC NSCLC: TACKLING HER2 OVEREXPRESSION TO ELEVATE OUTCOMES

ROOM 04

 LIVESTREAMED  SNACKS PROVIDED  ACCME ACCREDITED BY OTHER PROVIDER

Panel: Raffaele Califano, UK; Nicolas Girard, France; Antonio Passaro, Italy

10:30 **Welcome and Introduction**

10:35 **STATE OF SCIENCE: Role of Biomarker Testing in NSCLC**

10:50 **FROM BENCH TO BEDSIDE: Efficacy of HER2-Directed ADCs for HER2-Overexpressing NSCLC**

11:05 **PRACTICAL CARE CONSIDERATIONS: Integrating HER2-Directed ADCs into Treatment Algorithms for HER2-Overexpressing NSCLC**

11:20 **Questions, Take-Home Learning and Evaluation**

13:30 - 14:30 IS07: SATELLITE EBAC/CME SYMPOSIUM BY PEERVOICE ON BEHALF OF BAYER: PIONEERING PRECISION: A REAL-WORLD ROADMAP TO OPTIMAL OUTCOMES IN NTRK FUSION-POSITIVE AND HER2-MUTANT ADVANCED NSCLC

ROOM 05

 LIVESTREAMED  SNACKS PROVIDED  ACCME ACCREDITED BY OTHER PROVIDER

Chair: Solange Peters, Switzerland

13:30 **Welcome and Introduction**
Solange Peters, Switzerland

13:35 **Patient Voices in Lung Cancer: Mapping Challenges, Unmet Needs, and the Path Forward**
Merel Hennink, Netherlands

13:45 **Precision Oncology Approaches in the Treatment of NTRK Fusion-Positive Advanced NSCLC to Optimize Clinical and Patient Outcomes**
Merel Hennink, Netherlands; Stephen Liu, USA

14:05 **Advancements in Clinical Research for HER2-Mutant Advanced NSCLC: Redefining Treatment Strategies with Targeted Therapy to Optimize Outcomes**
Merel Hennink, Netherlands; Stephen Liu, USA

14:25 **Closing Remarks & Conclusions**
Solange Peters, Switzerland

15:00 - 16:00 IS09: SATELLITE CME SYMPOSIUM BY PHYSICIANS' EDUCATION RESOURCE ON BEHALF OF SUMMIT THERAPEUTICS, INC.: A NEW ERA OF TARGETED THERAPY FOR ADVANCED NSCLC: EXPLORING FUTURE DIRECTIONS FOR BISPECIFIC ANTIBODIES AND ADCs

ROOM 04

Chair: Sandip Patel, USA

15:00 Program Introductions

Sandip Patel, USA

15:05

Unlocking the Potential of Biospecific Antibodies in Advanced NSCLC

Myung-Ju Ahn, Republic of Korea

15:40

Bracing for Impact: A New Wave of ADCs in NSCLC

Giannis Mountziros, Greece

15:55

Posttest Assessment and Concluding Remarks

Sandip Patel, USA

 LUNCH PROVIDED

 ACCME ACCREDITED BY OTHER PROVIDER

13:45 - 14:45

IS11: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: MAXIMISING A MULTIDISCIPLINARY APPROACH: SHAPING THE FUTURE OF LUNG CANCER CARE WITH IMMUNOTHERAPY

ROOM 04

Chair: Natasha Leighl, Canada

13:45

Welcome and Introductions

Natasha Leighl, Canada

13:48

Panel Discussion: Enhancing Outcomes in Early-Stage NSCLC and Limited-Stage SCLC Through MDT Collaboration

Natasha Leighl, Canada, Matthias Guckenberger, Switzerland, Erin Gillaspie, USA

14:25

Future Outlook for Metastatic NSCLC: Navigating the Evolving Treatment Landscape

Natasha Leighl, Canada

14:35

Q&A and Meeting Close

All Faculty

 LIVESTREAMED

 LUNCH PROVIDED

 NOT FOR CME CREDIT

13:45 - 14:45

IS12: INDUSTRY SPONSORED SYMPOSIUM BY JOHNSON & JOHNSON: ADVANCING EGFR-MUTANT NSCLC CARE

ROOM 08

Chair: Luis Paz-Ares, Spain

13:45

Welcome and Introductions

Luis Paz-Ares, Spain

13:52

Treatment-Naïve Disease: Making the First Move

Sanjay Popat, UK

14:12

Overcoming Treatment Resistance: Key Strategies

Anne-Marie Dingemans, Netherlands

14:27

Panel Discussion

All Faculty

14:42

Closing Remarks

Luis Paz-Ares, Spain

 LIVESTREAMED

 SNACKS PROVIDED

 NOT FOR CME CREDIT

13:45 - 14:45 IS13: INDUSTRY SPONSORED SYMPOSIUM BY NUVATION BIO INC.: UNDER THE MICROSCOPE: FOCUSING ON ROST+ NSCLC

ROOM 01

Chair: Charu Aggarwal, USA

13:45 Role of ROST1 Fusions in NSCLC

Charu Aggarwal, USA

13:55 Optimizing Outcomes Through Testing

Jürgen Wolf, Germany

14:15 Selecting an Optimal Treatment Approach for Patients

Javier de Castro, Spain



13:45 - 14:45 IS14: INDUSTRY SPONSORED SYMPOSIUM BY REGENERON: NSCLC REIMAGINED: NOVEL TREATMENT STRATEGIES IN ADVANCED NSCLC

ROOM 05

Chair: Pilar Garrido, Spain

13:45 Welcome and Introduction

Pilar Garrido, Spain

13:50 The First-Line Frontier: Reviewing ICI-based Treatment Combinations for Advanced NSCLC

Pilar Garrido, Spain

14:05 A Spotlight on Squamous Histology: Exploring the Evolving Treatment Landscape for Patients with Advanced Squamous NSCLC

Biagio Ricciuti, USA

14:20 Reshaping the Standard: Current and Future Post-progression Strategies for Advanced NSCLC

Federico Cappuzzo, Italy

14:35 Panel Discussion and Meeting Close



18:30 - 19:30 IS15: INDUSTRY SPONSORED SYMPOSIUM BY NATERA: SIGNATERA ULTRASENSITIVE MRD TESTING FOR LUNG CANCER

ROOM 05

Presenter: Michael Krainock, USA

18:30 Introduction to ctDNA and Natera MRD Portfolio

18:40 Unmet Needs in Lung Cancer and Potential Applications for MRD


18:45 Early-Stage Risk-Stratification Clinical Data

18:55 Early Recurrence Detection Clinical Data

19:05 ICI Treatment Response Monitoring Clinical Data

19:15 Real World Case Studies

19:20 Future Directions and Q&A



18:30 - 19:30

IS10: SATELLITE CME SYMPOSIUM BY PHYSICIANS' EDUCATION RESOURCE ON BEHALF OF ASTRAZENECA: TUMOR BOARD: ADVANCES IN MANAGING EGFR-MUTANT NSCLC - APPLYING EVIDENCE ACROSS THE DISEASE CONTINUUM

ROOM 04

Chair: Tina Cascone, USA

18:30 Program Introductions

Tina Cascone, USA

18:35 Spotlight on the Management of Early-Stage EGFR-Mutant NSCLC

Christina Baik, USA

18:45 At the Frontline: Current and Emerging Therapeutic Approaches for EGFR-Mutant Metastatic NSCLC

David Planchard, France

19:05 Combating EGFR-TKI Resistance: Outlook for Metastatic NSCLC in the Second-Line Setting and Beyond

Tina Cascone, USA

19:20 Posttest Assessment & Audience Q&A

Tina Cascone, USA



NON-PROFIT PRESENTATION SUNDAY, SEPTEMBER 7, 2025

10:45 - 11:30

NP01: NON-PROFIT PRESENTATION BY BRISTOL MYERS SQUIBB FOUNDATION: TRANSFORMATIVE INSIGHTS: IMPACT OF BMS FOUNDATION-FUNDED PROGRAMS IN LOW-AND MIDDLE-INCOME COUNTRIES

ROOM 12

Chair: Ray Osarogiagbon, USA

Panel: Nestory Masalu, Tanzania, Ricardo Sales dos Santos, Brazil, Zixiao Ma, China

INDUSTRY SPONSORED SYMPOSIA MONDAY, SEPTEMBER 8, 2025

13:45 - 14:45 **IS16: INDUSTRY SPONSORED SYMPOSIUM BY DAIICHI SANKYO, INC.: MULTIDISCIPLINARY CARE FOR PATIENTS WITH BRAIN METASTASES IN EGFRm NSCLC OR SCLC**

ROOM 01

Chair: Hossein Borghaei, USA

13:45 **Introduction and Housekeeping**

Hossein Borghaei, USA

13:50 **Brain Metastases in Lung Cancer**

Hossein Borghaei, USA, Seema Nagpal, USA

13:55 **Case Study A: Previously Treated EGFRm NSCLC**

Hossein Borghaei, USA, Seema Nagpal, USA, Kristin Higgins, USA

14:15 **Case Study B: Previously Treated SCLC**

Hossein Borghaei, USA, Seema Nagpal, USA, Kristin Higgins, USA

14:30 **Audience Q&A**

14:40 **Summary and Close**

Hossein Borghaei, USA

13:45 - 14:45 **IS17: INDUSTRY SPONSORED SYMPOSIUM BY BOEHRINGER INGELHEIM INTERNATIONAL GMBH: TARGETED THERAPIES, PERSONALIZED CARE: PATIENT-CENTERED ADVANCES FOR THE TREATMENT OF NSCLC AND SCLC**

ROOM 08

Chair: Christine Lovly, USA

13:45 **Chair's Welcome and Introductions**

Christine Lovly, USA

13:50 **Targeting HER2 in NSCLC: How Have Patients Responded to Emerging Therapies?**

Tatsuya Yoshida, Japan

14:10 **T-Cell Engagers and the Next Wave of Combination Therapies for Advanced SCLC**

Tiziana Leal, USA

14:30 **Panel Discussion: How Can These Approaches Benefit Patients in the Clinic?**

All Faculty



13:45 - 14:45

IS18: INDUSTRY SPONSORED SYMPOSIUM BY MSD: A DECADE OF PROGRESS: ADVANCES IN IMMUNOTHERAPY FOR NSCLC?

ROOM 05

Chair: Martin Reck, Germany

13:45 **Welcome & Introduction: 10 Years of IO in Metastatic NSCLC, What's Next?**

Martin Reck, Germany

14:00 **Early-Stage and Locally Advanced NSCLC**

Enriqueta Felip, Spain

14:12 **Patient Case(s)**

Mir Alireza Hoda, Austria

14:25 **Subcutaneous IO in Clinical Practice**

Enriqueta Felip, Spain

14:35 **Panel Discussion, Q&A and Closing**

All Faculty

13:45 - 14:45 **IS19: INDUSTRY SPONSORED SYMPOSIUM BY ASTRAZENECA: METASTATIC EGFRm NSCLC: ADAPTING TO PATIENTS, GROUNDED IN EVIDENCE**

ROOM 04

Chair: Helena Yu, USA

13:45 **Welcome and Introductions**

Helena Yu, USA

13:49 **EGFR-TKIs as Backbone Therapy for EGFRm NSCLC**

Patrick Forde, USA

13:59 **Novel Combinations Therapies in EGFRm mNSCLC: What Could and Should Be Done**


Stephanie Saw, Singapore

14:14 **Understanding Patient Preferences When Living with Lung Cancer**

Luca Ostacoli, Italy

14:27 **Panel Discussion and Closing Remarks**

All Faculty



Hours of Operation:

REGISTRATION DELEGATE HELP DESK MOBILE APP HELP DESK

- Fira Gran Via (North Entrance)**
Friday, September 5 15:00 - 19:00
Saturday, September 6 07:30 - 18:30
Sunday, September 7 07:30 - 17:00
Monday, September 8 08:00 - 17:00
Tuesday, September 9 08:00 - 14:00

SPEAKER LOUNGE

- Hall 8.0 - Ground Floor**
Friday, September 5 15:00 - 19:00
Saturday, September 6 07:30 - 18:30
Sunday, September 7 07:30 - 17:00
Monday, September 8 08:00 - 17:00
Tuesday, September 9 08:00 - 13:00

WELLNESS LOUNGE

- Hall 8.0 - Ground Floor**
Saturday, September 6 09:00 - 16:00
Sunday, September 7 09:00 - 17:00
Monday, September 8 09:00 - 17:00
Tuesday, September 9 09:00 - 14:00

AWARDS LUNCHEON

- Hall 8.0 - Room 01-02, Ground Floor**
Saturday, September 6 11:30 - 13:00

IASLC BUSINESS MEETING

- Hall 8.0 - Room 09, Ground Floor**
Monday, September 8 14:45 - 15:30

PRESS & MEDIA WORK ROOM

- Press & Media Center, First Floor**
Saturday, September 6 07:00 - 18:00
Sunday, September 7 08:00 - 18:00
Monday, September 8 08:00 - 18:00
Tuesday, September 9 08:00 - 14:00

PRESS CONFERENCE SCHEDULE

- CC7 AB - Press Conference Room**
Saturday, September 6 17:45 - 18:45
Sunday, September 7 10:45 - 11:45
Monday, September 8 10:45 - 11:45
Tuesday, September 9 10:15 - 11:15

EXHIBIT HALL

- Hall 8.1 - First Floor**
Saturday, September 6 17:45 - 19:15
Sunday, September 7 10:00 - 15:30
Monday, September 8 10:00 - 15:30
Tuesday, September 9 10:00 - 13:00

POSTER DISPLAY

- Hall 8.1 - Exhibit Hall, First Floor**
P1:
Sunday, September 7: 10:00 - 15:30
Presenters in Attendance: 10:30 - 12:00
P2:
Monday, September 8: 10:00 - 15:30
Presenters in Attendance: 10:30 - 12:00
P3:
Tuesday, September 9: 10:00 - 13:00
Presenters in Attendance: 10:00 - 11:30
Poster Session supported by
Johnson & Johnson

POSTER TOURS

- Hall 8.1 - Exhibit Hall, First Floor**

CONTINUING MEDICAL EDUCATION (CME) AND CERTIFICATE OF ATTENDANCE

Credits can be claimed in the IASLC Lung Cancer 360 starting September 9 through December 31, 2025. Log in using your Lung Cancer 360 Username and Password, select the sessions you attended, and download your certificate. If you are new to Lung Cancer 360 or forgot your password, click the Reset Password link. For assistance, please email education@iaslc.org.

A Conference evaluation will be sent via email at the conclusion of the Conference.

- For more information on CME please visit:
wclcl.iaslc.org/cme-information

ONSITE SERVICES



NURSING MOTHER'S LOUNGE

A reserved area for nursing mothers is available in Hall 8.0, located just beyond Room 10.



PRAYER ROOM

A designated multifaith prayer room is located directly at the entrance to Hall 8.0.



FIRST AID ROOM

The First Aid Room is located in Hall 8.0, at the rear of Room 07.



LUGGAGE DROP

Luggage drop will be available in the registration area on Tuesday, September 9.



SPEAKER LOUNGE

Designated area in Hall 8.0 for all oral presenters to upload and review their slides. Coffee and refreshments will be available.



EXHIBITOR LOUNGE

A dedicated space, located in Hall 8.1 - Exhibit Hall, for exhibitor staff to relax and recharge away from the busy show floor.



For more information on presenter resources please visit:
wclcl.iaslc.org/presenter-resources



EMERGENCY INFORMATION

In case of an emergency within the Fira Gran Via venue, please call **+34 93 233 41 00**. This number activates all onsite emergency protocols and enables incident tracking.

EXPLORE. ENGAGE. RECHARGE.

Make the most of your time at WCLC 2025 with curated experiences that add depth and dimension to your conference experience.

From exclusive lounges and wellness retreats to hands-on exhibits and share-worthy social moments, this year's event is filled with opportunities to learn, connect, and recharge.



VISIT THE IASLC BOOTH (#101)

📍 **Hall 8.1 - Exhibit Hall, First Floor** 🕒 **Open during Exhibit Hall Hours**

Don't miss the chance to connect with the IASLC team and learn about all the exciting activities and initiatives we have planned! At the demo kiosks, be the first to navigate through the new IASLC Thoracic Circle or explore all online educational material IASLC Members can enjoy through Lung Cancer 360.

Enjoy a dedicated lounge for IASLC members, where you can also have your professional photo taken. Not a member yet? No problem! You can join anytime—even right at the booth—and start enjoying exclusive benefits. Stop by the Committee Corner—a dedicated space for connection, collaboration, and celebration! Throughout the meeting, committee members and attendees are welcome to gather, network, and share ideas in an informal setting. The space will also feature special recognition of our outgoing chairs and a warm welcome for the new ones. Come by and be part of the ongoing conversations that help shape our community!

There's also a **fun activity** waiting for you, with the chance to win fantastic prizes.




IASLC PATIENT ADVOCACY LOUNGE

📍 **Hall 8.1 - Exhibit Hall, First Floor** 🕒 **Open during Exhibit Hall Hours**

A valued feature at WCLC, we warmly welcome all patients/survivors, caregivers/partners, and advocates, to enjoy exclusive access to this lounge. It's designed as a space to relax, connect, and recharge, with comfortable seating options and charging points for your devices.

Supported by: **Johnson & Johnson**



IASLC PODCAST STUDIO

📍 **Hall 8.1 - Exhibit Hall, First Floor**

Check out Lung Cancer Considered in action at the IASLC podcast studio. Hosts Dr. Narijst Florez and Dr. Stephen Liu will lead meaningful conversations with researchers, healthcare professionals, patients, and advocates who are making a difference in thoracic cancer treatment. *Do you want to listen to previous episodes?*

Tune in here! www.iaslc.org/LungCancerConsidered

Supported by: **MERCK**



WCLC 2025 PHOTOBOOTH & SOCIAL MEDIA ACTIVATION ZONE

📍 **Hall 8 - Ground Floor**

Whether you are a social media user or simply want to capture a special moment from WCLC 2025, be sure to stop by for a photo—solo or with fellow attendees! Our team is ready to help you snap the perfect shot. Choose your country's flag or favorite tag, flash your biggest smile, and strike a pose! If you would like, share your photos using **#WCLC25** and connect with us across major social media platforms!



IASLC WELLNESS CHALLENGE

Join us for the IASLC Wellness Challenge, a four-day event held alongside WCLC 2025! Using the IASLC Wellness Challenge 2025 app, your step count will be converted into points, giving you the chance to win prizes and enjoy some friendly competition with your peers. Each participant will be assigned to a regional team, celebrating our global community. Earn bonus points by engaging in various activities and working towards your wellness goals.

Learn more at: hekahealth.com/iaslc25



MEETING PODS

📍 **Hall 8.1 - Exhibit Hall, First Floor**

🕒 **Open during Exhibit Hall Hours**

We recognize the value of meaningful discussions that happen when you connect with fellow experts from around the world. The meeting pods are designed to provide attendees with the opportunity to hold spontaneous meetings while at WCLC 2025. No prior reservations are needed - meeting pods are available on a first-come, first-served basis. If others are waiting, we kindly ask that you limit your meeting to a maximum of one hour. While not fully soundproof, the meeting pods are conveniently set up with meeting tables and can accommodate 4 to 8 people.


IASLC ACADEMY AMAZING CASE RACE

This activity will take learners through five interactive, thoracic oncology case-based simulations. Each simulation provides a real-world scenario to exercise your decision-making skills with immediate results and feedback.



IASLC VOICES IN ACTION

Be part of something bigger, share your voice! We invite IASLC members to visit our video station and record a short message. Whether it's your story, your work, or why the IASLC community matters to you, this is your chance to connect and inspire others. These videos will help amplify the power of our global community.



DELEGATE LOUNGES AND CHARGING AREA

Supported by:



📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

Enjoy access to multiple lounges across the exhibit floor—perfect for taking a break, catching up with fellow attendees, or using the power points to recharge your devices.

All WCLC 2025 attendees are welcome to use these lounges.

EXHIBITOR LOUNGE

📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

GARDEN LOUNGES

📍 Hall 8.1 - Exhibit Hall, First Floor 🕒 Open during Exhibit Hall Hours

Take a break, enjoy some fresh air, and treat yourself to a refreshing ice cream or freshly squeezed smoothie in the outdoor garden lounges, conveniently located at the entrance of Exhibit Hall 8.1, leading to Plenary Hall 6

WELLNESS LOUNGE

📍 Hall 8.0 - Ground Floor

🕒 Saturday, September 6 09:00 - 16:00
 Sunday, September 7 09:00 - 17:00
 Monday, September 8 09:00 - 17:00
 Tuesday, September 9 09:00 - 14:00

Launched for the first time in San Diego, the Wellness Lounge returns to Barcelona following the incredible positive feedback received. Designed as a quiet retreat, the lounge offers delegates a space to decompress, relax, and take a break from the bustling session rooms and common areas. It also serves as a safe space for our international attendees battling jet lag, providing a comfortable spot to take a power nap and recharge.

Stay Energized and Hydrated! CATERING SERVICES AT WCLC 2025

You won't go hungry at WCLC 2025! We invite you to take advantage of the complimentary catering services available to all registered delegates. Enjoy a variety of refreshments and meals throughout the Conference.

Complimentary coffee, tea, soft drinks, and a selection of snacks will be available in Exhibit Hall 8.1 as well as in the Hall 8 Cafe.

COFFEE BREAKS

📍 Hall 8.1 - Exhibit Hall, First Floor
 Sunday, September 7 10:30 - 12:00
 Monday, September 8 10:30 - 12:00
 Tuesday, September 9 10:00 - 11:30

WELCOME RECEPTION

The Welcome Reception offers an opportunity to network in a relaxed setting. Enjoy regional canapés and drinks while connecting with fellow delegates and exhibitors.

📍 Hall 8.1 - Exhibit Hall, First Floor
 Saturday, September 6 17:45 - 19:15

CONFERENCE LUNCHES

Standing working lunches will be available in the Exhibit Hall, offering a variety of hot and cold items. Additionally, Industry Symposia Organizers often provide packed lunches for delegates attending their sessions.

📍 Hall 8.1 - Exhibit Hall, First Floor

🕒 Saturday, September 6:
 See 'Special Lunches'
 Sunday, September 7:
 13:15 - 15:15
 Monday, September 8:
 13:15 - 15:15
 Tuesday, September 9:
 See 'Special Lunches'

SPECIAL LUNCHES AT WCLC 2025

All delegates are welcome to attend these special sessions, which include lunch. Access is available on a first-come, first-served basis until maximum capacity is reached.

AWARDS LUNCHEON

📍 Hall 8.0 - Room 01-02, Ground Floor
 Saturday, September 6 11:30 - 13:00

WORK-LIFE HARMONY: REDEFINING BALANCE IN THE DEMANDING FIELD OF ONCOLOGY

📍 Hall 8.0 - Room 12, Ground Floor
 Sunday, September 7 13:45 - 14:45

INCLUSION IN ACTION: ADDRESSING HIDDEN AND EMERGING INEQUITIES IN THORACIC ONCOLOGY

📍 Hall 8.0 - Room 10, Ground Floor
 Monday, September 8 13:30 - 14:45

Supported by: **Johnson & Johnson**

NAVIGATING GENDER EQUITY IN THE DAILY LIFE OF A THORACIC ONCOLOGIST

📍 Hall 8.0 - Room 03, Ground Floor
 Monday, September 8 13:45 - 14:45

Supported by: **Johnson & Johnson**

CLOSING LUNCH - NOT SO TRIVIAL: A WCLC INTERDISCIPLINARY QUIZ CHALLENGE

📍 Plenary, Hall 6
 Tuesday, September 9 14:15 - 15:45

Download Now! WCLC 2025 MOBILE APP

All sessions will be audio recorded and made available on the Mobile App - along with the presentation slides - within 24 hours after each session. Abstracts and all posters are also accessible via the Mobile App. Log-in details have been sent to your registered email.

If you need assistance, please visit the WCLC 2025 Help Desk in the registration area or contact us at: wclc2025-registration@icevents.com.


Mobile App Supported by:



Mobile App Features:

- ✔ Full Scientific Schedule
- ✔ Abstract Book, Program Book
- ✔ Venue and Exhibit Floor Plan
- ✔ Presentation Slides and Recordings (Within 24 Hours)
- ✔ Opportunity to Create Personalized Schedule
- ✔ Networking Features to Connect with Delegates and Faculty
- ✔ Notification Alerts
- ✔ Livestream of Plenary Sessions, IASLC Award Luncheon and IASLC Business Meeting

Download the WCLC 2025 App:



FIRST FLOOR


CC8 & CC8.1
SUPPORTER OFFICES
PRESS & MEDIA WORK ROOM
EXHIBIT HALL
POSTERS, POSTERS &
POSTER TOURS
WALKWAY TO PLENARY HALL 6

GROUND FLOOR

ROOMS 01 - 12
MEETING ROOMS A - D
SPEAKER LOUNGE
STARS LOUNGE
WELLNESS LOUNGE

NORTH ACCESS

HALL 8.0 - GROUND FLOOR





**2026 World Conference
on Lung Cancer**

SEPTEMBER 12 - 15, 2026 | SEOUL, REPUBLIC OF KOREA

Save the Date!
SEPTEMBER 12 - 15, 2026
SEOUL, REPUBLIC OF KOREA

wclc.iaslc.org



#WCLC26



AKT1, BRAF, PTEN, RET are tumor profiling biomarkers

NGS biomarker reports in 24 hours

Visit us at Booth #205

Make treatment decisions without waiting weeks for next-generation sequencing (NGS) results. With the Oncomine™ Dx Express Test, your lab can deliver NGS reports in as little as 24 hours.*

- **Turnaround time of as little as 24 hours**, from tissue sample to report
- **Minimal DNA and RNA input requirements**, capable of analyzing small and challenging samples such as core-needle biopsies and fine-needle aspirates

Request the Oncomine Dx Express Test from your lab to make the best-informed treatment decisions and minimize delays in patient care.

*Timing varies by number of samples and type of run.

Learn more at thermofisher.com/oncomine-express-test

For In Vitro Diagnostic Use. © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **FLY-11063969 0725**



Advancing precision oncology & Reshaping cancer care

We are committed to **redefining healthcare** and are **working tirelessly to get in front of cancer**. By connecting the best of Health&Care, we're striving to **transform the lives** of people with **lung cancer**. Our goal is to change the devastating course of lung cancer and adapt those **learnings to transform outcomes** in other cancers.

Scan to learn more at
<https://innovativemedicine.jnj.com/emea/>



CP-525095 | June 2025
©Janssen Pharmaceutica NV

Johnson & Johnson
The Health & Care Company